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 2 
Abstract 
The Spondyloarthritides (SpA) are a group of genetically and pathophysiologically related 
diseases. Ankylosing spondylitis (AS), the prototypic SpA family member, is a systemic 
inflammatory disease primarily affecting the axial skeleton, characterised by sacroiliitis 
and bone formation, promoting joint inhibition. AS is highly heritable; approximately 90% 
of AS susceptibility is defined by an individuals’ genetic background, to which the MHC 
class I molecule HLA-B27 contributes approximately 30%. This association was 
discovered 40 years ago, yet the pathogenic role of HLA-B27 remains elusive.  
Dendritic cells (DCs) belong to the myeloid lineage and as the principal antigen presenting 
cells (APCs) of the immune system, activate naïve T cells and contribute to the balance 
between activation and suppression of the immune response. If affected by HLA-B27, DCs 
are therefore likely to contribute to the T cell-mediated aspects of AS pathogenesis. 
Studies in our laboratory, using HLA-B27 transgenic (HLA-B27 TG) rats, have revealed 
HLA-B27-mediated effects on DC populations. The affected DCs induce abnormally high 
levels of IL-17 production from T cells; CCR6+ IL-17-secreting cells appear to be 
important in driving pathology both in the HLA-B27 TG rats and in AS patients. We 
therefore aimed to perform the first characterisations of the phenotype and functions of 
DCs and other myeloid populations purified directly from AS patients, to understand their 
role in AS pathogenesis.  
Analyses of circulating myeloid populations revealed that AS patients have a reduced 
proportion of the CD1c-expressing blood DCs, offset by an increase in CD14- CD16+ 
mononuclear cells. Interactions between CD14- CD16+ mononuclear cells and CD4+ T 
cells generated high levels of IL-6 secretion, required for the generation of Th17 cells. 
CD14- CD16+ mononuclear cells also induced T cells to express CCR6, and may therefore 
contribute to pathology by promoting Th17 responses. Interestingly, our data also indicate 
that APCs of mucosal origin may make a significant contribution to the systemic 
inflammation observed in AS patients. These observations give new insights into the 
pathogenic mechanisms in AS.  
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1.1 Spondyloarthritides 
The spondyloarthritis (SpA) family of diseases is heterogeneous but shares many genetic 
and pathophysiological features. Originally, SpA was considered a variant of the well-
known and characterised disease rheumatoid arthritis (RA) (1). However, Moll et al 
recognised the need for further classification of these rheumatoid factor negative diseases, 
subsequently termed “seronegative spondarthritides” (1). Ankylosing spondylitis (AS) is 
the prototypic and most studied SpA family member (1-3). Since the original Moll and 
Wright description, there have been various classification criteria, with the most recent 
classification by the Assessment of SpondyloArthritis international Society (ASAS) 
assigning the following diseases as SpA family members: AS, psoriatic arthritis (PsA), 
reactive arthritis (ReA), arthritis associated with inflammatory bowel disease (SpA-IBD), 
undifferentiated SpA (uSpA), juvenile SpA (jSpA) and acute anterior uveitis. Diseases of 
the SpA family share several physiological characteristics including spondylitis, 
sacroiliitis, peripheral arthritis, enthesitis, uveitis, psoriasis and inflammatory bowel 
disease (IBD) (1, 2, 4, 5). Disease comorbidities may additionally affect tissues including 
the heart, lungs and kidneys (6).  
The ASAS classification criteria subdivide SpA patients into two groups according to 
whether they have dominant axial (axial SpA) or peripheral (peripheral SpA) joint disease 
(7, 8). These groups are not exclusive, as patients assigned to the axial SpA group may 
develop peripheral joint involvement. As there was a recognition that many patients with 
axial SpA did not have radiographic sacroiliac changes meeting the modified New York 
criteria for AS (7, 8), the ASAS axial SpA was developed to incorporate both patients with 
AS and those with non-radiographic axial SpA. Patients can be classified with axial SpA 
through either an imaging or a clinical arm (Figure 1.1). For the imaging arm, patients 
require chronic back pain, evidence of sacroiliitis on imaging (x-ray or MRI) and at least 
one other SpA feature. Alternatively, patients without the required radiographic evidence 
of sacroiliitis can still be classified with axial SpA via the clinical arm for which they 
require chronic back pain, a positive HLA-B27 and at least 2 other specified SpA features 
which include uveitis, psoriasis and IBD. The ASAS criteria are outlined in Figure 1.1.  
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Figure 1.1: ASAS criteria for SpA classification 
Adapted from Rudwaleit et al, describing the classification criteria for patients with axial disease, 
either AS or non-radiographic axial SpA (left) and those presenting only with peripheral/extra-
articular symptoms (right) (7). Sacroiliitis on imaging is defined through use of x-ray and MRI. IBP = 
inflammatory back pain. ASAS = Assessment of SpondyloArthritis international Society. SpA 
classification criteria from 2011 onwards. 
Patients with peripheral arthritis and/or enthesitis and/or dactylitis but no axial disease can 
fulfil the ASAS criteria for peripheral SpA if they meet a number of other specified SpA 
features which include HLA-B27 positivity, IBD and clinical uveitis (Fig. 1.1). Despite 
these advancements regarding clinical characterisation of SpA, this remains a 
heterogeneous group and the aetiology and pathogenesis of this disease remain elusive. 
1.1.1 Ankylosing spondylitis 
Ankylosing Spondylitis (AS) is a chronic inflammatory disease belonging to the SpA 
family (9). AS affects 0.1 to 1.4% of the global population (4). AS susceptibility is highly 
influenced by an individual’s genotype, with around 95% of AS sufferers expressing the 
MHC Class I molecule HLA-B27 (4).  AS primarily affects the axial skeleton and is 
characterised by spinal inflammation, particularly sacroiliitis, bone formation and joint 
damage (4). As shown in Figure 1.2, severe spinal changes and loss of spinal function are 
associated with AS.    
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Figure 1.2: Progression of Ankylosing Spondylitis 
This picture highlights the postural changes associated with AS disease progression. This figure 
was adapted from Little et al (10). 
AS is associated with IBD, uveitis and psoriasis with 10%, 25% and 10% of AS patients 
presenting with these extra-articular manifestations respectively (11, 12). Furthermore, 
approximately 50% of AS patients display evidence of subclinical intestinal inflammation 
(4, 13). Characteristic of all SpA family members is the development of enthesitis; 
inflammation associated with entheses, the sites of tendon or ligament adhesion to bone (5, 
14). Approximately 25% of patients are thought to display evidence of peripheral enthesitis 
(15). Enthesitis and subsequent erosion of the associated bone in AS patients leads to joint 
ossification (syndesmophyte growth), contributing to the development of AS (16). The 
details of the relationship between inflammation and pathological changes in bone 
formation are currently under debate (17, 18). Several studies report a disconnection 
between inhibition of inflammation using of anti-tumour necrosis factor ! (TNF!) 
treatment, and prevention of structural progression (19, 20). In contrast, anti-
TNF! treatment has been shown to slow bone formation in AS patients, and 
Maksymowych et al observed a preference for bone formation to occur at sites of 
inflammation (21, 22). Despite this uncertainty regarding the relationship between 
inflammation and bone formation, the wide range of extra- and articular manifestations in 
addition to axial involvement indicate the complexity of this disease. 
Despite the fact that the biological processes involved in AS development and disease 
perpetuation remain unclear, several therapeutic agents have shown efficacy in 
approximately 60% of patients (23). The current most effective therapy is TNF! blockade, 
but this is only partially successful in reducing disease symptoms, including inflammation 
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(11). Furthermore, this so-called “biological therapy” remains ineffective for a large 
proportion of AS patients. The unknown aetiology and pathogenesis of AS partially 
contribute to the paucity of disease-specific therapies and the ineffectiveness of current 
therapeutics.  
1.1.2 Genetics of ankylosing spondylitis 
All SpA family members are linked through their association with the MHC Class I 
molecule, HLA-B27 (3). However, the role of HLA-B27 in disease development is still not 
clear. Two seminal papers in 1973 first described the association between AS and HLA-
B27 (24, 25). In the study by Brewerton et al 96% of patients, compared to 4% of HCs, 
expressed HLA-B27 (24). Of the Caucasian European population, approximately 8% carry 
the HLA-B27 gene, and 0.5% of HLA-B27+ individuals develop AS (11). The frequency 
of HLA-B27 in the general population differs according to ethnicity and geographical 
location (4, 11). Given that the relationship between AS and HLA-B27 is one of the 
strongest genetic associations described (11, 26), it is not surprising that HLA-B27 tissue 
typing is used as a diagnostic marker in suspected AS patients, and is included in the 
ASAS classification criteria (Figure 1.1). 
The association between AS and HLA-B27 is complex; several HLA-B27 haplotypes are 
associated with disease (27). There are over 50 coding subtypes of HLA-B27 (11, 27), the 
majority of which are too rare to be comprehensively assessed for disease association (11, 
28). However at least 12 subtypes exhibit strong associations with AS development (11). 
To be specific, HLA-B*2701-08, HLA-B*2710, HLA-B*2714-15 and HLA-B*2719 all 
infer AS disease susceptibility (11, 29-35). European cohorts are dominated by the HLA-
B*2702 and HLA-B*2705 subtypes (HLA-B*2705 is most prevalent); these subtypes are 
equally associated with SpA (29, 36). In Asian populations, HLA-B*2704 is the dominant 
HLA-B27 variant, and has been shown to have a stronger AS association than HLA-
B*2705 (28). Not every HLA-B27 subtype associated with AS is necessarily pathogenic. 
Early studies indicated that HLA-B*2709 was protective against AS, however more recent 
investigations have refuted this (11, 27, 37, 38). Although HLA-B27 expression is strongly 
associated with SpA, it accounts for less than 50% of the genetic risk associated with 
disease (11). In fact, the HLA-B27 contribution may be as low as 20-30% (4).  
The genetic background of AS patients contributes approximately 90% to disease 
susceptibility (11, 27). Other MHC genes may exhibit association with AS, including 
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HLA-B60 and HLA DR1 (28), but their importance is thought to be minor. Multiple genes 
outside the MHC region contribute to the genetic make-up of AS patients. For instance, 
single nucleotide polymorphisms (SNPs) within the interleukin-23 receptor (IL-23R) gene 
and the IL-23 signalling molecule STAT3 are also associated with AS (11, 27, 28, 39-42). 
Interestingly, the IL-23R polymorphisms associated with AS additionally confer 
susceptibility to IBD (43) and psoriasis (44), two common extra-articular manifestations of 
AS patients. Given the close relationship between IBD, psoriasis and AS, it was interesting 
to note that the IL-23R AS susceptibility association was not due to the concurrent 
development of these extra-articular manifestations (27, 39). Therefore, IL-23R 
polymorphisms may inextricably link AS, IBD and psoriasis. Despite this clear association 
between IL-23R polymorphisms and SpA, the mechanism by which IL-23R SNPs drive 
SpA remain undetermined. 
Another AS susceptibility gene additionally identified through genome-wide association 
studies (GWAS) was the endoplasmic reticulum aminopeptidase gene, ERAP1 (11, 27, 28, 
39, 40). The ERAP1 SNP in AS patients is restricted to HLA-B27+ individuals (45). This 
ERAP1 SNP may reduce the activity of the ERAP1 protein, which is involved in MHC 
class I peptide loading and cleavage of cytokine receptors, including IL-1RII (28, 46). 
However, the importance of these functions in AS pathogenesis have still to be elucidated 
(27). Interestingly, no associations between IBD, psoriasis and ERAP1 have been 
identified (11, 28).  
The role of the killer cell immunoglobulin-like receptors (KIRs), expressed on cytotoxic 
natural killer (NK) cells, in relation to AS susceptibility has been investigated recently 
(11). KIRs, principally KIR3DL1 and KIR3DL2, recognise a specific epitope causing 
“differential NK cell activation” in response to cells expressing B*2708 (11), one of the 
HLA-B27 alleles strongly associated with AS susceptibility (11, 30). Furthermore, Chan et 
al observed an upregulation of KIR3DL2 expression on SpA NK cells and CD4+ T cells 
(47). Therefore, given this association between KIRs and AS, at a genetic and 
immunological level, these receptors may be involved in AS pathogenesis. 
Through the GWAS studies, several other candidate genes influencing AS susceptibility 
were identified: Anthrax toxin receptor 2 (ANTXR2) and TNF (ligand) superfamily, 
member 15 (TNFSF15) (11, 28). The ANTXR2 gene encodes the capillary morphogenesis 
protein – 2 (11, 28, 40). TNFSF15 is a ligand for death receptor 3 (DR3), a member of the 
TNF superfamily. Binding of TNFSF15 to DR3 has been shown to induce proliferation of 
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Th17 cells, a subtype of T cells associated with the pathogenesis of AS (48, 49). 
Interestingly, TNFSF15 is also associated with Crohn’s disease (CD) (50). 
AS is additionally associated with SNPs of the IL-1 gene complex, especially IL-1R2 and 
CARD9 (11, 28, 39, 40). These SNPs may further support the involvement of Th17 cells in 
AS pathogenesis, as CARD9 is involved in Th1 and Th17 differentiation (11, 51). Overall, 
many of the genetic associations identified through the use of GWAS studies have 
highlighted a potential role for several immune pathways in the development and/or 
pathogenesis of this disease. Specifically, associations were observed between AS and the 
IL-23R/Th17 axis, antigen presentation, the innate arm of the immune system and the Th1 
pathway. The exact mechanisms by which many of these AS associated genes influence 
development of this disease remain unknown. However, these newly identified 
associations have prompted and directed research into understanding their role in AS 
pathogenesis. Several of the resultant proposals will be discussed below. 
1.1.3 Involvement of the immune response 
The genetic signature of AS implicates cells of the immune system in the pathogenesis of 
disease, particularly CD4+ T cells and the dendritic cells (DCs) that activate them. The 
immune system orchestrates the host’s defence mechanisms directed towards invading 
pathogenic organisms, through the mobilisation of effector immune cells. Regulatory 
immune processes also prevent potentially damaging responses to self-antigen and 
harmless bacteria (commensals). The balance between immunity (pathogenic antigen) and 
tolerance (commensals/food) is essential for maintaining homeostasis. 
The immune system is comprised of two branches. The innate immune system 
encompasses cells and molecules that respond first. This rapid response functions to 
eradicate potentially harmful antigens and secretes molecules that initiate inflammation 
and cell recruitment. In contrast, the adaptive immune response comprises antigen-specific 
populations of T cells and B cells and is essential for the generation of long-lived 
immunological memory, on which vaccine efficacy relies. Failure to regulate these innate 
and adaptive responses may result in the development of chronic inflammation and 
autoimmune disease. An understanding of some of the components of the immune system 
is necessary before the pathogenesis of AS can be investigated.  
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1.2 T cells 
T cells are an effector immune population of the adaptive immune response. Specific T cell 
populations co-ordinate the defence mechanisms required to eradicate and protect against 
pathogens through the secretion of immunomodulatory hormones known as cytokines, 
through their ability to lyse infected cells, and by promoting the activation and 
differentiation of B cells. T cells also regulate the immune response, inhibiting aberrant 
immune responses against self-antigen and commensal bacteria.  
1.2.1 T cell populations 
T cells, which express the CD3 molecule, can be subdivided into two types dependent 
upon their expression of the glycoproteins CD4 and CD8. In addition, T cells can be 
further subdivided based on their expression of the T cell receptor (TcR) composed of 
either !", or #$ subunits. The majority of CD4+ and CD8+ T cells express TcR!" (52). 
TcRs are highly polymorphic and bind to a restricted set of major histocompatibility 
complex (MHC) molecules, complexed to short self- or pathogen-derived peptides, in 
addition to commensals, food antigen and allergens. During their development, cells each 
expressing their own unique TcR, are selected based on their capacity for binding MHC: 
peptide complexes in the thymus (53). Once selected, CD4+ T cells interact with MHC 
class II molecules, whilst CD8+ T cells interact with MHC class I expressing cells (53). 
Therefore, T cells exiting the thymus display a vast repertoire of antigen-specific TcRs 
able to mediate protection against a multitude of potential pathogens (54).  
Antigen-inexperienced T cells are known as naïve T cells. Naïve CD4+ T cells in humans 
express the molecules CD45RA, CD62L, CD27 and lack expression of CD45RO (55, 56). 
They recirculate throughout secondary lymphoid organs (SLOs), due to their expression of 
CD62L (57-59), until they are activated by an antigen-presenting cell (APC) expressing the 
correct MHC: peptide complex. This constant recirculation of T cells increases the 
probability that these specific T cell: APC interactions will occur. Following activation, 
CD4+ and CD8+ T cells differentiate into effector populations that participate in primary 
and secondary immune responses (immunological memory), becoming activated, 
regulatory and memory T cell populations. Activated CD4+ T cells in humans are 
identified predominantly through their expression of intermediate levels of the interleukin-
2 receptor (IL-2R), CD25 (60-63). Furthermore, CD25+ activated T cells upregulate 
CD45RO and lack expression of CD45RA (64). Activated cells, directed by their 
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interaction with the antigen-specific APC, home to the tissue from which the APC 
originated and execute their effector functions. Activated CD8+ T cells secrete granules 
that can lyse cells in a contact dependent manner. CD4+ T cells contribute to the immune 
response primarily through their secretion of immune-active soluble molecules, called 
cytokines. Through cytokine expression, they drive the activation of surrounding cells and 
cell recruitment. Furthermore, T cell: APC interactions result in the differentiation of 
specific CD4+ activated T cell phenotypes, which will be discussed in more detail below.  
Prevention of aberrant responses directed against self-antigen or commensal bacteria is 
partially achieved through the function of regulatory T cells (Tregs). During the process of 
thymic selection, natural Tregs (nTregs) are generated. These are identified through their 
expression of the transcription factor forkhead box P3 (FOXP3), high levels of CD25, 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), transforming growth factor " 
(TGF-"1) and tumour necrosis factor receptor 2 (TNFR2) (65-68). The suppressive 
functions of nTregs are mediated through secretion of immunomodulatory cytokines 
including TGF" and IL-10, in addition to contact dependent mechanisms potentially 
mediated by a combination of CTLA-4 and TGF-"1 (66, 67, 69). Peripheral naïve CD4+ T 
cells can also differentiate into Treg populations following APC interaction: inducible 
Tregs (iTregs) express CD4, CD25 and FOXP3 and are dependent upon TGF" for their 
development from naïve T cells in vivo (70). A subset of iTregs that exert their 
immunosuppressive functions through secretion of IL-10 are often referred to as Tr1 cells 
(71, 72). Overall Tregs, regardless of their site of induction or mode(s) of action, function 
to control and inhibit aberrant immune responses.  
Induction of the adaptive response is central to the development of immunological 
memory. Memory permits rapid, specific, improved adaptive responses towards previously 
encountered antigen. In humans, memory cells are identified by their expression of low 
levels of CD45RA and CD25, and high expression of CD45RO (73). Functionally distinct 
memory T cell populations can be differentiated based on their homing capabilities: central 
memory cells (TCM) express CCR7, enabling peripheral lymph node homing, whilst 
effector memory cells (TEM) are CCR7- permitting their migration to peripheral tissues 
(74, 75). TEM retain the ability to rapidly secrete effector cytokines following antigen 
exposure, whilst TCM are thought to differentiate into effector cells following 
restimulation (74, 75). Classification of human CD4+ T cell populations is depicted in 
Figure 1.3. 
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Figure 1.3: Human CD4+ T cell subsets 
Four populations of human CD4+ T cells exist in human blood. Recirculating CD4+ naïve T cells 
express CCR7, permitting entry into secondary lymphoid organs. Following APC stimulation, cells 
that upregulate CD25 and lose CD45RA can be subdivided into activated and regulatory (Treg) 
subsets. Regulatory T cells are further identified through their expression of FOXP3, CTLA-4 and 
TGF-!1. Following clearance of antigen, memory cells persist and upon re-stimulation induce a 
rapid, efficacious immune response. 
1.2.2 Effector CD4+ T cell phenotypes 
Following activation, naïve CD4+ T cells develop into effector cells (Fig. 1.4) that home to 
peripheral tissues or SLOs and contribute to the immune response. The immune system has 
evolved to respond to a vast array of potential pathogens, each requiring a different 
effector response. These include pathogenic bacteria and viruses, parasitic multicellular 
organisms, neoplastic cells, food antigens, and commensal bacteria. In 1986, Mossman and 
Coffman first described the differentiation of murine CD4+ helper T cell (Th) cells into 
populations with the ability to secrete different cytokines. These populations were called 
Th1 and Th2 (76). Equivalent human Th populations were identified in 1991 (77). 
Originally Th1 and Th2 populations were defined on the basis of their secretion of specific 
cytokines and their differential capacity to support specific types of B cell responses (76). 
The Th1 subset secretes interferon # (IFN#), IL-2 and granulocyte macrophage colony-
stimulating factor (GM-CSF) (77, 78). In contrast, Th2 cells produce IL-4, IL-3, IL-5 and 
IL-13 (76, 77, 79). Furthermore, Th1 cells are preferentially able to kill intracellular 
pathogens, whilst Th2 cells mediate expulsion of extracellular pathogens (80-82). Mature 
Th1 and Th2 cells have a distinct set of genes that transcriptionally regulate their 
phenotype and function. The majority of studies investigating Th differentiation were 
performed using mice, however human studies have confirmed many of these 
observations. Th1 differentiation requires upregulation of the transcription factors signal 
transducer and activator of transcription 4 (STAT4), STAT1 and T-box expressed in T 
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cells (T-bet) (83-85). Signalling through the TcR and IL-12R mediate activation of 
STAT4, and upregulate the IL-12R"2 on T cells, promoting induction of a Th1 phenotype 
(86-88). The primary sources of IL-12 in this setting are thought to be two types of APC: 
dendritic cells (DCs) and macrophages (89). In addition to IL-12, IL-27 and IFN# 
additionally promote the differentiation and proliferation of Th1 cells (90-93).  
A different form of transcriptional regulation is employed for the differentiation of Th2 
cells. STAT6, GATA binding protein 3 (GATA-3), c-Maf and nuclear factor of activated 
T-cells (NFAT) are the major transcription factors involved in promotion of the Th2 
phenotype (94-97). IL-4, the dominant cytokine inducer of Th2 cells inhibits the 
upregulation of IL-12R"2 on dividing CD4+ T cells, upregulates IL-4R! and activates the 
transcription factor STAT6 thereby promoting the differentiation of Th2 cells (92, 94, 98, 
99). The interaction between transcription factor STAT5 and IL-2 has been reported to 
promote a Th2 phenotype through regulation of IL-4 signalling (100). The source of IL-4 
within SLOs remains unclear, however mast cells, eosinophils, basophils and activated 
Th2 cells have all been shown capable of IL-4 production (101). In addition to their 
differential transcriptional and functional phenotypes, Th1 and Th2 cells actively inhibit 
the generation of the opposing subset. For example, secretion of IL-10 by Th2 cells 
inhibits the secretion of IL-12 by macrophages, thereby blocking Th1 differentiation (102). 
In contrast, IL-12 actively inhibits expression of GATA3 within dividing cells, 
consequently inhibiting the generation of the Th2 subset (98). Given the nature of these 
counter-regulatory processes, following naïve CD4+ T cell activation, the resulting mature 
Th1 or Th2 CD4+ populations secrete either IFN# (Th1) or IL-4 (Th2). 
More recently, several murine disease models highlighted a role for IL-17-secreting CD4+ 
T cells in disease pathogenesis (103-105). These observations led to the identification of a 
third CD4+ effector T cell subset designated Th17 cells (106). Th17 cells secrete IL-17A, 
IL-17F, IL-22, IL-6 and tumour necrosis factor ! (TNF!) and express the IL-23R (105, 
107). Differentiation of murine Th17 cells is dependent upon IL-6 and TGF" (108), 
although IL-1" may substitute for TGF" in humans (107, 109). The master transcriptional 
regulators of Th17 cells are ROR#t and STAT3 (109-111). IL-23 has been shown to 
promote the survival and not the differentiation of Th17 cells (112). Studies have found 
Th17 differentiation to be independent of STAT1, STAT4, STAT6 and T-bet (106). Th17 
cells are now considered to be an independent lineage of CD4+ effector T cell that may 
contribute to host defence against extracellular pathogens and/or autoimmune disease (113, 
114). Th17 and Th1 differentiation appear to be counter-regulatory. The Th1 associated 
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cytokine IFN# inhibits development of Th17 cells through downregulation of the IL-23R 
(106). Unlike Th1 and Th2 cells, the stability of Th17 cells in vivo is unclear. IL-17-
secreting CD4+ T cells under inflammatory conditions have been shown to acquire Th1 
attributes, including IFN# secretion (115-118). Furthermore, given that murine Th17 and 
Treg differentiation both involve the cytokine TGF", a reciprocal relationship between 
these opposing inflammatory and regulatory effector cells may exist. In the presence of 
inflammation, IL-6 may promote Th17 generation, whilst under steady-state conditions 
retinoic acid (RetA) has been shown to inhibit IL-6 production and the associated Th17 
induction (108, 119, 120). Overall, human Th17 cells represent a distinct lineage of CD4+ 
T cells, require ROR#t, IL-6 and IL-1" for their development and are thought to participate 
in immunogenic immune responses that may contribute to the development or perpetuation 
of inflammatory diseases. 
 
Figure 1.4: Human CD4+ T cell phenotypes 
Human CD4+ effector populations can be subdivided into five populations: Th1, Th2, Th9, Th17 
and Th22. Each population is defined by their cytokine secretion profile. This diagram describes 
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the functions of the individual populations and the molecules involved in their differentiation. 
Following the interaction between APCs and naïve CD4+ T cells in SLOs, under specific conditions 
Tregs can be generated in the periphery in order to control immune responses. Adapted from Jiang 
et al (121). DC = dendritic cell, TcR = T cell receptor. Transcription factors for each effector CD4+ T 
cell population are in bold. 
In recent years, two further CD4+ effector T cell subsets have been identified: Th9 and 
Th22 cells. Th9 cells were ascribed their name through their preferential secretion of IL-9, 
in addition to IL-10 (122, 123). They were generated in vitro in the presence of TGF" and 
IL-4 and were observed to promote chronic inflammation, despite their secretion of IL-10 
(122). The transcription factors PU-1 (124) and interferon regulatory factor 4 (IRF4) (125) 
regulate Th9 development. Th9 cells have been identified and are increased in the blood of 
allergic patients compared to healthy controls (126). This CD4+ effector population is 
thought to promote allergic and inflammatory responses whilst enhancing tumour killing 
(126, 127).  
Th22 cells, as their name suggests secrete IL-22. Th17 cells and NK cells also secrete IL-
22, however in contrast to the Th17 subset, Th22 cells do not secrete IL-17 (121, 128, 
129). The transcription factors involved in the generation of Th22 cells have yet to be 
determined, however Th22 cells have been generated in vitro through co-culture with a 
population of APC called plasmacytoid DCs (pDCs). Their development was dependent 
upon IL-6 and TNF! (130). This effector population may be involved in skin-associated 
immune responses (128-130). 
CD4+ T cells interact with B cells within SLOs facilitating their production of antibodies 
(131). This specific CD4+ T cell population, referred to as follicular T-helper cells (TFH) 
promote B cell activation and function and germinal centre formation (121). Tfh cells are 
thought to represent an independent CD4+ T cell lineage regulated by the transcription 
factor (TF) B-cell lymphoma 6 (Bcl-6) and the cytokines IL-6 and IL-21 (132, 133). Long-
term humoral immunity is thought to be dependent on this interaction between B and Tfh 
cells (121). 
The contribution of these CD4+ effector populations to AS pathogenesis will be discussed 
below. 
1.2.3 Cytokines 
Immunomodulatory hormones, cytokines or interleukins (IL) are small molecules secreted 
or expressed by numerous immune populations, often in response to specific stimuli (134). 
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Cytokines are composed either of a solitary polypeptide chain or dimeric polypeptides and 
perform their functions in an antigen non-specific manner (135). Cytokines are pleiotropic 
in their functional activities: cell activation and recruitment, alteration of barrier 
homeostasis, haematopoiesis, differentiation and function of immune populations. They 
also influence the generation of immunogenic and tolerogenic immune responses. 
Cytokines mediate the majority of their functions through engagement of their specific 
receptor. Depending on receptor expression, and on the particular function of the receptor-
expressing cells, these small molecules can act either in an autocrine, paracrine or 
endocrine manner. Currently, 36 interleukins have been described and are designated IL-1 
through to IL-36 (136, 137). Furthermore there are several additional cytokine families 
distinct from the interleukin nomenclature including the interferon (IFN) and TNF receptor 
families (135). Cytokines can be categorised on the basis of their structure, class of binding 
receptor, function and source. To provide context for their potential role in AS 
development, I have categorised several cytokines according to their role in the immune 
system (Table 1.1). Given their functional promiscuity, several cytokines belong to 
multiple categories. For example, IL-6 and IL-1" are involved in the recruitment and 
activation of immune populations, and therefore contribute to the inflammatory response. 
Murine and human studies have also identified a requirement for IL-6 in the differentiation 
of Th17 cells (108, 138), and IL-1" drives the differentiation of human Th17 cells (109). 
Numerous cytokines that contribute to inflammation and AS pathogenesis, in the context 
of this study, are described in Table 1.1. 
Table 1.1: Classification of inflammatory and T cell associated cytokines and growth factors 
Cytokines were subdivided according to their involvement in inflammation, T cell differentiation or 
function, and cell development (growth factors). The predominant sources and functions of the 
listed cytokines are provided. Th1 – T helper 1 cell, Th2 = T helper 2 cell, Th17 = T helper 17 cell, 
Treg = regulatory T cell, DCs = dendritic cells, TNF" = tumour necrosis factor ", GM-CSF = 
granulocyte macrophage-colony stimulating factor, Flt3L = FMS-like tyrosine kinase 3 ligand. 
Classification Cytokine Source Function Reference 
Inflammation IL-1! 
 
 
Monocytes Th17 
differentiation, cell 
proliferation and 
inflammation  
(109, 139) 
 IL-6 Monocytes, 
Fibroblasts, 
Endothelial cells 
Cell activation and 
recruitment, Th17 
differentiation 
(109, 140) 
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 TNF" Macrophages, 
Monocytes, 
Neutrophils, T 
cells, NK cells 
Inflammation, cell 
activation and 
recruitment 
(141) 
T cells  IL-4 Th2, Basophils, 
Neutrophils, 
Eosinophils 
Th2 differentiation, 
Ab production, 
inflammation 
(99, 142) 
 IL-5 
 
Th2, Mast cells B cell and 
Eosinophil function 
(77, 143) 
 IL-10 Treg, 
Monocytes, Th2 
Inhibit immune 
responses, immune 
cell differentiation 
(144) 
 IL-12 Macrophages, 
DCs 
Th1 differentiation, 
cytokine induction, 
growth factor 
(145) 
 IL-13 Th2, CD8+ T 
cells 
Inflammation, Ab 
switching, Allergy 
(146) 
 IL-17A Th17 CD4+ T 
cells 
Cell activation, 
Cytokine induction 
(147) 
 IL-17F Th17 CD4+ T 
cells 
Inflammation, 
Cytokine induction 
(148) 
 IL-22 Th17, Th22 Tissue repair, Anti-
microbial defence 
(149) 
 IL-23 Macrophages, 
DCs 
Th17 survival and 
differentiation 
(150) 
 IFN$ 
 
T cells, NK cells Viral infections, cell 
recruitment, 
immune cell 
function 
(151) 
 TGF! Macrophages, T 
cells, B cells, 
endothelial 
cells, 
keratinocytes, 
chondrocytes 
Treg differentiation, 
inflammation, 
wound repair, cell 
function 
(152) 
Growth 
Factors 
GM-CSF T cells, 
Macrophages 
Myeloid cell 
development, 
Inflammation 
(153) 
 Flt3L T cells Haematopoiesis, 
DC development 
(154, 155) 
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1.2.4 Chemokines and their receptors 
Chemokines are another form of immunomodulatory hormone that direct leukocyte 
migration, a process known as chemotaxis. Similar to cytokines, chemokines are small 
molecules that exert their functions through binding to cell surface receptors. Four 
chemokine families have been described. They are classified by structural differences 
relating to the location of the first two cysteine residues, forming CC, CXC, XC and CX3C 
families (156). The first chemokine to be described was designated IL-8, now known as 
CXCL8 (156, 157). In 2006, 46 human chemokines and 18 interacting receptors had been 
identified (158). The discrepancy between the number of chemokines and the chemokine 
receptors highlights the redundancy and promiscuity within the chemokine system (Fig. 
1.5) (159).  
 
Figure 1.5: Human chemokine receptor promiscuity 
Diagram depicting chemokine ligand and receptor promiscuity. Receptor: ligand partnerships are 
classified as either homeostatic or inflammatory. In certain circumstances, the function of the 
ligands may be both homeostatic and inflammatory; these are classed as having dual function. 
Chemokines are depicted only by their number: for example, CCR7 binds to CCL19 and CCL21. 
The name of the receptor indicates the class of both receptor and ligand. Chemokines in red have 
unique binding capacity to the specific receptor. Chemokines in black bind multiple receptors. 
Diagram adapted from Zlotnik et al, 2006 and Moser et al, 2001 (158, 160). 
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In addition to their structural categorisation, chemokines can be classified as either 
homeostatic or inflammatory (160-162). Homeostatic chemokines, including CCL19 
(ELC) and CCL21 (SLC) are expressed locally within SLOs or peripheral tissue. Their 
primary functions are to organise lymphoid structures to facilitate the adaptive immune 
response and, under steady state conditions, recruit immune populations to peripheral 
tissues to maintain homeostasis (160, 161). In contrast, inflammatory chemokines, 
including CCL5 (RANTES) and CCL3 (MIP-1!), permit and direct migration of cells 
towards sites of inflammation, allowing their participation in the ongoing immune 
response (160). Cells actively migrate in response to engagement of chemokine with 
specific receptors on their surface. These seven transmembrane G-protein coupled 
receptors (GPCRs) activate numerous signalling pathways, resulting in directional cell 
migration. GPCRs are composed of an extracellular N-terminus, permitting chemokine 
binding, and an intracellular C-terminus, providing a platform for the intracellular 
signalling molecules (163-165). Following binding, chemokines induce activation of the 
receptor-associated G proteins, phosphatidylinositol-4, 5-bisphosphate (PIP2) and the 
subsequent signalling pathways including phosphatidylinositol-3 kinase (PI3K), Rho and 
Ras family members and the mitogen activated protein kinase (MAPK) pathway (166, 
167). GPCR signalling can be prevented by the administration of Bordetella pertussis 
toxin. Use of this technique has demonstrated the involvement of the Gi family of G 
proteins in chemokine signalling (168, 169). Phosphorylation of these signalling molecules 
induces activation of STAT transcription factors and mediates cell migration (166). In 
addition to activation of the JAK/STAT pathway, intracellular calcium levels are increased 
causing protein kinase C activation mediating signal transduction (168). Proteins of the 
Rho and Ras family, activated following chemokine binding, enable changes to cell 
structure allowing active migration (168, 170). Chemokine receptor nomenclature (CC, 
CXC, XC and CX3C) is identical to that described for chemokines (156). The relationship 
between chemokines and their receptors and the redundancy of the chemokine system is 
depicted in Fig 1.5. 
The chemokine receptor profile of immune populations often referred to as an “address 
code”, influences migration to a particular tissue destination. For example, CCR10 
expression mediates homeostatic migration to the small intestine (171, 172), whilst CCR4 
is required for migration to the skin under steady state and inflammatory conditions (173-
175). Within Peyer’s patches (PPs), CCR6 is required for migration of DCs to the 
subepithelial dome, necessary for efficient capture of intestinal antigen (176). A murine 
study by Wurbel et al, reported an increased susceptibility to the induction of intestinal 
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inflammation in CCR9 knock-out (KO) mice compared to wild-type (WT) controls (177). 
Thus, the chemokine receptor profile of immune populations mediates their migration to 
and within specific SLOs and peripheral tissue, and is required for the effective generation 
and control of immune responses. The relationship between chemokine receptors, their 
expression, tissue migration, function, and association with the specific T cell phenotypes 
described in section 1.2.2 is presented in Table 1.2. 
Table 1.2: Chemokine function 
Expression of homeostatic and T cell phenotype-associated chemokine receptors (158, 160, 178). 
Sites of migration or chemokine: chemokine receptor interactions are provided. SLOs = secondary 
lymphoid organs, BM = bone marrow and TFH = follicular T helper cells. 
Receptor Expression Tissue T cell phenotype 
CCR4 T cells Thymus, Skin, SLOs Th1, Th2, Treg 
CCR6 T cells, B cells Intestine, Skin, SLOs Th17, Treg 
CCR7 T cells, Thymocytes Thymus, SLOs  
CCR9 T cells, B cells, 
Thymocytes 
Small Intestine, 
Thymus 
 
CCR10 T cells Intestine, Skin  
CXCR3 T cells Inflamed tissue Th1 
CXCR4 T cells, B cells, 
Thymocytes 
BM, SLOs, peripheral 
tissue 
 
CXCR5 TFH, B cells SLOs TFH 
CXCR7 Hematopoietic cells Thymus, SLOs, 
peripheral tissue 
 
XCR1 CD141+ DCs   
 
As depicted in Table 1.2, several chemokine receptors are expressed by specific T cell 
phenotypes. For instance, CXCR5 expression by TFH is required for effective B cell 
stimulation and antibody production (179). Expression of this chemokine receptor 
mediates trafficking of TFH cells to the B cell follicle (179). The T cell associated 
chemokine receptors can be used for the identification of effector populations. For 
example, CCR6 expression is reported to be restricted to the Th17 CD4+ effector 
population (180, 181) whilst CXCR3 is commonly associated with the Th1 phenotype 
(182, 183). Expression of CCR3, CCR4 and CCR8 are frequently associated with Th2 cells 
(160, 182, 183). However, whether these phenotype-associated chemokine receptors are 
required for T cell function, similar to CXCR5 and TFH cells, remains unclear. Overall, the 
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chemokine receptor profile of immune populations can infer migration patterns, cell 
phenotype and subsequent function. 
1.3 Dendritic cells 
1.3.1 What is a dendritic cell? 
Dendritic cells (DCs) are haematopoietic cells of the myeloid lineage that reside in 
peripheral tissues and SLOs. Langerhans cells (LCs), a skin-resident DC population, were 
first described by Paul Langerhans in 1868 (184). However, it was not until the 1970s that 
seminal papers by Steinman et al further characterised this tissue resident population (185, 
186). The morphological appearance of this myeloid population contributed to their 
classification as DCs; they constantly protract and retract pseudopods or “dendrites” (185). 
DCs are highly proficient in their ability to stimulate T cell proliferation and have been 
described as the principal APCs of the immune system (186). Given their location at sites 
of environmental exposure to antigens and immune response induction (SLOs), and their 
ability to prime the adaptive immune system, DCs represent a significant link between the 
innate and adaptive branches of the immune system. Broadly speaking, DCs are the 
primary migratory subset responsible for communicating signals from the peripheral 
environment to SLOs where they direct lymphocyte differentiation. Consequently, DCs are 
involved in maintaining immune homeostasis through regulation of immunity and 
tolerance. Under steady state conditions, immature DCs sample their environment and 
actively acquire antigen. DCs are unique in their ability to migrate from peripheral tissue to 
SLOs via afferent lymphatics, unlike macrophages that also belong to the myeloid lineage 
(187, 188). Following entry to SLOs they form complex interactions with antigen-specific 
T cells and direct their differentiation. During migration and in the absence of 
inflammatory stimuli, DCs adopt a semi-mature phenotype and are able to induce 
differentiation of Tregs and consequently promote tolerogenic responses (189-192). 
Paradoxically, DCs are also essential for the induction of protective immunogenic 
responses directed against pathogenic organisms. Consequently, in the presence of 
inflammatory stimuli, migrating DCs upregulate co-stimulatory and major 
histocompatibility (MHC) molecules, allowing efficient antigen presentation and induction 
of active immunity against pathogenic organisms (184). Overall, DCs represent the bridge 
between innate and adaptive immunity and are specialised in their ability to influence 
immune response induction.  
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In mice and men, DCs can be subdivided into two fundamental populations: conventional 
DCs (cDCs) and plasmacytoid DCs (pDCs). cDCs are the prototypic DC in terms of 
morphology, function and location as described above. pDCs, as will be discussed in 
greater depth below, may appear morphologically similar to cells of the lymphoid lineage 
(193). Among DCs, pDCs are unique in their ability to secrete high concentrations of type 
I IFNs in response to viruses (194). pDCs are classified as a subset of DC based on their 
ability to stimulate proliferation of naïve T cells, the hallmark function of DCs (195). 
To date, three human DC-related syndromes have been reported. Dendritic cell, monocyte, 
B and NK lymphoid deficiency syndrome (DCML), caused by a mutation of the GATA-
binding factor 2 results in the complete eradication of blood DCs, tissue cDCs, monocytes, 
B cells, NK cells, and myeloid and lymphoid progenitors. DCML patients suffer from 
severe bacterial and viral infections and develop distinct forms of cancer (196, 197). 
Mutations of the IRF8 gene lead to an increase in circulating granulocytes, accompanied 
by a reduction in blood monocytes and DCs, dermal DCs and reduced IL-12 production 
(198). Again, these patients suffer from severe bacterial and viral infections (198). The 
final DC syndrome involves a mutation of a phosphotransferase involved in nucleotide 
homeostasis called adenylate kinase 2 (AK2) (199). These patients develop a form of 
severe combined immunodeficiency (SCID): reticular dysgenesis (199). Weakened 
development of nucleated cells is characteristic of this disorder, and Emile et al have 
recently found Langerhans cells to be deficient in AK2 patients (199). 
Understanding the roles of DCs in human immunity is complicated by several factors: 
tissue localisation affects functional specialisation; DCs and macrophages are often 
misidentified; there are difficulties associated with obtaining human tissues; and the 
numbers of recovered cells are often low. In addition, DCs in tissues have become 
specialised, leading to the generation of numerous DC subpopulations. I will compare 
human, rat and mouse DC populations to allow comparisons between animal and human 
studies that may contribute to the understanding of AS pathogenesis. 
1.3.2 Human myeloid cell classification 
1.3.2.1 DCs 
Identification of human peripheral DC populations has been hindered due to the difficulties 
faced in obtaining human tissues and sufficient numbers of cells. Consequently the 
majority of human DC profiling has been performed on mature circulating blood 
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populations. These DCs account for approximately 1% of blood leukocytes (200). Initial 
phenotypic analyses of human DCs relied on their high expression of MHC II and CD11c, 
their lack of several lineage markers including CD3 and CD19, and their ability to prime 
naïve T cells (186, 200, 201). While the use of several additional human DC markers has 
permitted further characterisation of human DC subsets (200, 202, 203), precise 
identification of human DCs still requires use of multiple surface markers.  
There are two main populations of human DCs (202): pDCs and cDCs. pDCs were 
identified by their CD123+ CD45RA+ CD68hi MHC II+ CD11c- phenotype (202, 204, 205).  
When immature, pDCs have a distinctive lymphoid-like morphology; they are circular 
with large nuclei (204). Upon activation these cells develop processes and adopt the typical 
“dendritic” DC morphology (202, 204). Survival, activation and maturation of pDCs, 
which is IL-3 dependent, facilitates their ability to prime naive T cells (202).  
A surface phenotype of CD123- CD45RO+ CD11chi MHC II+ CD68lo was initially used to 
identify cDCs. Unlike pDCs, they mature in the absence of external growth factors (202, 
204, 205). Many investigators have since shown that human cDCs can be further 
subdivided into at least 2 populations, based on the expression of surface antigens: BDCA-
1 (CD1c)+, and BDCA-3 (CD141)+ DCs (200, 202, 203, 206).  
1.3.2.2 Blood CD1c+ DCs 
CD1c+ DCs, which express the BDCA-1 antigen, belong to the myeloid lineage. They 
express the myeloid specific markers CD13 and CD33 (202, 207). As CD1c+ DCs 
represent approximately 0.6% of human peripheral blood mononuclear cells (PBMCs) 
(208), they are the dominant circulating DC population in humans. Furthermore, it has 
been reported that blood CD1c+ DCs account for approximately 20-50% of total CD11c+ 
cells (209). CD1c+ DCs express greater levels of the DC-specific intracellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN), IL-1R and Langerin compared to CD141+ 
DCs (210). CD1c+ DCs express a variety of Toll-like receptors (TLRs) including TLRs 1-
4, 6-8 and 10 that are involved in pathogen recognition (200, 210, 211).  
1.3.2.3 Blood CD141+ DCs 
Similar to the CD1c+ population, CD141+ (BDCA-3) DCs belong to the myeloid lineage 
and express the myeloid lineage specific markers CD13, CD33 and CD11c (207). They 
represent an extremely small proportion of human blood leukocytes, comprising 0.03-
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0.05% of PBMCs (200, 203, 207). Consequently, CD141+ DCs account for 3% of the 
circulating cDC pool (212). This small DC population has been shown to preferentially 
express TLR3 and TLR 10 (210, 213) but also express numerous other TLRs including 
TLR 1, 2, 6 and 8 (200, 210). Further surface phenotypic characterisation identified that 
nectin-like molecule 2 (Necl2), C-type lectin domain family 9, member A (CLEC9A) and 
XCR1 are uniquely expressed by this DC subset (212, 214, 215).  
1.3.2.4 Blood pDCs 
Blood pDCs lack the myeloid specific linage markers CD11c, CD13 and CD33 (195, 216). 
Furthermore, they lack expression of molecules associated with lymphocytes, monocytes 
and granulocytes (CD3, CD14, CD15, CD19 and CD56). They can however be identified 
through their unique expression of CD303 (BDCA-2), CD304 (BDCA-4), CD123 (IL-
3R!) and CD45RA (202, 217). pDCs are the second largest DC population in blood, 
representing approximately 0.3% of total PBMCs (217). In contrast to other human DCs, 
they have been shown to express a “pre-T-cell receptor alpha chain” commonly associated 
with lymphocytes (193, 208, 218). pDCs express a unique TLR panel, including high 
levels of the intracellular TLRs 7 and 9, highlighting their involvement in anti-viral 
defence (210, 219). Human CD303+ pDCs additionally express Immunoglobulin-like 
transcript 7 (ILT7) (220, 221). They predominantly reside within blood and lymphoid 
tissues and enter lymph nodes via the blood circulation (222). 
1.3.2.5 Monocytes 
Monocytes are a relatively large myeloid circulating blood leukocyte population (10%) 
(223, 224). Monocytes give rise to resident intestinal macrophages (225) and in animal and 
human studies have been reported to develop into DCs under inflammatory conditions 
(226-230). However the contribution of monocytes to intestinal DCs under steady state and 
inflammatory conditions has recently been disputed (225). In humans, 90% of human 
monocytes express CD11c and MHC II (207, 231). Previously, monocytes have been 
defined based on the expression of CD16 and CD64 (232), and divided into CD16+ CD64+, 
CD16+ CD64-, CD16- CD64+, and CD16- CD64- populations. In some analyses, CD64 was 
not used in monocyte subset identification. (233). However, without addition of anti-CD64 
it is not possible to distinguish CD64+ macrophages from CD64- DCs (234). Recent studies 
have used CD14 and CD16 to identify three populations of human blood monocytes: 
CD14+ CD16- (235), CD14+ CD16+ (236) and CD14- CD16+ subsets (237). The CD14- 
CD16+ population will be discussed separately below. CD14+ CD16- “classical” 
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monocytes account for approximately 85% of circulating monocytes, whilst CD14+ CD16+ 
monocytes are the smallest population (5%) (237). There are several surface phenotypic 
differences between these monocytic populations: CD14+ CD16- monocytes express 
CD11c, MHC II, CCR2, CD62L, and low levels of CX3CR1 whilst CD14+ CD16+ 
monocytes express CD11c, MHC II, CX3CR1, lymphocyte function-associated antigen 1 
(LFA-1) and lack expression of CCR2 and CD62L (Table 1.3) (238).  
1.3.2.6 CD16+ mononuclear cells 
The CD14- CD16+ human mononuclear population represents approximately 7% of blood 
monocytes (237). Classification of these cells as a monocytic population remains 
controversial. A proportion of the MHC II+ CD11c+ CD14- CD16+ cells express 6-sulpho 
LacNAc (SLAN), historically termed M-DC8+ cells due to the specific binding of the M-
DC8 monoclonal antibody (239, 240). SLAN is a carbohydrate modification of the P 
selectin ligand, P selectin glycoprotein ligand 1 (PSGL-1) (239). PSGL-1 binds to P 
selectin on endothelial cells and platelets and mediates cell rolling and adhesion (241-243). 
These original studies classified this SLAN+ subset as a third blood DC subset based on 
their morphology, ability to present antigen and subsequently activate naïve T cells and 
induction of antigen-specific cytotoxic lymphocyte (CTL) responses (240). However 
several groups report that regardless of SLAN expression, CD14- CD16+ mononuclear 
cells represent a third monocytic population, involved in the surveillance of blood vessels 
and absent from peripheral tissues under steady state conditions (229, 237, 244). The 
functions of these SLAN+ and SLAN- populations will be discussed in greater detail 
below. Regardless of their classification, CD14- CD16+ mononuclear cells are smaller and 
of lower granularity than both CD14+ monocyte populations (237). They lack expression 
of the cutaneous lymphocyte antigen (CLA), expressed on all other DC subsets, and 
express low levels of the myeloid marker CD33 (209, 237). Furthermore, it has been 
reported that CD14- CD16+ mononuclear cells express lower levels of both CD11b and 
CD163, surface molecules identifying cells belonging to the myeloid and 
macrophage/monocyte lineages respectively (237, 245). 
Both CD14+ CD16+ monocytes and CD14- CD16+ mononuclear cells have higher levels of 
CX3CR1 expression then CD14+ CD16- monocytes (237). Murine monocytes can be 
subdivided into two populations on the basis of CX3CR1 expression, a chemokine receptor 
for the membrane-bound ligand fractalkine (229). CX3CR1 is expressed on cells 
committed to the myeloid lineage, including macrophages and some DCs (229, 246, 247). 
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Based on surface phenotypic markers and functional analysis, Ly6C+ CX3CR1lo and Ly6C- 
CX3CR1hi murine monocytes are thought to be equivalent to the human CD14+ CD16- and 
CD14- CD16+ populations respectively (229, 237, 248). However, given that the CD14- 
CD16+ population is heterogeneous, containing SLAN- and SLAN+ cells, the true 
classification of this population remains highly contentious (237, 239).  
CD14- CD16+ mononuclear cells circulate through blood vessels (237). However SLAN+ 
cells, a subset of this mononuclear population, have been reported to reside within healthy 
human skin (249, 250). Furthermore, SLAN+ cells are present in inflamed tissues including 
tonsil, skin, Peyer’s patches (PPs) and CD ileal mucosa (249-252).  
Circulating CD14- CD16+ mononuclear cells and both putative CD14+ monocyte 
populations express TLRs 1, 2 and 4-9, although the former population expressed lowest 
levels of TLR 5 and TLR 7 (237). Furthermore, each population differs in their expression 
of multiple chemokine, scavenger and cytokine receptors (Table 1.3). In addition, CD14- 
CD16+ mononuclear cells have been reported to express receptors for C5a and C3a, 
complement mediators (239).  
Table 1.3: Surface receptor expression of monocytes and CD14- CD16- mononuclear cells 
Differential expression of chemokine, scavenger and cytokine receptors by CD14+ CD16- and 
CD14+ CD16+ monocytes, and CD14- CD16+ mononuclear cells. 
Population Chemokine 
Receptors 
Scavenger 
receptors 
Cytokine Receptors 
CD14+ CD16- CX3CR1lo, 
CCR1hi, CCR2hi, 
CCR3+, CCR5hi, 
CCR9lo, CXCR4hi 
CD68+, CD209+, 
CD36hi, CD163hi, 
CXCL16lo 
IFN$R1+, IFN$R2+, 
IL-2R$lo, IL-6R+, IL-
10R"lo, IL-12R!1lo, 
IL-17R"hi 
CD14+ CD16+ CX3CR1int, 
CCR1hi, CCR2lo, 
CCR3+, CCR5hi, 
CCR9lo, CXCR4lo 
CD68+, CD209+, 
CD36int, CD163lo, 
CXCL16lo 
IFN$R1+, IFN$R2+, 
IL-2R$hi, IL-6R+, IL-
10R"hi, IL-12R!1hi, 
IL-17R"int 
CD14- CD16+ CX3CR1hi, 
CCR1int, CCR2-, 
CCR3+, CCR5lo, 
CCR9lo, CXCR4lo 
CD68+, CD209+, 
CD36lo, CD163-, 
CXCL16hi 
IFN$R1+, IFN$R2+, 
IL-2R$hi, IL-6R+, IL-
10R"hi, IL-12R!1hi, 
IL-17R"int 
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Overall, human blood contains two populations of bona fide monocytes: CD14+ CD16- and 
CD14+ CD16+ subsets, and a CD14- CD16+ mononuclear population. Approximately 50% 
of the CD14- CD16+ cells express SLAN, resulting in a degree of dubiety relating to the 
classification of this population, which represents either a third blood DC or a third blood 
monocyte population. 
A summary of the surface marker expression and location of CD1c+ and CD141+ cDCs, 
pDCs and CD14- CD16+ mononuclear cells is provided in Table 1.4. 
Table 1.4: Human DC classification 
Cell surface antigen expression on CD1c+ and CD141+ cDCs, CD303+ pDCs and CD16+ 
mononuclear cells. 
Cell population Surface Phenotype Location 
CD1c (BDCA-1+) MHC Class II 
CD11c 
CD1c (BDCA-1) 
CD13 
CD33 
DC-SIGN 
IL-1R 
LANGERIN 
CD4 
CD45RO 
CLA 
CD2 
DEC-205lo 
CD62L 
CD11b 
 
Blood, lymphoid and 
peripheral tissue. 
pDC (BDCA-2/4+) MHC Class II 
CD123 
CD303 (BDCA-2) 
CD304 (BDCA-4) 
CD45RA 
ILT7 
CD68 
CD4 
CLA 
DEC-205int 
CD62L 
 
Blood and lymphoid 
tissue. Rare pDCs found 
in peripheral tissue. 
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CD141 (BDCA-3+) MHC Class II 
CD11c 
CD141 (BDCA-3) 
CD13 
CD33 
CLEC9A 
XCR1 
CD4 
CD45RO 
CLA 
Necl2 
DEC-205hi 
CD62L 
CD11blo 
Blood, lymphoid and 
peripheral tissue. 
CD14- CD16+ MHC Class II 
CD11c 
CD14 
SLAN+/- 
CD33 
CD4 
CD16 
CD62L- 
CX3CR1hi 
CD163- 
CD11blo 
CD36lo 
CCR2- 
Mainly found in blood. 
SLAN+ cells in skin 
inflamed tonsil, PPs, and 
ileal mucosa. 
 
1.3.2.7 Lymphoid tissue DCs 
Human DCs were first identified in the kidney as MHC II+ interstitial cells (253). 
Following this discovery, DCs were subsequently identified in several lymphoid and non-
lymphoid organs. Splenic DCs have been shown to reside within the subcapsular zone, T 
cell areas, marginal zone and B cell follicles (254, 255). Poulin et al have described 3 
human splenic DC subsets: CLEC9A- CD141- CD303- equivalent to the CD1c+ population, 
CLEC9A- CD141int CD303+ pDCs and a CLEC9A+ CD141+ DC subset (203). Even though 
equivalent blood DC populations exist, the splenic DC populations are present at a higher 
frequency, with cDCs and pDCs representing 1% and 0.1% of total splenic cells 
respectively (254). The majority of splenic DCs express CD11c and HLA-DR and are 
reportedly immature given their lack of CD83 expression (254, 255).  
pDCs (CD1a- CD3- CD4+ CD8- CD123+) are the major thymic DC population and undergo 
maturation upon CD40 and IL-3 stimulation (208, 256-260). The surface phenotype of 
thymic pDCs is similar to that of the equivalent blood population; CD45RA+ CD13lo 
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CD33lo (258). In contrast, a subset of thymic pDCs expressed CD2, CD5 and CD7 (261, 
262). Despite representing the minor DC population, HLA-DR+ CD11c+ myeloid thymic 
DCs have been identified and can be subdivided based on their CD11b expression (259, 
260). Thymic DCs were identified within both the cortex and medulla regions, with a 
significant proportion of DCs residing at the cortico-medullary junction indicating 
potential involvement in negative selection (259, 260).  
Before widespread use of the newly identified DC specific antigens by Dzionek et al (202), 
five populations of tonsil resident DCs were identified according to their expression of 
HLA-DR, CD11c, CD13 and CD123 (263): HLA-DRhi CD11c+ CD83+; HLA-DRint 
CD11c+ CD13lo CD45RA+ CD2+; HLA-DRint CD11c+ CD13hi CD45RA- CD2-; HLA-DRint 
CD11c CD123-; and HLA-DRint CD11c- CD123+ populations. However the functions of 
these DC populations were not assessed, preventing confirmation that these populations 
each represent bona fide DCs. More recently, using more up-to-date human DC markers, a 
recent publication by Segura et al identified and functionally characterised CD141+, CD1c+ 
and pDC thymic resident DC populations (264). 
Again, using up-to-date human DC markers, several lymph node (LN) DCs have been 
identified. These LN DC populations will consist of recently arrived migratory 
populations, alongside resident LN populations. Comparison of skin-draining LNs with 
tonsil-resident DCs enabled identification of several populations of skin-migrating DC 
populations: Langerhans DCs (HLA-DR+ CD11c+ CD1a- CD206-), CD1a+ DCs (HLA-DR+ 
CD11c+ CD1a+ CD206+) and a CD206/CD209 expressing DC population (265). LN-
resident DCs were similar to blood DCs: pDCs, CD141+, and CD1c+ cDCs (265). As in the 
thymus pDCs were the dominant LN DC subset, with CD1c+ DCs being the dominant 
myeloid DC population (265). LN resident DCs expressed low levels of CD83 indicating 
immaturity (265).  
From these data we can infer that tissue equivalents of blood CD141+ and CD1c+ cDCs 
and CD303+ CD304+ pDCs exist in several human lymphoid tissues, including the thymus 
and spleen.  
1.3.2.8 Non-lymphoid tissue DCs 
Langerhans cells (LCs - MHC II+ CD11c+ CD207+ CCR6+) and dermal DCs (MHC II+ 
CD11c+ CD1c+ CCR2+ DC-SIGN+) were initially described as the two cDC populations 
residing in human skin (266, 267). However, it is now clear that dermal DCs can be 
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divided based on their expression of CD14 and CD1a (266-268). Human pDCs (BDCA-2+ 
DC-SIGN+) have been identified in healthy human dermis. However, in contrast to the 
thymus, pDCs are a minor skin resident DC population (269).  
The intestine, exposed to the greatest antigenic load, has been shown to contain CD1c+ and 
CD141+ DCs; both populations lack CD1a expression (270). A recent study by Dillon et al 
identified HLA-DR+ CD11c+ CD1c+ DCs in human colonic and small intestinal tissue 
(271). CD1c+ DCs represent a larger leukocyte population in the lamina propria (LP) 
compared to peripheral blood (271). Furthermore, LP CD1c+ DCs possessed a more 
activated phenotype compared to their blood counterparts through elevated levels of CD86, 
CD83, CD40 and HLA-DR expression (271). Another report has identified CD141+ DCs 
in human PPs, MLN and LP (272). Several studies have reported an absence of pDCs from 
colonic mucosa (270, 271, 273). To align with murine studies, discussed below, CD103+ 
and CD103- DC subsets have been identified in human mesenteric LNs (MLNs) and 
intestinal tissue (274-276). Furthermore, CD103+ DCs could be subdivided based on the 
expression of CD141 and signal-regulatory protein ! (SIRP!). Two populations were 
observed: CD141- SIRP!hi, and CD141+ SIRP!lo/- (275). 
Lung CD1c+ and CD141+ cDCs have recently been characterised: HLA-DR+ CD11c+ 
CD1c+ CD11b+ CX3CR1+ SIRP!- and HLA-DRlo CD11clo CD141+ CD11b- CX3CR1- 
SIRP!- (277). Interestingly, CD141+ lung DCs appear to represent a larger proportion of 
DCs compared to their blood counterparts (277). Similar populations have additionally 
been identified in the kidney through the use of humanised mice (272). However, these 
studies suggest that lung DC populations lack CD103 expression (272). Immature pDCs 
(HLA-DR+ CD123+) have been identified in human lung (278).  
As in lymphoid tissues, CD141+ and CD1c+ DC populations can be identified in several 
non-lymphoid tissues including the skin, intestine and lung. However, in contrast to 
lymphoid tissue and blood, pDCs represent a minor DC population in non-lymphoid tissue. 
1.3.3 DC development 
1.3.3.1 cDCs 
cDCs are hematopoietic cells belonging to the myeloid lineage. Under steady state 
conditions they are continuously replaced by BM derived precursors. Monocytes have 
been shown not to be the precursors for steady state DCs as was originally thought, at least 
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within the intestine (225, 230, 279). cDCs have a relatively short life span, in contrast to 
pDCs (279, 280). The majority of work on DC development has come from murine 
studies, however some human data has been reported (222, 281, 282). Hematopoietic stem 
cells (HSCs) in the BM have the potential to develop into progenitors for both the myeloid 
or lymphoid lineages, the common myeloid progenitor (CMP) and the common lymphoid 
progenitor (CLP) respectively (222, 283). CMPs represent the first stage in myeloid 
lineage commitment. CD34+ CD38+ IL-3R!lo CD45RA- cells that lack numerous lineage 
markers are suggested to represent human CMPs (281). Following commitment to the 
CMP stage, Flt3L and colony stimulating factor 1 (Csf-1), also known as macrophage 
colony-stimulating factor (M-CSF), are involved in the differentiation of the CMP to the 
macrophage DC progenitor (MDP) (222, 284, 285).  The MDP can give rise to either 
monocytes that exit the BM and enter the circulation or to the common DC progenitor 
(CDP) (222). The transition from MDP to CDP is dependent upon Flt3L, STAT3 and PU.1 
(222), with the CDP now being restricted to the subsequent development of DCs, both 
cDCs and pDCs (286, 287). Under the influence of Flt3L and the transcription factor PU.1, 
CDPs differentiate into pre-cDC that exit the BM, circulate in blood and seed lymphoid 
and peripheral tissues, where they develop in situ into mature cDC populations (222, 288). 
Macrophages and pDCs do not develop from pre-cDCs in vivo (230, 289). Based on this 
linear commitment model, HSCs give rise to CMPs that subsequently become limited in 
their potential for cell development through their differentiation into MDPs and 
subsequently CDPs. CDPs have the ability to generate pDCs and cDCs, controlled by 
specific transcription factors and cytokines. Pre-cDCs represent the final progenitor in the 
differentiation of HSCs to cDCs. However, Ishikawa et al. report that human CMPs and 
CLPs can give rise to identical populations of DC, although CLPs may be less efficient 
than CMPs (290). In addition to circulating cDC precursors that seed tissues and 
differentiate in situ (288), circulating mature DC populations exist in human blood (209). 
The precise role of these circulating blood DCs in the immune response remains 
undetermined. 
1.3.3.2 pDCs 
The precise development pathway of human pDCs remains undetermined. pDCs were 
originally thought to develop from lymphoid precursors egressing the BM, due to their 
lack of expression of myeloid cell antigens including CD33 and CD11c (205). To support 
their lymphoid origin, genetic defects of the lymphoid exclusive transcription factor Spi-B 
have been reported to inhibit pDC development, whilst cDCs remained unaffected (291, 
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292). Furthermore, pre-TcR! and %5, markers of immature lymphocytes, are expressed on 
the surface of murine pDCs (293). In the mid 2000s, it was shown that human pDCs could 
be generated from both CLPs and CMPs. However pDCs, like cDCs, showed a tendency to 
be generated through CMPs (282). Development of human and murine pDCs has been 
shown to be augmented by Flt3L, as was described for cDCs (294-296). Subsequent 
identification of the conserved pDC specific TF E2-2 indicates a distinct developmental 
pathway from cDCs (297). This pDC specific TF is involved in the regulation of Spi-B, 
CD303, IL-7 and IRF7 (297). The current consensus regarding pDC development involves 
a shared pathway with cDCs, and has been characterised through the use of murine 
adoptive transfer studies. Similar to cDCs, BM HSCs give rise to CMPs and subsequently 
MDPs (222) under the control of numerous TFs. As previously mentioned, human 
progenitor candidates have been identified (222, 281). Under the control of Flt3L, STAT3 
and PU.1 MDPs develop into CDPs that can give rise to mature pDCs, dependent upon E2-
2 (297), that enter the circulation and migrate to lymphoid tissues (222). 
1.3.4 DC function 
DCs are the principal APCs of the immune system and act as a bridge between the innate 
and adaptive branches. Maintenance of tissue homeostasis is at least partially controlled by 
DC populations specialised for their surrounding environment.  
1.3.4.1 Antigen presentation and T cell priming 
Following the identification of DCs in 1973, Steinman et al characterised this population 
as potent inducers of T cell proliferation (186). Immature DCs reside in peripheral tissues 
where they survey their environment. They acquire antigen, migrate to SLOs, and induce 
immunogenic or protective responses (184). Additionally, DCs resident in lymphoid 
tissues act as sentinels of the immune system (184). In the immature state, DCs are 
proficient at internalising and processing antigen through several distinct mechanisms 
(298-301). Antigen uptake is an active DC process and occurs via macropinocytosis, 
engulfment and endocytosis, mediated through a variety of surface receptors (298). 
Macropinocytosis is a continuous non-specific mechanism whereby soluble antigen is 
captured through rearrangement of the DC cytoskeleton, specifically membrane ruffling 
and formation of vesicles (298, 300). In contrast, the process of endocytosis lends a degree 
of specificity to DC antigen uptake (300). This process is mediated through the expression 
of several cell surface receptors: Fc# and Fc& receptors, the mannose receptor, and DEC-
205 (298). For example, human LCs residing in the epidermis enhance their ability to 
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acquire IgE associated antigen through elevated surface expression of Fc&R1 (302). 
Following uptake, the complete FcR: antigen complex is degraded for antigen presentation 
(298). This process additionally permits capture of large antigens (298, 302).  
Blood DCs express both CD64 (Fc#RI) and CD32 (Fc#RII) that actively mediate antigen 
phagocytosis (303). It should be noted that whilst recent studies have shown CD64 
expression to discriminate between macrophages and DCs, with macrophages expressing 
high levels of CD64, DCs can also express low levels of this Fc receptor (225, 234). 
Mannose receptors are highly expressed on the surface of DCs and mediate the 
internalisation of numerous glycoproteins (298, 300). Following capture, receptor: antigen 
complexes are internalised, resulting in antigen delivery to cytoplasmic endosomes for 
trafficking and degradation, allowing recycling of the surface receptor (298). DEC-205 is a 
surface membrane receptor, related to the macrophage mannose receptor, involved in 
receptor-mediated endocytosis (304). Following antigen binding, the receptor is 
internalised by vesicle formation and transferred to the antigen processing compartment 
(304). Additionally, DCs appear able to engulf apoptotic bodies that may result in the 
generation of tolerogenic responses to self or cross-presentation and activation of targeted 
immune responses to harmful antigen (305). 
Regardless of the route of antigen uptake, T cells require the antigen to have been 
processed by the DC and presented, as epitopes, on the cell surface bound to MHC (306). 
Intracellular antigen is classically presented to CD8+ T cells via MHC I molecules whilst 
extracellular antigen is associated with MHC II molecules and CD4+ T cells responses. 
Surface MHC I is expressed on the majority of nucleated cells (307) whilst MHC II 
expression is restricted to APCs. Antigen processing for the MHC I pathway occurs in the 
cytosol via proteasome targeted degradation of endogenous proteins, often through 
ubiquitination, resulting in the generation of short peptide sequences (308, 309). Following 
proteasome-mediated antigen degradation, peptides are transported into the endoplasmic 
reticulum (ER) by the transporter associated with antigen processing (TAP) whereupon 
they are clipped by ER aminopeptidases (310-312). TAP constitutes part of the “peptide 
loading complex” (PLC) situated within the ER, composed of several molecules including 
MHC I, "2 microglobulin ("2m), tapasin and ERp57 (311, 313). MHC I molecules, when 
associated with the PLC bind high affinity antigenic peptides, whereupon the MHC I: "2m: 
antigen complexes are released from the PLC and translocate to the cell surface (311).  
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In contrast to the MHC I processing pathway, the endocytic pathway is the site of antigenic 
peptide binding to MHC II molecules (311, 314). Following extracellular capture, antigen 
is continuously degraded by vesicle-mediated proteolysis. Antigen is then transported 
through a pathway of increasingly acidic and proteolytically active vesicles known as early 
endosomes, late endosomes and lysosomes (315). MHC II molecules are generated in the 
ER, where they are stabilised through their association with the invariant chain (CD74) and 
transported to the endosome pathway (311, 316, 317). MHC II entry into late endosomes 
results in cleavage of CD74, with only a peptide residing within the MHC II binding 
groove remaining. This peptide is termed the class II-associated invariant chain peptide 
(CLIP) (318). CLIP removal by a glycoprotein called DM mediates binding of antigenic 
peptides, generated through cathepsin-induced degradation, into the MHC II binding 
groove (319). MHC II molecules bound to high affinity antigen are subsequently 
transported to the cell surface.  
Under specific circumstances, including viral infections, exogenous antigen may be 
processed and presented by the MHC I pathway resulting in the DC induction of cytotoxic 
CD8+ T cell responses (307, 320). This immunological process is termed cross-
presentation and is essential for effective clearance of multiple intracellular pathogens. DC 
subset specialisation relating to cross-presentation has been reported and will be discussed 
in more detail below.  
Following antigen processing and receipt of maturation signals, DCs down-regulate their 
expression of Fc receptors, including CD64 (303), and reduce their macropinocytic uptake. 
DC maturation is associated with a reduction in their ability to capture antigen (298). 
Accompanying this downregulation of phagocytic uptake, mature DCs upregulate 
expression of their surface co-stimulatory molecules and MHC: antigen complexes and 
alter their chemokine receptor profile. These adaptions change DC function from 
environmental sampling (immature DCs) to T cell stimulation and immune response 
induction (mature DCs). 
DCs carrying antigen migrate from tissue to the T cell zone of SLOs, tissues that 
orchestrate interactions between DCs and antigen specific T cells. This migration process, 
either via blood or lymphatics is CCR7 dependent (321). The subsequent interaction 
between DCs and T cells is mediated through MHC: antigen complexes and the TcR. This 
interaction involves the development of a molecular structure called the immunological 
synapse (322, 323). Adhesion molecules including LFA-1 (T cell) bind to intracellular 
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adhesion molecule 1 (ICAM1 - DC), CD4 and CD8 are also involved in the initial 
connection and stabilisation of the interaction between T cells and DCs (322). If antigen-
specific T cells recognise the cognate MHC: antigen complex on the surface of the DC 
(signal 1), their migration is inhibited and the resulting synapse leads to the activation and 
maturation of both the DC and the T cell. This synapse is composed of TcR: MHC 
complexes surrounded by an intricate network of co-stimulatory molecules (signal 2), 
including CD28 engaged by CD80/CD86 expressing DCs, and adhesion molecules (324). 
TcR: MHC engagement, when sustained for several hours in the presence of co-
stimulatory molecule binding, leads to the activation of phosphatidylinositol 3-kinase 
(PI3K) and release of intracellular calcium stores (325, 326). These pathways drive 
changes to the cells expression profiles within a few hours (327). Maintenance of the 
synapse is dependent upon TcR-driven signals and permits production of IL-2 for T cell 
survival and proliferation (326). T cell proliferation occurs within 24-48 hours following 
immunological synapse formation. Synapse abrogation may result from the engagement of 
cytotoxic T-lymphocyte antigen 4 (CTLA-4), expressed on T cells, with the DC expressing 
CD28 ligands CD80 and CD86 (326). Following the DC: T cell interaction, the majority of 
DCs die in situ by apoptosis (328). 
DCs play an important role in the induction of both immunogenic and tolerogenic immune 
responses. Peripheral DCs acquiring apoptotic cells in the absence of exogenous “danger” 
signals, may retain their immature profile and induce tolerance through promotion of Treg 
differentiation (329). However, more recent evidence suggests that tolerogenic responses 
require a degree of DC maturation, at least upregulation of MHC and co-stimulatory 
molecules (190). DCs involved in tolerance induction are thought not to secrete IL-12 
(189, 190, 330). These tolerance-inducing DCs are said to be “semi-mature”. It is also 
possible, however, that distinct populations of DCs may be specialised for the induction of 
tolerogenic responses. Murine studies have suggested that CD8!+ DCs may preferentially 
induce tolerance (329, 331) whilst similar observations have been reported for human 
CD141+ DCs (332). However, CD8! DC deficient mice are not deficient in their 
generation of Tregs (333, 334). Alternatively, indoleamine-pyrrole 2,3-dioxygenase (IDO) 
expressing DCs have been reported to mediate inhibition of T cell responses (335). 
Another school of thought involves the class of danger signal received by the migrating 
DCs. TNF! stimulated DC have been shown to induce IL-10 secreting T cells, in contrast 
to those stimulated with LPS (330). These data suggest that specific stimuli may affect 
DCs ability to promote either tolerance or immunity. However, the precise mechanisms 
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and signal(s) required for the induction of tolerance versus immunity remain to be 
determined.     
An illustration of the DC: CD4+ T cell interaction, and the immunological synapse, is 
shown in Figure 1.6. 
 
Figure 1.6: Immunological synapse between DC and CD4+ naïve T cell 
Depiction of the molecules involved in the immunological synapse that occurs between DCs and 
naïve antigen-specific CD4+ T cells in SLOs. The synapse is stabilised through the interaction of 
co-stimulatory molecules and adhesion molecules. DC secretion of IL-12 during TcR engagement 
skews Th differentiation to a Th1 phenotype. Alternatively, TcR signalling in the presence of IL-4 is 
required for Th2 differentiation. Figure adapted from (325). 
The defining feature of DCs is their ability to stimulate naïve T cell proliferation and direct 
the subsequent immune responses. However, this is a rather simple definition. 
Environmental conditioning, DC subsets and exogenous stimuli all add complexity to this 
process. The specialised functions of DC subsets will be discussed below. 
1.3.4.2 CD141+ DCs 
Of blood myeloid populations, CD141+ DCs express the highest levels of TLR3 (200). 
Stimulation of isolated blood DCs with the TLR3 ligand Poly I:C, identified CD141+ DCs 
as the preferential inducers of IFN#-secreting CD4+ T cells and secretors of IFN" (200). 
IFN" promotes the cross-presenting properties of DCs (200, 336, 337). Following TLR3 
stimulation, CD141+ DCs express high quantities of several molecules belonging to the 
MHC I antigen processing pathway, including TAP 1 and TAP 2, and were more effective 
at cross-presentation than CD1c+ DCs (200). However, under steady state conditions, it is 
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important to note that CD141+ and CD1c+ blood DCs are both capable of cross-
presentation (200).  
CLEC9A is exclusively expressed on CD141+ human DCs. Murine studies report 
CLEC9A to be involved in the identification of necrotic cells and cross-presentation of 
antigens derived from these cells (338). Blood CD141+ DCs have been found to be capable 
of cross-presentation to CD8+ T cells following ingestion of necrotic cells (200, 212, 339). 
Skin and blood-derived CD141+ DCs excel in the ability to cross-present soluble antigen 
(340). Similar to the data from Jongbloed et al, skin CD141+ DCs only exhibited this 
characteristic following TLR3 stimulation (200, 340). In addition to IFN", CD141+ DCs 
additionally secreted elevated levels of IL-12p70, IFN!, IFN%, TNF! and CXCL10, in 
contrast to CD1c+ DCs (200, 340-342). Given the role of IL-12p70 in the generation of 
Th1 cells, and their preferential capacity for cross-presentation under inflammatory 
conditions, these results indicate that CD141+ DCs may preferentially induce Th1 
responses and excel at cross-presentation (200). 
In contrast to the studies described above, skin-resident CD141+ DCs have been shown to 
be potent secretors of the regulatory cytokine IL-10, and to express high levels of the 
immunoregulatory receptor immunoglobulin-like transcript 3 (ILT3) (332). The apparent 
regulatory phenotype of this population was supported by several additional observations: 
CD141+ skin DCs inhibited T cell proliferation in an IL-10-dependent manner; and they 
induced CTLA-4 expression on interacting CD4+ T cells, shown to represent functionally 
viable Tregs in vivo (332). However, the DC population used in these studies expresses 
CD14, and may therefore not represent true tissue equivalents of blood CD141+ DCs. 
Notably, CD141+ CD14- skin-resident DCs assessed by Haniffa et al efficiently induced 
CD4+ and CD8+ effector T cell proliferation (340). While it is possible that, human DCs 
may functionally adapt in response to tissue-specific environmental conditioning, further 
analysis is required to fully elucidate the functional characteristics of this cross-presenting 
population. 
Basic leucine zipper transcription factor, ATF-like 3 (Batf3) and IRF-8 are TFs involved in 
the development of murine CD8!+ DCs (343-345). Human CD141+ DCs express both 
Batf3 and IRF-8 (200, 203). Consequently, both their ability to cross-present antigen and 
their TF regulation indicate that human CD141+ DCs are equivalent to murine CD8!+ DCs. 
This relationship will be discussed in more detail below. 
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1.3.4.3 CD1c+ DCs 
Blood CD1c+ DCs express TLR4, unlike CD141+ DCs (211). Following TLR4 stimulation 
via Escherichia coli (E.coli), CD1c+ DCs predominantly secrete IL-10 and IDO, 
accompanied with low levels of TNF!, IL-6 and IL-12 (211). Supporting a potential 
regulatory role for this circulating population, CD1c+ DCs have also been shown to supress 
T cell proliferation in an IL-10 dependent manner (211). However, another study found 
CD1c+ DCs to be the dominant producers of the pro-inflammatory cytokine IL-8 following 
TLR stimulation (346). 
Isolated lung and blood CD1c+ DCs induce CD103 expression on interacting CD8+ T cells 
in a TGF-"1 dependent manner (347). CD103 binds to E-cadherin and retains effector and 
memory T cells within epithelia (347, 348). Consequently, lung CD1c+ DCs may promote 
expression of CD103 on interacting CD8+ T cells and promote their accumulation within 
epithelium, thus enhancing clearance of viral pathogens (347).  
Environmental conditioning may promote maintenance of intestinal homeostasis. Retinoic 
acid (RetA) is one of several molecules thought to contribute to this process (119, 349, 
350). A specific subset of murine intestinal DCs (CD103+) are reported to secrete high 
levels of RA, resulting in the induction of gut-homing T cells and Treg differentiation 
(119, 349-351). Until recently, equivalent human DC populations had not been identified. 
Sato et al found blood CD1c+ DCs, when compared to the CD141+ subset, express elevated 
levels of the retinaldehyde dehydrogenase 2 (RALDH2) enzyme responsible for the 
conversion of retinal to RetA, (352). This expression was accompanied by an increase in 
aldehyde dehydrogenase (ALDH) activity following stimulation (352). In addition to 
circulating CD1c+ DCs, mesenteric lymph node (MLN) CD103- DCs showed similar levels 
of ALDH activity compared to the CD103+ population (352). These MLN results are 
different from the findings of murine studies (119, 349, 350). When the functional 
consequences of this ALDH activity in human blood DCs was assessed, CD1c+ DCs 
induced expression of the gut-homing molecule !4"7 and secretion of the Th2-associated 
cytokines IL-4, IL-5 and IL-13 (352). These data suggest that CD1c+ DCs may drive 
mucosal Th2 and Treg responses. 
Alternatively, CD1c+ DCs have recently been shown capable of promoting Th17 
differentiation (277). Blood, lung and small intestinal CD1c+ DC express higher levels of 
the TF interferon regulatory factor 4 (IRF4) than other myeloid populations and IRF4 was 
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required for the differentiation of the CD1c+ population (277). IRF4 may therefore be 
important for the survival or proliferation of CD1c+ DCs (277). Compared to the CD141+ 
population, lung CD1c+ DCs were the major producers of IL-23 (277), previously shown 
to promote the survival of Th17 cells (112). Furthermore, these IL-23-secreting lung 
resident CD1c+ DCs preferentially promoted the differentiation of IL-17A+, and IL-17+ 
IFN#+ CD4+ T cells (277). Therefore lung-resident CD1c+ DCs may promote Th17 
responses. 
Taken together these results suggest that CD1c+ DCs might adapt to the surrounding 
environment and are capable of inducing different immune responses in different contexts. 
1.3.4.4 CD14- CD16+ mononuclear cells 
Classification of CD14- CD16+ mononuclear cells either as a DC or monocyte subset 
remains unclear, partly due to the presence of SLAN+ and SLAN- subpopulations. 
Regardless of the classification, the function of this subset has been addressed by several 
groups and is discussed below. 
Blood monocytes were initially divided into two subsets: CD14+ CD16- and CD14+ CD16+ 
cells. In 2010, CD16+ monocytes were further subdivided into two populations: CD14+ 
CD16+, and CD14- CD16+ populations (237). Much of the initial phenotyping of CD14- 
CD16+ mononuclear cells was performed when they were included within the original 
CD14+ CD16+ population. Following TLR 2 and 4 stimulation, CD14+/- CD16+ monocytes 
were observed to be the dominant TNF!-producing monocyte population under steady 
state and inflammatory conditions (244, 353). In addition to their proinflammatory 
function, CD14+/- CD16+ monocytes excel in the uptake of antigen by Fc# mediated 
phagocytosis, due to their CD16 (Fc#RIII) expression (354). 
However, following separation of CD16+ monocytes into CD14+ CD16+ monocytes and a 
CD14- CD16+ mononuclear population, the proinflammatory profile was attributed to the 
CD14+ CD16+ monocyte population (237). This population has subsequently been shown 
to be expanded in disease (355). Functional analyses of the newly defined CD14- CD16+ 
mononuclear population suggested homology with the murine Ly6Clo patrolling monocyte 
subset (248, 356). Human CD14- CD16+ mononuclear cells do not enter tissues under 
steady state conditions but actively patrol blood vessel endothelium in a LFA-1 dependent 
manner (237). CD14- CD16+ mononuclear cells were in fact found to be refractory to TLR 
stimulation, unlike CD14+ CD16+ monocytes (237). However, this population was capable 
 53 
of TNF!, IL-1" and CCL3 production following viral, TLR 7 or TLR 8 stimulation (237). 
Response to TLR 7 and 8 stimulation appears to be characteristic of CD14- CD16+ 
mononuclear cells (237, 249, 252, 357). Unlike both CD14+ monocyte populations, CD14- 
CD16+ mononuclear cells exhibited poor phagocytic capacity (237). These CD14- CD16+ 
cells appear to be functionally distinct from both CD14+ monocyte subsets and appear 
refractory to TLR stimulation. 
Despite this classification of three blood monocyte populations, the CD14- CD16+ 
“population” is heterogeneous for the marker SLAN (M-DC8), previously used to isolate a 
“third” DC population (240). Also, CD16+ “monocytes” have the potential to develop into 
migratory DCs and transmigrate through epithelium (358). In the studies described above 
by Cros et al suggesting endothelial surveillance, the SLAN subsets were not individually 
assessed.  
The functional attributes of CD14- CD16+ SLAN+ cells will now be described, and they 
will be subsequently referred to as SLAN+ cells. In contrast to the findings by Cros et al, 
SLAN+ cells secrete proinflammatory cytokines upon TLR stimulation: IL-1", IL-6, IL-12, 
IL-23, TNF!, macrophage inflammatory protein 1! (MIP-1!) and MIP-1" (249, 346, 359). 
Following co-culture with T cells, SLAN+ cells induce differentiation of Th17 and Th1 
cells, observed to secrete more IL-17, IL-22, IFN# and TNF! than T cells induced by 
CD1c+ DCs (249, 359). SLAN+ DCs also secrete IL-12 and TNF! in response to TLR 7 
and TLR 8 stimulation (252, 357). These findings suggest that upon activation SLAN+ 
cells promote the immune response through secretion of proinflammatory cytokines and 
the differentiation of Th1 and Th17 cells. 
A final reported function of SLAN+ cells relates to their interaction with NK cells. TLR 4 
stimulated SLAN+ cells enhance expression of the activation marker CD69 on interacting 
NK cells (360). This cellular activation was reciprocal and promoted IFN# secretion in an 
IL-12-dependent manner (360). Furthermore, Th1 differentiation was promoted through 
DC: NK crosstalk (360). Overall, SLAN+ cells appear to orchestrate immune responses 
through their interaction with other hematopoietic cells.  
1.3.4.5 pDCs 
Circulating pDCs enter inflamed LNs and secrete large quantities of type I IFNs, in 
response to viral infections, after TLR 7 and TLR 9 engagement (194, 361, 362). This IFN 
response to viral infections is the prototypic function of pDCs. In addition to the role of 
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type I IFNs in viral clearance, pDCs can promote the differentiation of memory and 
effector cells (363), T cell survival (364) and CD8+ T cell function (365). Furthermore, 
pDCs produce an array of cytokines and chemokines following TLR stimulation, other 
than type I IFNs, which can functionally influence immune populations associated with 
both the adaptive and innate arms of the immune response. These cytokines include: IL-6, 
IL-8, TNF!, CCL3, CCL5 and CXCL10 (366, 367). 
Human pDCs that have been directly isolated from patients are reported to possess low 
antigen presenting capabilities (220). However, following stimulation by viruses or TLR 
ligands, pDCs are capable of direct antigen presentation to CD4+ T cells (368) and cross-
presentation (369), thereby adopting a similar functional role to cDCs (220). 
1.3.5 Rat DC classification 
Rats are used as transgenic models for many autoimmune and chronic diseases including 
SpA, creating the need to understand rat DC biology. The animal models used to 
understand the pathogenesis of SpA will be described in more detail below. Rat studies 
rely on identification of DCs through expression of the surface markers CD11c, MHC 
Class II and CD103 (370). Rat DCs can then be further differentiated based on their CD4 
and SIRP! (CD172a) profile (370).  
DCs in the rat intestine have been extensively studied. They were initially divided into two 
subsets: - CD4- CD172a- and CD4+ CD172a+, with the latter population accounting for 50-
60% of DCs migrating from the intestine in lymph and reportedly having greater antigen 
processing and presentation capabilities (370, 371). CD4+ CD172a+ DCs were originally 
thought to be a precursor for the CD4- CD172a- population, however their similar turnover 
rates in vivo have led to the rejection of this hypothesis (371). The CD4- CD172a- DC 
population has been reported to possess tolerogenic properties, taking up apoptotic cells 
and migrating to T cell areas of SLOs (372). However, more recent analysis has shown that 
these DCs did not preferentially induce differentiation of Tregs (373). Analysis of CD11b 
expression allowed further subdivision of rat intestinal DCs. CD103+ MHC II+ migrating 
DCs could be divided into CD172ahi CD11blo, CD172aint CD11bhi, and CD172alo CD11bint 
populations (374). The CD172ahi CD11blo subset secretes the highest levels of IL-12p40 
and IL-6 following TLR activation (374, 375). 
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Two major splenic DC subsets have been identified: the CD4+ CD172a+ CD5+ MHC II+ 
subset is the minor population, accounting for approximately 10% of total splenic DCs. 
CD4- CD172a- CD11b- CD5- MHC II+ cells represent the major DC population (376). Rat 
pDCs (CD4+ MHC II+ CD3- CD11b-) express a variety of lymphoid and myeloid antigens 
including CD172a, CD5, CD90 and CD200 (377). This subset produces vast quantities of 
type I IFN following TLR 7 and TLR 9 stimulation (377). 
1.3.6 Murine DC classification 
All murine cDCs express CD11c and MHC II. cDC precursors (pre-cDCs) seed peripheral 
and lymphoid tissue where DCs develop in situ. In lymphoid tissue, murine cDCs can be 
subdivided into two populations on the basis of CD8! and CD11b expression: CD11c+ 
MHC II+ CD8!+ XCR1+ CD11b-/lo CD172a- (CD8+ DCs) and CD11c+ MHC II+ CD8!- 
XCR1- CD11b+ CD172a+ (CD11b+ DCs) (222). CD8+ DCs are the minor lymphoid 
resident population, express high levels of the Flt3L receptor CD135, proliferate in 
response to Flt3L and are diminished in Flt3L-/- mice (222, 284, 378). Development of this 
population is dependent upon the TF Batf3 and inhibitor of DNA binding 2 (ID2) (334, 
379-382). CD8+ DCs excel in the cross-presentation of antigens, MHC I presentation, and 
are the main source of IL-12 (343, 379, 383-385). Furthermore, this population captures 
apoptotic cells and subsequently induces tolerogenic responses (331, 386). 
The CD11b+ DC population is the most abundant lymphoid DC population and is also 
responsive to Flt3L (222, 284, 378). Development of CD11b+ DCs is dependent upon the 
TFs RelB, Notch RBP-J and IRF4 (222, 387, 388). CD11b+ DCs are believed to chiefly 
process antigen through the MHC II pathway, partially through their higher expression 
levels of the MHC II machinery than CD8+ DCs (222, 383). 
In peripheral tissues, several DC subsets have been categorised based on CD103 and 
CD11b expression: CD103+ CD11b- CD8+/- XCR1+ CLEC9A+ CX3CR1- (CD103+ CD11b-
), CD103+ CD11b+ CD8- XCR1- CLEC9A- CX3CR1- (CD103+ CD11b+), CD103- CD11b+ 
CD8- XCR1- CLEC9A- CX3CR1+ (CD103- CD11b+) and CD103- CD11b- CX3CR1- 
(CD103- CD11b-) DCs have been identified in the intestinal lamina propria (LP) and 
intestinal afferent lymphatics (222, 389). The CD103+ CD11b- and CD11b+ DC subsets 
dominate the majority of peripheral tissues, accounting for approximately 1-5% of 
leukocytes (222). The proportions change in different tissues. For instance, CD103+ 
CD11b+ DCs dominate the small intestinal mucosa (389). Peripheral tissue CD103+ 
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CD11b- and lymphoid CD8+ DC subsets are thought to be related in terms of function 
(cross-presentation) and origin (334, 380). 
pDCs are mainly found within the circulation or lymphoid tissues. They can be identified 
as CD11clo MHC IIlo CD45+ CD4+ B220+ Ly6C+ CD172a+ CLEC9A+ cells (222). In 
response to TLR 7 or TLR 9 stimulation they secrete large quantities of type I IFNs (390-
392), as described above for human pDCs. 
1.3.7 Comparing DC populations between species 
Recently, human and murine DC subsets have been compared. CD141+ DCs are 
considered equivalent to the mouse CD8+ DCs (200, 203, 212, 340, 393). Despite the fact 
that these subsets share similar functional (cross-presentation), phenotypic (CLEC9A, 
Necl2 and XCR1) and developmental similarities (Batf3), CD141+ DCs do not express 
CD8 (394). In addition, rat CD172alo lymph-migrating DCs are presumed equivalents of 
human CD141+ DCs and murine CD8+ DCs based on their shared uptake of apoptotic 
material (372) and TLR3 expression (375). 
Murine CD11b+ DCs share a similar genetic transcriptional profile to human CD1c+ DCs 
(393). For example, genes similarly expressed by LN resident CD11b+ and CD1c+ DCs 
include those involved in the inflammatory response, MHC II processing pathway and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-'B) signalling (393). 
Murine and human pDCs were additionally found to be genetically and functionally related 
and were distinct from all cDC populations (194, 361, 362, 390-393). Table 1.5 describes 
the relationship between lymphoid tissue murine and human DC populations. 
Table 1.5: Comparison of human and murine DC populations 
Common functional, phenotypic and developmental similarities exist between several human and 
murine DC populations. These are depicted in table 1.5. TF = transcription factors and Ag = 
antigen. 
Human Murine Phenotype Function TF 
CD141+ CD8+/CD103+ CD11c+ MHC II+ 
XCR1+ CLEC9A+ 
Necl2+ CD11blo 
Cross-
presentation, 
tolerance 
Batf3, 
IRF8, Flt3 
CD1c+ CD11b+ CD11c+ MHC II+ 
CD11b+ SIRP"+ 
MHC II Ag 
presentation, 
(Th17 induction?) 
Flt3, IRF4 
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CD303+ 
pDC 
B220+ pDC TLR 7, TLR 9, 
MHC II+ 
Type I IFN 
production 
following TLR 7/9 
stimulation 
Flt3, E2-2, 
Spi-B 
 
1.4 Intestinal immune system 
Control of immunogenic and tolerogenic immune responses is of great importance in the 
intestine because of the high antigenic load and the deleterious consequences of 
inappropriate immune activation. The intestine, composed of the stomach, small intestine 
(SI), caecum, large intestine (colon) and rectum, harbours commensal bacteria, food 
antigens, and pathogenic bacteria. Specifically, the human intestine is occupied by 
approximately 1014 microorganisms (395). Consequently, the intestinal immune system has 
had to adapt to continuous exposure to innocuous and harmful antigen, in order to prevent 
the development of aberrant immune responses whilst remaining responsive to harmful 
pathogens (396). Inflammatory bowel disease (IBD), either in the form of Crohn’s disease 
(CD) or ulcerative colitis (UC), results from the breakdown of intestinal homeostasis and 
occurs in approximately 1 in 500 individuals (397). Furthermore, patients suffering from 
chronic inflammatory diseases, including AS, commonly experience symptoms of IBD as a 
extra-articular manifestation of their disease (4, 13). Therefore, elucidating the pathways 
involved in intestinal homeostasis and inflammation may aid development of new 
therapeutics for both IBD and AS. 
To respond to the largest antigenic load in the body, the intestinal immune system has 
adapted structurally and functionally to deal with the numerous, contrasting antigens and 
stimuli (395). The intestinal immune system comprises the largest body surface area 
(400m2), enhanced through site specific development of villi (396). Secondly, the intestinal 
mucosa is separated from the lumen by a single layer of epithelium that is coated in a thick 
layer of mucus (395). Furthermore, this barrier secretes several antigenic peptides that 
maintain barrier function and act as a primary defence mechanism (395). In addition, there 
is continuous transport of mucosal IgA to the luminal surface (3g/day), this IgA aids the 
clearance of bacteria to maintain barrier homeostasis (395). The intestine harbours a larger 
population of T cells than any other tissue, with 60% of all T lymphocytes thought to 
reside here (396, 398). Within the intestinal mucosa, several discrete lymphoid organs 
reside, often in close proximity to the lumen and the associated antigen. These are referred 
to as the gut-associated lymphoid tissue (GALT), which consists of Peyer’s patches (PPs), 
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mesenteric lymph nodes (MLNs) and isolated lymphoid follicles (ILFs) (396). These SLOs 
mediate intestinal immune responses and are structurally adapted to meet the demands 
associated with the intestinal environment. For example PPs composed of distinct T and B 
cell areas, exist within the submucosa and are separated from the external environment by 
a single layer of epithelium known as the follicle-associated epithelium (FAE) (396). 
Scattered throughout this layer exist specialised epithelial cells involved in the uptake and 
transportation of antigen, called M cells (396). Within PPs, antigen-specific T and B cell 
activation occurs in situ, whereupon these lymphocytes egress the PP and migrate back to 
the intestinal mucosa to perform their regulatory or immunogenic functions (396). In 
additional to these organised structures, T lymphocytes reside within the lamina propria 
(LP) and intestinal epithelium (intraepithelial T lymphocytes - IELs) (396). The majority 
of intestinal lymphocytes are refractory to exogenous stimuli and are phenotypically 
appear to be effector populations that secrete cytokines including IFN# and IL-4 (396, 399, 
400). The majority of IELs are CD8+ T cells expressing the CD8!! homodimer, in contrast 
to circulating CD8!"+ T cells, and have been shown to possess cytolytic activity (401, 
402). In addition to the cells described above, the intestinal immune system contains a 
complex, unique system of mononuclear phagocytes, described in more detail below. 
1.4.1 Intestinal DCs 
Given the central role of DCs in the induction of immune responses, understanding how 
intestinal tissue homeostasis is achieved requires an understanding of the functions of 
intestinal DCs.  
Within the human intestine reside several cDC populations, defined on the basis of CD141 
and CD1c expression (270, 271, 403). pDCs are reported to be relatively rare within the 
intestinal mucosa (270, 271, 273). The precise function of these subsets remains relatively 
obscure, due to the difficulties in isolating these populations from human intestinal 
mucosa. A study by Dillon et al has examined the functions of peripheral blood (PB) and 
LP CD1c+ DCs, to assess the impact of intestinal environmental conditioning on DC 
function (271). Under steady state conditions LP DCs, compared to those isolated from 
PB, show elevated levels of several activation markers (CD40, CD83 and CD86) and 
cytokines including IL-6, IL-10 and TNF! (271, 404). However, human intestinal DCs 
have also been reported to express low levels of numerous activation markers, highlighting 
need for further investigation (404, 405).  
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Cytokines are involved in the regulation of both intestinal inflammation and homeostasis. 
TNF! is pro-inflammatory, but also inhibits IL-12 and IL-23 production (406, 407). 
Inhibition of myeloid IL-10 signalling through deletion of STAT3 leads to enhanced IL-12 
production and intestinal inflammation (408, 409). Subsequently, IL-6 and IL-10 have 
been shown to be involved in barrier homeostasis (410, 411). A variety of immune and 
endothelial cells secrete these cytokines, highlighting a potential role for LP DCs in tissue 
homeostasis through their cytokine profile. Furthermore, LP CD11c+ DCs appeared 
refractory to TLR 4 and TLR 5 stimulation, with low expression levels of both TLRs (271, 
404). This intestinal TLR hyporesponsiveness replicates findings reported in several 
murine and rat intestinal DC studies (375, 412).  Furthermore, LP CD1c+ DCs’ capacity to 
secrete IL-23 was only induced following TLR 7 and 8 stimulation, whilst IL-10 was 
upregulated in response to TLR 2 activation (271). Therefore the activation and function of 
this LP DC population may be mediated by intestinal conditioning and TLR stimulation. 
However the precise functions of human intestinal CD1c+ and CD141+ DC populations 
remain to be fully elucidated. 
The interaction of the intestinal environment with myeloid populations has been shown to 
be important in mediating cell function in both murine and human studies. Intestinal DCs 
are unique in their ability to induce !4"7 and CCR9 on interacting T cells, promoting 
migration and homing of effector T cell populations to the intestine (171, 172, 413). 
Human intestinal DCs may preferentially induce Th2 type immune responses, promoted 
through the expression of thymic stromal lymphopoietin (TSLP) by gut epithelial cells 
(414). This intestinal DC conditioning is important for tissue homeostasis as TSLP 
expression is reduced on epithelial cells isolated from CD patients. In turn, this may affect 
DC function and thus perpetuate inflammation as epithelial cell: DC crosstalk enhances 
DC secretion of the immunoregulatory cytokine IL-10 (414). This Th2 bias of human 
intestinal DCs is recapitulated in several murine studies where CD103+ intestinal DCs 
preferentially secreted IL-10 and induced Th2 responses (415, 416). However, murine 
intestinal CD103+ CD11b+ DCs have recently been shown to be the primary inducers of 
the Th17 phenotype (275). In addition, murine intestinal lymph or MLN CD103- DCs 
appear capable of the induction of IFN#-secreting and IL-17-secreting CD4+ T cells (349, 
389, 417).  
As stated above, IgA is abundant within the intestine and is plays important roles in the 
clearance of pathogens and preventing commensal organisms breaching the intestinal 
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barrier (395, 418). Intestinal DCs are more proficient at promoting B cell IgA class 
switching and IgA production than other lymphoid DC populations (418, 419). 
In addition to Th2 induction, IL-10 secretion, TLR hyporesponsiveness, IgA secretion and 
barrier maintenance, intestinal DCs have a specialised ability to direct Treg differentiation. 
Murine intestinal CD103+ DCs are specialised for the induction of FOXP3+ CD4+ T cells, 
with or without the addition of exogenous TGF" (119, 349, 351). Intestinal Treg 
differentiation was found to be dependent upon RetA production, with MLN CD103+ DCs 
expressing RALDH2 (349). This Treg induction is at the expense of Th17 differentiation 
(119). Thus, as a consequence of environmental conditioning, murine intestinal DCs, or at 
least a specific DC subset, preferentially induce tolerogenic responses through priming of 
Tregs in the presence of TGF" and RetA. An equivalent human Treg inducing DC subset 
has not yet been identified; although human CD103+ small intestinal LP DCs can induce 
FOXP3+ Tregs, the capacity for CD103- DCs to induce Tregs was not assessed in this 
study (420). Isolated human CD103- MLN DCs are reported to develop ALDH activity 
following stimulation with 1!,25-dihydroxyvitamin D3 (Vit D3), GM-CSF and RetA 
(352). In contrast, CD103+ DCs isolated from both human and murine LP have been 
shown to express IDO, implicated in Treg generation (421). 
Little is known about how human intestinal DCs are affected by inflammation. Under 
inflammatory conditions, expression of TLR 2 and TLR 4 is upregulated on intestinal DCs 
(404) and accumulation of activated DCs has been observed within inflamed tissue (405, 
422). The functions and detailed phenotypes of these populations have, however, not been 
assessed. 
Overall, intestinal DCs in both mice and men are conditioned by the intestinal environment 
to prevent aberrant responses to commensal bacteria and food antigens whilst remaining 
capable of inducing targeted immunogenic immune responses. Whether these differential 
functions are mediated by unique subsets, changes in environmental conditioning or a 
combination of both factors remains to be determined in humans. 
1.4.2 Intestinal macrophages 
Like DCs, macrophages are phagocytes critical for intestinal tissue homeostasis. Under 
steady state conditions human intestinal macrophages lack expression of the monocyte 
marker CD14 (423-426). However, CD14+ macrophages infiltrate inflamed mucosa, and 
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secreted pro-inflammatory cytokines including TNF! and IL-23 (427). Advances in flow 
cytometry have enabled identification of two populations of human intestinal macrophage: 
CD14lo, and CD14hi (225). In addition to CD14, human intestinal macrophages express 
CD11c, MHC II, CD13, CD33 and low levels of co-stimulatory molecules (423, 424, 426, 
428). Much of the functional characterisation of intestinal macrophages has been 
performed in the mouse. Murine macrophages are defined as MHC II+ CD11c+ F4/80+ 
CD64+ CX3CR1int/hi (225, 234). These CX3CR1-expressing cells extend dendrites into 
intestinal lumen, perhaps representing another method of antigen capture (429, 430). 
Intestinal macrophages have several regulatory and homeostatic functions, including 
maintenance of epithelial barrier function through secretion of IL-10 and prostaglandin E2 
(PGE2) (225, 431, 432), and regulation of Treg survival and function in situ (433).  
Following uptake and degradation of antigen, human intestinal macrophages do not secrete 
the pro-inflammatory hormones commonly associated with other tissue-resident 
macrophage populations (434). Specifically, human intestinal macrophages lack 
respiratory burst activity following stimulation with PMA or opsonized zymosan (435). 
However, this deficiency was overcome in IBD (435). Low expression of numerous 
pattern recognition receptors (PRRs) including CD14, CD64 and CD123 (IL-3R) and the 
signalling molecule MyD88 are thought to contribute to the differential functional capacity 
of intestinal macrophages (424, 436). However, human intestinal macrophages have been 
shown to express numerous TLRs (TLR 2-9) (426, 436). Control of murine intestinal 
macrophage pro-inflammatory activity is maintained by environmental conditioning 
through TGF" (436), and by expression of several inhibitory receptors including CD200R1 
(437). However, intestinal macrophages in CD200R mice exhibit normal phenotype and 
function (438). 
Some reports suggest that discrete monocyte populations independently gave rise to 
resident and inflammatory macrophage populations. Specifically, murine Ly6Clo and 
Ly6Chi monocytes generate resident and pro-inflammatory macrophages respectively 
(279). However, it has recently been shown that Ly6Chi macrophages generate both 
resident (CX3CR1hi) and pro-inflammatory (CX3CR1int) intestinal macrophage 
populations in situ (225, 439). A similar macrophage differentiation process has been 
postulated for human intestinal CD14lo (resident) and CD14hi (pro-inflammatory) 
macrophage populations. The pro-inflammatory CD14hi macrophages expand during CD 
(225, 427).  
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Overall, resident macrophages are refractory to exogenous stimuli and promote tolerogenic 
responses and homeostatic processes through Treg and epithelial barrier maintenance. 
However, during inflammation pro-inflammatory macrophages dominate the intestinal 
mucosa and secrete pro-inflammatory molecules including IL-23 and TNF!. Further 
characterisation of these populations in human intestinal mucosa is required. 
1.4.3 AS and the intestinal immune system 
Intestinal inflammation is inextricably linked to AS pathogenesis. AS patients often suffer 
from extra-articular disease manifestations; with approximately 10% of AS patients 
concurrently diagnosed with IBD, commonly in the form of CD (11, 12). Of patients 
initially diagnosed with CD alone, 54% of HLA-B27+ individuals subsequently develop 
AS in comparison to only 2.6% of HLA-B27- CD patients (440). In addition to those AS 
patients clinically diagnosed with IBD, at least 50% of AS patients show signs of 
subclinical intestinal inflammation (4, 11, 13). AS patients with IBD are associated with 
increased disease severity, as measured by function and disease activity (441-443). 
Together, these data indicate that disruption of intestinal homeostasis may contribute to the 
clinical and pathological features of AS. 
Further supporting a role for intestinal inflammation in SpA pathogenesis, a rat model of 
SpA failed to exhibit gut and joint pathology in the absence of intestinal flora, whilst skin 
inflammation was unaffected (444). These findings provide evidence for the interplay 
between the intestinal environment, specifically the gut flora, and SpA development. 
However, the presence and colonisation of several intestinal bacterial species did not differ 
between AS patients and healthy controls (445). Elucidation of the immune pathways 
involved in this interaction may improve the understanding of AS pathogenesis.  
1.5 Ankylosing spondylitis 
1.5.1 Inflammation associated with ankylosing spondylitis 
The tissues most afflicted by inflammation in AS include the sacroiliac joints (SIJ), sites of 
tendon/ligament attachment (entheses), axial skeleton, peripheral joints, intestine and the 
eyes (446). For several of these tissues the inflammatory infiltrate has at least partially 
been described.  
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Inflammation in AS is believed to first occur within the SIJs (446). This inflammation is 
associated with reduced BM cellularity, loss of synovium and cartilage, enthesitis and bone 
(syndesmophyte) formation (447). Synovitis is succeeded by pannus and connective tissue 
formation, leading to the destruction of local cartilage and bone (447). Following these 
destructive processes, bone formation occurs, leading to loss of joint function as is shown 
in Figure 1.2 (447, 448). Entheses are commonly believed to be the location for the initial 
inflammatory infiltrate (14, 16, 449, 450), however this claim has also been refuted by 
some (446, 447). The inflammatory infiltrate associated with AS SI joints has been 
characterised and is dominated by CD3+ T cell of both CD4+ and CD8+ lineages, 
fibroblasts, and CD14+ macrophages (451, 452). Furthermore, all infiltrating populations 
express elevated transcriptional levels of TNF! (451). CD3+ T cells and macrophages 
(CD68+) also dominate the cellular infiltrate in synovial inflammation (453). Similarly, 
HLA-DRhi CD163+ TNF!+ macrophages preferentially infiltrate both the synovial 
membrane and colonic LP of SpA patients (454, 455).  
In addition to the characterisation of the inflammatory infiltrate associated with the axial 
skeleton, articular and extra-articular tissues, the populations associated with entheseal 
inflammation have been described, where macrophages appear to dominate and very few 
infiltrating lymphocytes are observed (456). However, BM cellular infiltrate at sites of 
entheses mostly contain lymphocytes, with CD8+ T cells being the abundant population 
(457). Within affected joints, blood vessel formation may promote infiltration of 
inflammatory populations (452). These results indicate that both branches of the immune 
system, innate and adaptive, are involved in the pathogenesis of AS. 
Despite a relative abundance of information about inflammatory tissue infiltrate, the 
functional contributions of these immune populations to disease pathogenesis remain 
poorly understood. Much of what is known has been generated using animal models. 
1.5.2 Animal models of SpA and immune pathogenesis 
The HLA-B27 transgenic rats (HLA-B27 TG) have been the most important model for 
understanding the immunopathogenesis of SpA. Rats over-expressing the human HLA-
B*2705 and associated "2-microglobulin ("2m) genes (458) spontaneously develop a 
range of symptoms including intestinal inflammation, peripheral arthritis, uveitis and skin 
inflammation (444). This model has proved extremely useful in unravelling several key 
components regarding the pathogenesis of SpA disease, much of which will be discussed 
 64 
in greater detail below. This model has recently been adapted by increasing the "2m copy 
number/cell (459). Interestingly, this alteration enhances the severity of peripheral arthritis 
and promotes development of axial bone formation, spondylitis and enthesitis (459). In 
contrast to HLA-B27 TG rats, colitis failed to develop in this SpA model, both in terms of 
histological analysis and presence of diarrhoea (459). 
Murine SpA models have been described. TNF(ARE mice develop several SpA symptoms 
including IBD, peripheral arthritis, enthesitis, spondylitis and sacroiliitis (460, 461). This 
model relies on an induced deletion within the AU-rich elements of the TNF gene, leading 
to an increase in TNF production under steady state conditions in both the haematopoietic 
and stromal compartments (460, 461). Human TNF TG mice have additionally been 
observed to develop peripheral arthritis and bilateral sacroiliitis through matrix 
metalloproteinase (MMP) mediated bone erosion (462). These models indicate that TNF! 
can drive a range of pathologies, resembling SpA. 
Immunisation of specific mouse strains, including BALB/c, with human cartilage 
proteoglycan leads to the development of arthritis, and progressive erosion and formation 
of bone resulting in complete ankylosis of the SIJs (463). This murine model is of interest 
because it has been argued that AS associated enthesitis results from aberrant responses 
directed against cartilage (460, 464).  
A model developed to assess the processes of bone formation characteristic of AS involves 
co-habiting DBA/1 mice from separate litters at 2 months post-weaning (465). These mice 
develop ankylosis, particularly of the hind limbs and have enabled identification of several 
bone morphogenetic proteins (BMPs) involved in pathogenic bone formation (465, 466). 
Furthermore, ank/ank mice developed for the study of ankylosis development and 
progression are generated through mutation of the ank gene, encoding a pyrophosphate 
transporter, resulting in loss of function (460, 467). 
A recent murine model provides a mechanism by which IL-23 may drive enthesitis in AS 
and SpA. Systemic administration of IL-23, via minicircle technology, to the murine 
B10.RIII strain resulted in the development of entheseal inflammation within peripheral 
and axial joints (468). Furthermore, this murine model developed psoriasis and entheseal 
bone formation (468). IL-23 was shown to mediate these destructive effects partially 
through activation of an entheseal resident IL-23R+ CD3+ CD4- CD8- T cell population 
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(468). This model has provided insights into the potential mechanisms relating IL-23 and 
SpA development.  
1.5.3 Immunopathogenesis of AS/SpA 
Studies using animal models of SpA have shaped investigations aimed at understanding 
the pathogenesis of human disease. One such study identified a dominant role for CD4+ T 
cells, but not CD8+ T cells, in the pathogenesis of disease. These observations were 
surprising, given the contribution of HLA-B27, an MHC class I gene, to disease 
development. Several lines of evidence in the HLA-B27 TG rats now support a role for 
CD4+ T cells, and not CD8+ T cells, in disease development. CD4+ T cells infiltrate colonic 
tissues of HLA-B27 TG rats (469). Compared to CD8+ T cells, CD4+ T cells isolated from 
HLA-B27 TG rats and transferred into nude recipients, cause more severe disease (470). 
Furthermore, adult thymectomy or antibody-mediated depletion of CD8+ T cells failed to 
inhibit the development of arthritis and colitis in the HLA-B27 TG rat model (471). 
Additionally, a loss of function deletion in the CD8! gene did not affect the onset or 
severity of disease symptoms (472). Overall these data suggest that SpA development, at 
least in the HLA-B27 TG rat model, is CD4+ T cell mediated. 
T cell priming is dependent upon the interaction of naïve T cells with professional APCs. 
The importance of this interaction in SpA pathogenesis was highlighted through the use of 
athymic HLA-B27 TG rats. In this model, development of colitis was dependent upon the 
interaction between T cells and an HLA-B27-expressing APC (473). Furthermore, HLA-
B27 TG BM transfer into non-TG rats was efficient for disease transfer, highlighting the 
involvement of haematopoietic cells in disease development (474). Disease did not 
develop following T cell transfer into non-TG recipients (473). Subsequently, several 
studies have focused on the role of DCs, as the principal APC, in disease development. 
Initial studies found that HLA-B27 TG DCs, predominantly splenic DCs, were deficient in 
their ability to stimulate T cells (475, 476). Contributing to this deficiency was the fact that 
fewer DC: T cell conjugates formed when HLA-B27 was expressed on the DC (476). 
Subsequent investigations found impairment of immunological synapse formation between 
HLA-B27 TG DCs and CD4+ T cells compared to HLA-B7 TG controls (477, 478). A 
reduction in the frequency of T cell Ca+ signalling events following interaction with HLA-
B27 TG DCs was also observed (478). It has been suggested that interference of HLA-B27 
with co-stimulatory molecule engagement may partially account for this insufficient 
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interaction and that this may contribute to aberrant CD4+ T cell priming and subsequent 
inflammation (478). 
Proteomic analysis of HLA-B27 TG DCs identified upregulation of proteins related to the 
MHC class I processing pathway and the unfolded protein response (UPR) (477). The 
involvement of the UPR in AS pathogenesis will be discussed in detail below. In contrast, 
numerous “cytoskeleton-reorganising” proteins were downregulated in HLA-B27 TG DCs 
(477). Consequently HLA-B27 TG DCs were less motile than non-TG controls. The HLA-
B27 TG DCs also displayed alterations to cell morphology and a reduction in their 
expression of surface MHC II (477). The authors argue that these factors could contribute 
to the impaired immunological synapse formation and the reduction in number of DC: T 
conjugates, leading to aberrant T cell priming and perpetuating disease development. 
Relating to the T cell priming aspect of DC function, HLA-B27 TG rats have a higher 
proportion of activated CD4+ T cells in MLN and popliteal LNs (pLN) compared to WT 
littermates (479). Within these LNs, the proportions of IL-17A+, TNF!+ and IL-17A+ 
TNF!+ CD4+ T cells were expanded in HLA-B27 TG rats (479). In vitro experiments 
demonstrated that HLA-B27 TG splenic DCs preferentially drive differentiation and 
maintenance of Th17 cells in a contact dependent manner (479). Furthermore, IL-17+ 
mononuclear cells have been identified in the synovium of HLA-B27 TG rats, but are 
absent from non-TG controls (479). Thus, IL-17-secreting cells appear to be involved in 
the pathogenesis of SpA, in HLA-B27 TG animals. 
An alternative explanation for the aberrant immune response observed in these rats has 
been proposed. HLA-B27 TG rats lack a specific migratory intestinal DC subset, compared 
to WT littermates and HLA-B7 TG controls (480). This DC deficiency was systemic in 
HLA-B27 TG rats (480). This “missing” subset of CD172alo DCs (CD103+ MHC II+ 
CD11bint CD172alo) (480) has been reported to possess tolerogenic properties (372) and is 
analogous to the human CD141+ and murine CD8+ DC populations. This population has 
further been shown to be susceptible to apoptosis, providing a mechanism for the loss of 
this subset in HLA-B27 TG rats (477). The remaining HLA-B27 TG DCs were more 
activated, expressing higher levels of CD25, but did not display differences in the 
induction of naïve T cell proliferation (480). However, BM-generated DCs from HLA-B27 
TG rats were susceptible to cell death, and had an impaired capacity to drive T cell 
proliferation, whilst selectively promoting differentiation of IL-17-secreting cells (480). 
Th17 and Th1 cells are reported to be expanded in the colonic LP of HLA-B27 TG rats 
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(481). Overall, data from animal models suggest involvement of DCs and T cells in the 
pathogenesis of SpA. 
However, this SpA animal model has several disease-associated limitations that must be 
considered when relating HLA-B27 TG rat model findings to human disease: in order to 
develop disease symptoms, HLA-B27 TG rats have to express an extremely high HLA-
B27 and "2m copy number. To be exact, in the original 33-3 strain on a Fischer 
background (F344), 55 HLA-B*2705 and 66 "2m genetic copies per cell had to be 
introduced to induce symptom development (458). The genetic profile of SpA family 
members is not solely reliant on HLA-B27 expression as several other genes including IL-
23R and STAT3 elicit disease susceptibility (39). Furthermore there is little conclusive 
evidence to suggest involvement of spinal disease in terms of entheses inflammation in 
HLA-B27 TG rats, a hallmark symptom of AS (458, 482). 
1.6 Molecular pathogenesis of AS 
1.6.1 Molecular mimicry 
Numerous attempts have been made to understand the causes of AS, yet no definitive 
trigger has yet been identified. In the past, associations between infection and AS 
pathogenesis have been suggested. For instance, Klebsiella-enterobacter species have been 
reported to show a degree of immunological cross-reactivity with HLA-B27+ lymphocytes 
(483). Furthermore, 93% of inflamed AS patients were infected with Klebsiella-
enterobacter (483). In addition, levels of anti-Klebsiella pneumoniae antibodies in AS 
patients’ serum and SF and were elevated compared to healthy controls and RA patients 
(484, 485). Evidence suggests that the intestine may be the primary source of Klebsiella 
infection in AS patients, and it is argued that it is the principal microbial cause of AS 
pathogenesis (485). However, several investigators have failed to establish an association 
between Klebsiella infections and AS pathogenesis (486). Subsequently, the role of 
microbial infection and AS aetiology remains unclear. 
Other contributions of molecular mimicry to AS pathogenesis have been described. 
Molecular mimicry involves mistaken immune targeting of self-antigens; immune 
responses directed against bacterial antigens can target self-antigen bearing similar peptide 
sequences. In the context of AS, HLA-B27 may present arthritogenic peptides derived 
from host proteins to CD8+ T cells, resulting in the development of chronic inflammation 
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and/or autoimmune disease. The Klebsiella pneumoniae nitrogenase reductase enzyme has 
been reported to share amino acid homology with HLA-B*2705 molecules (487). 
Furthermore, Klebsiella pullulanase enzymes share amino acid sequences with HLA-B27 
molecules (488). These observations hint that direct recognition or molecular mimicry 
associated with Klebsiella species might be involved in the pathogenesis of AS.  
Further supporting a role for molecular mimicry in disease development, a self HLA-B27 
derived peptide has been identified as a natural ligand for several specific B27 subtypes 
highly associated with AS: HLA-B*2702, HLA-B*2704 and HLA-B*2705 (489). In 
conjunction, this peptide shows sequence homology with Chlamydia trachomatis (489), 
suggesting potential for cross-reactivity and disease perpetuation. Cartilage and bone 
derived peptides have additionally been suggested to bind to HLA-B27 (490), again 
supporting the capacity for the generation of autoimmunity.  
Self-antigen derived from vasoactive intestinal peptide receptor 1 (VIPR1) shares 
homology with the Epstein-Barr virus protein, pLMP2. Following binding to HLA-B*2705 
this may elicit activation of autoreactive T cells (491, 492). Similar responses were not 
generated following binding to the HLA-B*2709 subtype, not commonly associated with 
AS susceptibility (491, 492). Binding of antigenic peptides to AS-susceptible HLA-B27 
subtypes may therefore promote disease pathogenesis. 
The HLA-B27 molecule has 6 pockets capable of binding antigenic peptides, with the B 
pocket being the favoured region for determining the epitope presentation repertoire of 
HLA-B27 (11). This B binding pocket may be involved in arthritogenic peptide 
recognition, initiating joint specific disease (11). To support this, only a single amino acid 
substitution from aspartate to histidine is responsible for the different disease susceptibility 
profiles of the HLA-B*2705 and HLA-B*2709 subtypes; only HLA-B*2705 confers a 
disease association. This mutation occurs within the binding region of the MHC class I 
molecule, suggesting a possible role for arthritogenic peptide presentation due to the 
alterations in peptide binding. While it has been argued that HLA-B*2705 presentation of 
a unique set of peptides may initiate disease development, HLA-B*2709 AS patients have 
now been identified, weakening the plausibility of this hypothesis of arthritogenic peptides 
and molecular mimicry. Furthermore, HLA-B27 is an MHC Class I molecule and therefore 
conventionally presents antigens to CD8+ T cells. Animal models have discounted a role 
for CD8+ T cells in disease pathogenesis (470, 471). Together, these observations refute a 
role for arthritogenic peptide presentation and molecular mimicry in AS development. 
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Indeed, a specific HLA-B27 restricted antigen has yet to be discovered (493). However, 
further studies investing arthritogenic peptides are still being performed.   
1.6.2 Cell surface HLA-B27 dimer formation 
As described in section 1.3.4.1, MHC class I molecules such as HLA-B27 are associated 
with "2m and are expressed on the cell surface for interaction with CD8+ T cells (494). 
However, HLA-B27 shows a tendency to form atypical disulphide-bonded heavy chain 
homodimers (HLA-B272), which are expressed on the cell surface (495-497). These 
homodimers are not extra- or intracellularly complexed to "2m (497). This unusual 
conformation is mediated through an unpaired cysteine residue occurring at position 67 
and is believed to occur during endosomal processing by two distinct pathways (495, 496). 
Intracellular homodimers are formed in the ER but do not traffic to the surface, whilst 
homodimers expressed on the cell surface may arise from unstable heterodimers on the 
surface or located within the endosomal recycling compartments (496). Promoting the 
capacity for homodimer formation, HLA-B27 molecules are more likely to form 
complexes in the absence of TAP or tapasin, compared to other MHC class I molecules, 
enhancing the likelihood of HLA-B27 heterodimer instability (494, 498). 
Receptors for these atypical surface HLA-B272 molecules have been identified on 
lymphocytes, monocytes, DCs and NK cells (499, 500). HLA-B272 receptors include killer 
cell immunoglobulin-like receptor 3DL1 (KIR3DL1), KIR3DL2 and immunoglobulin-like 
transcript 4 (ILT4) (500). HLA-B272 molecules do not exhibit binding to the inhibitory 
immunoglobulin-like receptor (LILRB1 or ILT2) (499, 500). Furthermore, KIR3DL2 is a 
ligand for HLA-B272 surface molecules but not HLA-B27 heterodimers (496). KIR 
engagement of MHC class I molecules has been shown to prevent activation-induced cell 
death (AICD) of NK and T cells (47, 501). Subsequently, KIR activation may promote the 
survival of the leukocyte populations leading to the perpetuation of the inflammatory 
response. To this end, HLA-B272-expressing APCs have been shown to stimulate the 
proliferation and survival of activated KIR3DL2+ CD4+ T cells capable of IL-17 secretion 
(495). 
SpA patients express these atypical HLA-B272 molecules along with their receptors, 
specifically KIR3DL1 and KIR3DL2 (500). KIR3DL2+ NK cells and CD4+ T cells have 
shown to be expanded in the peripheral blood and SF of SpA patients compared to healthy 
controls (47, 495). Furthermore, peripheral blood NK cells isolated from SpA patients 
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exhibited elevated cytotoxicity activity and activation compared to those isolated from 
healthy controls (47). These data indicate preferential HLA-B272 binding in AS patients, 
leading to abnormal cell activation and inflammation (47). 
In addition, KIR3DL2-expressing CD4+ T cells isolated from SpA peripheral blood upon 
stimulation preferentially secrete elevated levels of IL-17A, IFN# and TNF! compared to 
B27- controls (495). The proportion of circulating KIR3DL2+ IL-17-secreting cells is 
increased in SpA patients compared to healthy controls (495). This population has been 
shown to be enriched for IL-23R-expressing cells, with SpA patients again having a 
greater proportion of circulating IL-23R+ KIR3DL2+ CD4+ T cells, compared to healthy 
controls (495). These populations were further enriched within inflamed joints compared 
to peripheral blood (495). These data indicate that SpA patients have an increased 
proportion of circulating and tissue-resident KIR3DL2+ Th17 cells, shown to proliferate in 
response to HLA-B272 molecules highlighting an additional role for HLA-B272 in AS 
pathogenesis. 
Investigation of HLA-B272 surface molecules has been hampered through a lack of 
specific antibodies. However several antibodies have recently been identified to bind these 
homodimers, including the HD6 monoclonal antibody (502, 503). Given the abnormalities 
of DC function in rat models of SpA, and the expression of MHC class I molecules on 
APCs, the expression of HLA-B272 molecules has been assessed on DCs. HLA-B272 
surface expression on monocyte-derived DCs was intensified following cell activation and 
appeared transient in nature (504). However, no difference was observed in homodimer 
expression between AS patients and healthy controls (505). 
Current data suggest that KIR3DL2 ligation, through binding of HLA-B272, may promote 
cell activation and cytokine release, with a higher proportion of KIR3DL2+ CD4+ IL-17A-
secreting T cells being observed in SpA patients. These cells may perpetuate disease 
pathogenesis. While the formation of HLA-B272 molecules and generation of free heavy 
chains is not restricted to those HLA-B27 subtypes associated with AS susceptibility (506), 
"2m dissociation from surface HLA-B27 heterodimers is more frequent in AS-associated 
HLA-B27 subtypes (507). Expression of these HLA-B272 molecules in vivo, in healthy 
controls and AS patients remains to be established. In addition, any HLA-B272 molecules 
formed in the ER that fail to reach the cell surface may be involved in a process termed ER 
stress, described below. Therefore HLA-B272 molecules may promote inflammation in AS 
patients through several pathways. 
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1.6.3 ER stress 
A separate hypothesis regarding the mechanism of AS development relates to the 
propensity for HLA-B27 to form intracellular homodimers within the ER (496). This 
protein misfolding leads to the accumulation of HLA-B27 molecules within the ER (508, 
509). It has been reported that approximately 70% of newly synthesised HLA-B27 heavy 
chains are misfolded within the ER (508, 509). This unique propensity for HLA-B27 to 
misfold within the ER is supported by several observations: HLA-B27 heavy chains have 
an increased tendency to enter the ER-associated degradation pathway (510); extended 
interactions with the ER chaperone molecule, binding immunoglobulin protein (BiP) have 
been observed; HLA-B27 protein folding and maturation is retarded compared to HLA-B7 
(511, 512). BiP is an ER chaperone molecule that binds to newly created proteins 
following ER translocation and forms stable interactions with misfolded proteins (508). 
This tendency for HLA-B27 to misfold within the ER is unique amongst MHC Class I 
molecules (508). 
ER homeostasis relies on the generation of stable protein complexes following protein 
influx, and the expulsion of misfolded proteins through endoplasmic-reticulum-associated 
protein degradation (ERAD) (508). Following sufficient aggregation of misfolded proteins, 
homeostasis is lost and ER stress pathways are initiated. These pathways are collectively 
known as the unfolded protein response (UPR) (508). The function of the UPR is to restore 
ER homeostasis through restoration of the protein folding, secretion and degradation 
pathways (508). Several proteins are responsible for the transduction of stress signals from 
the ER to the nucleus, to initiate the UPR: inositol requiring enzyme 1! (IRE1!), 
pancreatic ER eIF2! kinase (PERK) and activating transcription factor 6! (ATF6!) (513). 
Under homeostatic conditions, BiP is bound to the nuclear sensors inhibiting UPR 
activation (508). A diagram depicting the major ER stress pathways is shown in Fig. 1.7. 
The UPR initiates several pathways to restore homeostasis including induction of 
chaperone molecule generation (514, 515), promotion of ERAD (516) and autophagy 
activation (517, 518). If ER stress cannot be overcome, then apoptosis often ensues, 
accompanied by the release of pro-inflammatory factors including IL-6 and TNF! (493, 
498, 508). The UPR can also stimulate pro-inflammatory responses to repair damage 
caused by UPR induced cell death (519). Therefore, given the propensity for HLA-B27 to 
misfold and the biological responses associated with subsequent UPR activation, the roles 
of these pathways have been investigated both in AS and in animal models of SpA.  
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Figure 1.7: Diagram depicting ER stress pathways 
Pathways involved in the transmission and activation of ER stress and the unfolded protein 
response. uXPB-1 = unspliced XBP-1, sXBP-1 = spliced XBP-1. 
BM-derived macrophages from HLA-B27 TG rats exhibited elevated levels of BiP, CHOP 
and spliced XBP-1 expression, suggesting activation of the UPR. This pathway was 
promoted through IFN# exposure (520). The HLA-B27 TG rat model that expresses 
increased levels of "2m did not exhibit similar activation of the UPR pathway, and 
displayed reduced HLA-B27 misfolding (459). These observations support the relationship 
between HLA-B27 misfolding and UPR activation. However, the overexpression of "2m, 
despite a reduction of UPR activation, increased disease severity in terms of spondylitis 
and arthritis (459). Intestinal inflammation was severely diminished in this model, 
suggesting that HLA-B27 misfolding may be most important for SpA related intestinal 
inflammation (459). Consistent with this hypothesis, UPR over-activation has been 
observed in intestinal tissue isolated from UC and CD patients (521). 
Further investigations have highlighted differences in cell susceptibility to HLA-B27 
misfolding. Cells of the myeloid lineage, specifically macrophages, are more susceptible to 
HLA-B27 misfolding than isolated splenocytes, following cytokine exposure (522). Given 
this apparent myeloid propensity for ER stress, UPR activation and the inflammatory 
consequences of this pathway have been studied in greater detail in BM-derived 
macrophages. Following LPS and IFN# stimulation, upregulation of the UPR in HLA-B27 
TG BM-derived macrophages via BiP and XBP-1 splicing was observed (481). Activation 
of the UPR subsequent to HLA-B27 misfolding was observed to enhance IL-23 production 
(481). CD11b/c+ cells isolated from the LP of HLA-B27 TG rats showed selective 
upregulation of BiP and IL-23 and IL-12 secretion (481). Overall, HLA-B27 misfolding 
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may result in ER stress and UPR activation, and may augment TLR-4 induced IL-23 
secretion by myeloid cells.  
Despite evidence from animal models, described above, implicating a role for ER stress 
and UPR activation in the pathogenesis of SpA, similar observations have not been 
observed in human disease. Monocyte-derived macrophages from AS patients stimulated 
with IFN# and LPS did not exhibit upregulation of BiP or CHOP (523). Another study 
failed to detect a difference in BiP expression or XBP-1 splicing in monocyte-derived DCs 
and circulating lymphocytes isolated from AS patients (505). 
Intestinal samples from AS patients, CD patients and healthy controls were analysed for 
activation of the UPR and autophagy pathways. LP mononuclear cells failed to exhibit 
upregulation of the UPR pathway, although XBP-1 unspliced was upregulated in LP 
mononuclear cells (LPMCs) isolated from the chronically inflamed ileum of AS patients 
(524). In contrast, several autophagy associated genes were upregulated in response to 
misfolding in the chronically inflamed ileum of AS patients: autophagy-related protein 16-
1 (ATG16L1), immunity-related GTPase family M protein (IRGM) and microtubule-
associated proteins 1A/1B light chain 3A (MAP1LC3A) (524). Inhibition of the autophagy 
pathway in AS and CD patients and healthy controls reduced IL-23 secretion from LPMCs 
(524). Inhibition of the UPR did not replicate these IL-23-related observations (524). 
These findings reject a role for UPR activation and ER stress induction in human disease. 
However, HLA-B27 misfolding in AS patients may induce activation of the autophagy 
pathway enhancing IL-23 production, contributing to the elevated levels of IL-23 in AS 
and CD patients (524). 
1.7 Immunopathogenesis of AS 
The direction of many human AS studies have been influenced by the findings from the 
animal models described above. Consequently, many AS studies focus on serum cytokines 
and circulating T cells. 
1.7.1 Cytokines 
Serum isolated from AS patients and HCs is often analysed to determine the cytokine 
profile of AS patients. In terms of pro-inflammatory cytokines, TNF! and IL-8 have been 
found to be elevated in AS patients (525-527). Anti-TNF! therapies have shown a certain 
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degree of efficacy in disease inhibition, as discussed below, supporting a role for these 
inflammatory hormones in disease pathogenesis. The remaining cytokines associated with 
disease include those associated with the Th17 phenotype. For instance, the primary 
cytokine released by Th17 cells, IL-17A, has been found to be upregulated in AS patients 
compared to healthy controls in numerous studies (49, 181, 527-529). IL-6 promotes 
differentiation of Th17 cells in humans (107, 109) and has additionally been found to be 
upregulated in the serum of AS patients compared to healthy controls (49, 525-527). 
Furthermore, IL-6 expression correlated with markers of inflammation: erythrocyte 
sedimentation rate (ESR) and C-reactive protein (CRP), and spinal function (525, 526). 
However anti-IL-6 therapy (Tocilizumab) recently failed to show efficacy through 
inhibition of IL-6 engagement to the IL-6R (23).  
Supporting a role for the hypothesis that AS is a Th17 mediated disease, Th17 effector 
cytokines IL-6, IL-22, IL-23 and TNF! are upregulated in AS patient serum (49, 527-530). 
Furthermore, recombinant IL-23 has been shown to preferentially enhance IL-17 secretion 
by patient peripheral blood mononuclear cells (PBMCs) (528). However, a study by 
Wendling et al failed to detect upregulation of the IL-12/23 p40 subunit in patient serum, 
although IL-12/23p40 concentration was elevated in AS patient SF (531). However, 
current data indicates systemic upregulation of Th17-associated cytokines in AS. 
Supporting a Th1 circulating phenotype of AS patients, IFN# and IL-2R levels are reported 
to be elevated in serum (526, 532). IL-12p70, secreted by DCs and macrophages, and 
required for Th1 induction, has been reported to be elevated in patient serum compared to 
healthy controls (49). The role of Tregs in AS pathogenesis remains controversial, as will 
be discussed below; however several immunomodulatory molecules have been found to be 
upregulated in AS patient serum: IL-10 and TGF" (49, 532). Overall, the serum of AS 
patients contains a vast array of immunogenic (Th17 and Th1) and tolerogenic (Treg) 
associated cytokines, which may influence disease pathogenesis. 
Patient serum cytokine data predominantly implicate Th17 cells and TNF! in the 
pathogenesis of disease, however the cellular sources and functions of these cytokines have 
not yet been elucidated in AS.  
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1.7.2 T cells 
As described in section 1.2.2, numerous circulating T cell phenotypes have been identified 
in humans including Th1, Th2, Th17, Th22 and Tregs. In addition, several unusual T cell 
populations and CD8+ T cells have been studied in AS. 
A population of cytotoxic CD3+ CD4+ CD57+ CD28+ T cells is increased in AS patients 
compared to HCs. Further phenotypic analyses found this population to secrete IFN# and 
perforin upon activation, sharing a phenotypic and functional likeness with NK cells. This 
population increased in response to inflammation, as measured by ESR (533).  
A higher proportion of CD8+ IL-4+ regulatory T cells are also observed in AS patients 
compared to HCs (534). However, the functional attributes of this circulating population 
have not yet been elucidated. Classical CD8+ populations have been studied, with no 
difference being observed between AS patients and healthy controls (535).  
A higher proportion of circulating IL-23R+ T cells in AS patients compared to HCs has 
been observed, with the majority #/$ T cells (536).  These cells were found capable of IL-
17 secretion and may represent a source of IL-17 contributing to the elevated serum levels 
in AS patients (536).  
AS patients have been shown to have elevated proportions of circulating activated T cells 
compared to healthy controls (535, 537). Several studies have focused on Th17 cells and 
Tregs given their role in inflammatory disease and tolerance respectively. Correlating with 
the upregulation of Th17 associated cytokines (IL-17, IL-22, TNF!, IL6 and IL-23) in 
patient serum, several studies support the involvement of Th17 cells in disease 
pathogenesis (181, 527, 530, 535, 538, 539). The circulating Th17 cells express CD4, 
CD45RO, CCR6 and CCR4 (181). Despite this, several studies reject the idea that 
circulating Th17 cells contribute to AS pathogenesis (536, 540). However, the 
overwhelming majority of studies suggest a contribution of Th17 cells to AS pathogenesis, 
given that cytokines they secrete are upregulated in patient plasma and that they expand in 
AS patient blood. 
IL-22-secreting T cells (Th22) (181, 530) are increased in the blood of AS patients, as in 
other inflammatory diseases including RA, psoriasis and SLE (129, 530, 541, 542). In 
addition, Th1 and Th2 cells are reportedly increased in AS patient plasma compared to 
healthy controls, although these observations remain disputed (181, 527, 535). In terms of 
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activated circulating T cell populations, AS patients appear dominated by the Th17 and 
Th22 pathogenic populations. 
Similar to the studies described above investigating the phenotype of circulating T cells in 
AS patients, data on the proportions of circulating Tregs is controversial. Numbers of 
Tregs, predominantly identified through their expression of FOXP3, may be increased 
(527, 538), decreased (539, 543) or unchanged (540) compared to healthy controls. 
Furthermore, CCR4+ CD4+ T cells are elevated in AS patients and may represent a 
regulatory population given their observed correlation with IL-10 serum levels (532). 
Clearly, the role of Tregs in AS pathogenesis requires further investigation. 
1.7.3 Myeloid cells 
Only three studies have investigated the function of myeloid derived cells in AS 
pathogenesis, albeit through the generation of monocyte-derived DCs (moDCs). Firstly, 
proteomic analysis of AS patient monocytes revealed an increase in proteasome associated 
proteins, and molecules associated with TLR signalling, vascular endothelial growth factor 
(VEGF) and integrin pathways (544). This data set suggests alterations to the function of 
circulating monocytes in terms of their response to exogenous signalling and antigenic 
processing. 
CD14+ monocytes isolated from blood and grown in the presence of IL-4 and GM-CSF for 
approximately 7 days are termed moDCs. Many DC based studies exploit this technique, 
given the relative ease of generating large numbers of moDCs, and subsequently compare 
those generated from patients and healthy controls. DCs generated under these conditions 
are thought to replicate the phenotype and function of inflammatory DCs (545). Using this 
system, moDCs isolated from AS patients express lower levels of MHC II under resting 
conditions, although the functional consequences of this observation have yet to be 
determined (546, 547). Despite this apparent down-regulation of MHC II, no difference in 
the expression of co-stimulatory molecules including CD80, CD86 and CD83 has been 
observed (546, 547). Furthermore, in comparison to healthy controls, AS patient moDCs 
did not differ in their secretion of IL-23 following TLR 7, 8 and 3 stimulation and did not 
differ in their baseline cytokine production (547). Overall moDCs generated from AS 
patients have similar functions to those isolated from healthy controls. The phenotype and 
functions of in vivo DC and macrophage populations have not been assessed in AS. 
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1.7.4 Peripheral tissue 
Investigations in AS have focused on the intestine, facet joints and SF. Pathological 
changes at these sites in AS patients are termed extra-articular manifestations. 
Understanding the immunological pathways involved in the perpetuation of inflammation 
at these sites can aid the understanding of the relationship between these extra-articular 
sites, peripheral joints and AS development and pathogenesis. 
SF, more commonly associated with RA, isolated from AS patients has been shown to 
contain a higher proportion of CD4+ FOXP3+ Tregs compared to RA patients and AS 
patient blood (540, 548). These SF Tregs possess suppressive activity, inhibiting 
proliferation and cytokine production from effector CD4+ populations (548). However, 
another study noted that following isolation, SF Tregs failed to secrete IL-10, IL-2, IFN# 
or TNF! (549). Overall, these data suggest that Tregs are present within SF and may 
inhibit effector T cell populations. 
IL-17+ cells, predominantly myeloperoxidase (MPO) positive cells and CD15+ neutrophils, 
are increased in the facet joints of AS patients compared to osteoarthritis (OA) (540). 
These data are consistent with IL-17 involvement in disease pathogenesis, and also 
highlight a potential role for the innate immune response through secretion of IL-17. This 
study further characterised SF Th17 cells and observed no difference compared to OA 
samples (540). Furthermore, subchondral BM isolated from AS patients has been shown to 
contain a higher proportion of IL-23+ cells compared to OA patients, again involving 
MPO+ cells, however macrophages and DCs additionally contributed to this IL-23 
signature (550). 
As described throughout this introduction, there is a strong association between AS and the 
intestinal environment.  SpA symptoms do not develop in HLA-B27 TG rats raised under 
germ-free conditions, at least 50% of AS patients show evidence of intestinal 
inflammation, and 54% of IBD sufferers expressing HLA-B27 eventually develop AS (4, 
13, 440, 441). Unsurprisingly therefore, the intestinal environment of AS patients has been 
studied in some detail. 
Within the SI of AS patients, an increase in IL-23, IL-32 and TGF" mRNA transcripts has 
been observed compared to healthy controls (551, 552). Infiltrating cells with myeloid 
morphology and Paneth cells are responsible for producing this IL-23 (551). Perhaps 
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contradicting the systemic involvement of Th17 cells, IL-17A, IL-6, TNF! and IL-1" 
levels were relatively low compared to CD patients and HCs (551). Furthermore, IL-4 and 
IL-5 levels were elevated, suggesting intestinal Th2 polarisation in AS patients (551). 
AS patients who developed chronic ileal inflammation showed elevated transcript levels of 
FOXP3 and the regulatory associated cytokines IL-2, TGF" and IL-10 within the small 
intestine (552, 553). The increase in intestinal CD4+ IL-10-secreting Tregs may contribute 
to the levels of these cytokines (553). Specifically, there was a 5 fold increase in intestinal 
Tregs in AS patients compared to HCs, with 70-80% secreting IL-10 (553). Furthermore, 
blocking IL-10 promoted Th17 polarisation in LPMCs isolated from AS patients (553). 
These data suggest that functional Tregs within the intestine of AS patients may be 
actively inhibiting the expansion or development of Th17 cells in an IL-10-dependent 
manner. 
Given the increase in circulating Th22 cells in AS patients, and their association with 
inflammatory disease, the role of intestinal IL-22 has been investigated in AS. Within the 
inflamed small intestine of AS patients, there was a selective expansion of the IL-22-
secreting CD3- CD56+ NKp44+ NK cell subset in AS patients compared to healthy controls 
(554). No difference was observed in the IFN#-producing CD3- CD56+ NKp46+ NK subset 
(554). Accordingly, IL-22 levels were increased within intestinal tissue isolated from AS 
patients (554). Overall, IL-22 and IL-23 appear to dominate the cytokine profile of 
intestinal inflammation in AS patients whilst functional Tregs are expanded within this 
environment, presumably to dampen the ongoing inflammatory response. 
1.7.5 Treatment of AS 
1.7.5.1 Therapeutic categories used in the management of AS 
The treatment of AS has developed over recent years to include biological therapy, 
disease-modifying antirheumatic drugs (DMARDs) and non-steroidal anti-inflammatory 
drugs (NSAIDs). The biological therapies, NSAIDs and DMARDs commonly used in the 
treatment of AS are listed in Table 1.6. Biological therapies in AS are currently restricted 
to those targeting and inhibiting TNF!. They act to prevent TNF! engagement of the TNF 
receptor by binding to circulating TNF!. 
NSAIDs are moderately effective in the treatment of AS and are often the first course of 
disease treatment (4). Patients in whom NSAIDs fail to control symptoms progress, 
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depending on disease symptoms, to DMARD or biological therapy (4). However, 
DMARDs are not effective for the treatment of AS patients presenting with axial 
symptoms (23, 555, 556). 
Table 1.6: Drugs used in the management of AS 
Drugs commonly used in the treatment of AS can be subdivided into three categories: NSAIDs, 
DMARDs and biologics. Examples are listed in the table. 
Categories Examples 
NSAID COX-2 inhibitors, Ibruprofen, Naproxen, 
Etodolac, Diclofenac, Etoricoxib 
DMARD Sulphasalazine, Methotrexate, 
Azathioprine 
Biologic Adalimumab, Etanercept, Infliximab 
 
1.7.5.2 Assessment of disease activity 
In order to assess disease status, progression and therapeutic effectiveness, AS patients 
undergo several immunological and physiological tests. Levels of systemic inflammation 
are routinely determined by erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP). To assess disease activity and joint function, several distinct tests may be 
performed. These are outlined in Table 1.7. 
Table 1.7: Assessment of disease severity and therapeutic response 
Four tools, either in the form of a questionnaire or performed by a clinician, contribute to 
assessment of disease activity in AS. 
Functional Assessment Output Score 
Bath AS Disease 
activity index (BASDAI) 
Questionnaire to assess 
pain, fatigue and stiffness 
0-10 
Bath AS metrology 
index (BASMI) 
Clinical measurements to 
determine axial function 
0-10 
Bath AS functional 
index (BASFI) 
Questionnaire to assess 
functional limitations and 
patient mentality 
0-10 
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Bath AS patient global 
score (BAS-G) 
Patient assessment of 
disease impact over time 
0-10 
 
1.7.5.3 Effectiveness of therapeutics 
The effectiveness of biological therapy on AS patient disease activity is continually 
assessed. Furthermore, several studies have focused on the patient immunological profile 
following anti-TNF! treatment in order to elucidate the pathways involved in disease 
progression and the in vivo mechanisms underlying the response to blocking TNF!. 
Anti-TNF! has been shown to slow radiographic progression (22, 557, 558). Etanercept, 
amongst other anti-TNF! blockers, led to improvements in disease activity through 
BASDAI assessment, CRP, ESR and axial function (531, 559-561). In one study, anti-
TNF! therapy reduced BASDAI scores by 70% (561). 
With regards to the immunological response, circulating levels of several cytokines 
including IL-6, IL-17A, IL-23 and TNF! have been reduced following biological therapy 
(539, 561). However, TNF! blockers do not appear to inhibit IL-12/23p40 secretion (531). 
Associated with these alterations to the cytokine profile of AS patients following 
biological therapy, the proportion of activated T cells (537), Th1 (527) and Th17 (527, 
539) subsets returned to baseline levels. Furthermore, the numbers of circulating Tregs and 
serum TGB" increase in response to anti-TNF! treatment, supporting a shift from 
immunogenic to tolerogenic responses in AS patients. However, one study disputes this 
hypothesis with the observation that the proportion of CD8+ T cells and IFN#+ and TNF!+ 
CD4+ T cells increased following anti-TNF! treatment (562). 
Despite these advances in disease treatment, approximately 50% of patients remain 
unresponsive to current therapeutics (4, 23) highlighting the need for further investigation 
of the pathways involved in disease pathogenesis to guide development of future 
therapeutics. 
1.8 Hypotheses and aims 
Investigations using animal models of SpA suggest a role for DCs in the pathogenesis of 
SpA. Specifically, we observed a systemic DC defect in the HLA-B27 TG rat model of 
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SpA, with the CD103+ MHC II+ CD11bint CD172alo subset absent from intestinal lymph 
and MLNs (480). The absence of this reportedly tolerogenic DC subset (372) supported the 
differentiation and maintenance of a Th17 type immune response, characterised through 
the preferential secretion of IL-17 by CD4+ T cells cultured with HLA-B27 TG BM-
derived DCs (480). Furthermore, no studies have yet investigated the phenotype and 
functions of circulating DC populations in AS patients. Therefore the aim of my thesis was 
to study the phenotype and function of circulating DCs in AS, directly ex vivo, to elucidate 
any potential role in the development or perpetuation of AS.    
Based on previous work from our laboratory we hypothesised that the human CD141+ DC 
population, equivalent to the CD11bint CD172alo rat DC population, would be absent or 
significantly reduced in AS patients compared to HCs. We also hypothesised that the 
remaining AS patient DCs would subsequently induce aberrant immune responses through 
the generation of pathogenic T cells, as in the HLA-B27 TG rats. In order to test these 
hypotheses we identified and analysed the proportions of circulating DCs (chapter 3) and 
assessed their ability to induce T cell proliferation and chemokine receptor expression 
(chapter 6). Furthermore, we characterised the circulating T cell profile of AS patients 
(chapter 4) in order to identify the T cell populations dysregulated with disease, and permit 
inferences regarding the ongoing in vivo DC: T cell priming events. We also set out to 
elucidate the immunological mechanisms involved in the perpetuation of peripheral 
disease in AS patients, specifically the SF (chapter 5) and the intestine (chapter 8). The 
immune populations involved in AS pathogenesis were subsequently assessed for their 
relationship with patient clinical parameters (chapter 7). By performing these experiments, 
we hoped to elucidate the immunological pathways involved in disease development and 
perpetuation, with the hope of identifying future molecules or cellular populations that 
could be targeted for much-needed future AS therapeutics.  
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Chapter 2: Materials and Methods 
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2.1 Patient blood samples 
Patients were recruited from the rheumatology clinic run by Dr David McCarey and Dr 
Anne McEntegart at the Glasgow Royal Infirmary. All patients had been clinically 
diagnosed with AS and had consented to donating blood or synovial fluid (SF) samples to 
this project. For each patient the following information was collected (Figure 2.1): Spinal 
disease levels (identification of sacroiliitis, peripheral arthritis and spinal disease – 
cervical, thoracic and lumbar), extra-articular manifestation diagnoses (presence of IBD, 
uveitis, arthritis and psoriasis), HLA-B27 status, inflammatory markers (ESR and CRP), 
disease duration, disease score (bath ankylosing spondylitis disease activity index 
(BASDAI) and ankylosing spondylitis disease activity score (ASDAS)) and disease 
treatment protocol. Categories of treatment protocol included: non-steroidal anti-
inflammatory drugs (NSAIDs); disease modifying anti-rheumatic drugs (DMARDs); and 
biological therapy. The patient samples were predominantly collected under the ethical 
application titled “Institute of Infection, Immunity and Inflammation Research Tissue 
Bank” (REC reference: 11/S0704/7). Healthy controls (HCs) were recruited from within 
the Institute of Infection, Immunity and Inflammation at the University of Glasgow. Each 
individual gave informed consent and completed consent forms that complied with the 
ethical application entitled “Acquisition of healthy donor peripheral blood to provide 
normal values to allow interpretation of disease states in terms of immune system 
function” granted by the College of Medical, Veterinary & Life Sciences Ethics 
Committee for Non-Clinical Research Involving Human Subjects. Initially, no restrictions 
were set on the age of HCs, however as the project progressed only individuals )30 years 
of age were recruited. Restrictions on participation included: age, disease status and a bias 
towards male participation was encouraged to control more closely for the characteristics 
of the AS patient population. 
2.2 Intestinal samples 
Small intestinal and colonic samples were obtained from the National Health Service 
Greater Glasgow and Clyde (NHSGGC) Biorepository. Excess tissue samples were 
collected during intestinal surgery under the Biorepository NHSGGC ethics application 
entitled “Mononuclear phagocytes in intestinal tissues”,  
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Figure 2.1: Patient data collection sheet 
Data sheet used to collect clinical data during clinic or from patient files for every AS patient 
participating in this study through donation of blood samples. 
application number 65. Patient consent was gained for every sample processed. Samples 
were collected from the pathologist at the Southern General Hospital, Glasgow and stored 
Information on ankylosing spondylitis patients who have blood sent to university 
for testing 
 
Date      
 
Affix patient label here                                                    Sacroileitis only…MRI…. 
                                            
                                                                                         Peripheral arthritis…No…….. 
 
                                                                                         Spinal disease(which  levels) 
                                                                          
                                                                                         ……Not known…………… 
                                                                                          
                                                                                         ……………………………… 
                                                                                           
Other coexisting clinical diagnoses 
  
            IBD 
 
 Uveitis 
 
 Psoriasis 
 
 
HLA B27 status(+/-/unknown)…+ve. 
 
 
ESR…4…..                                CRP…0.3…… 
 
  
Onset of symptoms…2007………..                        Year diagnosis made …2009….. 
 
 
BASDAI score…2.76…… 
 
ASDAS…0.7…………... 
 
Spinal VAS score……2……… 
 
 
Treatment 
 
NSAIDs……Diclofenac……………………… 
 
DMARD……Nil…………………………. 
 
Biologic therapy……Nil……………………….. 
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in sterile PBS on ice until used. Patient information for every sample was provided. 
Clinical parameters collected included: sex, age, ethnic group, disease type, smoking 
status, alcohol consumption, reason for and type of surgery, current medication, blood 
pressure, previous medical history including previous surgeries and any other relevant 
donor information. 
2.3 Cell culture medium 
Cells were cultured in 10% complete media (R10) consisting of: Roswell park memorial 
institute (RPMI) 1640 medium supplemented with 10% fetal calf serum (FCS), 2mM L-
Glutamine, 100U/ml penicillin, 100µg/ml streptomycin and 50µM 2-mercaptoethanol 
(Invitrogen, UK). 
2.4 Blood collection 
Whole blood was collected in green 6ml vacutainer lithium/heparin tubes (BD 
Biosciences). All venepuncture procedures were carried out by qualified medical 
practioners based at the Glasgow Royal Infirmary (AS patients) or at the clinical facility in 
the British Heart Foundation (BHF) building at the University of Glasgow (HCs). Blood 
was processed within 2 hours of sample collection. 
2.5 PBMC isolation 
To isolate peripheral blood mononuclear cells (PBMCs), 10ml of whole blood was layered 
on top of 4ml of histopaque – 1077 (Sigma-Aldrich, Poole, UK) and spun at 2,100rpm for 
20 minutes at room temperature, with no brake being applied. For optimal separation, both 
blood and histopaque should be at room temperature before processing. This gradient 
generates 5 layers: - plasma, PBMCs, histopaque, granulocytes and red blood cells. 
Aliquots of plasma (1.5ml) were stored at -80°C for subsequent analysis. The PBMC layer 
was harvested and washed twice in FACS buffer: PBS (Gibco, Life Technologies, Paisley, 
UK), 2% FCS and 2mM EDTA (Sigma-Aldrich), at 1,500rpm for 5 minutes at 4°C. Cells 
were counted and resuspended at 2-5 x 106 cells/ml of R10 or FACS buffer. 
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2.6 Flow cytometry and monoclonal antibodies 
2.6.1 Surface staining 
Cells were spun down in 6ml FACS tubes (BD Biosciences, UK) at 1,500rpm for 5 
minutes. Supernatant was removed and cells incubated with Fc block (5µl - eBioscience) 
for 10 minutes at 4°C. Without washing, cells were incubated with fluorescently labelled 
antibodies for a further 25 minutes at 4°C in the dark. Cells were washed in FACS buffer, 
again at 1,500rpm for 5 minutes. Supernatant was removed. If a biotinylated antibody had 
been used in the antibody cocktail a streptavidin step was required. Under these 
circumstances, 200ul of fluorescently labelled streptavidin mix was added to the 
appropriate tubes and incubated at 4°C in the dark for 20 minutes. In the final 5 minutes of 
the streptavidin step or main antibody step, 3ul of DAPI (50ng/ml - Invitrogen) or 20µl of 
7AAD (Biolegend) was added to all sample tubes to stain dead cells. All antibodies were 
subsequently washed off in 2ml of FACS buffer by centrifuging at 1500rpm for 5 minutes 
at 4°C. Cells were resuspended in 200µl of FACS buffer and run on the BD LSR II (BD 
Biosciences) or MACS Quant analyser (Miltenyi Biotech). All data analyses were 
performed using FlowJo software (Tree Star Inc., USA - versions 8.8.4 or 9.2). Antibodies 
used for flow cytometry are listed in Table 2.1. 
Table 2.1: List of monoclonal antibodies used for flow cytometry 
Primary antibodies were conjugated to various fluorochromes: FITC, PE, PE-CY5, PERCP, PE-
CY7, APC, APC-CY7, AF700, V450, V500, BV421 and BV605. Several antibodies used in my 
staining panels were biotin conjugated and therefore I used several streptavidin conjugates 
including PERCP, PE-CY7, V450, BV421, BV605 and Q-DOT 605. m = mouse, r = rat. 
Marker Clone Isotype Source Conc. Conjugate 
CD3  UCHT-1 mIgG1k Biolegend 1:40 FITC 
CD4  OKT4 mIgG2b Biolegend 1:200 Biotin 
CD8  HIT8a mIgG1k Biolegend 1:200 Biotin 
CD1c AD5-8E7 mIgG2a Miltenyi Biotec 1:10 APC 
CD11b  ICRF44 mIgG1k Biolegend 1:20 APC 
CD11c  B-Ly6 mIgG1k BD Biosciences 1:20 PE-CY5/V450 
CD14 M5E2 mIgG2a Biolegend 1:40 FITC/AF700 
CD15 W6D3 mIgG1k Biolegend 1:40 FITC 
CD16 3G8 mIgG1k Biolegend 1:40 PE-CY7 
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CD19 HIB19 mIgG1k Biolegend 1:40 FITC 
CD25 BC96 mIgG1k Biolegend 1:40 PE 
CD33 WM53 mIgG1k Biolegend 1:40 APC 
CD40 5C3 mIgG1k Biolegend 1:10 APC 
CD45 HI30 mIgG1k Biolegend 1:40 BV510 
CD45RA HI100 mIgG2b Biolegend 1:20 APC-CY7 
CD56 MEM-188 mIgG2a Biolegend 1:40 FITC 
CD64 10.1 mIgG1k Biolegend 1:40 APC 
CD69 FN50 mIgG1k Biolegend 1:40 PE 
CD80 2D10 mIgG1k Biolegend  1:40 APC 
CD86 IT2.2 mIgG2b Biolegend 1:10 APC 
CD103 B-ly7 mIgG1k eBioscience 1:40 PE-CY7 
CD115 12-3A3-
1B10 
rIgG2a eBioscience 1:200 Biotin 
CD123 6H6 mIgG1k Biolegend 1:20 PE-CY5 
CD135 BV10A4H2 mIgG1k Biolegend 1:10 APC 
CD141 1A4 mIgG1k BD Biosciences 1:20 PE 
CD163 GH1/61 mIgG1k Biolegend 1:200 Biotin 
CD172a SE5A5 mIgG1k Biolegend 1:200 Biotin 
CD206 15-2 mIgG1k Biolegend 1:10 PE 
CD209 eB-h209 rIgG2ak eBioscience 1:40 PE-CY7 
CD303 AC144 mIgG1 Miltenyi Biotech 1:40 PE 
CD304 AD5-17F6 mIgG1 Miltenyi Biotech 1:40 PE 
CCR2 48607 mIgG2b R + D Systems 1:20 PE 
CCR4 1G1 mIgG1k BD Biosciences 1:40 APC 
CCR6 11A9 mIgG1k BD Biosciences 1:20 APC 
CCR9 248621 mIgG2a R + D Systems 1:5 APC 
CCR10 314305 rIgG2a R + D Systems 1:10 APC 
CXCR3 G025H7 mIgG1k Biolegend 1:40 APC 
CX3CR1 2A9 rIgG2b MBL 1:10 PE 
Annexin V   BD Biosciences 1:50 PE 
FOXP3 PCH101 rIgG2a eBioscience 1:10 FITC 
HLA-B27 HLA-ABC-
m3 
mIgG2a AbD Serotec 1:100 FITC 
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HLA-B7 BB7.1 mIgG1 AbD Serotec 1:100 FITC 
IFN! 4S.B3 mIgG1k Biolegend 1:40 FITC 
IL-17A BL168 mIgG1k Biolegend 1:40 PE 
IL-23R 218213 mIgG2b R + D Systems 1:20 APC 
Ki67 B56 mIgG1 BD Biosciences 1:200 APC 
MHC II L243 mIgG2a Biolegend 1:40 APC-CY7 
ROR!t AFKJS-9 rIgG2b eBioscience 1:200 PE 
SLAN DD-1 mIgM Miltenyi Biotec 1:20 Biotin 
TcR"# IP26 mIgG1k Biolegend 1:40 PE-CY7 
 
2.6.2 FACS cell sorting 
PBMCs were processed as described above. Cells were counted, resuspended at 2 x106 
cells/ml in 10% complete media and left at 4°C overnight. Cell sorting was performed the 
day following PBMC isolation. Cells were re-counted before continuing with the FACS 
staining protocol. Cells were separated into sterile FACS tubes, washed in FACS buffer 
and incubated with Fc block for 10 minutes at 4°C. Without washing, cells were 
subsequently incubated with 400µl of the appropriate antibody mix for a further 25 
minutes at 4°C, in the dark. The cells were washed in FACS buffer, again at 1,500rpm for 
5 minutes. If a biotinylated antibody had been used in the main antibody cocktail, then a 
streptavidin step was required.  If this was the case, 400ul of the streptavidin mix was 
added to the appropriate tubes and incubated at 4°C in the dark for 20 minutes. On 
occasion, DAPI (50ng/ml) was added to sample tubes to stain dead cells for 5 minutes. All 
antibodies were then washed off in 2ml of FACS buffer by centrifuging at 1,500rpm for 5 
minutes at 4°C. Cells were then resuspended in FACS buffer at 2 x 106/ml and run on the 
FACSAria. Sorted cell subsets were collected in sterile 6ml FACS tubes containing 2ml of 
10% complete media. After sorting, a purity check was performed for every subset, except 
CD141+ DCs where too few cells were available. 
2.6.3 Intracellular cytokine staining 
Cells were resuspended in sterile FACS tubes at 2-3 x 106 cells/ml of 10% complete 
media. To measure steady state cytokine production, cells were incubated with Brefeldin A 
(10µg/ml, Sigma-Aldrich) and monensin (1µM, Biolegend, UK) or Brefeldin A, monensin, 
phorbol 12-myristate 13-acetate (PMA, 1µM, Sigma-Aldrich) and ionomycin (1µM, 
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Sigma-Aldrich) for stimulated samples. All samples were incubated at 37°C for 4.5 hours 
in the dark. After incubation, cells were washed in FACS buffer. Surface staining was 
performed as described in the FACS staining description (section 2.6.1). After washing off 
all antibodies in FACS buffer, cells were resuspended in 1ml of fix/perm buffer 
(eBioscience intracellular staining kit). Cells were then incubated at room temperature for 
30 minutes before being washed twice in 2ml of 1x PERM buffer at 1,500rpm, 4°C for 5 
minutes. Supernatant was removed and 10µl of Fc block was added to every tube and 
incubated in the dark at 4°C for 5 minutes. Without washing, and in 1x PERM buffer, 
antibodies were added directly to the appropriate tubes and incubated at 4°C, in the dark 
for a further 45 minutes. Following incubation, cells were washed twice in 2ml of 1x 
PERM buffer at 1,500rpm, 4°C for 5 minutes. Cells were then run on the LSR II 
instrument. 
2.7 Naïve T cell isolation 
PBMCs from whole blood are isolated as described above. Naïve CD4+ T cells were 
isolated from the PBMC fraction using a Naïve CD4+ T Cell isolation kit II (Miltenyi 
Biotec). Cells were washed in FACS buffer at 1,500rpm for 5 minutes at 4°C. Cells were 
then resuspended in 40µl/107 cells of MACS buffer (PBS, 0.5% FCS and 2mM EDTA) 
and 10µl/107 cells of naïve CD4+ T cell biotin antibody cocktail II (containing antibodies 
against CD8, CD14, CD15, CD16, CD19, CD25, CD34, CD36, CD45RO, CD56, CD123, 
CD235a, HLA-DR and TcR#/$). Cells were then mixed and incubated for 10 minutes at 
4°C, following which they were washed using 2ml/107 cells of MACS buffer at 1,500rpm 
for 5 minutes. Supernatant was then completely removed. Cells were subsequently 
resuspended in 80µl/107 cells of MACS buffer and 20µl/107 cells of anti-biotin 
microbeads. Cells were incubated for 15 minutes at 4°C and then washed in 2ml/107 cells 
of MACS buffer as previously described. Cells were resuspended in 500µl of MACS 
buffer and placed on ice until ready for separation. To separate the naïve T cells, magnetic 
separation with LS columns (Miltenyi Biotec) was performed. LS columns were washed 
with 3ml of MACS buffer, to which the sample was then applied. The column was then 
washed 3 times with 3ml of MACS buffer. The flow through from the sample and the 
subsequent washes were collected together and this contained isolated naïve CD4+ T cells. 
Cells were counted and resuspended at 20,000 cells/ml of R10.  
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2.8 Carboxyfluorescein succinimidyl ester (CFSE) 
staining 
Cells to be stained with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) were 
first washed in PBS to remove all culture supernatant. Subsequently, *107 cells were 
resuspended in 1ml of PBS. For cell counts >107, volumes were scaled up appropriately. 
To this, 1µl/ml of a 5mM stock of CFSE was added (final concentration - 5µM). Cells 
were incubated at room temperature, in the dark, for 3 minutes whilst shaking. After 
staining, cells were washed immediately in 10% complete media at 1,500rpm for 5 minutes 
at 4°C. Cells were then recounted and resuspended in R10. 
2.9 Allogeneic mixed leukocyte reaction (MLR) 
Individual cell subsets from HCs and AS patients: CD1c+ and CD141+ DCs, CD16+ 
mononuclear cells and CD14+ monocytes, were isolated using the FACSAria. The DCs 
were then resuspended at the following concentrations: CD141+ - 1500, CD1c+ - 12000, 
CD16+ - 24000 and CD14+ monocytes – 24000 (number of cells/100µl). Doubling 
dilutions of each DC/monocyte subset except CD141+ DCs were performed in a round 
bottomed 96 well tissue culture plate (Corning, USA) using 10% complete media. Isolated 
naïve CFSE+ T cells, from another HC, were resuspended at 20,000 T cells/100µl in 10% 
complete media. To every co-culture well, 100µl of CFSE+ naïve T cells were added. As 
controls, T cells and DCs were also plated out separately, with T cells alone being 
stimulated with 10µg concanavalin A (Sigma-Aldrich). MLRs were incubated at 37°C and 
5% CO2 for 5 days, in the dark.  After 5 days, the 96 well plate was spun down at 
1,500rpm for 5 minutes. To analyse cytokine production from these co-cultures, 100µl of 
supernatant was transferred to a fresh 96 rounded well plate, sealed and stored at -20°C. 
The remaining cells were washed twice in FACS buffer at 1,500rpm, 4°C for 5 minutes. Fc 
block was added to every well with cells left to incubate at 4°C for 10 minutes. Without 
washing, cells were incubated with 50µl of the cocktail composed of antibodies specific for 
CD4, CD25 and either CCR6 or CXCR3. Cells were incubated with the antibodies for 30 
minutes at 4°C in the dark. Antibodies were washed off using FACS buffer and 50µl of 
streptavidin cocktail was added to all appropriate wells for 20 minutes at 4°C in the dark. 
Again, DAPI was added in the final 5 minutes of the streptavidin step to identify dead 
cells. After staining, all antibodies were washed off. Cells were subsequently transferred to 
6ml FACS tubes and analysed on the BD LSR II. 
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2.10 Cytospins and H&E staining 
Cells to be analysed by cytospins were individually sorted using the FACS aria.  
Approximately 30,000 cells were resuspended in 200µl of PBS.  Slides were labelled and 
cells were applied to the slide using the funnel/filter card/harness apparatus. Cells were 
spun at 450rpm for 6 minutes. Cells were then left to air dry at room temperature. For 
hematoxylin and eosin (H&E) staining, the Rapid Romanowsky (RA Lamb) staining kit 
was used. Polysine slides (VWR International) are immersed in fixative, followed by 
hematoxylin and eosin staining for 30 seconds. The slides were washed in distilled water 
and left to dry at room temperature. Once completely dry, a drop of DPX mountant (VWR 
International) was applied, allowing attachment of a cover slip that is further fixed in place 
using nail polish. Cells and pictures were taken using a light microscope and cell^B 
software (Olympus, UK). 
2.11 Annexin V staining 
To identify cells undergoing early apoptosis, Annexin V staining was performed. Cells 
were counted and transferred to 6ml FACS tubes. After washing the cells in FACS buffer, 
the protocol for extracellular FACS staining was carried out as described above (section 
2.6.1). Following extracellular staining, cells were washed twice in cold PBS followed by a 
wash using 1x annexin binding buffer (diluted in PBS, BD) at 1,500rpm, 4°C for 5 
minutes. Supernatant was removed and the PE-conjugated annexin V antibody (BD) was 
added directly to the cells (used at 1:50) and incubated at room temperature in the dark for 
15 minutes. 200µl of 1x annexin V binding buffer was added to every tube while samples 
remained on ice. Samples were run on the LSR II within an hour of staining. 
2.12 Synovial fluid processing 
Synovial fluid (SF) samples were transferred into 50ml centrifuge tubes and spun at room 
temperature for 10 minutes at 2,100rpm. Supernatants were aliquoted and stored at -80°C 
for analysis. If a cell pellet was present, cells were resuspended in a 50:50 mix of 10% 
complete media and PBS. Intense pipetting was occasionally required to disintegrate the 
pellet. A histopaque gradient was used to isolate SF mononuclear cells (SFMCs): - 10ml of 
the cell suspension was layered carefully onto 4ml of histopaque 1077. All reagents were 
at room temperature. Tubes were centrifuged at 2,100rpm, room temperature for 20 
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minutes. The SFMC layer was then isolated and processed as described in the PBMC 
isolation protocol (section 2.5). 
2.13 Isolation of RNA 
After cell suspensions had been generated, cells were washed in PBS to remove culture 
supernatant and spun at 13,000rpm for 10 minutes. Supernatant was completely aspirated 
and cells were resuspended in buffer RLT (Qiagen). The volume of RLT added was 
dependent upon cell number and RNA extraction kit to be used: for samples containing 
*100,000 cells, cells were resuspended in 75µl of buffer RLT and stored at -20°C. RNA 
was extracted using the RNeasy micro kit (Qiagen) for these samples. However for 
samples containing )100,000 cells, 350µl of buffer RLT was used to lyse the cell pellet 
and with the RNeasy mini kit used to extract RNA. All samples were stored at -20°C until 
RNA was to be extracted. The kit-specific protocols were followed but are described 
briefly as follows: cell suspension was lysed using QIAshredder spin columns (Qiagen) 
and spun at 13,000rpm for 2 minutes using a bench top centrifuge. To this, 1 volume of 
70% ethanol was added, mixed thoroughly, transferred to an RNeasy (mini kit) or RNeasy 
MiniElute spin column (micro kit) and spun for 15 seconds at 10,000rpm. After which, 
flow-through was discarded. Columns were washed with 350µl of buffer RW1 at 
10,000rpm for 15 seconds. On column DNase digestion was then carried out by adding 
10µl DNase I stock and 70µl buffer RDD (previously mixed) directly to the spin column 
membrane for 15 minutes at room temperature. If using the RNeasy mini kit, the column 
was washed three times, first with 350µl of buffer RW1 for 15 seconds at 10,000rpm 
followed by two washes (15 seconds/2 minutes) with 500µl of buffer RPE. For the RNeasy 
micro kit, the third wash is replaced with addition of 500µl of 80% ethanol to the spin 
column followed by centrifugation for 2 minutes at 10,000rpm. Following this, the 
MiniElute spin column was centrifuged at 13,000rpm for 2 minutes with the lid open to 
dry the membrane. For both kits, the final step involved the spin columns being placed in a 
fresh collection tube and RNase free water being added to the spin column - 14µl (RNeasy 
micro) or 30µl (RNeasy mini), incubated at room temperature for 5 minutes and spun for 1 
minute at 10,000rpm. RNA was then stored at -20°C in 1.5ml collection tubes until cDNA 
was to be generated. The concentration of RNA (ng/µl) was measured using a nanodrop 
(Amersham Biosciences) immediately before cDNA generation. 
 93 
2.14 Generation of cDNA 
To generate cDNA, the SuperScript First-Strand Synthesis System for RT-PCR kit 
(Invitrogen, UK) was utilised, using approximately 18ng of RNA. The manufacturers 
protocol for cDNA synthesis using Oligo (dT) was followed. Briefly, cDNA generation 
was carried out in 0.2ml eppendorfs or in a 96 well PCR plate. Each sample requires a 
minus reverse transcriptase (RT) control and a fully transcribed sample. The first step 
requires the generation of a master mix. For every sample (sample or minus RT control) 
the following are required: 1µl of 10nM dNTP mix, 1µl of 0.5µg/µl oligo(dT)12-18 primer, 
the volume of RNA required to generate 18ng cDNA (*5µl) and DEPC-treated water to 
give a final volume of 10µl. Using a TProfessional thermocycler (Biometra), samples were 
incubated at 65°C for 5 minutes followed by a 1 minute incubation at 4°C. The second 
master mix was generated during this incubation, containing the following for every 
sample: 2µl of 10x RT buffer, 4µl 25mM MgCl2, 2µl of 0.1M DTT, 1µl of RNaseOUT 
(40U/ml) and either 1µl SuperScript II RT (sample) or 1µl DEPC-treated water (minus RT 
control). Following addition of the second master mix, samples were subjected to the 
following incubations: 42°C for 52 minutes followed by 70°C for 15 minutes with samples 
subsequently held at 4°C. At this point, 1µl of RNase H is added to every tube and 
incubated at 37°C for 20 minutes. The samples are then stored at -20°C. 
2.15 Quantitative real time PcR 
Gene expression was determined by quantitative reverse transcription polymerase chain 
reaction (qRT-PcR) using Brilliant III Ultra Fast SYBR qRT-PcR Master Mix (Agilent). 
Reactions were performed in MicroAmp Fast Optical 96-well reaction plates (Applied 
Biosystems). Reagents for each reaction include: 10µl SYBR green, 0.4µl primer mix, 
0.3µl reference dye (diluted 1:500 with DEPC-treated water, 30nM final concentration), 
8.3µl DEPC-treated water and 1µl of cDNA (diluted 1:5 with DEPC-treated water). Plates 
were covered with an optical adhesive cover (Applied Biosystems) and centrifuged at 
400G for 1 minute. Plates were analysed using a 7500 Fast Real-Time PCR System 
machine (Applied Biosystems). PCR protocol: 95°C incubation for 10 minutes followed by 
40 cycles composed of 15 seconds at 95°C followed by a 60°C incubation for 1 minute. 
Melt curves were performed for each experiment to determine primer suitability and assess 
PcR performance. Samples were assayed in triplicate with expression levels normalised to 
TATA binding protein (TBP). Results analysed and presented using the 2-(C(t) method. 
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  Table 2.2: Primers used for qRT-PCR 
 
2.16 Luminex 
To measure cytokine levels in plasma and culture supernatants, a custom-made Luminex 
from R & D systems was used. The following cytokines were assayed: IL-1", IL-4, IL-5, 
IL-6, IL-10, IL-17, GM-CSF, IFN# and TNF!. The luminex kit protocol was followed. 
Briefly, plasma samples were diluted 1:4 with the specific calibrator diluent with culture 
supernatants analysed neat. The luminex plate was washed with the appropriate buffer and 
liquid was removed using a vacuum. All cytokine microparticles were mixed with 50µl 
being added to every well. To the microparticles, 50µl of standard or sample was added to 
the appropriate wells and allowed to incubate on a shaker for 3 hours at room temperature. 
The plate was then washed 3 times using wash buffer. Liquid was again removed under 
vacuum. To every well 50µl of biotin antibody cocktail was added and left to incubate at 
room temperature on a shaker for 1 hour. The wash step was repeated, after which 50µl of 
streptavidin PE was added to every well and again incubated at room temperature for 30 
minutes. The plate was washed 3 times and following liquid removal, 100µl of wash buffer 
was added to every well and the plate was left on the shaker for 5 minutes to disperse 
microparticles before being run using the Bio Plex 200 system luminex plate reader (Bio-
Rad, CA, USA). Cytokine levels were extrapolated from the standard curve. 
2.17 Elisa 
Several cytokines measured were not available in the Luminex format. Therefore I 
performed several enzyme-linked immuno sorbent assays (ELISA) to test for cytokines 
including Flt3L, IL-23 and IL-12p70 (R&D systems). The protocol involved adding 
Gene Forward Reverse Ref 
ATF4 GACCACGTTGGATGACACTTG GGGAAGAGGTTGTAAGAAGGTG (521) 
ATF6 TCAGACAGTACCAACGCTTATGC GTTGTACCACAGTAGGCTGAGA (521) 
A20 AAGAAACTCAACTGGTGTCGAGAA TGCCGTCACCGTTCGTT (563) 
BiP TGCTTGATGTATGTCCCCTTA CCTTGTCTTCAGCTGTCACT N/A 
EIF2" GCTCTTGACAGTCCGAGGAT CATTGCCCCAGGCAAACAAG (521) 
PERK TGCCTGGCTCGAAGCACCAC TGGTGCATCCATTGGGCTAGGA (521) 
TBP 
sXBP-1 
AGACCTTCCTGTTTACCCTTG 
AGACAGCGCTTGGGGATGGAT 
TAGCTGTGGGTGACTGCTTGG 
CCTGCACCTGCTGCGGACTC 
N/A 
(521) 
uXBP-1 AGACAGCGCTTGGGGATGGAT CCTGCTGCAGAGGTGCACGTAG (521) 
zDC GAGCTTTGGGACACAGGACAC TGTGCAAAGTTGCAAGCAGTA N/A 
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appropriate volumes of assay diluent and standard or sample to a pre-coated ELISA plate 
according to the plate plan. Samples were incubated for 2 hours at room temperature. 
Plates were washed with the appropriate wash buffer, with the conjugate (200µl) 
subsequently added to every well and incubated for 2 hours at room temperature. Plates 
were washed again, and incubated for 30 minutes with the appropriate substrate solution. 
Stop solution (50µl) was added to every well and developed for 20 minutes. The plate was 
then read at 450nm using an MRX microplate reader (Dyn-ex technologies, USA).  
2.18 Cell survival assay 
DC subsets were sorted using the FACSAria. The cells were washed in PBS and 
resuspended at 1 x 106 cells/ml of PBS. Cells from a HC and an AS patient sample were 
stained with either CFSE (5µM) as previously described, or the eFlour V450 proliferation 
dye (eBioscience). If eFlour V450 proliferation dye was used, cells were stained with 
10µM (final concentration) for 10 minutes in the dark with intermittent shaking. After 
staining, cells were washed in FACS buffer and re-counted. Cells were resuspended at the 
following cell concentrations per 100µl of 10% complete medium: CD1c – 30,000 or 
40,000 cells, CD16 – 40,000 or 50,000 cells, monocytes – 100,000 cells. Cells isolated 
from a HC and an AS patient were mixed together 1:1 in 96 well round bottomed culture 
plates. An aliquot from each well was analysed on the BD LSR II for analysis at the 0 hour 
time point. Cells were incubated at 5% CO2 and 37°C for 24 hours or 48 hours. After, co-
culture cells were harvested and analysed using the BD LSR II.  
2.19 Human colonic and small intestine cell isolation 
To isolate cells from patient surgical samples, a protocol was adapted from one developed 
for the isolation of cells from murine intestinal samples by the laboratory of Professor 
Allan Mowat. For surgical specimens, the fat and muscle layers were removed before 
processing. The muscle layer, for some experiments was digested in the same manner as 
colonic and small intestinal tissue. Samples were first transferred to 50ml falcons (Greiner 
Bio-one) containing HBSS (Gibco) supplemented with 2% FCS. Tissue was cut into 0.5cm 
sections and kept in 2% FCS/HBSS on ice until digestion. Tissue was vigorously shaken; 
the supernatant discarded, and resuspended in 20ml of 2mM EDTA/HBSS (pre-warmed) 
to remove the epithelial layer. For colonic specimens, the tissue was placed in a shaking 
incubator at 37°C for 15 minutes before being shaken vigorously again and supernatant 
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discarded. Tissue was then washed in HBSS (pre-warmed). This step was repeated a total 
of three times. For small intestinal samples, tissue in 20ml of 2mM EDTA/HBSS was 
placed at 37°C in a shaking incubator for 30 minutes before being shaken vigorously, 
supernatant discarded and washed in HBSS (pre-warmed). This was followed by a second 
incubation, similar to that described above but of only 15 minutes duration. After the final 
EDTA step, cells were washed in HBSS and resuspended in 20ml of pre-warmed 10% 
complete media containing the following enzymes: Collagenase VIII (1mg/ml, Sigma-
Aldrich), Collagenase D (1.25mg/ml, Roche Diagnostics GmbH, Mannheim, Germany), 
Dispase (1mg/ml, Gibco) and DNase (30µg/ml, Roche). Tubes were then placed in a 
shaking incubator (37°C) for 45 minutes; additional vigorous shaking was performed every 
10 minutes to aid digestion. The supernatant was then passed through a 100µM cell 
strainer (BD Falcon). Any remaining undigested tissue was returned to the tube, 20ml of 
fresh enzyme mix was added and returned to the shaking incubator (37°C) until tissue was 
completely digested. Again tubes were shaken vigorously every 10 minutes. Supernatant 
removed after 45 minutes was filtered through a 40µM cell strainer (BD Falcon) and 
centrifuged at 1,500rpm for 5 minutes. Supernatant was discarded and cells were 
resuspended in FACS buffer and kept on ice. After the remaining tissue was fully digested, 
supernatant was filtered as previously described, centrifuged and resuspended in FACS 
buffer. After cell suspensions were combined, cells were counted and left on ice until use. 
2.20 Histology 
A number of human small intestinal and colonic samples were fixed in 10% neutral 
buffered formalin for 24 hours. Jim Reilly and Shauna Kerr, histology technicians within 
the Institute of Infection, Immunity and Inflammation at the University of Glasgow, 
processed the samples and performed H&E staining. Sections were then viewed using a 
light microscope and pictures were taken using the cell^B software (Olympus). 
2.21 Statistics 
Results are presented with +/- standard error of the mean (SEM) or standard deviation 
(SD). Data were analysed using either a Student’s t test or a Mann Whitney, followed by a 
Bonferroni post test using GraphPad prism (San Diego, CA, USA). Statistical tests were 
performed as described in figure legends. For patient correlative data, linear regression, 
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Kruskal Wallis Spearman correlative tests were performed with Dunn multiple 
comparisons post test. Values of p<0.05 were considered statistically significant.  
   
 
 
 
 
Chapter 3: Characterisation of blood mononuclear 
cell populations 
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3.1 Introduction 
Human dendritic cells (DCs) are often identified based on the expression of MHC II, lack 
of common lineage markers and their ability to stimulate naïve T cells (200, 201, 208). 
Recent advances in surface phenotyping and cell isolation have enabled the 
characterisation of several human DC subsets circulating in peripheral blood (207-209). 
However, application of these experimental developments is severely lacking in some 
areas of human research. One such area involves the analysis and quantification of human 
DC subsets in patients with ankylosing spondylitis (AS). Due to the involvement of DCs in 
directing and controlling immune responses, and given that our previous work indicated a 
role for DCs in SpA development using the HLA-B27 transgenic (HLA-B27 TG) rat 
model (480), it was important to fully characterise the role of DCs in human AS, with a 
view to improving future disease therapies. Therefore, the aim of the project was to 
contribute to the understanding of AS pathogenesis by investigating differences in the 
frequency and phenotype of human DC subsets, conventional (cDC) and plasmacytoid 
(pDC), between patients with AS and healthy controls (HCs). In addition, other related 
inflammatory cells, including monocytes were investigated for the purposes of 
comparison.  
3.2 Patient characteristics 
AS patients were recruited from the clinics at the Glasgow Royal Infirmary run by Dr 
David McCarey and Dr Anne McEntegart. Patient information regarding disease severity, 
treatment and duration was collected and is summarised in Table 3.1, together with 
information about HCs used in the study.  
Due to the nature of the disease, the majority (75.5%) of AS patients used in this study 
were older, male participants. In order to control for this, the majority (58.6%) of recruited 
HCs were also male (Table 3.1). Furthermore, all patients at time of analysis presented 
with long-standing disease, with minimum disease duration being 7 years (Table 3.1). 
Unfortunately, samples from newly diagnosed patients (<2 years) were not received during 
this study.  
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Table 3.1: Clinical characteristics of patients and healthy controls 
For the analysis of cDC and pDC blood populations, 45 AS patients and 29 HCs were used. 
Patient characteristics were collated and are summarised below. Information for some clinical 
parameters were not available for all patients. Percentages represent proportion of all patients 
used in the study. Spinal disease was assessed based on the presence or absence of cervical, 
thoracic and lumbar involvement. Levels were categorised based on the number of sites involved: 
1 site = level 1, 2 sites = level 2 and 3 sites = level 3. Combination therapy consists of DMARD and 
NSAID treatment. N/A = Not applicable. Mean ± SD is shown. 
 AS Patients 
 
Healthy Controls 
Age (yrs) 54.87 ± 12.2 40.66 ± 12.5 
Sex – Male/Female 34/9 17/12 
Disease Duration (yrs) 28.8 ± 12.5 N/A 
B27 – Pos/Neg (% B27+) 41/4 (91%) 6/23 (21%) 
BASDAI 4.09 ± 2.27 N/A 
BASMI 4.18 ± 2.48 N/A 
ESR (mm/hr) 14.62 ± 13.19 N/A 
CRP (mg/L) 6.89 ± 9.17 N/A 
Bilateral Sacroiliitis – No. (%) 30 (66.7%) N/A 
Spinal disease   
    Absent – No. (%) 4 (8.9%) N/A 
    Level 1 – No. (%) 9 (20%) N/A 
    Level 2 – No. (%) 6 (13.3%) N/A 
    Level 3 – No. (%) 5 (11.1%) N/A 
Extra-articular Disease   
    IBD – No. (%) 3 (6.7%) N/A 
    Uveitis – No. (%) 4 (8.9%) N/A 
    Psoriasis – No. (%) 3 (6.7%) N/A 
    Arthritis – No. (%) 8 (17.8%) N/A 
Medication   
    DMARDs – No. (%) 1 (2.2%) N/A 
    NSAIDs – No. (%) 18 (40%) N/A 
    Combination – No. (%) 2 (4.4%) N/A 
    Biologics – No. (%) 7 (15.6%) N/A 
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On average, patients presented with mid-range disease scores, (BASDAI 4.09, BASMI 
4.18) measured on scales of 0-10 and 0-10 respectively (Table 3.1). Alongside disease 
score, two factors relating to inflammation were examined – erythrocyte sedimentation rate 
(ESR) and C-reactive protein (CRP). When describing a HC population, ESR and CRP 
levels were considered normal if below 10 (Dr David McCarey, personal communication). 
AS patients used in this study had average ESR and CRP values of 14.62 and 6.89 
respectively (Table 3.1). Therefore, the AS patients in our cohort showed evidence of 
ongoing inflammation but not to the extent observed in other inflammatory diseases 
including rheumatoid arthritis (RA) (564). Involvement of the axial skeleton and SIJs are 
characteristic of AS, and can lead to joint deformity. Based on magnetic resonance 
imaging (MRI) and X-rays, patients are assessed for the presence of vertebral fusion or 
structural changes within the cervical, thoracic and lumbar regions of the spine, in addition 
to the presence of unilateral or bilateral sacroiliitis. Approximately 70% of patients 
presented with evidence of bilateral sacroiliitis (Table 3.1). For the remaining 15 patients, 
data regarding presence of sacroiliitis was not recorded or available, although two patients 
that were assessed displayed a total lack of SIJ involvement. Within this patient cohort, 
spinal disease affecting one area of the spine (Level 1 – Table 3.1), predominantly within 
the cervical and lumbar regions, was most prevalent.  
AS is commonly associated with the presence of extra-articular disease manifestations 
including IBD, uveitis, psoriasis and arthritis. The most common comorbidity in the study 
cohort was the presence of peripheral arthritis (approximately 20% - Table 3.1). The 18 
incidences of extra-articular disease manifestations are attributable to 15 individuals. The 
patients with two comorbidities all presented with peripheral arthritis in addition to IBD, 
uveitis or psoriasis. The final aspect to be considered when analysing data obtained from 
patient cohorts relates to the contribution of disease treatments. Common therapies in this 
cohort included disease-modifying anti-rheumatic drugs (DMARDS), non-steroidal anti-
inflammatory drugs (NSAIDs) and biological therapies (Biologics - Table 3.1). The most 
common therapy (40%) was through administration of NSAIDs, including ibuprofen, co-
codamol, diclofenac and etoricoxib. 15% of patients were receiving biological therapy, 
predominantly in the form of etanercept and adalimumab. Only two patients were 
receiving combination therapy involving both DMARDs and NSAIDs. All experiments 
involving DC characterisation in the blood of AS patients and HCs involve either all or 
subgroups of the individuals described in Table 3.1. Relationships between experimental 
findings and disease parameters will be described and discussed in Chapter 7. 
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3.3 Identification of peripheral blood DC subsets 
DCs represent around 0.5-1% of peripheral blood mononuclear cells (PBMCs). To identify 
cDC subsets, a suitable gating strategy was devised (Fig. 3.1). A staining panel described 
by Jongbloed et al (200) was used at the outset, and altered for specific experiments when 
required (Fig. 3.1A). Firstly, doublets and dead leukocytes were excluded from analysis. 
Due to the paucity of DCs in blood, it is advantageous to exclude large cell populations not 
required for analysis, in addition to those cells expressing similar surface markers to DCs. 
Lineage markers included CD3 (T cells), CD14 (monocytes), CD15 (neutrophils), CD19 
(B cells) and CD56 (NK cells). Cells lacking expression of all lineage markers were 
analysed for expression of the DC markers, CD11c and MHC II. Cells co-expressing 
CD11c and MHC II can be subdivided into three distinct subsets based on the expression 
of CD141 (BDCA-3) and CD16 (Fig. 3.1A): CD141+ CD16- (CD141+ DCs), CD141- 
CD16- and CD141- CD16+ populations. The CD141- CD16- DCs are the only subset to 
express CD1c and are henceforth referred to as CD1c+ DCs (Fig. 3.1A). To further 
characterise and identify these cell populations, CD14 expression was assessed. CD14 is a 
marker of human monocytes, which can also co-express CD11c and MHC II. Both DC 
subsets (CD1c+ and CD141+) and the CD14- CD16+ mononuclear population lacked or 
expressed negligible levels of CD14, in comparison to the CD14+ CD16- classical 
monocytes (Fig. 3.1B). Using this gating strategy it is possible to clearly identify and 
isolate two DC subsets (CD141+ and CD1c+ DCs) and one mononuclear cell population 
(CD16+ CD14-).  
To complement the investigation of cDC subsets in AS patients, pDCs were also studied. 
To identify pDCs, doublets, dead cells and lineage positive cells were excluded, and pDCs 
were identified through co-expression of CD123, CD303 (BDCA-2) and CD304 (BDCA-4 
- Fig. 3.2A). Cells lacking expression of all lineage markers (LIN-), whilst co-expressing 
CD123+ and MHC II+ were further analysed for the expression of CD304 (Fig. 3.2A). All 
CD123+ MHC II+ CD304+ cells were classified as pDCs. Activation can affect cell 
morphology (545), so the size and granularity profiles of pDCs in AS patients and HCs 
were compared (Fig. 3.2B). No difference in morphology was observed. In addition, 
CD123+ MHC II+ cells from both HCs and AS patients expressed comparable levels of the 
pDC marker CD303 (Fig. 3.2C), whereas CD123- MHC II+ cells did not express it, further 
identifying CD123+ cells as pDCs.  
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Figure 3.1: Gating strategy for the identification of blood monocytes and DCs 
Dendritic cells (DCs) were identified in the peripheral blood of HCs and AS patients through the 
expression of several cell surface markers. (A) Doublets were excluded using the FCS-H vs FSC-A 
gate. DAPI+ dead cells were excluded and live cells were subdivided on the expression of LIN 
markers (CD3, CD14, CD15, CD19 and CD56) and MHC II. DCs are LIN- CD11c+ MHC II+. This 
population was subdivided into CD14- CD16+ mononuclear cells and CD141+ (BDCA-3) and CD1c+ 
(BDCA-1) DCs. The CD141- CD16- DC population expresses CD1c – histogram (right). (B) LIN- 
CD11c+ MHC II+ cells were subdivided on CD14 expression. The CD14 negative fraction contains 
CD141+ and CD1c+ DCs in addition to the CD14- CD16+ mononuclear population based on CD141 
and CD16 expression. CD14+ monocytes resided in the CD14+ fraction. 
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Figure 3.2: pDCs in peripheral blood 
Gating strategy used to identify plasmacytoid dendritic cells (pDCs) in peripheral blood of HCs and 
AS patients.  (A) Doublets were excluded using the FCS-H vs FSC-A gate. DAPI+ dead cells were 
excluded. Live cells were subdivided on the expression of LIN markers (CD3, CD14, CD15, CD19 
and CD56) and MHC II. Human pDCs co-express MHC II, CD123 and CD304 (BDCA-4). (B) pDCs 
in HCs and AS patients have identical FSC-A and SSC-A profiles. (C) Human pDCs in HCs (blue) 
and AS patients (red) uniformly express CD303 (BDCA-2). CD303 expression was compared to 
CD123- MHC II+ cells (grey shaded histogram), including CD11c+ MHC II+ cDCs.  
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3.4 Quantification of DC and monocyte subsets in AS 
patients and HCs 
3.4.1 cDCs and pDCs 
My aim was to investigate the role of cDCs and pDCs in AS pathogenesis. The gating 
strategies developed for cDCs (Fig. 3.1A) and pDCs (Fig. 3.2A) were therefore used to 
quantify these populations in AS patient and HC blood. Initially, total numbers of PBMCs 
per ml of blood were compared between HCs and AS patients, and a significant increase in 
the number of PBMCs in AS patients was observed (Fig. 3.3A). Due to the strong genetic 
association between HLA-B27 and AS, HLA-B27 involvement was assessed in relation to 
PBMC number. No effect of HLA-B27 expression on PBMC numbers in AS patients or 
HCs was observed (Fig. 3.3A). The proportions of total cDCs (CD1c+ and CD141+ 
subsets) in the blood of AS patients and HCs were also compared (Fig. 3.3B and 3.3C). 
The CD16+ mononuclear population was excluded from the total cDC analysis, as the 
classification of these cells remains controversial. A slight trend towards fewer DCs as a 
percentage of live cells in AS patients was observed, however, this was found not to be 
statistically significant (p=0.0545 – Fig. 3.3C). No difference was observed in the 
proportion of cDCs when analysed as total cell number/ml of blood. Furthermore, HLA-
B27 expression appeared to have no effect on the proportion of total DCs found in AS 
patients or HCs (Fig. 3.3C). However, this study was not sufficiently powered to fully 
understand the function of HLA-B27 with respect to these immunological parameters.  
Our laboratory has previously shown that HLA-B27 TG rats lack the tolerogenic CD172alo 
DC subset within intestinal lymphatics and MLNs (480). Initially it was hypothesised that 
CD141+ DCs, the human equivalent of the tolerogenic CD172alo rat DCs, would be 
deficient in AS patients compared to HCs. No significant difference in the proportion of 
CD141+ DCs between HCs and AS patients was observed, in terms of the percentage of 
CD11c+ MHC II+ DCs, percentage of total live cells, or total cell number/ml of blood (Fig. 
3.4A). However, in AS patients CD1c+ DCs represented a significantly lower proportion of 
total CD11c+ MHC II+ cells than in HCs (Fig. 3.4B). This difference was not reflected as 
proportion of total live cells or absolute cell number (Fig. 3.4B). This significant reduction 
of CD1c+ DCs could represent the slight decline in total DCs observed in AS patients (Fig. 
3.3C and Fig. 3.4B). Initial evaluation of pDCs showed no significant difference between 
HCs and AS patients in terms of percentage of live cells and total cell number (Fig. 3.4C). 
Overall, my data suggests that there are only slight differences in the proportions of blood   
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Figure 3.3: Enumerating DCs in AS patients 
Number and frequency of blood DCs in AS patients and HCs. (A) Number of PBMCs/ml of blood 
was enumerated in AS patients and HCs. 33 HCs and 47 AS patients were used for analysis. (B) 
Of the LIN- (CD3, CD14, CD15, CD19 and CD56) CD11c+ MHC II+ population, CD141+ and CD1c+ 
(CD141- CD16-) cells were combined to analyse total DCs. (C) Proportion of total DCs as 
percentage of live cells (left) and total cell number/ml of blood (x103 – right). 29 HCs and 43 AS 
patients were compared. Data analysed by Mann-Whitney test, * = p<0.05. HC red dots = B27+ 
individuals, AS red dots = B27- patients. All graphs show mean.     
 
  
  
B 
CD16 
C
D
14
1 
Total DC 
C 
%
 o
f L
iv
e 
C
el
ls
 
HC AS 
N
o.
 o
f D
C
s/
m
l o
f 
bl
oo
d 
(1
03
) 
HC AS 
A 
N
o.
 o
f P
B
M
C
s/
m
l o
f 
bl
oo
d 
(1
06
) 
HC AS 
0.0
0.5
1.0
1.5
2.0
0
10
20
30
40
0
1
2
3
4 *
LIN- CD11c+ MHC II+ 
 107 
 
Figure 3.4: Enumeration of pDCs and DC subsets in AS patients and HCs 
Comparison of blood CD141+ DCs, CD1c+ and pDCs between AS patients and HCs. (A) Analysis 
of AS patient and HC CD141+ DCs (30 HCs/45 AS patients) represented as % of CD11c+ MHC II+ 
cells (left), % of live cells (centre) and total cell number/ml of blood (right). (B) Proportion of CD1c+ 
DCs (29 HCs/43 AS patients) represented as % of CD11c+ MHC II+ cells (left), % of live cells 
(centre) and total cell number (103)/per ml of blood (left) between HCs and AS patients. (C) pDCs 
compared between HCs (n=29) and AS patients (n=43) as % of live cells (left) and total cell 
number (103)/per ml of blood (right). HCs shown in open circles/bars, AS patients depicted by filled 
circles/bars.  All graphs show mean. Mann-Whitney statistical used, * = p<0.05. HC red dots = 
B27+ individuals, AS red dots = B27- patients. Graphs show mean + SD.    
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DCs between HCs and AS patients, with a significant, proportional reduction in the major 
blood DC population (CD1c+ DCs) in AS patients. Additionally, no difference was 
observed when comparing the few HLA-B27- and HLA-B27+ AS patients or HCs for all 
DC subsets analysed in terms of percentage of total CD11c+ MHC II+ cells and live cells 
(Fig. 3.4).  
Circulating DC proportional analyses of AS patients and HCs revealed a large deviation 
around the mean for each cohort (Fig. 3.3 and 3.4).  Given this considerable variation in 
DC proportions, two HCs were analysed over time to assess cDC subset stability (Fig. 3.5). 
A HC with an initial low ratio of CD1c+ DCs: CD16+ mononuclear cells (15.1%: 84.5%) 
was re-assessed 6 months after initial characterisation (Fig. 3.5A). Proportions of CD11c+ 
MHC II+ subsets remained relatively stable over time, with the CD1c+: CD16+ cell ratio 
after 8 months equating to 20.9%: 77.1% (Fig. 3.5A). Additionally, DC proportions of a 
second HC with an initial high ratio of CD1c+: CD16+ cells (45.8%: 51.7%) were assessed 
18 months later (Fig. 3.5B). At the later time point there was a slight shift towards the 
CD16+ mononuclear population, with a ratio of 32.2%: 62.6% (CD1c+ DCs: CD16+ 
mononuclear cells – Fig. 3.5B). From this very small dataset, it appears that the proportion 
of CD1c+: CD16+ cells remains relatively stable over time. 
3.4.2  CD14- CD16+ mononuclear cells 
The CD14- CD16+ mononuclear population is not homogeneous. In a recent publication, 
Cros et al define three blood monocyte subsets (237) - CD14+ CD16-, CD14+ CD16+ and 
CD14- CD16+ - based on surface marker expression and subsequently their functional roles 
in immune responses have been described (229, 353, 565, 566). This “third” CD14- CD16+ 
monocyte subset equates to our CD14- CD16+ mononuclear population. However, 
classification of this CD14- CD16+ mononuclear cell population remains controversial. 
CD14- CD16+ cells have recently been shown to be heterogeneous for M-DC8 (237, 240), 
which is also known as 6-sulfo LacNAc or SLAN, as it will be referred from here onwards. 
In some samples, the gating strategy used in Fig. 3.1 was altered to accommodate staining 
for SLAN (Fig. 3.6). LIN- live, single cells were analysed for CD14 expression (Fig. 
3.6A), and CD14 negative cells that expressed both CD11c and MHC II were subdivided 
into the three myeloid populations, as defined in Fig. 3.1A. Subsequently, the CD14- 
CD16+ mononuclear cell population can be separated into two distinct subsets based on the 
expression of SLAN (Fig. 3.6A). Levels of SLAN expression on the CD16+ subset 
appeared similar for both HCs and AS patients (Fig. 3.6B).    
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Figure 3.5: Changes in HC blood DC and mononuclear cell proportions over time 
DCs and mononuclear cells in blood from two HC donors were analysed at two different time points 
to estimate the stability of DC proportions over time. (A) HC DCs were compared at 0 months (top) 
and 6 months (bottom). LIN- CD14- CD11c+ MHC II+ cells were subdivided based on the expression 
of CD141 and CD16. Numbers represent the proportions of the 3 subsets depicted in the right 
hand plots, as a percentage of total CD11c+ MHC II+ cells. (B) HC DCs were compared at 0 
months (top) and 18 months (bottom), using the strategy in A. Gating strategy used in Fig. 3.1A 
was used for this analysis. 
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Figure 3.6: Gating strategy for CD16+ SLAN- and CD16+ SLAN+ cells  
Peripheral blood DCs and monocytes were identified by the expression of several cell surface 
markers. (A) FSC-A vs SSC-A gate is used to exclude dead cells. Doublets are excluded by FCS-
H vs FSC-A. Remaining dead cells (DAPI+) are excluded and live cells subdivided on the 
expression of LIN markers (CD3, CD15, CD19 and CD56) and MHC II. LIN- CD14+ cells are 
classical monocytes.  CD14- CD11c+ MHC II+ cells are divided into CD141+ DCs, CD1c+ DCs and 
CD16+ cells that are either CD16+ SLAN- or CD16+ SLAN+. The SLAN+ gate is set based on the 
isotype control. (B) Representative histograms of a HC and AS patient sample showing SLAN 
expression on live LIN- CD11c+ MHC II+ CD14- CD16+ cells. Isotype in grey filled histograms 
(monoclonal Mouse IgM), and SLAN expression depicted in red. 
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Using the gating strategies described in Fig. 3.1A and Fig. 3.6A, the proportions of total 
CD14- CD16+ mononuclear cells, CD16+ SLAN+ and CD16+ SLAN- subsets were 
compared between AS patients and HCs (Fig. 3.7). A trend towards an increase in the 
proportion of CD11c+ MHC II+ CD16+ cells was observed (Fig. 3.7A), but this did not 
reach statistical significance (p=0.0552). Furthermore, this trend towards increased CD16+ 
cells was not observed as percentage of live cells or total cell number (Fig. 3.7A). 
Additionally, when the CD16+ SLAN+ and SLAN- subsets were analysed separately, no 
differences were detected between AS patients and HCs in terms of proportion or cell 
number of CD16+ SLAN+ (Fig. 3.7B) and CD16+ SLAN- cells (Fig. 3.7C). Additionally, 
HLA-B27- AS patients and HLA-B27+ HC individuals were highlighted to see if this 
phenotype would be associated with any changes in cell populations, however no patterns 
were detected (Fig. 3.7). Overall, slight variations in the proportions of blood DC and 
mononuclear cell populations were observed in AS patients – specifically AS patients have 
a reduced proportion of circulating CD1c+ DCs accompanied with a trend towards an 
increase in the CD14- CD16+ mononuclear population. 
3.5 Identification and quantification of blood monocytes 
Due to the role of monocytes in inflammation and their possible contribution to the DC 
pool in non-lymphoid tissues during inflammatory responses (225, 234), it was important 
to study blood monocyte subsets in AS patients and HCs. The gating strategy used in Fig. 
3.1 was modified to accommodate monocyte subsets. LIN- live single cells co-expressing 
CD11c and MHC II could be subdivided into four subsets, classified as CD14+ CD16- (A) 
and CD14+ CD16+ (B) monocytes, CD14- CD16+ (C) mononuclear cells and cDCs (D – 
Fig. 3.8A). The presence of the CD1c+ and CD141+ cDC subsets in population D was 
confirmed by flow cytometry (Fig. 3.8B). Additionally, the CD14- CD16+ subset was 
shown to be heterogeneous for SLAN and represents the CD16+ mononuclear population 
described in previous figures (Fig. 3.8C).  
Blood monocyte subsets are often depicted as a “waterfall” (237) based on the expression 
of CD14 and CD16, as shown in the gating strategy in Fig. 3.8A. Representative plots 
depicting this monocyte waterfall in HCs and AS patients are shown in Fig. 3.9A. 
Consistent with previous publications (236, 237, 567, 568), CD14+ CD16- monocytes 
represent the major blood monocyte subset accounting for approximately 80-85% of 
CD11c+ MHC II+ blood monocytes. Next, the CD14- CD16+ heterogeneous population 
contributes around 10% to the monocyte pool, with the CD14+ CD16+ monocytes  
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Figure 3.7: Comparison of CD16+ cells between AS patients and HCs  
Comparison of CD11c+ MHC II+ CD14- CD16+ cells and SLAN- and SLAN+ subsets between AS 
patients and HCs. (A) Analysis of single DAPI- LIN- CD11c+ MHC II+ CD16+ cells from HCs and AS 
patients; % of CD11c+ MHC II+ population (left), live cells (centre) and total cell number (103)/ml of 
blood (right). 29 HCs and 43 AS patients were used for this analysis.  This CD16+ CD11c+ MHC II+ 
population was then divided into CD16+ SLAN+ (B) and CD16+ SLAN- (C). Percentage of CD16+ 
CD11c+ MHC II+ (left) and % of total CD11c+ MHC II+ CD14- cells (right) were calculated for 9 HCs 
and 11 AS patients. Each point represents one individual. HC red dots = B27+ individuals, AS red 
dots = B27- patients. Graphs represent mean + SD.  
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Figure 3.8: Identification of monocytes in peripheral blood 
Identification of monocyte subsets from peripheral blood. (A) Initially, live cells and doublets were 
excluded using FSC-A vs SSC-A, FSC-H vs FSC-A and DAPI- gates. Live cells (DAPI-) were 
subdivided on the expression of LIN markers (CD3, CD15, CD19 and CD56) and MHC II. Total 
CD11c+ MHC II+ LIN- cells were separated on CD14 and CD16. Four populations (A, B, C and D) 
were identified. (B) The CD14- CD16- population (D) is predominantly composed of blood CD1c+ 
and CD141+ DCs. This population is heterogeneous for SLAN, and represents the CD11c+ MHC II+ 
CD14- CD16+ population described earlier (C).  
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representing the smallest monocyte subset (5%, Fig. 3.9A). Comparative analyses of the 
proportions of blood monocyte subsets between AS patients and HCs revealed no 
significant differences, with the CD14- CD16+ population consisting of both SLAN- and 
SLAN+ cells (Fig. 3.9A). Furthermore, no significant differences between AS patients and 
HCs were observed in terms of percentage of live cells or total cell number/ml of blood 
(Fig. 3.9B).  
3.6 DC morphology 
To further characterise the DC populations, peripheral blood DC subsets and CD14- CD16+ 
mononuclear cells were sorted by flow cytometry to analyse cell morphology. Cytospins 
were prepared and cells were stained with hematoxylin and eosin (H & E) to identify any 
differences in cell morphology and associated structures between HCs and AS patients. 
Representative pictures of CD141+ DCs (Fig. 3.10A), CD1c+ DCs (Fig. 3.10B), pDCs (Fig. 
3.10C) and CD14- CD16+ mononuclear cells (Fig.3.10D), containing SLAN+ and SLAN- 
subsets, were taken and analysed. Interestingly, all blood DC subsets and CD14- CD16+ 
mononuclear cells possessed lobulated nuclei, often associated with neutrophils (Fig. 
3.10). In contrast, isolated pDCs (LIN- CD123+ MHC II+ CD304+) were lymphoid in 
appearance, with large spherical nuclei and minimal cytoplasm. CD141+, CD1c+ and 
CD16+ subsets all possessed ruffled membranes, however there was little evidence of 
dendrite formation immediately following isolation from peripheral blood (Fig. 
3.10A/B/D). DCs, when first discovered in 1973, were given their name due to the 
presence of characteristic dendrites (185). However, based on the cell structure 
representations depicted in Fig. 3.10, no dendrite formation was detected on cells directly 
isolated from peripheral blood. As activation can affect cell morphology, it was decided to 
investigate whether cell stimulation would induce morphological changes, with particular 
reference to dendrite formation. Interestingly, 18-hour lipopolysaccharide (LPS) 
stimulation of all CD11c+ MHC II+ subsets induced dramatic changes in nuclear 
morphology (Fig. 3.11A-C), with the nuclei for each subset changing from a lobulated 
shape to a round, compact structure (illustrated with arrows in Fig. 3.11B). In addition, all 
subsets developed cytoplasmic inclusions and dendrites (Fig. 3.11B). Despite these 
changes, no differences in cell morphology were observed between AS patients and HCs.  
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Figure 3.9: Quantification of blood monocyte subsets 
Comparison of blood monocyte subsets in healthy controls (HC) and AS patients (AS). The gating 
strategy described in Fig. 3.8 was used to quantify proportions of CD14+ CD16-, CD14+ CD16+ and 
CD14- CD16+ mononuclear cell populations. (A) Examples of monocyte “waterfall” FACS plots 
generated for a HC (left) and an AS patient (right). Quantification of subsets as proportion of 
CD11c+ MHC II+ cells (A). Numbers associated with the contour plots represent the proportion of 
CD11c+ MHC II+ cells. (B) The proportion of live cells (left) and total cell number (right) for each 
subset is depicted. Cell number is represented as no. of cells per ml of blood (103). All graphs show 
mean + SD.   
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Figure 3.10: Comparison of DC morphology between AS patients and HCs 
DC subsets were flow sorted from AS patients and HCs by using the gating strategy described in 
Fig. 3.1. Cytospins of purified populations were stained with hematoxylin and eosin. Representative 
pictures generated for CD141+ DCs (A), CD1c+ DCs (B) and pDCs (C) from an HC (left) or AS 
patient (right). (D) Cytospins for the heterogeneous CD11c+ MHC II+ CD14- CD16+ population, 
containing both SLAN- and SLAN+ subsets. DC-associated cellular features, including lobulated 
nuclei and ruffled membranes are highlighted. 
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Figure 3.11: Comparison of activated DC morphology between AS patients and HCs 
DC subsets from peripheral blood of AS patients and HCs were sorted by flow cytometry, using the 
gating strategy described in Fig. 3.1. Cells were stimulated with 100ng/ml of LPS for 18 hours. 
Representative pictures generated for CD141+ DCs (A) and CD1c+ DCs (B) from a HC (left) and an 
AS patient (right) are shown. (C) Cytospins for the heterogeneous population of CD11c+ MHC II+ 
CD14- CD16+ cells, containing both SLAN- and SLAN+ subsets. Compact nuclei, dendrite formation 
and the presence of cytoplasmic inclusions are highlighted by the black arrows. 
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3.6.1 Cell viability 
The unusual lobulated nuclear morphology of DC subsets isolated straight from peripheral 
blood was unexpected and it was hypothesised that these cells could be undergoing 
apoptosis. Following initial studies, all cell-sorting experiments were carried out the day 
following cell isolation, with samples stored at 4°C overnight. Thus, it was important to 
confirm whether the DC morphology depicted in Fig. 3.10 was true, or if it was due to 
cells undergoing apoptosis after overnight incubation. Therefore, survival of cDCs was 
assessed and compared under four conditions using an annexin V survival assay: cells 
freshly isolated from blood; cells isolated and then sorted immediately; cells isolated and 
left overnight at 4°C; and cells that were isolated, incubated at 4°C overnight and then 
sorted using flow cytometry. LIN- cells co-expressing CD11c and MHC II were classified 
as total cDCs for this experiment (Fig. 3.12A). Annexin V and DAPI were used to assess 
cell viability with individual single stains (Fig. 3.12B) being used to set the relevant gates. 
DAPI+ Annexin V+ cells were classed as dead. The proportions of dead and apoptotic cells 
were then compared (Fig. 3.12C). Less than 3% of cells died in every condition (Fig. 
3.12C). Furthermore, no significant differences were observed, with relation to cells going 
under apoptosis, between those isolated fresh or stored overnight (4% vs 3.1%); or 
between those flow sorted directly after isolation or those stored overnight and then 
isolated (0.18% vs 0.76% - Fig. 3.12). 
A similar experiment was performed to assess cell survival of pDCs. The gating strategy 
used to assess pDC viability is shown in Fig. 3.13A. As before, pDCs were identified as 
LIN- MHC II+ CD123+ CD304+ cells (Fig. 3.13A). The same protocol as used for cDCs 
was adopted for pDC survival analysis. DAPI and Annexin V singles (Fig. 3.13B) were 
used to set individual gates, with DAPI+ Annexin V+ cells again being classified as dead 
cells. For every condition, approximately 1% of cells were DAPI+ Annexin V+, indicating 
that pDCs are viable following overnight incubation and cell sorting (Fig. 3.13C). With 
regards to apoptosis, approximately 2-3% of pDCs were apoptotic under all conditions 
(Fig. 3.13C). It was therefore concluded that those cDCs and pDCs that remained after an 
overnight incubation at 4°C and the subsequent cell sorting protocol were viable for 
subsequent experiments. Therefore the unusual morphology of human blood DCs cannot 
be attributed to granulocytic cellular infiltration or cell death.   
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Figure 3.12: Survival of cDC subsets after overnight incubation and flow cytometry sorting 
Cell survival was not affected by overnight (o/n) incubation or flow cytometric sorting. (A) Gating 
strategy to identify DCs. Initially doublets were gated out (left) and single LIN- cells (centre) were 
analysed for expression of CD11c and MHC II (right). (B) DAPI single- (left) and Annexin V single-
stained samples (right) were used to set the appropriate gates. (C) Proportion of DAPI+ Annexin V+ 
CD11c+ MHC II+ cells were compared between freshly isolated cells (left), cells left at 4°C o/n 
(centre – left), freshly isolated cells after sorting (centre – right) and o/n cells after sorting (right). 
Numbers represent proportion of DAPI+ Annexin V+ CD11c+ MHC II+ cells (dead cells), and DAPI- 
Annexin V+ CD11c+ MHC II+ cells (apoptotic). LIN = CD3, CD14, CD15, CD19 and CD56.  
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Figure 3.13: Survival of pDC subsets after overnight incubation and flow cytometry sorting 
Cell survival of pDCs was not affected by overnight (o/n) incubation or flow cytometric sorting. (A) 
Gating strategy to identify pDCs. Singlet LIN- cells (left) were analysed for CD123 and MHC II 
expression (centre). pDCs are CD123+ MHC II+ CD304+ (right). (B) DAPI single- (left) and Annexin 
V single-stained samples (right) were used to set the appropriate analysis gates. (C) Proportions of 
DAPI+ Annexin V+ CD304+ CD123+ cells were compared between freshly isolated cells (left), cells 
left at 4°C o/n (centre – left), freshly isolated cells after sorting (centre – right) and o/n cells after 
sorting (right). Numbers represent proportion of DAPI+ Annexin V+ CD123+ CD304+ cells, and 
DAPI- Annexin V+ CD123+ CD304+ cells (apoptotic). LIN = CD3, CD14, CD15, CD19 and CD56.  
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3.7 Maturation status of DCs and monocytes in AS 
patients and HCs 
While DCs migrate from tissue via lymphatics to lymph nodes to activate naïve T cells 
resulting in the induction of T cell responses, they undergo several phenotypic changes in 
order to facilitate changes in cell function. During DC migration in response to foreign 
antigen, surface molecules involved in antigen presentation and co-stimulation are 
upregulated, including MHC II, CD80, CD86 and CD40 (569). Thus, the activation status 
of circulating cells can infer detail regarding cell maturation, function and migration. 
Therefore we set out to assess the expression of CD40, CD80 and CD86 on the surface of 
CD141+ and CD1c+ DCs, CD14+ CD16- and CD14+ CD16+ monocytes and the CD14- 
CD16+ SLAN+/- mononuclear populations. Representative histograms of co-stimulatory 
molecule expression on CD1c+ cDCs is shown in Fig. 3.14A. Furthermore, representative 
histograms depicting co-stimulatory molecule expression on CD14+ CD16- monocytes are 
depicted in Fig. 3.14B. Quantification of co-stimulatory molecule expression was 
subsequently performed for 5 HCs and 8 AS patients (Fig. 3.15). No differences in 
expression of CD40 (Fig. 3.15A), CD80 (Fig. 3.15B) or CD86 (Fig. 3.15C) between AS 
patients and HCs were observed for any of the myeloid populations analysed. However, 
differences existed between myeloid subsets. CD141+ DCs expressed higher levels of 
CD40 compared to their CD1c+ counterparts, with the converse applying for CD86. The 
SLAN+ and SLAN- CD14- CD16+ subsets did not differ in their expression of CD40 and 
CD86, although CD86 was expressed at higher levels compared to both cDC subsets. The 
CD14+ CD16+ monocytes expressed higher levels of CD40 and CD86 compared to CD14+ 
CD16- monocytes (Fig. 3.15). CD86 expression on both monocyte populations was similar 
to that of the CD14- CD16+ SLAN+ and SLAN- subsets. CD80 expression was minimal on 
all cell populations (Fig. 3.15B). Overall, no difference was observed between AS patients 
and HCs in terms of co-stimulatory molecule expression on DCs, monocytes and CD14- 
CD16+ mononuclear populations.  
3.8 Further characterisation of DCs and monocytes 
To further characterise myeloid cell subsets in AS patients and HCs, it was important to 
look at expression of several key surface markers. The aim of this characterisation was to 
further understand the identity of several cell subsets and the inter-relationship between 
subsets.   
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Figure 3.14: Co-stimulatory molecule expression on cDC and monocyte subsets 
Expression of CD40, CD80 and CD86 on blood cDC and monocyte subsets. (A) cDC subsets and 
CD16 mononuclear cells (DAPI- LIN- CD14- CD11c+ MHC II+ - top) were analysed for expression of 
CD40, CD80 and CD86. Representative histogram plots are shown for CD1c+ DCs (bottom). (B) 
CD14+ CD16- and CD14+ CD16+ monocytes (top) were studied for the expression of the activation 
molecules CD40, CD80 and CD86. Representative histograms depicting CD40, CD80 and CD86 
expression on CD14+ CD16- monocytes (bottom). Isotypes are shown in shaded grey histograms 
with marker shown in red. 
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Figure 3.15: Expression of DC co-stimulatory molecules – CD40, CD80 and CD86 
Comparison of CD40, CD80 and CD86 on blood cDC and monocyte subsets between AS patients 
and HCs. Level of CD40 (A), CD80 (B) and CD86 (C) on cDC and monocyte subsets for AS 
patients (filled circles) and HCs (empty circles). Subsets analysed: CD141+ (CD141) and CD1c+ 
DCs (CD1c), CD14- CD16+ SLAN+ (SLAN+) and CD14- CD16+ SLAN- (SLAN-) mononuclear cells, 
CD14+ CD16+ (CD16+) and CD14+ CD16- (CD14+) monocyte subsets. Expression was assessed by 
%MFI: geometric mean of marker expression – geometric mean of subset isotype. AS red dot = 
B27- patient. All graphs show mean. 5 HCs and 8 AS patients were used for analysis. 
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3.8.1 Monocytes 
To clarify the differences between monocytes and DCs, the surface marker profile of both 
CD14+ monocyte subsets - CD14+ CD16- and CD14+ CD16+ - was assessed. In humans, 
CD11b and CD64 are predominantly expressed on monocytes and macrophages. In 
conjunction, CX3CR1 can be used to identify monocyte subsets in both mice and men 
(229). Both monocyte subsets expressed high levels of CD11b (Fig. 3.16A), CD64 (Fig. 
3.16B) and CX3CR1 (Fig. 3.16C), and at relatively similar levels. However direct 
comparison of these markers, especially CD11b and CD64, is difficult due to differences in 
background isotype staining. As expected, both monocyte subsets were negative for the 
DC marker CD135 (Fig. 3.16D).  
3.8.2 DCs 
CD141+ and CD1c+ DC subsets isolated from a HC were subsequently analysed for the 
surface expression of CD11b, CD64, CD135 and CX3CR1, compared to the appropriate 
isotype-matched negative control for each cell subset (Fig. 3.17). CD141+ DCs were found 
to lack expression of CD11b and CD64 (Fig. 3.17A/B). However, CD1c+ DCs expressed 
intermediate levels of both these markers (Fig. 3.17A/B), when compared to CD14+ CD16- 
monocytes (Fig. 3.16A/B). Based on the surface phenotype of the DC subsets described so 
far, it was no surprise that the CD141+ DCs lacked CX3CR1 expression whilst the CD1c+ 
DCs expressed intermediate levels of this molecule (Fig. 3.17C). CX3CR1 levels on 
CD1c+ DCs were described as intermediate given the high levels of CX3CR1 expression 
observed on CD14+ monocytes (Fig. 3.16C). As stated previously, CD135 is a marker 
commonly associated with DC subsets and their progenitors (286, 570-572). Interestingly, 
CD135 was predominantly expressed on the CD141+ DC subset, with little expression 
being detected on the CD1c+ DC subset (Fig. 3.17D). Overall, CD141+ and CD1c+ DC 
subsets differed in their expression of the surface markers analysed. CD141+ DCs lacked 
expression of the monocyte/macrophage markers CD11b, CD64 and CX3CR1, but 
expressed CD135 (Fig. 3.17). In contrast, CD1c+ DCs did not express CD135 but did 
display intermediate levels of CD11b, CD64 and CX3CR1 (Fig. 3.17), compared to blood 
monocytes (Fig. 3.16). 
3.8.3 CD14- CD16+ mononuclear cells 
Due to the heterogeneity regarding SLAN expression within the LIN- CD11c+ MHC II+ 
CD14- CD16+ population, expression of the same surface markers described above were  
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Figure 3.16: Surface phenotype of CD14+ CD16- and CD14+ CD16+ monocytes 
PBMCs were isolated from peripheral blood of a healthy control, and CD14+ monocyte subsets 
were analysed for expression of CD11b (A), CD64 (B), CX3CR1 (C) and CD135 (D). The 
appropriate isotype control – Mouse IgG1# (CD11b, CD64 and CD135) and Rat IgG2b (CX3CR1) 
are represented in grey filled histograms. Marker expression is depicted in red for each monocyte 
subset. Expression of these markers on CD14+ CD16- (left) and CD14+ CD16+ (right) monocytes is 
presented. Gating strategy described in Fig. 3.6A was used for this analysis. 
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Figure 3.17: Expression of CD11b, CD64, CD135 and CX3CR1 on DC subsets 
PBMCs were isolated from peripheral blood from a healthy control and analysed for the expression 
of several surface markers including CD11b (A), CD64 (B), CX3CR1 (C) and CD135 (D). The 
appropriate isotype controls – Mouse IgG1# (CD11b, CD64 and CD135) and Rat IgG2b (CX3CR1) 
are shown in the grey filled histograms. Marker expression is depicted in red for each DC subset. 
Expression of these markers on CD141+ DCs (left) and CD1c+ DCs (right) is depicted above. 
Gating strategy described in Fig. 3.6A was used for this analysis. 
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investigated for both SLAN- and SLAN+ subsets. Both subsets expressed CD11b at 
intermediate levels (Fig. 3.18A) when compared to CD14+ monocytes (Fig. 3.16A). 
CD11b expression was slightly lower on the CD16+ SLAN+ subset than the CD16+ SLAN- 
population (Fig. 3.18A). CD64 was expressed at intermediate levels on both SLAN subsets 
(Fig. 3.18B) in comparison to monocytes (Fig.3.16B). CX3CR1 was expressed 
homogenously on total CD14- CD16+ cells (Fig. 3.18C). Both CD16+ SLAN- and CD16+ 
SLAN+ subsets lacked expression of CD135 (Fig. 3.18D), unlike conventional CD141+ 
DCs (Fig. 3.17D). Overall, CD16+ SLAN- and CD16+ SLAN+ mononuclear cells had a 
very similar profile of surface marker expression for CD11b, CD64, CX3CR1 and CD135. 
Although CD16+ SLAN+ cells had slightly lower levels of CD11b expression than CD16+ 
SLAN- cells, this difference would be insufficient to distinguish between the two subsets 
based on this analysis. 
3.8.4 CD115 expression on blood mononuclear cells 
CD115, through its interaction with CSF-1 is critical for macrophage function and survival 
(573, 574). When cDC subsets were assessed for CD115 expression, it was noted that the 
CD141+ population completely lacked CD115 expression, whilst the CD1c+ subset was 
heterogeneous for this marker (Fig. 3.19A). Additionally, monocyte subsets were analysed 
for the expression of CD115 (Fig. 3.19B/C). Progression along the monocyte “waterfall” 
from population A to C (Fig. 3.8A) was accompanied by an increase in CD115 expression. 
CD14+ CD16- lacked detectable surface CD115, whilst the CD14+ CD16+ monocyte 
population expressed intermediate levels of this molecule. The majority of the CD14- 
CD16+ population homogenously expressed high levels of CD115 (Fig. 3.19B/C).  
3.9 Expression of zDC by circulating myeloid populations  
Recently, expression of the transcription factor Zbtb46 (zDC) has been reported to be 
specific to the DC lineage, thereby allowing separation of monocytes/macrophages and 
DCs (575). Due to the uncertainty regarding the identity of the CD14- CD16+ population 
(monocyte or DC), zDC expression was tested on CD14+ CD16- monocytes, CD14- CD16+ 
mononuclear cells and CD1c+ DCs (Fig. 3.20A) by qRT-PcR. All subsets tested were 
compared to CD14+ CD16- monocytes, as they had previously been shown to lack 
expression of this transcription factor (575). CD1c+ DCs expressed high levels of zDC, 
confirming their identity as a putative cDC subset (Fig. 3.20A). Expression of zDC on the 
heterogeneous population of CD14- CD16+ cells was found to be minimal and similar to  
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Figure 3.18: Surface phenotype of CD16+ SLAN- and CD16+ SLAN+ mononuclear cells 
PBMCs were isolated from peripheral blood of a HC and CD16+ mononuclear subsets were 
analysed for the expression of several surface markers. (A) Histograms showing CD11b 
expression on SLAN+ and SLAN- CD16+ subsets. FACS plot of SLAN and CD11b expression on 
total CD14- CD16+ cells. (B) Histograms show expression of CD64 on CD16+ subsets. (C) 
Expression of CX3CR1 on total CD11c+ MHC II+ CD14- CD16+ cells. (D) Expression of CD135 on 
CD16+ subsets. The appropriate isotype controls – Mouse IgG1# (CD11b, CD64 and CD135) and 
Rat IgG2b (CX3CR1) are shown in the grey filled histograms. Marker expression is depicted in red. 
Gating strategy described in Fig. 3.6A was used for this analysis. 
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Figure 3.19: Surface expression of CD115 on DC and monocyte subsets 
PBMCs were isolated from peripheral blood of a HC. CD11c+ MHC II+ cell subsets were analysed 
for the expression of CD115. (A) Histogram plots showing CD115 expression on CD141+ (left) and 
CD1c+ (right) DC subsets. (B) CD115 expression on mononuclear cell subsets – CD14+ CD16- 
(left), CD14+ CD16+ (centre) and CD14- CD16+ (right). (C) Representative FACS plots of CD115 
expression on CD14+ CD16- (left), CD14+ CD16+ (centre) and CD14- CD16+ (right) cell subsets. 
Numbers represent percentage of parent population. Isotype control (Rat IgG2a#) is represented 
by the grey solid histograms. Marker expression is depicted in red for each subset. Gating strategy 
described in Fig. 3.1A was used for analysis. 
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Figure 3.20: Zbtb46 (zDC) expression by DC and monocyte subsets 
PBMCs were isolated from peripheral blood of HCs and AS patients; DC/monocyte subsets were 
flow sorted for qRT-PcR analysis of Zbtb46 (zDC) expression. (A) Quantification of zDC expression 
in HCs (left) and AS patients (right) in CD14+ monocytes, CD1c+ DCs and CD14- CD16+ 
mononuclear cells. Monocytes were used as the reference subset (1) and mRNA expression is 
relative to the endogenous control, TATA binding protein (TBP). Data were analysed using a 
Mann-Whitney test. * = p<0.05. Error bars show mean + SD, au = arbitrary units. 
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that observed for CD14+ CD16- monocytes (Fig. 3.20A). No difference in subset zDC 
expression was observed between AS patients and HCs (Fig. 3.20A). However, due to the 
discovery of the heterogeneity within the CD14- CD16+ population, it was important to 
characterise zDC expression by CD16+ SLAN- and CD16+ SLAN+ subsets. Unfortunately, 
this experiment did not work and will have to be repeated to establish zDC expression on 
both subsets of CD14- CD16+ mononuclear cells. 
3.10 Discussion 
Inadequate tools and markers available for identification of DCs initially hampered their 
quantification and functional assessment in disease pathogenesis. Due to the location, 
function and diversity of DC populations, understanding their involvement in disease 
induction and pathology may enable improved development of disease therapeutics. 
Human DC biology has advanced through the identification of several human DC specific 
markers and utilisation of gene arrays permitting cross-species analysis (202, 203, 209, 
210, 393, 576). Analysis of DC populations in chronic and autoimmune diseases, has led to 
their exploitation for use in disease specific targeted therapies. To date, patients have been 
shown to successfully tolerate DC therapy, although efficacy of these therapies remains 
uncertain (577-579). However, recent advances in generating human tolerogenic DCs have 
shown promise for future treatment strategies in RA (580).  
Functional assessment and quantification of DCs has been performed for several diseases 
including RA and systemic lupus erythematosus (SLE) (217, 581-585). To the best of my 
knowledge, not one paper has been published examining the function and phenotype of 
peripheral blood DC subsets in AS ex vivo. Previous studies have relied on the generation 
of monocyte-derived DCs (moDCs) (546, 547). In these studies, blood monocytes are 
cultured in vitro, predominantly in the presence of GM-CSF and IL-4 to generate moDCs. 
These cultures generate large cell numbers for analysis and overcome the difficulties 
associated with isolating rare populations. The in vitro generated AS patient and HC 
moDCs were assessed functionally with regard to: cytokine secretion and maturation 
status. Robbins et al have shown that GM-CSF-cultured in vitro derived moDCs are more 
representative of monocytes/macrophages than of DCs (393). Therefore, moDCs do not 
sufficiently represent in vivo human DC populations. To investigate the properties of bona-
fide DCs, AS patient and HC DC populations were examined ex vivo. It was predicted that 
there would be differences between AS patient and HC DCs because of the recently 
identified systemic DC defect in HLA-B27 TG rats, a model of spondyloarthropathy (SpA) 
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(480). HLA-B27 TG rats lacked a specific subset (CD172alo CD11bint CD103+) of 
intestinal DCs, whilst the remaining DC populations preferentially induced Th17 responses 
(479, 480). Additionally, this missing CD172alo population has previously been shown to 
possess tolerogenic properties (372). Therefore, DCs in HLA-B27 TG rats may be 
involved in the development of SpA through loss of tolerance. Accordingly, detailed 
functional and phenotypic analyses of AS patient DCs may improve the understanding of 
this chronic inflammatory disease. 
For blood DC analysis, all or a fraction of 45 AS patients and 29 HCs were used. Patient 
clinical parameters including disease severity (BASDAI and BASMI), inflammation status 
(ESR and CRP), spinal disease levels, extra-articular tissue involvement and disease 
treatment protocols were collated and are portrayed in Table 3.1. AS is historically 
associated with young males (4), and the patient cohort corresponds with this assessment 
with 75% being male. The average age of the patient cohort was approximately 55 years, 
and would therefore initially appear to contradict the link between AS and young males. 
However, typical disease duration was approximately 30 years signifying early disease 
onset. Most patients expressed HLA-B27 (91%); this MHC I molecule provides the 
strongest genetic association of any inflammatory disease (11, 26). Characteristics of the 
study cohort include mid-range disease scores and low levels of the inflammatory markers 
ESR and CRP (Table 3.1). These features support the notion that AS is a disease associated 
with low levels of chronic spinal inflammation and bone formation, rather than severe 
inflammatory infiltrate as is observed in RA (564). Patients presented with various levels 
of spinal disease (sacroiliitis and/or bony changes within spinal regions), with 
approximately 30% of patients presenting with extra-articular disease. The presence of 
individual extra-articular manifestations may affect circulating immune populations, 
however this cohort is insufficiently powered to assess this hypothesis. Furthermore, 
disease treatment regimens and levels of inflammation may affect the immunological 
profile of patients. For example, anti-TNF! treatment has been reported to increase 
circulating myeloid DCs in the blood of AS patients (586). These correlations will be 
analysed and discussed in chapter 7.  
Using the patient and HC cohorts described in Table 3.1, the initial aim was to identify and 
enumerate circulating DC and monocyte populations. In blood, several populations of 
mononuclear cells were detected, including two cDC subsets, CD141+ and CD1c+ DCs 
(Fig. 3.1); two monocyte populations, CD14+ CD16- and CD14+ CD16+ (Fig. 3.1); pDCs 
(Fig. 3.2A) and a CD14- CD16+ mononuclear population (Fig. 3.6). Classification of the 
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CD14- CD16+ mononuclear population remains contentious, and it is often referred to as 
the third blood monocyte population in humans (231, 236, 237, 354, 587). However, this 
subset is not homogeneous as approximately 60% express the historical DC marker M-
DC8 or SLAN (Fig. 3.7B) (237, 239, 240, 588). Throughout this thesis I will try to address 
the heterogeneity of this population through phenotypic analyses, with the hope of 
elucidating the identity of this subset.  
AS patients had significantly more PBMCs per ml of blood compared to HCs (Fig. 3.3A). 
This finding can perhaps be attributed to the inflammatory environment associated with 
disease development. Compared to HCs, a trend towards a reduced proportion of total 
cDCs (CD141+ and CD1c+ subsets) was observed in AS patients, although this did not 
reach significance (Fig. 3.3.C). Several groups have reported reduced proportions of 
circulating DC in diseased individuals. One such disease is RA, in which the reduction in 
circulating DCs was attributed to enhanced recruitment to the inflamed synovium, where 
DCs are thought to contribute to disease pathogenesis through IL-23p19 secretion and 
induction of Th17 responses (217, 582). The study carried out by Jongbloed et al compared 
only 12 RA patients and HCs in addition to excluding CD141+ cDCs from their myeloid 
DC analysis (217). These discrepancies prevent direct correlation of these studies, however 
results presented here suggest that the proportion of total circulating cDCs did not differ 
dramatically between AS patients and HCs.  
Given the reported importance of DCs in driving disease pathology in diseases such as RA 
and our observations in the HLA-B27 TG rat model, it was not prudent to rule out a 
potential role for DCs in AS pathogenesis based on total cDC analysis alone. As discussed, 
circulating cDCs can be subdivided into two subsets on the basis of their expression of 
CD141 and CD1c. The MHC II+ CD103+ CD11bint CD172alo DC subset in rats is 
equivalent to the CD141+ human DC subset. As previously shown, this migrating intestinal 
population was absent from intestinal lymph of HLA-B27 TG animals (480). Loss of this 
tolerogenic population promoted generation of Th17 responses (480). It was therefore 
hypothesised that compared to HCs, the CD141+ cDC subset would be reduced or absent in 
AS patients. The obtained results, however, led to rejection of this hypothesis as no 
differences either in proportion or number of CD141+ cells between AS patients and HCs 
were detected (Fig. 3.4A). This population accounts for approximately 0.02% of live 
PBMCs, and thus given the rarity of this blood population, slight changes may be difficult 
to detect.  
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The original hypothesis was formed on the basis of lymph migrating and MLN resident 
populations in HLA-B27 TG rats. As blood was the only tissue available for this study, it 
is still possible that tissue resident CD141+ DCs are deficient in AS patients. The presence 
of mature circulating blood DCs in mice and rats remains controversial (Vuk Cerovic, 
unpublished results) (207, 390), again hindering direct comparison of our human and rat 
observations. Future studies could isolate and investigate the role of intestinal CD141+ 
DCs in human disease. Another consideration relates to the suitability of HLA-B27 TG 
rats for assessing AS pathogenesis. Although these animals develop SpA-like symptoms, 
their degree of spinal involvement is minimal (458). Consequently, this model may not 
adequately replicate human disease, especially that of AS. Although it is not possible to 
ignore the chance that CD141+ cDCs may be diminished within afflicted tissues such as 
the intestine, these data show that circulating CD141+ DCs were not diminished in AS 
patients, allowing rejection of the hypothesis at the present time. 
The major blood cDC population (CD1c+ DCs, ~95%) was significantly reduced in AS 
patients, as proportion of CD11c+ MHC II+ cells (Fig. 3.4B). This observation was not 
reflected when presented as total cell number or proportion of live cells. The reduction as 
proportion of CD11c+ MHC II+ may reflect expansion of the other LIN- CD14- CD11c+ 
MHC II+ population: CD14- CD16+ mononuclear cells. This will be discussed in depth 
later. However, to complete the thorough characterisation of circulating DC subsets, pDCs 
were enumerated. No significant difference was observed between AS patients and HCs in 
terms CD123+ CD304+ pDCs (Fig. 3.4C). Therefore, due to observations in the HLA-B27 
TG rat model and their role in the induction and skewing of immune responses, cDCs and 
not pDCs became the focus of the project. Consequently, pDCs were not included in 
subsequent analyses regarding maturation and functional assessment. Therefore future 
studies are required to elucidate the role of pDCs disease pathogenesis. 
Initial results suggest that some cDC populations are altered in AS patients. For these 
analyses, patient clinical parameters were not considered, but clinical and immunological 
correlative analyses were performed and are discussed in Chapter 7. That being said, the 
effect of HLA-B27 on immunological parameters was assessed throughout this study. 
Even though the genetic association between AS and HLA-B27 was described 40 years 
ago (24), the role of this gene in disease pathogenesis still remains elusive. Thus, the aim 
was to identify any relationship between HLA-B27 expression and frequency of blood DC 
populations. Unfortunately this study was not sufficiently powered to draw any definitive 
conclusions regarding HLA-B27 involvement, as only 6 HLA-B27+ HC individuals and 4 
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HLA-B27- AS patients were included. Despite this, no obvious patterns regarding HLA-
B27 involvement and blood DC parameters were observed (Fig. 3.4 and 3.5). Larger 
patient and HC cohorts would be required to fully assess the role of HLA-B27 expression 
in disease pathogenesis and circulating myeloid populations.  
Quantification of AS patient and HC blood DCs highlighted a high degree of variation 
within both cohorts. This is an unfortunate yet unavoidable aspect of working with clinical 
samples. Within the HC cohort, the proportion of CD1c+ DCs as percentage of CD11c+ 
MHC II+ cells ranged from 12% to 76%. This variation prompted a study where cDC 
proportions were monitored over time in individual blood donors. Proportional analysis of 
CD141+ and CD1c+ DCs and CD14- CD16+ mononuclear cells was performed using two 
HC individuals. These results suggest that populations do not vary drastically over time 
(Fig. 3.5). Given that proportions appear relatively stable over time, above and below 
average cell subsets proportions may not be attributable to underlying or unknown 
infections, exercise or stress. Taken together, the variation within both cohorts may not be 
attributable to inflammation. However, as only two HCs were used for this analysis, 
further experiments should be performed to validate these observations. Furthermore, 
comparative analysis of AS patient samples over time was not performed. Given the 
clinical and immunological parameter variation within the patient cohort, it would be of 
interest to assess DC proportions over time.  
As stated above, classification of the CD14- CD16+ mononuclear population is 
controversial. A significant proportion (60%) of CD14- CD16+ mononuclear cells express 
the surface marker SLAN or M-DC8 (Fig. 3.7B). SLAN+ cells are reported to possess DC-
like morphology (239, 240, 588). The majority of SLAN+ cells expressed CD16 whilst 
lacking expression of CD1c, CD14, CD19, CD56, CD2 and CD83. SLAN+ CD16+ cells 
were capable of stimulating T cells in an mixed leukocyte reaction (MLR), presenting 
antigen via recall responses and promoting cytotoxic T cell responses to a greater extent 
than CD14+ monocytes (240). Recently, SLAN+ cells have been reported to be principal 
producers of IL-12p70, IL-1" and IL-23p19 following TLR stimulation, with several 
groups suggesting a role for this pro-inflammatory, Th1 associated DC population in 
psoriasis and SLE pathogenesis (249, 252, 359). These findings support the premise that 
CD14- CD16+ SLAN+ cells are a distinct subset of circulating DCs. Principal component 
analysis (PCA) performed by Cros et al showed clustering of total CD14- CD16+ 
mononuclear cells, regardless of SLAN expression (237). These results appear to 
contradict the supposition that SLAN+ cells are distinct from their SLAN- counterparts. 
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Importantly though, CD14- CD16+ cells expressed a discrete set of genes in comparison to 
CD14+ CD16- and CD14+ CD16+ cells (237). These differentially expressed genes 
included scavenger receptors (CXCL16 and CD163) and apolipoproteins (237). These data 
suggest that the CD14- CD16+ cells express a distinct set of genes, differentiating them 
from CD14+ CD16- and CD14+ CD16+ monocytes. Consequently, CD14- CD16+ cells may 
represent a different stage of monocyte differentiation. In support for this statement, the 
murine equivalents of the CD14- CD16+ mononuclear population (Ly6Clo monocytes) have 
been recently reported to be derived from the murine equivalent of CD14+ CD16- 
monocytes (Ly6Chi monocytes) under steady state conditions (589). 
Alternatively, the CD14- CD16+ cells may not represent a third blood monocyte 
population. In addition to PCA analysis, Cros et al functionally assessed these subsets in 
vivo. Purified monocytes and total CD14- CD16+ mononuclear cells were transferred into 
Rag2-/- Il2rg-/- CX3CR1-/gfp mice (237). CD14- CD16+ cells were observed to attach and 
migrate along blood vessel endothelium (237). The authors concluded that human CD14- 
CD16+ mononuclear cells were equivalent to the “patrolling” Gr1- murine monocyte subset 
(237). Whilst performing this surveillance function, CD14- CD16+ cells were functionally 
distinct from CD14+ CD16- monocytes in terms of ROS production, MPO and lysozyme 
expression and phagocytosis uptake (237). Of note CD14- CD16+ mononuclear cells 
phagocytosed particles less efficiently than CD14+ CD16- monocytes (237). Taken 
together these results suggest that CD14- CD16+ mononuclear cells are functionally 
distinct from CD14+ CD16- blood monocytes. In contrast to Hansel et al, Cros et al found 
blood CD14- CD16+ cells to be somewhat anti-inflammatory (237, 249, 252). Despite these 
recent publications, classification of CD14- CD16+ mononuclear cells, either as a DC or 
monocyte population, remains uncertain. Given the functional and phenotypic 
heterogeneity of the CD14- CD16+ mononuclear population, SLAN+ and SLAN- cells may 
reflect different stages of monocyte maturation. Alternatively, the CD14- CD16+ 
population may contain both DCs (SLAN+) and monocytes (SLAN-). Chapter 6 
concentrates on the functional capabilities of DCs, CD14+ CD16- monocytes and CD14- 
CD16+ mononuclear cells isolated from AS patients and HCs.  
Given the involvement of the CD14- CD16+ mononuclear population in RA and SLE 
pathogenesis, and the observation that CD1c+ DCs were significantly reduced in AS 
patients as proportion of CD11c+ MHC II+ cells, CD14- CD16+ mononuclear cells were 
identified and enumerated in AS patients and HCs (249, 252, 359). No difference in the 
proportion of SLAN+ and SLAN- subsets was observed between AS patients and HCs (Fig. 
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3.7). However, a trend towards increased proportions of circulating total CD14- CD16+ 
mononuclear cells in AS patients was observed. CD14- CD16+ cells are identified within 
the LIN- CD14- CD11c+ MHC II+ population, together with CD141+ and CD1c+ DCs. 
Therefore, the reduction in CD1c+ DCs, as proportion of CD11c+ MHC II+, may be 
counterbalanced by an increase in CD14- CD16+ mononuclear cells. Consequently, AS 
patients may have an increased proportion of circulating CD14- CD16+ mononuclear cells 
compared to HCs. Published reports have not yet reached consensus regarding the pro- or 
anti-inflammatory properties of this population, and thus it would be important to study the 
functions of these cells to establish whether they could have a role in AS disease 
pathogenesis.  
Monocytes are rapidly recruited to sites of inflammation where they contribute to the 
immune response through secretion of pro-inflammatory cytokines (237, 238, 359, 590). 
Additionally, monocytes are believed by some to contribute to the tissue DC pool under 
steady state and inflammatory conditions (226, 228, 591-593). Again this topic is highly 
contentious with recent studies disputing this supposed monocyte function (225, 234). 
Much of this confusion results from use of overlapping markers used to identify DCs and 
macrophages. As discussed previously, in vitro moDCs have been utilised for AS DC 
phenotypic and functional analyses. Given the importance of monocyte functions in the 
immune response, and their exploitation for DC analysis in AS studies, CD14+ CD16- and 
CD14+ CD16+ monocytes in AS patients and HCs were identified and enumerated. No 
differences were observed in the proportions of either monocyte subset between AS 
patients and HCs (Fig. 3.9), which has not previously been reported in AS. Overall, these 
results suggest that changes in the frequencies of circulating blood monocytes do not 
change with AS disease pathology. Assessing monocyte and tissue resident macrophage 
function in AS patients and HCs may however provide important information regarding 
monocytes and disease pathogenesis. 
Overall, we have observed small changes to the proportion of circulating myeloid 
populations in AS patients. Compared to HCs, AS patients have a reduced proportion of 
CD1c+ DCs that may be counterbalanced by CD14- CD16+ mononuclear cells. 
Consequently, these populations may be involved in disease pathogenesis given their 
reported functions in vivo. Functional assessment of both populations will be presented and 
discussed in Chapter 6. 
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Murine DCs were initially characterised by Ralph Steinman in 1973 as adherent cells that 
constantly extend and retract processes (dendrites) and possessed large “contorted” nuclei 
(185). Based on these observations, the morphology of circulating myeloid populations in 
AS patients and HCs was characterised (Fig. 3.10). These experiments could additionally 
aid classification of CD14- CD16+ monocytes based on their morphological appearance. 
Unfortunately, SLAN+ and SLAN- subsets were not individually purified for this 
experiment. Both DC subsets (CD141+ and CD1c+) uniformly possessed lobulated nuclei, 
commonly associated with granulocytes. However, as the majority of granulocytes are 
removed from blood leukocytes during the density gradient stage of blood separation, and 
through exclusion of lineage positive cells (including CD15 and CD56) during cell sorting 
we can reject the possibility of granulocyte contamination contributing to the unusual 
morphological appearance of these myeloid populations. Steinman et al referred to DCs as 
possessing “contorted” nuclei (185). Therefore the “lobulated” nuclei most likely represent 
previously described DC morphologic characterisations. However, given their unusual 
appearance and the potentially harsh methods used to isolate immune populations, it was 
possible that cell death was contributing to these morphological characteristics. However 
cell death and apoptosis, assessed by annexin V and DAPI staining, were minimal 
following cell isolation (Fig. 3.12). Therefore, lobulated nuclei can be considered 
characteristic of live human circulating DCs. In support, several papers have published 
similar findings regarding blood cDC morphology (202, 594). Despite the unusual 
morphology of blood DCs, no differences between AS patients and HCs were seen. 
However, morphological assessment in terms of dendrite formation and number of 
cytoplasmic granules was not performed, and consequently, it is possible that there are 
subtle morphological differences between AS patient and HC DCs.   
Morphological analysis was additionally performed for CD14- CD16+ mononuclear cells 
and pDCs. Interestingly, CD14- CD16+ mononuclear cells possessed similar morphology 
to that of blood cDC populations (Fig. 3.9D). Unfortunately morphology of SLAN+ and 
SLAN- subsets was not individually assessed. These experiments did not enable exclusive 
classification of CD14- CD16+ as a DC or monocyte population based on morphology 
alone, although it was notable that the appearance of CD14- CD16+ cells closely resembled 
that of blood cDCs. In contrast, pDCs were similar to lymphocytes in morphology with 
large nuclei and little surrounding cytoplasm (Fig. 3.9C). Similarly, no morphological 
differences between AS patients and HCs for CD14- CD16+ mononuclear cells and pDCs 
were observed.  
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Cell migration from peripheral tissue to lymph nodes is often associated with maturation 
and alterations to the cellular phenotypic and functional attributes. Therefore, myeloid cell 
morphology was assessed following cell activation: overnight culture in the presence of 
LPS (Fig. 3.11). Following activation, cell nuclei contracted generating a more compact 
structure, dendrites were extended and cytoplasmic inclusions could be identified, 
supporting previous observations (595). Overall, activation altered the morphology of 
CD141+ DCs, CD1c+ DCs and CD14- CD16+ mononuclear cells. These data suggest that 
cell morphology adapts to the surrounding environment. 
As previously mentioned, the maturation status of DCs may influence whether the induced 
immune response is pro-inflammatory or tolerogenic. Upregulation of co-stimulatory 
molecules is associated with immunogenic responses, whilst semi-matured DCs are 
thought to promote tolerogenic responses (184, 190, 329, 596, 597). Given the importance 
of cell maturation in DC: T cell priming, assessment of DC maturation in AS patients and 
HCs was measured through expression of the co-stimulatory molecules CD40, CD80 and 
CD86 (Fig. 3.15). Expression of these co-stimulatory molecules was additionally assessed 
on CD14- CD16+ SLAN+/- mononuclear cells and the two CD14+ monocyte subsets. CD40, 
CD80 and CD86 expression was comparable between AS patients and HCs for all 
populations. These results indicate that myeloid populations in AS patients are unlikely to 
favour tolerogenic or immunogenic responses. However, these experiments were 
performed on circulating populations, and given the previously discussed dubiety 
surrounding blood DC function, these findings may not be indicative of tissue resident 
myeloid cell maturation. Therefore, analysis of tissue resident DC subsets may be more 
informative, with regards to the immune responses being induced at sites of inflammation. 
In turn these experiments could illuminate the function of individual populations in disease 
pathogenesis. That being said, co-stimulatory molecule expression on DC subsets was 
assessed using only 5 HCs and 8 AS patients. However, one study analysing moDCs in AS 
patients and HCs similarly found no difference in the expression of CD40 and CD86 (546), 
supporting our observations.  
Despite no differences being observed with regards to the cell maturation status of AS 
patient and HC myeloid populations, several differences were detected between individual 
cell populations (Fig. 3.15). DC subsets expressed similar levels of CD80 and CD86. 
However the CD141+ DC subset expressed significantly elevated levels of CD40 compared 
to CD1c+ DCs. CD40-CD40L DC: T cell interactions are important for the induction of 
CD8+ T cell responses (598). Therefore, preferential expression of CD40 by CD141+ DCs 
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supports their function as the principal cross-presenting DC population (200, 212, 340). In 
contrast to cDCs, monocytes and CD14- CD16+ mononuclear cells expressed high levels of 
CD86. This result suggests that circulating monocytes achieve a higher activation status 
than that of DCs under steady state and inflammatory conditions, potentially reflecting 
their differential roles in the propagation of immune responses.  
To further characterise the five myeloid populations of interest (DCs, monocytes and 
CD14- CD16+ mononuclear cells), several surface markers related to cell function and 
lineage commitment were analysed. CD135, the receptor for FMS-like tyrosine kinase 
ligand 3 (Flt3L) controls development and expansion of DCs in vivo (571, 572, 599). 
Expression of CD135 was restricted to CD141+ cDCs (Fig. 3.16). These results are 
obtained from one HC individual, and should be repeated. However, this differential 
CD135 expression could infer involvement of distinct progenitors and growth factors for 
the generation of CD141+ and CD1c+ DCs. Murine CD103+ DCs express higher levels of 
CD135 compared to their CD11b/CD1c+ counterparts (380). CD141+ DCs are thought to 
be equivalent to murine lymphoid CD8+ DCs and non-lymphoid CD103+ DCs (212, 340). 
Therefore, CD135 expression on human DC subsets mirrors that of their equivalent murine 
DC populations. This data could suggest that Flt3L is not required for the generation or 
maintenance of CD1c+ DCs. However, both CD141+ and CD1c+ DCs have been previously 
reported to be generated in vitro using CD34+ progenitor cells cultured in the presence of 
Flt3L, and furthermore both subsets have been shown to expand following in vivo Flt3L 
administration (203, 214, 571, 572, 600). Therefore the role of Flt3L in CD1c+ DC 
generation and maintenance remains undetermined. 
CD115, the receptor for CSF-1, is involved in the development of the macrophage lineage 
and is essential for their survival and function (Fig. 3.19) (573, 574). As for murine 
CD11b+ DCs, CD115 expression was restricted to the CD1c+ subset (380). These results 
suggest that several CD1c+ DC characteristics are associated with the 
monocyte/macrophage lineage. Overall CD135 and CD115 were expressed on CD141+ and 
CD1c+ DCs respectively. As stated above, these results could suggest utilisation of 
alternative precursors for the generation of CD141+ and CD1c+ DCs. However, further 
investigation is required. Characterisation of human circulating DC precursors, in addition 
to CD34+ haematopoietic stem cells may aid characterisation of human DC development.  
CD11b, CD64 and CX3CR1 are surface markers often used to identify and discriminate 
between monocyte/macrophage and DC populations. CD11b in mice and men is 
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predominantly expressed on cells of the myeloid lineage including DCs and macrophages 
(222, 573), and  all subsets except CD141+ DCs expressed CD11b, albeit at different levels 
(Fig. 3.16, 3,17 and 3.18). Lack of CD11b on CD141+ DCs corroborates an original study 
published by Dzionek et al, and supports their distinction from all other myeloid 
populations (202). CD64 expression, used to differentiate macrophages and monocytes 
from DCs in mice and men (225, 234, 601), was similar to that of CD11b. CD64 and 
CD11b expression on CD1c+ DCs further suggests a close relationship with the 
monocyte/macrophage lineage. In comparison to CD14+ monocytes, CD14- CD16+ 
mononuclear cells expressed lower levels of both CD64 and CD11b. This variation in 
marker expression may support the hypothesis that CD14- CD16+ mononuclear cells 
represent a differentially matured blood monocyte subset. However, these experiments are 
insufficient to fully address the classification of CD14- CD16+ mononuclear cells. 
CX3CR1 is expressed on monocytes, DCs and macrophages (246, 602). Examination of 
HC circulating myeloid populations revealed that CD141+ cDCs completely lacked 
expression of CX3CR1. Based on the expression of CX3CR1, CD11b, CD115 and Flt3L, 
CD141+ DCs therefore represent putative DCs. CX3CR1 was homogenously expressed on 
all other myeloid subsets assessed. Given the association between CD115 and the 
monocyte/macrophage lineage, it was therefore surprising that CD14+ CD16- monocytes 
were deficient in CD115 expression. This observation disputes a previous publication 
where CD115 was found to be highly expressed on both CD14+ monocyte populations 
(238, 565). Despite the same antibody clone being used in both experiments, the 
discrepancy between these results remains unexplained. CD115 was expressed at 
intermediate levels on CD14+ CD16+ monocytes, with highest levels being observed on 
CD14- CD16+ mononuclear cells. However, caution should be taken when interpreting 
these results as all surface phenotyping analyses were performed only once.  
Recently, several surface markers and transcription factors have been identified that may 
allow discrimination between myeloid populations (575, 603-605). One such transcription 
factor is Zbtb46 (zDC), shown to be DC specific in mice and men (575, 603). zDC 
expression was assessed on CD14+ CD16- monocytes, total CD14- CD16+ mononuclear 
cells and CD1c+ DCs (Fig. 3.20), which was expected to clarify lineage commitment of the 
CD14- CD16+ mononuclear population. In both HCs and AS patients, CD1c+ DCs 
expressed high levels of zDC, confirming that these cells are part of the DC lineage. 
Therefore, despite their association with the macrophage lineage in terms of surface 
marker expression, zDC expression confirms these cells as putative DCs. CD14+ 
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monocytes and CD14- CD16+ mononuclear cells expressed three to four times lower levels 
of zDC than CD1c+ DCs. CD141+ DCs could not be assessed due to poor yields after 
purification but have previously been reported to express zDC to similar levels of CD1c+ 
DCs (575, 603). These results suggest that CD14- CD16+ mononuclear cells do not belong 
to the cDC lineage. However, as previously discussed, CD14- CD16+ mononuclear cells 
are heterogeneous for SLAN expression, with CD16+ SLAN+ cells reported to represent a 
third blood DC population (240). Unfortunately, zDC expression of SLAN subsets was not 
performed. In order to clarify the debate regarding lineage commitment of CD14- CD16+ 
cells, zDC expression on individual subsets should be performed. If CD14- CD16+ SLAN+ 
cells do indeed represent a third DC population, they would be expected to express similar 
levels to that of CD1c+ DCs.  
In conclusion, AS patients appear to have a slightly altered immunological profile 
compared to HCs in terms of the circulating myeloid populations. A slight but significant 
reduction in circulating CD1c+ cDCs was counterbalanced by an increase in circulating 
CD14- CD16+ mononuclear cells. However, this increase was not associated with 
preferential expansion of either SLAN- or SLAN+ subsets. As different functional 
properties have been attributed to the CD14- CD16+ mononuclear population (237, 249, 
252, 359), further clarification regarding identity and functional characterisation of this 
population is required to fully understand their role in disease pathogenesis.  Based on 
previous functional characterisations, I hypothesise that the CD14- CD16+ population 
contains both monocytes (SLAN-) and DCs (SLAN+). However to test this hypothesis, 
several functional and transcriptional analyses would have to be performed on the 
individual subsets, including: naïve T cell proliferation, antigen presentation, cytokine 
production and zDC expression. In addition, these data also suggest that despite CD141+ 
and CD1c+ cells represent putative DC populations, the ontogeny of these populations may 
be distinct. These findings could have important implications for DC-based therapies.  
As stated previously, a defining feature of DCs is their ability to stimulate naïve T cells 
leading to the induction of specific immunogenic or tolerogenic immune responses. 
Consequently, analysis of T cell subsets and their expression of chemokine receptors can 
indicate the type of immune response induced following DC: T cell interaction. 
Furthermore, these studies can provide information relating to the site(s) of disease 
induction and perpetuation. Therefore in the next chapter, circulating AS patient and HC T 
cells were analysed in terms of activation status and chemokine receptor expression. 
 143 
 
 
 
 
 
 
 
Chapter 4: Role of T cells in AS pathogenesis 
 
  
 144 
4.1 Introduction 
DCs interact with T cells to orchestrate protective or tolerogenic immunity. Following DC: 
T cell crosstalk, T cells migrate to the tissue from which the interacting DC migrated. 
Within this tissue, they perform a variety of functions: they secrete cytokines that direct 
and control the immune response; they induce cell death in neighbouring cells; or they may 
inhibit aberrant responses. These functions depend on the phenotype of T cell subsets 
induced at priming (60, 80), and these consequently define the profile of the resulting 
immune response. When immune responses are not appropriately controlled, aberrant 
responses to self or harmless antigens can cause disease. Characterisation of these disease-
causing T cell responses can provide knowledge about pathogenic pathways and can be 
beneficial to the generation of new treatment strategies. Published work relating to AS and 
T cells focus on the identification and characterisation of Th1, Th2, Th17 and Th22 CD4+ 
T cell subsets circulating in the blood of patients. Many of these studies suggest pathogenic 
roles for Th17 and Th22 T cells in disease development (181, 495, 527, 530). This focus 
on CD4+ T cells in AS patients is due to the results obtained from animal models of SpA. 
These results exclude involvement of CD8+ T cells in disease development, despite their 
role in responding to antigen presented on MHC class I molecules such as HLA-B27. 
CD8+ T cells, in the HLA-B27 transgenic rat model, are insufficient to transfer disease to 
nude recipients, whilst inhibition of CD8+ T cell responses did not inhibit SpA progression 
(470-472). Although CD8+ T cells are not a primary focus for AS research, IL-4+ CD8+ T 
cells are found at increased frequencies in AS patients (606). Despite much research, 
consensus relating to the pathogenic functions of T cells in AS has not yet been reached. 
Consequently, I set out to examine the proportions of naïve, memory, activated and 
regulatory T cells in the blood of AS patients, and to address some of their functions, 
through examination of their cytokine secretion and chemokine receptor expression 
profiles. 
4.2 Patient characteristics 
AS patients were recruited from the Glasgow Royal Infirmary Ankylosing Spondylitis 
clinic run by Dr David McCarey and Dr Anne McEntegart. The results described in this 
chapter use all or a fraction of the participants whose information is depicted in Table 4.1. 
Many of the patients used for blood DC analysis were also assessed for T cell subsets and 
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are therefore included in the clinical information provided below. Clinical parameters 
assessed included disease duration, severity and treatment. 
Table 4.1: Patient Characteristics for T cell analysis 
For T cell analysis, 27 AS patients and 14 HCs were used. Patient and HC data were collated and 
tabulated below. Some patient records were incomplete or unavailable, and therefore, percentages 
represent proportion of total patients used in the study. Spinal disease levels were classified based 
on the number of sites involved: cervical, thoracic and/or lumbar: 1 site = level 1, 2 sites = level 2 
and 3 sites = level 3. Combination therapy refers to those patients receiving both DMARDs and 
NSAIDs. N/A = Not applicable. Mean ± SD. 
 AS Patients Healthy Controls 
Age (yrs) 54.96 ± 11.5 49.7 ± 10.2 
Sex – Male/Female 24/3 9/4 
Disease Duration (yrs) 28.6 ± 12.8 N/A 
B27 – Pos/Neg (% B27+) 24/3 (89%) 1/13 (7%) 
BASDAI 3.65 ± 2.3 N/A 
BASMI 4.3 ± 2.71 N/A 
ESR (mm/hr) 12.52 ± 10.9 N/A 
CRP (mg/L) 5.99 ± 5.16 N/A 
Bilateral Sacroiliitis – No. (%) 19 (94.7%) N/A 
Spinal disease   
    Absent – No. (%) 5 (29.4%) N/A 
    Level 1 – No. (%) 5 (29.4%) N/A 
    Level 2 – No. (%) 3 (17.65%) N/A 
    Level 3 – No. (%) 4 (23.56%) N/A 
Extra-articular Disease   
    IBD – No. (%) 1 (4.76%) N/A 
    Uveitis – No. (%) 4 (19.05%) N/A 
    Psoriasis – No. (%) 2 (9.52%) N/A 
    Arthritis – No. (%) 2 (10.53%) N/A 
Medication   
    DMARDs – No. (%) 0 (0%) N/A 
    NSAIDs – No. (%) 11 (68.75%) N/A 
    Combination – No. (%) 1 (6.25%) N/A 
    Biologics – No. (%) 4 (25%) N/A 
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Due to the overlap between the groups, many of the patient characteristics for blood cDC 
analysis are similar to this T cell patient cohort. The majority of AS patients were HLA-
B27+ (89%) and male, and the average age was 55 years. HCs were also predominantly 
male but were slightly younger with an average age of 50 years, and the majority (93%) 
were HLA-B27-. Again, disease was longstanding in patients with an average duration of 
28.6 years. Unfortunately, within this patient cohort, no newly diagnosed (<2 years) 
patients were included, which might have allowed comparison of immunological 
parameters at onset of disease with those patients experiencing long term, chronic disease. 
Disease severity was determined through BASDAI and BASMI assessment, whilst levels 
of inflammation were assessed using ESR and CRP levels. BASDAI (0-10) and BASMI 
scores (0-10) averaged 3.65 and 4.3 respectively. Inflammatory marker values below 10 
are considered normal for the Glasgow general population (Dr David McCarey, personal 
communication). Consequently, this patient cohort can be considered as mildly inflamed, 
with average values of 12.52 and 5.99 for ESR and CRP respectively. Similar to the blood 
DC patient cohort, information relating to levels of spinal disease was not consistently 
available. Of the 27 patients used for analysis, 18 patients (66.7%) presented with bilateral 
sacroiliitis whilst 1 patient completely lacked evidence of sacroiliitis. For the remaining 8 
patients, data were not recorded. Likewise, information about the degree of spinal disease 
(bony changes or fusion within the cervical, thoracic or lumbar regions of the spine) was 
not always available; these details were only available for 17 out of 27 patients. Patients 
presenting with complete absence of spinal disease or only one affected site were most 
abundant. As described previously, AS patients often present with extra-articular 
manifestations: IBD, uveitis, psoriasis and peripheral arthritis. Within this cohort, 8 
patients presented with extra-articular disease, with uveitis being the most common 
amongst them. One patient had developed two extra-articular manifestations: uveitis and 
peripheral arthritis. Disease treatment was the final clinical parameter considered for the 
patient cohort, with treatment strategies subdivided into four groups: DMARDs, NSAIDs, 
combination (DMARD + NSAID) and biological therapy. As for the blood DC group, 
NSAIDs were the most common form of treatment (69%) while 23% of patients were 
receiving biological therapy. The potential effects of these clinical factors on patient 
immunological parameters will be discussed in more depth in Chapter 7. All, or a subset of 
these patients were used for the following T cell analyses, which will focus on the 
phenotype and functions of T cells in AS patients. 
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4.3 T cell subsets in peripheral blood 
To identify CD4+ T cell subsets in the blood of AS patients, the gating strategy depicted in 
Fig. 4.1A was used. First, cell debris was gated out based on the FSC vs SSC profile. 
Subsequently, doublets and dead (DAPI+) cells were excluded from further analysis. CD4+ 
TcR!"+ cells were then subdivided into 4 subsets based on expression of CD25 and 
CD45RA (Fig. 4.1A): CD45RA+ CD25-, CD45RA- CD25-, CD45RA- CD25int and 
CD45RA- CD25hi. To further characterise these CD4+ T cell subsets, cells were 
additionally stained for the CD4+ Treg transcription factor FOXP3, which controls Treg 
development and function (607). The results were consistent with published data, showing 
that all CD45RA- CD25hi cells expressed FOXP3 (Fig. 4.1B), whilst the majority of 
CD45RA- CD25int cells lacked FOXP3 expression. The CD4+ TcR!"+ CD45RA- CD25hi 
cells were therefore considered to be Tregs. Thus, based on expression of CD45RA, CD25 
and FOXP3, our CD4+ T cell subsets were classified as naïve (CD45RA+ CD25-), memory 
(CD45RA- CD25-), activated/effector (CD45RA- CD25int) or Treg (CD45RA- CD25hi 
FOXP3+) populations (Fig. 4.1C).  
Following identification of four CD4+ T cell subsets, the proportions of total circulating 
CD4+ TcR!"+ T cells as well as the individual T cell subsets were compared between AS 
patients and HCs. No difference in the proportion of total CD4+ TcR!"+ T cells between 
AS patients and HCs was observed, in terms of percentage of live cells or cell number/ml 
of blood (Fig. 4.2A). The individual subsets were analysed in terms of percentage of CD4+ 
TcR!"+ cells, percentage of live cells and absolute cell number/ml of blood. Again, no 
significant differences were seen between AS patients and HCs for naïve (Fig. 4.2B), 
memory (Fig. 4.2C), activated (Fig. 4.3A) and Treg (Fig. 4.3B) populations. In blood, 
naïve CD4+ T cells represented the major population, comprising 45-50% of total CD4+ 
TcR!"+ T cells, activated (CD45RA- CD25int) CD4+ T cells represented approximately 
25% of this T cell pool, and memory T cells and Tregs (CD45RA- CD25hi) contributed 
approximately 15% and 5% respectively (Fig. 4.2 and 4.3). In addition to analysing the 
proportions of CD4+ T cell subsets, the aim was to investigate whether HLA-B27 
expression affects the T cell profile observed in AS patients and HCs. However, too few 
samples of HLA-B27+ HCs and HLA-B27- AS patients were available to power this aspect 
of the study. Data from these individuals are highlighted in red (Fig. 4.2 and 4.3).  
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Figure 4.1: Identification of peripheral blood T cell subsets 
Four T cell subsets can be identified in peripheral blood. PBMCs were isolated using Ficoll 
gradient, with cells identified by flow cytometry. (A) Gating strategy used to identify CD4+ T cells. 
First, doublets and dead cells (DAPI+) were excluded from analysis. Single live cells (top, right) 
were analysed for expression of CD4 and TcR"! (bottom left), with CD4+ TcR"!+ cells being 
subdivided into four subsets based on CD25 and CD45RA expression (bottom, right). (B) FOXP3 
expression on live CD4+ TcR"!+ CD25+ CD45RA- T cells. Gate based on isotype. (C) Identification 
of four T cell subsets – activated (CD25lo CD45RA-), naïve (CD25- CD45RA+), memory (CD25- 
CD45RA-) and regulatory T cells (CD25hi CD45RA-). Arrows highlight the individual T cell subsets. 
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Figure 4.2: Comparison of T cell subsets in AS patients and HCs 
No differences in the proportions of total, naïve and memory CD4+ T cell subsets between HCs 
(empty circles) and AS patients (filled circles). (A) % of live cells (left) and no. of CD4+ TcR"!+ T 
cells/ml of blood (105 - right) for AS patients and HCs. (B) Analysis of naïve CD4+ T cells (CD25- 
CD45RA+) in terms of proportion of CD4+ TcR"!+ T cells (left), % of live cells (centre) and no. of 
cells/ml of blood (105 – right) in AS patients. (C) Quantification of memory CD4+ T cells (CD25- 
CD45RA-) in terms of proportion of CD4+ TcR"!+ T cells (left), % of live cells (centre) and no. of 
cells/ml of blood (105 – right). All graphs show mean. HC red dots = B27+ individuals, AS red dots = 
B27- patients. HC = 14, AS = 27.     
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Figure 4.3: Comparison of CD25+ T cell subsets in AS patients and HCs 
AS patients (filled circles) have similar frequencies of activated and regulatory T cells compared to 
HCs (empty circles). (A) Analysis of activated CD4+ T cells (CD25lo CD45RA-) in terms of 
proportion of CD4+ TcR"!+ T cells (left), % of live cells (centre) and no. of cells/ml of blood (105 – 
right). (B) Quantification of regulatory CD4+ T cells (CD25hi CD45RA-) in terms of proportion of 
CD4+ TcR"!+ T cells (left), % of live cells (centre) and no. of cells/ml of blood (105 – right). All 
graphs show mean. HC red dots = B27+ individuals, AS red dots = B27- patients. HC = 14, AS = 
27.   
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4.4 Chemokine receptor expression on circulating T cells 
Following activation, chemokine receptors are upregulated on the surface of T cells, 
directing their migration to specific tissues. When a T cell encounters and interacts with a 
DC in a lymph node, it is “instructed” to return to the tissue from which the DC originated 
(172, 413, 608, 609). For example, intestinal DCs instruct T cells to return to the intestine 
by inducing expression of the gut homing markers CCR9 and !4"7 (171, 172). Thus, 
analysing the array of chemokine receptors expressed on the surface of T cells makes it 
possible to deduce what tissues these cells are likely to migrate towards. An example of 
chemokine receptor staining is shown in Fig. 4.4A. The gating strategy described in Fig. 
4.1 was implemented and CD4+ TcR!"+ CD45RA- CD25int activated T cells were analysed 
for expression of CCR4 (Fig. 4.4A). The CCR+ gate was set using the appropriate isotype 
control antibodies for each CD4+ T cell subset. 
Expression of the chemokine receptors CCR4, CCR6, CCR9, CCR10 and CXCR3 were 
assessed in this study for the four T cell populations shown earlier. CCR9 promotes 
migration to the small intestine (171, 172); CCR10 induces migration of lymphocytes to 
mucosal sites and skin whilst CCR4 is the major promoter of skin migration (173-175, 
610-612). CCR6 is expressed by mucosal lymphocytes, cells migrating to sites of 
inflammation and DCs residing in Peyer’s patches (176, 180, 613). In addition to directing 
cell migration, several chemokine receptors are associated with specific T cell effector 
types. For example, CCR6 is used as a surrogate marker for Th17 cells (180, 181), while 
CXCR3 is predominantly expressed on Th1 cells and promotes migration to inflammatory 
sites (182, 183, 614). This panel of chemokine receptors was chosen given their 
associations with tissues involved in disease pathology (skin, intestine and joint) or 
expression on disease associated T cell phenotypes (Th1 and Th17). Expression of CCR4, 
CCR6, CXCR3, CCR9 and CCR10 on activated, memory, regulatory and naïve T cells 
isolated from a HC are shown in Fig. 4.5 and 4.6. A significant proportion of all T cell 
populations, except naïve T cells (Fig. 4.5D), were found to express CCR4, CCR6 and 
CXCR3 (Fig. 4.5). Strikingly, the majority of Tregs expressed CCR4 (Fig. 4.5C). A 
fraction of naïve CD4+ T cells expressed CXCR3 (Fig. 4.5D). Few CCR9+ cells were 
detected (Fig. 4.6). CCR10 expression followed the pattern of CCR4, CCR6 and CXCR3, 
with a proportion of all subsets except naïve T cells expressing this mucosal/skin homing 
chemokine receptor (Fig. 4.6). Expression of the above-mentioned chemokine receptors 
were compared between AS patients and HCs. CCR4 was expressed at similar proportions 
on activated, memory, naïve and Treg subsets in AS patients and HCs (Fig. 4.7). When  
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Figure 4.4: Detection of chemokine receptor expression on CD4+ T cells 
Identification of chemokine receptor (CCR) expression on CD4+ T cells. (A) To identify T cell 
subset CCR expression, doublets and dead cells (DAPI+) were excluded from further analysis. 
Single live cells (top centre) were analysed for expression of CD4 and TcR"! (top right), with cells 
co-expressing both markers being subdivided into four subsets based on CD25 and CD45RA 
expression (bottom left). As an example of CCR expression, CD25lo CD45RA- activated T cells 
were analysed for expression of CCR4 (bottom centre). CCR4 gate was set based on the isotype 
(bottom right).  
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Figure 4.5: Expression of CCR4, CCR6 and CXCR3 on T cell subsets 
Representative chemokine receptor (CCR) staining on HC blood T cell subsets. Single DAPI- CD4+ 
TcR"!+ cells were subdivided into 4 T cell subsets and CCR+ expression was analysed. Activated 
(A), memory (B), regulatory (C) and naïve (D) T cell subsets were analysed for the expression of 
the chemokine receptors CCR4 (centre, left), CCR6 (centre, right) and CXCR3 (right). Gates for 
each individual CCR were set using the isotype plot (left). Numbers represent proportion of CCR+ T 
cells. Activated = CD25+ CD45RA-, memory = CD25- CD45RA-, regulatory = CD25hi CD45RA- and 
naïve = CD25- CD45RA+. Isotype for all CCRs was mouse IgG1#. 
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Figure 4.6: Expression of CCR9 and CCR10 on T cell subsets 
Representative chemokine receptor (CCR) staining on peripheral blood T cell subsets from a HC. 
Single DAPI- CD4+ TcR"!+ cells were subdivided into 4 T cell subsets and CCR+ expression was 
analysed. Activated (A), memory (B), regulatory (C) and naïve (D) T cell subsets were analysed for 
expression of the chemokine receptors CCR9 (centre, left) and CCR10 (right). Gates for CCR9 
were set using the specific isotype plot (left – Rat IgG2a). Gates for CCR10 were set using the 
specific isotype gate (centre, right – mouse IgG2a). Numbers represent proportion of CCR+ T cells. 
Activated = CD25+ CD45RA-, memory = CD25- CD45RA-, regulatory = CD25hi CD45RA- and naïve 
= CD25- CD45RA+. Numbers represent proportion of CCR+ T cells. 
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percentage of CCR+ CD4+ TcR!"+ cells, live cells and the CCR+ cell number/ml of blood 
were all analysed, interestingly, CCR6 and CXCR3 were differentially expressed in AS 
patients, compared to HCs (Fig. 4.7 and 4.8). The proportion of CCR6+ CD45RA- CD25int 
(activated) T cells was significantly increased in AS patients compared to HCs (Fig. 4.7A). 
However, the percentage of CCR6+ T cell among live cells and the absolute number of 
CCR6+ CD45RA- CD25int T cells per ml of blood did not differ between AS patients and 
HCs (Fig. 4.7). In contrast, CXCR3 was expressed on a significantly smaller percentage of 
activated and memory T cells in AS patients, with a reduced proportion of CXCR3 
memory T cells also being observed when represented as a percentage of live cells (Fig. 
4.8A and 4.8B). No difference in the proportion of CCR9+ and CCR10+ expressing CD4+ 
T subsets was observed between AS patients and HCs, expressed as either % of total CD4+ 
T cells (Fig. 4.9A), % of live cells (Fig. 4.9B) and cell number (Fig. 4.9C). Expression of 
chemokine receptors on HLA-B27+ HCs and HLA-B27- AS patients was compared but no 
conclusions could be drawn due to insufficient numbers of samples.  
4.5 T cell phenotype and cytokine secretion 
The expression of particular chemokine receptors is associated with specific T cell 
phenotypes. To corroborate above findings relating to chemokine receptor expression in 
AS patients, where differential expression of CCR6 and CXCR3 was observed on CD4+ 
TcR!"+ T cells, we investigated cytokine production by CD4+ TcR!"+ T cells in the blood 
of AS patients and HCs. The gating strategy used in these experiments was identical to that 
described in Fig. 4.1. Cytokine production was assessed by intracellular staining 4.5 hours 
after stimulation with PMA and ionomycin in the presence of brefeldin A and monensin 
(protein secretion inhibitors). Unstimulated CD4+ T cells produced barely detectable 
quantities of cytokines (Fig. 4.10A). Following stimulation, cells were analysed for the 
production of IL-17A and IFN#. These cytokines are diagnostic for specific T cell 
phenotypes: IL-17A is produced by Th17 cells, known to express CCR6; IFN# is the 
signature cytokine of Th1 cells, thought to preferentially express CXCR3 (180, 181, 183). 
Gates for analysis were set using specific isotype controls (data not shown). Staining for 
IL-17A and IFN# on stimulated CD4+ T cells identified 3 subsets of cytokine producing T 
cells: IFN#+ IL-17A-, IFN#- IL-17A+ and double-producing IFN#+ IL-17A+ CD4+ T cells 
(Fig. 4.10B). To identify non-CD4 cytokine producing cells, total single live cells from a 
HC were also assessed for IFN# and IL-17A production (Fig. 4.10C). The majority of IL-
17A producing cells were CD4+ (0.007% vs 0.173% - Fig. 4.10C). In contrast, a larger 
proportion of IFN#+ CD4- cells were present in HC blood  (5.18% vs 23.4% - Fig. 4.10C).  
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Figure 4.7: CCR4 and CCR6 expression in AS patients and HCs 
A greater proportion of activated T cells isolated from AS patients (filled circles) express CCR6 
compared to HCs (empty circles). Quantification of CCR4 and CCR6 expression on activated (A), 
memory (M), naïve (N) and regulatory (R) T cell subsets in AS patients and HCs. (A) The 
proportion of CCR4+ (left) and CCR6+ (right) CD4+ TcR"!+ T cell subsets in AS patients and HCs. 
The % of live cells (B) and total number of CCR+ cells/ml of blood (C) were also compared between 
AS patients and HCs for CCR4 (left) and CCR6 (right). Graphs show mean. HC red dots = B27+ 
individuals, AS red dots = B27- patients. Students unpaired T test (A, right), * p<0.05. 13 HCs and 
25 AS patients were used for analysis.      
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Figure 4.8: CXCR3 expression in AS patients and HCs 
CXCR3 expression is differentially expressed in AS patients (filled circles) compared to HCs 
(empty circles). Expression of CXCR3 was assessed on activated (A), memory (M), naïve (N) and 
regulatory (R) T cells in the blood of AS patients and HCs. (A) Proportion of CXCR3+ CD4+ TcR"!+ 
T cell subsets in AS patients and HCs. The % of live cells (B) and total number of CXCR3+ cells/ml 
of blood (C) were compared between AS patients and HCs for each T cell subset. All graphs show 
mean. HC red dots = B27+ individuals, AS red dots = B27- patients. Students unpaired T test or 
Mann-Whitney non-parametric test used where appropriate, * p<0.05. 7 HCs and 13 AS patients 
were used for analysis.     
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Figure 4.9: CCR9 and CCR10 expression in AS patients and HCs 
No difference in CCR9 and CCR10 expression on CD4+ T cells between AS patients (filled circles) 
and HCs (empty circles). Activated (A), memory (M), naïve (N) and regulatory (R) T cell subsets 
were assessed for the expression of CCR9 and CCR10. (A) The proportion of CCR9+ (left) and 
CCR10+ (right) CD4+ TcR"!+ T cell subsets in AS patients and HCs. The % of live cells (B) and 
total number of CCR+ cells/ml of blood (C) were also compared between AS patients and HCs for 
CCR9 (left) and CCR10 (right). All graphs show mean. HC red dots = B27+ individuals, AS red dots 
= B27- patients. CCR9 – 9 HCs and 13 AS patients, CCR10 – 18 HCs and 24 AS patients used for 
analysis.    
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Figure 4.10: Secretion of IL-17A and IFN! from peripheral blood CD4+ TcR"#+ T Cells 
CD4+ TcR"!+ cells can secrete IL-17A and IFN$ after 4.5 hour stimulation with PMA and 
ionomycin. Unstimulated (A) and stimulated (B) CD4+ TcR"!+ were analysed for expression of IL-
17A and IFN$ after 4.5 hour incubation at 37°C, 5% CO2. Gating strategy used to identify CD4+ 
TcR"!+ T cells is described in Fig. 4.1A. IL-17A+, IFN$+ and IL-17A+ IFN$+ secreting T cells were 
identified following PBMC stimulation. Percentages are proportion of CD4+ TcR"!+ cells. (C) IL-
17A (left) and IFN$ (right) cytokine secretion by total CD4+ and CD4- single DAPI- cells. 
Percentages represent proportion of live cells. (D) Representative plots showing IL-17A (left) and 
IFN$ (right) secretion by CCR6+ and CCR6- cells. Gates were set based on isotype controls. 
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In addition to detecting cytokine production from CD4+ TcR!"+ cells, expression of CCR6 
on the cytokine-producing cells was assessed. IL-17A secreting cells predominantly 
expressed CCR6, while IFN#+ CD4+ T cells were largely CCR6- (Fig. 4.10D).  
Quantification of cytokine producing cells revealed that AS patients appeared to have a 
higher proportion of CD4+ IL-17A+ T cells compared to HCs in terms of percentage of live 
cells, proportion of CD4+ TcR!"+ T cells and cell number (Fig. 4.11A, 4.11B and 4.11C). 
The proportion of CD4+ IFN#+ and CD4+ IFN#+ IL-17A+ T cells were assessed, however 
no differences in the frequencies of these populations were observed between AS patients 
and HCs (Fig. 4.11A/B/C). Although AS patients may have a lower proportion of 
circulating IFN#-secreting cells, compared to HCs (Fig. 4.11A/B). Unfortunately, due to 
insufficient numbers of samples, statistical analysis could not be performed and thus it is 
not possible to draw any definitive conclusions from these data sets. However, a trend 
towards increased circulating IL-17A+ CD4+ T cells in AS patients was observed. 
Quantification of CCR6 expression on cytokine producing cells confirmed the initial 
observations; AS patients seemed to have a greater proportion of CCR6+ cells expressing 
IL-17 (Fig. 4.12A). The majority of IL-17A+ CD4+ T cells (~85%) expressed CCR6, in 
both HCs and AS patients (Fig. 4.12B). However, statistical analysis could not be 
performed on these data sets due to insufficient numbers of data points. In contrast to IL-
17A secreting cells, only 8% of IFN#+ CD4+ TcR!"+ in both AS patients and HCs 
expressed CCR6 (Fig. 4.12C). Interestingly, the majority (~85%) of IFN#+ IL-17A+ CD4+ 
T cells expressed CCR6, matching the proportion of IL-17A+ T cells (Fig. 4.12D). 
4.6 Plasma cytokines in AS patients 
Cytokines influence the immune response through diverse interactions with cells, and thus 
analysis of plasma cytokines in AS patients may reveal mechanisms involved in disease 
pathogenesis. Accordingly, we measured cytokines and growth factors attributed to T cell 
subsets (Th1, Th2, Th17 and Tregs) and inflammation in the plasma of HCs and AS 
patients. We were able to detect IFN#, IL-10, IL-4, IL-5, IL-17A, IL-23p19, IL-1", IL-6, 
TNF! and Flt3L (Fig. 4.13 and 4.14). In addition, levels of GM-CSF and IL-12 were 
measured but both cytokines fell below limit of detection. Of the cytokines produced by 
helper T cell subsets, only IL-4 (Th2) and IL-23p19 (Th17) were differentially expressed 
between AS patients and HCs. IL-4 was downregulated in AS patients (Fig. 4.13A), 
whereas levels of circulating IL-23p19 were significantly higher in AS patients than in 
HCs (Fig. 4.13B). However, it should be noted that plasma levels of all the cytokines  
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Figure 4.11: Quantification of IL-17A and IFN! secreting CD4+ TcR"#+ T Cells 
Comparison of intracellular IL-17A and IFN$ stores in CD4+ TcR"!+ T cells isolated from AS 
patients and HCs. The proportion of IL-17A+ (left), IFN$+ (centre) and IL-17A+ IFN$+ (right) 
secreting CD4+ TcR"!+ T cells in terms of % of live cells (A), % of CD4+ TcR"!+ T cells (B) and 
total cell number/ml of blood (C) for AS patients (filled circles/bars) and HCs (empty circles/bars) 
were assessed. For all data sets, 2 HCs and 4 AS patients were collated from two independent 
experiments. Error bars represent mean + SD. 
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Figure 4.12: CCR6 expression on cytokine secreting CD4+ TcR"#+ T Cells 
CD4+ TcR"!+ T cells producing IL-17A predominantly express CCR6. (A) Proportion of CCR6+ T 
cells secreting IL-17A were compared between AS patients (filled circles) and HCs (empty circles) 
in terms of % of live cells (left) and % of CD4+ TcR"!+ T cells (right). (B) Proportional analyses of 
AS patient and HC IL-17A+ secreting T cells expressing CCR6, in terms of % of live cells (left) and 
% of CD4+ TcR"!+ T cells (right). Percentage of CD4+ TcR"!+ IFN$+ (C) and CD4+ TcR"!+ IL-17A+ 
IFN$+ (D) T cells from AS patients and HCs that co-express CCR6. All graphs show mean. 
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Figure 4.13: Presence of T helper cytokines in AS patient and HC plasma 
Plasma cytokines associated with Th1, Th2, Th17 and regulatory T cells in AS patient and HC 
plasma were measured by luminex or ELISA. Levels of the Th1 associated cytokine IFN$ (A) and 
the regulatory cytokine IL-10 (B) in AS patient (filled circles) and HC (empty circles) plasma. (C) 
Th2 cytokines – IL-4 (left) and IL-5 (right) were detected in AS patient and HC plasma. (D) The 
Th17 associated cytokine profile of AS patients and HC plasma was assessed – IL-17A (left) and 
IL-23p19 (right). HLA-B27+ HC individuals and HLA-B27- AS patients are highlighted in red. ** p = < 
0.01 and *** p = < 0.001, by Mann Whitney T tests. 
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Figure 4.14: Presence of inflammatory cytokines and growth factors in AS patient and HC 
plasma 
Plasma cytokines associated with inflammation and haematopoiesis in AS patients and HCs were 
analysed. (A) Analysis of IL-1! (top left), IL-6 (top right) and TNF" (bottom) in AS patient and HC 
plasma. Cytokines were measured by Luminex. (B) The haematopoietic growth factor – Flt3L – 
was measured in plasma isolated from AS patients and HCs using ELISA. HLA-B27+ HC 
individuals and HLA-B27- AS patients are highlighted in red. * p = < 0.05 and ** p = < 0.01. A Mann 
Whitney T test was used for TNF" analysis, whilst an unpaired students T test was used for Flt3L 
analysis. All graphs show mean. 
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measured – IFN# (Th1), IL-10 (Tregs), IL-4 and IL-5 (Th2) and IL-17A and IL-23p19 
(Th17) – averaged below 50pg/ml (Fig. 4.13). Two cytokines indicative of inflammation, 
IL-6 and TNF!, were upregulated in AS patient plasma compared to HCs (Fig. 4.14C). 
Plasma IL-1" levels were similar in AS patients and HCs (Fig. 4.14A). Again, 
concentrations of all inflammatory associated cytokines averaged below 50pg/ml (Fig. 
4.14A). Plasma Flt3L was significantly upregulated in AS patients (170pg/ml) compared to 
HCs (130pg/ml - Fig. 4.14B). The relationship between HLA-B27 expression and plasma 
cytokine levels was assessed and is depicted in Fig. 4.13 and Fig. 4.14. However, too few 
HLA-B27+ HCs and HLA-B27- AS patients were available; this aspect of the study had 
insufficient power to assess the relationship between HLA-B27 expression and plasma 
cytokine concentrations. 
Overall, no differences were noted in proportions of naïve, activated, memory and 
regulatory T cell subsets between AS patients and HCs. However, a significantly higher 
proportion of activated T cells from AS patients expressed the Th17-associated chemokine 
receptor CCR6, and a lower proportion of both memory and activated T cells from AS 
patients expressed the Th1-associated CXCR3 chemokine receptor. Furthermore, these 
data also indicate that AS patients have a higher proportion of circulating CCR6+ IL-17A 
producing CD4+ T cells. Furthermore, we observed higher levels of the Th17-associated 
cytokines IL-23p19, IL-6 and TNF! in AS patients. All together these data suggest a role 
for Th17 cells, in accordance with published data.  
4.7 Discussion 
In this chapter, the phenotypic and functional properties of peripheral blood CD4+ T cell 
subsets in AS patients were investigated. The majority of studies examining the role of T 
cells in AS have focused on quantifying circulating CD4+ T cell subsets (Tregs and Th17 
cells), T cell activation, antigen reactivity and plasma cytokines (530, 537, 543, 549, 615, 
616). Several studies have focused on alternative T cell populations including #$ T cells 
(536) and CD8+ T cells (534, 617). This bias towards the study of CD4+ T cells originates 
from a number of influential reports. Initially, athymic HLA-B27 TG rats were shown to 
develop SpA-like symptoms following transfer of T cells, where CD4+ T cells were more 
efficient than CD8+ T cells (470). Not only did this paper highlight a role for T cells in 
disease induction, but it also identified CD4+ T cells to be more pathogenic than CD8+ T 
cells. This result was surprising given that HLA-B27 is a MHC class I molecule classically 
involved in antigen presentation to CD8+ T cells and the strong genetic link between AS 
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and HLA-B27. These results have been confirmed more recently when eradication of 
CD8!"+ T cells by thymectomy, antibody depletion or use of CD8!-/- rats failed to inhibit 
disease progression (471, 472). Despite intensive efforts trying to identify the role of CD4+ 
T cells in the disease pathogenesis, no consensus regarding their role has yet been reached. 
Several studies indicate involvement of pathogenic Th17 cells in disease development 
(495, 527, 530, 539, 618) although this is disputed by others (540, 553). Overall, the exact 
role of Th17 cells in AS pathogenesis remains to be determined. Until now, no detailed 
analysis of circulating naïve, activated, memory and regulatory T cell subsets has been 
performed in AS patients. With the aim of generating a greater understanding of AS 
immunopathogenesis I performed phenotypic and functional analyses of CD4+ T cell 
subsets.  
The majority of the patients in this study were male and HLA-B27+. AS is often described 
as a disease predominantly affecting young males, with approximately 95% of patients 
expressing HLA-B27 (4). Therefore our small patient cohort is representative of European 
AS patients. Patient characteristics here are similar to those in Chapter 3, due to some 
patient overlap and recruitment of patients from the same AS clinic. HC cohort parameters 
were sufficiently similar to those of AS patients to permit comparative analyses. AS 
patient disease severity scores and levels of inflammatory markers were relatively low; AS 
is not often associated with severe systemic inflammation (564). The majority of patients 
had developed bilateral sacroiliitis, with 45% exhibiting signs of spinal disease. However, 
data regarding spinal disease was not available for 10 patients, making correlations 
between spinal disease severity and immunological factors very difficult. Approximately 
40% of patients had developed extra-articular manifestations, with uveitis being the most 
widespread. Excluding patients for whom extra-articular disease manifestation data was 
not available, 20% of our patient cohort suffered from uveitis. Sampaio-Barros et al report 
that of their cohort, 15% of AS patients were diagnosed with uveitis (619, 620). However, 
our study was insufficiently powered to draw any definitive conclusions regarding the 
prevalence of IBD, psoriasis, uveitis and peripheral arthritis.  
Treatment strategies, previously shown to affect immunological factors (539, 586, 621, 
622), must be considered when working with patient cohorts. Similar to our blood DC 
cohort, the majority of patients were receiving treatment with NSAIDs. However, 
information regarding disease treatment was available for only 60% of patients. Despite 
these shortcomings, the effect of these individual clinical parameters will be assessed and 
discussed in Chapter 7. 
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Using the patient and HC cohorts described above, the proportions of blood T cell subsets 
were analysed. Given that many patients exhibit a degree of inflammation, we 
hypothesised that AS patients would have a higher proportion of circulating CD4+ T cells 
compared to HCs. Naïve, memory, activated and regulatory T cell subsets were identified 
in AS patients and HCs based on the expression of CD45RA, CD25 and FOXP3 (Fig. 4.1). 
No differences were observed in the proportions of any of the T cell subsets between AS 
patients and HCs (Fig. 4.2 and 4.3). Furthermore, the total number of circulating CD4+ T 
cells was not increased in AS patients (Fig. 4.2A). Consequently, we can disprove our 
hypothesis. Very few published studies in AS have quantified the proportions of these T 
cell subsets. The only study to have performed similar analyses is that by Dejaco et al 
(623), where no difference in the proportion of blood naïve, memory, activated and 
regulatory CD4+ T cell subsets in the blood of AS patients compared to HCs was observed 
(623). Of note, they and others identified a population of “chronically stimulated” memory 
CD4+ T cells (CD3+ CD4+ CD28- CD57+) that represented a larger population in AS 
patients compared to HCs (533, 623). These “chronically stimulated” memory CD4+ T 
cells were described to contribute to disease pathogenesis through their accumulation 
within inflamed tissue and secretion of IFN# and pathogenic granules (623). In this study 
however, this effector CD4+ T cell population was not investigated.  
Several studies have investigated the proportion and function of Tregs in AS pathogenesis. 
Some have reported a reduction of circulating Tregs in AS patients, whilst others, 
including ourselves failed to identify any difference in Treg proportions between AS 
patients and HCs (543, 549, 623, 624). To complicate matters further, one group observed 
an increase in circulating Tregs in AS patients (553). These discrepancies may partially be 
attributed to the use of small patients cohorts, inconsistent use of surface markers including 
CD25, CD127 and FOXP3, and variation in the antibody clones used to identify CD4+ 
Treg populations. Data presented here suggests that circulating Tregs are not affected in 
AS and therefore may not contribute to disease pathogenesis. However, accumulation of 
this immunosuppressive subset at sites of inflammation, including SF and the intestine, 
may remain important in disease pathogenesis. Supporting this hypothesis, functional 
Tregs have been reported to represent a larger proportion of the leukocyte population in SF 
compared to that in blood (548, 549). Furthermore, Ciccia et al observed significant 
increases in the proportion of intestinal Tregs identified in AS patients presenting with 
chronic ileal inflammation compared to HCs (553). These Tregs were found to secrete 
large amounts of IL-10 and suppress T cell proliferation ex vivo (553). These results 
suggest that functional Treg responses are occurring within inflamed peripheral tissues to 
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suppress inflammation. Overall, compared to HCs we observed no difference in the 
proportion of total circulating CD4+ Tregs in AS patients. However, recent publications 
suggest that functional Tregs reside within sites of inflammation in AS patients (548, 553), 
and may represent candidates for the development of future therapeutics. Expansion of 
these populations in vivo may lead to the inhibition of the pathogenic immune response.  
In addition to the quantification of individual circulating T cell subsets, one of the aims 
was to investigate the influence of HLA-B27 expression on the immunological profile of 
AS patients. Unfortunately the study was insufficiently powered to test this objective, 
having too few HLA-B27- patient samples and too few HLA-B27+ HC samples (Fig. 4.2 
and 4.3). However, Wu et al were unable to identify differences between HLA-B27- (n=37) 
and HLA-B27+ (n=12) HC individuals in terms of circulating Treg proportions (624). In 
contrast, Poddubnyy et al found that anti-TNF! naïve HLA-B27+ patients had a lower 
proportion of IL-10+ CD8+ T cells compared to HLA-B27- patients. Therefore, HLA-B27 
expression may affect the development of IL-10 secreting cells (625). These data suggest 
that HLA-B27 expression may affect specific cellular aspects of the immune profile of AS 
patients, highlighting the need for larger studies to functionally assess the role of HLA-
B27 in disease development. 
Overall, we were unable to identify any differences in the proportions of circulating naïve, 
memory, activated and Treg populations in AS patients, consistent with the findings by 
Dejaco et al (623). Therefore, we can conclude that T cell proportions are not 
quantitatively affected in AS patients despite the ongoing disease processes. Patient 
clinical parameters may influence our analysis of blood cell populations in AS patients. In 
fact, one study in RA reported that blood CD4+ CD25hi Tregs negatively correlated with 
CRP, highlighting the importance of evaluating these clinical/immunological relationships 
(626). Detailed analysis of these relationships will be discussed in Chapter 7.  
Several groups have investigated the involvement of T cells in AS pathogenesis through 
analyses of their function and effector phenotype (Th1/Th2/Th17/Treg/Th22) (181, 470, 
480, 495, 530, 537, 586). To corroborate these studies, the function and migration patterns 
of CD4+ T cells in AS patients and HCs were investigated. Following DC: T cell 
interactions, chemokine receptors are upregulated on the surface of antigen specific T 
cells. The array of chemokine receptors induced on the T cells promotes directed migration 
to specific tissues where they exert their functions, resulting in the promotion of 
immunogenic or tolerogenic immune responses. Furthermore, expression of chemokine 
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receptors, given their association with specific Th cell phenotypes, can indicate the T cell 
subsets involved in disease pathogenesis. Published data examining the chemokine 
receptor profile of AS patients T cells has focused on CCR4 and CCR6 expression. CCR4 
induces T cell migration to the skin, a tissue commonly affected in AS patients (173, 175). 
CCR4 is proposed to be involved in cell migration to rheumatic joints, as is CXCR3 (627). 
CCR6 is often studied due to its use as a surrogate marker for IL-17 secreting Th17 cells 
(180, 181). In order to identify alterations to the migration patterns of AS patient T cells, 
expression of CCR4, CCR6, CCR9, CCR10 and CXCR3 were assessed on T cells. 
Circulating memory, activated and regulatory T cell populations from HC expressed all the 
chemokine receptors analysed (Fig. 4.5 and 4.6). Strikingly, the majority (~95%) of Tregs 
expressed CCR4, the highest expression of any chemokine receptor studied (Fig. 4.7A). 
This finding supports published studies where CD4+ CD25hi FOXP3+ T cells specifically 
expressed high levels of CCR4 (628, 629). This characteristic feature of Tregs may permit 
migration into and surveillance of the skin epithelial barrier, the largest organ in the body. 
However Tregs additionally express high levels of CCR6, suggesting that circulating T 
cells express an array of chemokine receptors mediating their migration to a multitude of 
tissues, mediated by chemokine engagement. In contrast to memory, activated and 
regulatory subsets, naïve CD4+ T cells lacked expression of all chemokine receptors, 
except CXCR3 (Fig. 4.5 and 4.6). CXCR3 is thought to be rapidly upregulated on naïve T 
cells following activation. Therefore the small population of CXCR3+ CD45RA+ CD25- 
naïve T cells may represent newly activated T cells. The absence of chemokine receptors 
prevents directed tissue migration, allowing naïve T cells to recirculate through and survey 
lymphoid tissues in a CCR7 dependent manner (630-632). CCR9 expression on all subsets 
was minimal, perhaps suggesting that only a small proportion of T cells in the blood home 
to the gut.  
Comparison of chemokine receptor expression on AS patients and HCs revealed no 
differences in expression of CCR4, CCR9 and CCR10 on any of the CD4+ T cell subsets 
(Fig. 4.7 and 4.9). Accordingly, these results suggest that the migration of CD4+ T cells 
toward tissues including the skin and intestine are not altered in AS patients. This 
observation was surprising given that the skin and intestine represent common sites of 
extra-articular inflammation in patients. Furthermore, these results appear to contradict the 
hypothesis that the intestine is a site of induction in SpA (4, 440, 444, 480). However, 
parameters measured in blood do not necessarily reflect pathological processes occurring 
in peripheral tissues, and therefore based on these results alone it is only possible to 
conclude that mucosal-homing primed cells do not appear to be increased in the blood of 
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AS patients. Also no differences were detected in the frequency of CD4+ T cells expressing 
CCR4 (Fig. 4.7). This observation contradicts previously published reports where the 
frequency of CCR4+ CD4+ T cells was upregulated in blood of AS patients compared to 
HCs (532, 624). Differences in antibody clone, gating strategies and patient cohorts could 
account for these different results. It would be interesting to analyse co-expression of 
chemokine receptors in the future to further define the complete chemokine receptor 
profile of T cells in AS patients and HCs. 
In contrast to CCR4, CCR9 and CCR10, both CCR6 and CXCR3 were differentially 
expressed on circulating AS CD4+ T cells compared to HCs. Activated T cells from AS 
patients expressed significantly elevated levels of CCR6 compared to HCs (Fig. 4.7A). 
CCR6 promotes migration of cells to inflamed tissues including the skin and the intestine 
(180). Inflammation in AS patients often occurs within the spine, SIJs and extra-articular 
tissues. Therefore, one could predict that CCR6 mediates cell migration to these sites. 
Furthermore, CCR6 is often expressed by Th17 cells (180, 181). Confirming this 
relationship, the majority of IL-17A+ cells expressed CCR6 (~85% - Fig. 4.12B). Given 
the increase in circulating CCR6+ CD4+ T cells, the capacity of CD4+ T cells to secrete IL-
17A was investigated. Indeed, a trend towards a higher proportion of IL-17+ CD4+ T cells 
in AS patients was seen (Fig. 4.11). However, only 2 HCs and 4 AS patients were used, 
and thus this experiment will need to be repeated before firm conclusions can be drawn. In 
addition, examination of other Th17-associated molecules such as expression of ROR#t, 
IL-17F and IL-22 by CCR6+ T cells would complement the investigation of Th17 cells in 
AS.  
The higher proportion of circulating CCR6+ CD4+ T cells, with the ability to secrete IL-17, 
may represent circulating Th17 cells, thought to be pathogenic in AS (495, 527, 530, 539). 
Several groups have previously reported increased Th17 proportions in the blood of AS 
patients, supporting my observations (527, 530, 538, 539, 633). Only two reports have 
addressed the contribution of Th17 cells within extra-articular tissue of AS patients. Ciccia 
et al were unable to detect any significant Th17 polarisation in AS patient intestinal tissue 
(551), but, interestingly, compared to HCs they observed expansion of IL-10-secreting 
Tregs in the intestine of AS patients (551, 553). These results suggest that the intestinal 
environment of AS patients supports the generation of Tregs that subsequently control 
Th17 responses. Retinoic acid (RetA) has previously been shown to promote generation of 
Tregs at the expense of Th17 cells and therefore may contribute to the phenomenon 
described by Ciccia et al (119, 551, 553). Consequently, it would be interesting to analyse 
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RetA levels in AS and HC intestinal tissue and further assess the impact of intestinal Th17 
and Treg populations in AS pathogenesis. However in the study conducted by Ciccia et al, 
a proportional comparison of intestinal Th17 cells between AS patients and HCs was not 
performed (553). The second study investigating peripheral Th17 cells involved use of 
tissue isolated from the facet joints of AS patients. Appel et al observed an increase in IL-
17+ cells within these facet joints, despite the absence of circulating Th17-phenotype T 
cells (540). These experiments identified neutrophils and MPO positive cells to be the 
main producers of IL-17 (540). Therefore, within the joints of AS patients the secretion of 
IL-17 from innate leukocytes may be involved in the pathogenesis of AS. However, the 
role of Th17 cells and IL-17 in disease pathogenesis especially within the extra-articular 
tissues requires further investigation. 
In contrast to our findings regarding CCR6 expression on CD4+ activated T cells, a 
significant reduction was observed in the frequency of CXCR3+ activated and memory T 
cells in AS patients compared to HCs (Fig. 4.8). This phenomenon has not been reported 
before in AS. CXCR3 is associated with the Th1 phenotype and migration of cells to 
inflamed tissues (182, 183, 614). A reduction in CXCR3+ CD4+ T cells accompanied with 
an increase in circulating CCR6+ CD4+ T cells could suggest a shift in T cell phenotype 
from Th1 to Th17 in patients. Thus, these observations support a role for Th17 cells in the 
pathogenesis of AS. Alternatively, loss of circulating CXCR3+ cells may not just represent 
a shift in T cell phenotype: given the propensity for CXCR3 to induce migration to 
inflammatory sites, activated and memory CXCR3+ cells may accumulate within inflamed 
tissues. To support this hypothesis, CXCR3 has previously been shown to induce SF cell 
migration in juvenile idiopathic arthritis (JIA) patients (634). Analysis of CXCR3+ cells 
within inflamed tissues, expression of Th1 associated cytokines, and assessment of the 
induction of CXCR3+ T cells following DC: T cell interactions could further elucidate the 
role(s) of CXCR3+ T cells in AS pathogenesis. Partially addressing this question, we 
analysed the proportions of circulating IFN#-secreting CD4+ T cells in AS patients, the 
prototypic Th1-associated cytokine (Fig. 4.11). We hypothesised that production of this 
cytokine would be reduced in patients given the downregulation of CXCR3 expression. 
However, compared to HCs, no difference was observed in the proportion of IFN#+-
secreting CD4+ T cells between AS patients and HCs (Fig. 4.11). However due to 
insufficient sample numbers, we cannot irrefutably exclude the possibility that proportions 
of IFN#-secreting cells differ between AS patients and HCs. A power calculation can be 
performed to calculate the minimum sample size required to ensure confidence in our 
observations. With respect to the frequency of IFN#+ CD4+ T cells in AS patients and HCs, 
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using a power calculation we determined the sample size required to identify potential 
differences between our cohorts. As proportion of live cells, 7% and 11% of CD4+ IFN#+ 
cells were detected in AS patients and HCs respectively (Fig. 4.11A). Given a SD of 4 
within the AS patient cohort, where the “known (mu(0))” and “unknown mu(1))” mean 
values of the population were 7 and 11 respectively, a sample size of 8 was required. 
Given an SD of 10 within the HC cohort and using the identical mu(0) and mu(1) values, a 
sample size of 50 was required. Therefore, to determine any potential difference between 
our cohorts, with respect to the proportion of IFN#+ CD4+ T cells, a sample size of between 
8 and 50 individuals would be required. 
T cells and other immune cells influence immune responses through secretion of cytokines, 
which are also important for lineage development, T cell priming, and cell activation. 
Therefore, the levels of plasma growth factors and cytokines related to these processes 
were analysed by luminex and ELISA. In contrast to our results suggesting that a higher 
proportion of circulating IL-17-secreting cells is present in AS patients, we did not observe 
a corresponding increase in plasma IL-17A concentration (Fig. 4.13A). Similarly, Zhang et 
al did not observe an increase in plasma IL-17A despite an increase in circulating IL-17+ 
CD4+ T cells (530). These findings suggest that Th17 cells, if involved in AS pathogenesis, 
may not exert their effects through increases in plasma IL-17A. Th17 cells secrete a variety 
of other cytokines such as IL-6, TNF!, IL-22 and IL-17F that may be involved in disease 
pathogenesis (635, 636). Of interest, and something that will be partially addressed in 
Chapter 6, relates to the involvement of AS DCs in driving this potential Th17 phenotype. 
For example, DCs have been shown to produce IL-6, necessary for the generation of Th17 
cells along with TGF" (108, 637). Additionally, Hansel et al report that SLAN+ DCs 
secrete large amounts of the Th17-associated cytokines IL-23 and IL-6, promoting 
generation of IL-17+ IFN#+ T cells (249). Therefore, the slight increase in CD14- CD16+ 
mononuclear cells, including SLAN+ DCs (Fig. 3.7A), in AS patients may contribute to the 
expansion of Th17 cells in AS patients. However, as the in vivo functions of human blood 
DCs remain obscure, identification of an equivalent tissue resident DC population may 
help elucidate pathways involved in disease pathogenesis.  
As suggested earlier, Th17 cells may contribute to AS pathogenesis via an IL-17 
independent mechanism. Th17 cells have been reported to secrete an array of cytokines 
including IL-6, TNF! and IL-22 (635, 636). Although increased in AS patients, IL-6 and 
TNF! levels were very low (<30+g – Fig. 4.14A). In fact, a monoclonal antibody that 
targets and blocks the IL-6R has been reported to be ineffective in AS clinical trails (23). 
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However, the functional attributes of these cytokines in AS have not been assessed and 
may still play a pathogenic role in disease progression. Intracellular cytokine staining for 
IL-6 and TNF! could be performed to assess whether Th17 cells may contribute to plasma 
levels of these cytokines. In addition, Th17 cells have been shown to excel in the provision 
of B cell help through induction of antibody production including IgA and IgM, whilst 
remaining partially refractory to Treg-mediated suppression (120). Therefore, promotion of 
B cell responses and sustained activation in vivo may represent additional pathways 
through which Th17 cells may mediate disease pathogenesis in an IL-17-independent 
manner. 
As discussed above, AS patient IL-17A levels were not different from those observed in 
HCs, whilst IL-6 and TNF! were significantly upregulated. Furthermore, IL-23p19 was 
also significantly elevated in AS patient plasma (Fig. 4.13D). Both IL-6 and IL-23p19 
have previously been reported to be upregulated in AS patients (49), supporting data 
presented here. As both cytokines are involved in the generation and maintenance of Th17 
cells in both mice and men (108, 109, 120, 635), these observations lend further support to 
a pathogenic role for Th17 cells in AS. Therefore, the elevated levels of IL-6, IL-23p19 
and TNF! in AS patients could contribute to pathogenic immune responses, potentially 
through development of Th17 cells. Aside from inflammation and Th17 associated 
cytokines, no difference in IFN# (Th1) and IL-10 (Treg) levels were detected between AS 
patients and HCs. 
Further supporting a shift in circulating T cell phenotype of our patient cohort, the Th2 
associated cytokine IL-4 was downregulated in AS patients compared to HCs (Fig. 4.13C). 
However, IL-5 did not correlate with IL-4 as no difference was observed between HCs and 
AS patients (Fig. 4.13C). These data could suggest that activated Th2 cells known to 
secrete both IL-4 and IL-5 do not contribute to this observation. Alternatively IL-4-
secreting populations, including mast cells, may be reduced in AS patients.  
Cytokines are also involved in driving the development of immune populations. Flt3L, a 
haematopoietic growth factor, is upregulated in AS patient plasma compared to HCs (Fig. 
4.14B). To the best of my knowledge, this observation has not previously been described 
in AS. Given the integral role of Flt3L in the development of DCs (284, 287) and the 
observation that AS patients have a significantly reduced population of CD1c+ cDCs (Fig. 
3.4B), plasma Flt3L may be increased in AS patients to promote development of cDCs in 
order to rectify this deficiency. This idea is supported by the observation that DC subsets 
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expand in humans in vivo following Flt3L administration (572). Further experiments to 
support or disprove this hypothesis could include enumeration of DC progenitors in blood 
of AS patients and HCs. If this reduction in CD1c+ DCs in AS patients contributes to 
disease pathogenesis, Flt3L could be a potential target for future therapies. Alternatively, if 
mature blood cDCs migrate into peripheral tissue, then their presence may be exaggerated 
within peripheral tissue supporting the need for investigation into the function of blood 
DCs in vivo, and analysis of tissue-resident DC populations in HCs and AS patients 
including the intestine and skin. 
Overall, a differential chemokine receptor profile on activated T cells was observed in AS 
patients compared to HCs. Specifically, the proportion of CCR6+ circulating activated T 
cells increased, while the proportion of CXCR3+ cells decreased in AS patients. A trend 
towards a higher proportion of IL-17+ CCR6+ T cells in AS patients’ blood was observed, 
along with elevated levels of the Th17-polarising cytokines, IL-6 and IL-23p19. These 
results suggest that Th17 cells may play an important role in AS pathogenesis. 
Interestingly, it was additionally observed that the myeloid cell growth factor Flt3L may be 
elevated in AS patients to compensate for their loss of CD1c+ cDCs. 
Our results to date have identified alterations to the circulating myeloid and T cell profile 
in AS patients. However, I next sought to address their contribution to the inflammatory 
response within inflamed extra-articular tissues of AS patients. Subsequently, using 
synovial fluid (SF) samples isolated from the peripheral joints of AS patients, the cDC and 
T cell subsets residing within this inflamed tissue were characterised.  
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5.1 Introduction 
Patients with SpA often develop extra-articular manifestations including uveitis and skin 
inflammation. AS patients, often with peripheral arthritis, can experience build up of 
synovial fluid (SF) within the joint space. This causes severe pain within the joint and 
inhibits joint function, whereupon SF is often removed to alleviate these symptoms. 
Analysis of the cells recruited to the joint, their surface phenotype and the SF cytokine 
milieu can help elucidate the mechanisms of disease pathology. 
The majority of SF studies in AS patients focus on the presence of T cell subsets, their 
function and the cytokines they produce. Specifically, functional Tregs have been isolated 
from AS patient SF (548, 549). A variety of Th1 and Th2 associated cytokines have been 
detected in AS patient SF, including IL-12/IL-23 p40 (531, 638). To date, the presence of 
conventional and plasmacytoid DCs in AS SF has not been investigated. Unlike AS, 
several groups have isolated cDCs and pDCs from RA SF, where cDCs have been shown 
to accumulate within SF, in addition to having a more activated phenotype compared to 
their blood counterparts (217, 581). As DCs principally induce and direct immune 
responses, it is important to identify and assess their functions in SF. Therefore, we set out 
to identify and phenotype cDC and pDC subsets within AS SF. To generate context for the 
DC data, other cell types such as monocytes and T cells were also studied.  
5.2 Patient characteristics  
For the SF analyses described in this chapter 4 patient samples were analysed. Details of 
these patients are shown in Table 5.1.  
Table 5.1: Patient characteristics for SF analysis 
For the characterisation of SF cDC and pDC subsets, samples from four AS patients were used. 
ESR, CRP, disease duration and treatment protocol information were available for all AS patients. 
ID Sex Tissue Age 
(yrs) 
ESR 
(mm/hr) 
 
CRP 
(mg/L) 
Duration 
(yrs) 
Treatment 
1 Female Shoulder 68 28 7 32 Adalimumab 
2 Male Knee 50 22 29 13 Etoricoxib, 
Sulphasalazine 
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3 Male Knee 35 5 24 3 Etoricoxib, 
Sulphasalazine 
4 Male Knee 60 18 36 23 None 
 
Three of the four patients were male, and three SF samples were aspirated from the knee 
(Table 5.1). When comparing patients 1 and 2 (Fig. 5.7 and Fig. 5.8), several observations 
regarding inflammatory markers and disease treatment are relevant. AS patient 1, at time 
of analysis, was receiving anti-TNF! treatment (Adalimumab – Table 5.1). CRP levels 
were also within the normal range (<10, Dr David McCarey – personal communication). 
The treatment protocol of AS patient 2 included an NSAID (Etoricoxib) and a DMARD 
(Sulphasalazine). Values of 22 (ESR) and 29 (CRP) for patient 2 indicate ongoing 
inflammation. Furthermore, the remaining two AS patients presented with high levels of 
CRP. Interestingly patient 4, who at time of analysis was not receiving any form of 
treatment, had long-standing disease with high levels of CRP. These differences, and their 
potential effects on the DC subsets and cytokines will be discussed below. 
5.3 Synovial fluid mononuclear phagocytes 
There are no reports describing the myeloid profile of SF isolated from AS patients. 
Therefore, DC populations in AS patient SF were characterised using the techniques 
developed to identify blood DCs. To do this, gating strategies used for peripheral blood 
cDC, monocyte and pDC analysis were adopted to identify similar subsets within SF. 
5.3.1 cDCs and monocytes 
Two DC subsets were identified in AS patient SF. The gating strategy used to identify 
these subsets is depicted in Fig. 5.1A. First, cell debris was gated out by FSC-A and SSC-
A with doublets subsequently removed according to their FSC-A/FSC-H characteristics 
(Fig. 5.1A). Dead cells (DAPI+) were also excluded from further analysis. Single, live 
leukocytes were assessed for the expression of LIN markers (CD3, CD15, CD19 and 
CD56). All LIN- CD14- cells were analysed for co-expression of CD11c and MHC II (Fig. 
5.1A). These single DAPI- LIN- CD14- CD11c+ MHC II+ cells could be subdivided into 
two cDC populations: CD1c+ and CD141+ DCs (Fig. 5.1A). Based on their surface marker 
expression, these two DC subsets appeared to be analogous to the DC populations found in 
peripheral blood.  
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To identify monocyte populations within SF, single DAPI- leukocytes were assessed for 
CD11c and MHC II expression (Fig. 5.1B). The CD11c+ MHC II+ cells were further 
analysed for expression of monocyte markers CD14 and CD16 (Fig. 5.1B), and three 
CD11c+ MHC II+ subsets were identified based on differential expression of these markers 
(Fig. 5.1B – populations 1, 2 and 3). Populations 1 and 2 are equivalent to the CD14+ 
monocyte subsets identified in peripheral blood. Population 1 is the CD14+ CD16- 
monocyte fraction, whilst population 2 can be identified as the CD14+ CD16+ monocyte 
population (Fig. 5.1B). The CD14- CD16+ mononuclear population appears to be absent 
from SF tissue (Fig. 5.1B). Population 3 consists of the two cDC populations identified in 
SF and peripheral blood (Fig. 3.1A and Fig. 5.1B). 
As discussed in chapter 3, CD14- CD16+ mononuclear cells can be subdivided into two 
populations based on the expression of SLAN. In order to confirm the absence of the 
CD14- CD16+ population in SF, cells were further assessed for the expression of CD16 and 
the associated SLAN+ and SLAN- subsets (Fig. 5.2). Initially, SF monocyte subsets were 
assessed and compared to blood monocytes analysed on the same day (Fig.5.2A). When 
live LIN- CD11c+ MHC II+ cells were analysed for CD14 and CD16 expression (Fig. 
5.2A), no CD14- CD16+ cells were observed in the SF sample. Furthermore, CD11c+ MHC 
II+ SF cDCs were assessed for the expression of SLAN (Fig. 5.2B). Mouse IgM was used 
as the isotype control. Most SF CD11c+ MHC II+ cells lacked expression of SLAN (Fig. 
5.2B). However as this experiment did not include a positive control, and since it is known 
that SLAN+ cells exist in blood (Fig. 3.6A), these analyses were subsequently repeated 
using unmatched blood and SF processed and analysed on the same day. These samples 
were used to further confirm or reject the presence of any live LIN- SLAN+ leukocytes in 
SF (Fig. 5.2C). Gates were set using the isotype. Peripheral blood was used as a positive 
control, and as expected, a population of SLAN+ cells could be identified (Fig. 5.2C). In 
contrast, very few live LIN- leukocytes in SF expressed SLAN (Fig. 5.2C). In all these 
experiments, we were unable to detect definitive populations of CD14- CD16+ SLAN+ or 
CD14- CD16+ SLAN- mononuclear cells in SF isolated from AS patients (Fig. 5.1 and Fig. 
5.2). However, our staining could suggest that a small population of CD16- SLAN+ cells 
exist in SF, however in order to confirm this further analyses would have to be performed. 
5.3.2 Plasmacytoid DCs 
pDCs are the primary secretors of type I interferons and are key contributors to the 
immune response against viral infections (639). In order to identify SF pDCs, the gating  
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Figure 5.1: Identification of CD141+ and CD1c+ Synovial Fluid DC Subsets 
CD141+ and CD1c+ DCs can be found in synovial fluid (SF) isolated from AS patients. (A) Gating 
strategy used to identify SF DC subsets. Doublets and dead cells (DAPI+) were excluded from 
analysis. Live single cells that lacked expression of LIN markers were analysed for CD14 
expression. CD14- cells co-expressing CD11c and MHC II were divided into CD141+ and CD1c+ 
DC subsets. (B) Identification of monocytes in SF. Single DAPI- LIN- cells were analysed for CD11c 
and MHC II expression. LIN- CD11c+ MHC II+ cells were divided into three subsets: CD14+ CD16- 
(1), CD14+ CD16+ (2) and CD14- CD16- (3). Subset 3 contained SF DCs – CD141+ and CD1c+ 
populations. LIN = CD3, CD15, CD19 and CD56. 
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Figure 5.2: Presence of CD16+ CD11c+ mononuclear cells and SLAN subsets in SF 
Absence of CD14- CD16+ mononuclear cells and the respective SLAN subsets from AS SF. SF 
from one AS patient was assessed for the occurrence of the SLAN+ and SLAN- subsets of CD16+ 
mononuclear cells. (A) DAPI- LIN- CD11c+ MHC II+ cells were analysed for the presence of CD16+ 
CD14- cells in HC blood (left) and AS patient SF (right). LIN contains markers against CD3, CD15, 
CD19 and CD56. (B) Total SF DCs (DAPI- LIN- CD14- CD11c+ MHC II+) were assessed for 
expression of SLAN. (C) Comparison of total mononuclear cells isolated from blood (top) and SF 
(bottom) cells for the presence of SLAN+ cells. Percentages represent the proportion of single, 
DAPI- LIN- (CD3, CD15, CD19 and CD56) cells used for analysis. Gates were set based on the 
isotype-matched negative control (left).  
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strategy used to identify blood pDCs was used. SF pDCs were detected in our cohort of AS 
patients using the gating strategy shown in Fig. 5.3A. pDCs were identified as single 
DAPI- LIN- cells, that co-expressed CD123 and MHC II and also expressed the pDC 
marker CD304 (Fig. 5.3A). To conclude, pDCs (DAPI- LIN- CD123+ MHC II+ CD304+) 
can be identified in AS patient SF (Fig. 5.3). In addition, quantification of SF pDCs (DAPI- 
LIN- CD123+ MHC II+ CD304+) was also performed, in terms of percentage of live cells. 
Approximately 0.2% of total SF live cells are pDCs (Fig. 5.3B), compared to the 0.3% of 
live cells found in blood (Fig. 3.4C). 
5.4 Surface phenotype of cDCs and monocytes 
We have identified two cDC subsets, two monocyte subsets and pDCs in AS SF. After 
identification of these cells, it was important to further characterise their surface phenotype 
to assess whether SF cDCs and monocytes possessed a surface phenotype similar to their 
blood counterparts. Thus, CD11b and CD86 expression was assessed on SF cDCs and 
monocytes (Fig. 5.4). Single live LIN- CD14- CD11c+ MHC II+ DCs were assessed for 
CD11b expression (Fig. 5.4A). The CD141+ DC subset expressed negligible levels of 
CD11b whilst the CD1c population homogenously expressed CD11b (Fig. 5.4A). These 
findings are similar to the CD11b expression profile on blood cDCs (Fig. 3.16A). Due to 
the inflammatory environment surrounding SF cDCs, it was also important to assess the 
activation status of cDCs isolated from this tissue. Therefore, expression of the co-
stimulatory molecule CD86 was assessed on both cDC subsets (Fig. 5.4B). Surprisingly, 
our findings show both cDC subsets were relatively immature, with CD86 absent from the 
cell surface, when compared to the observed levels of CD86 expression on CD14+ CD16- 
blood monocytes (Fig. 5.4B and 3.14B). 
Monocyte subsets – CD14+ CD16- and CD14+ CD16+ - were similarly assessed for CD11b 
and CD86 expression (Fig. 5.4C and Fig. 5.4D). Similar to blood monocytes (Fig. 3.18A), 
both CD14+ CD16- and CD14+ CD16+ SF monocyte populations homogenously expressed 
high levels of CD11b (Fig. 5.4C). The activation status of these myeloid cell populations 
was also assessed, and both SF monocyte subsets expressed low levels of CD86 (Fig. 
5.4D), although CD14+ CD16- monocytes expressed higher levels of CD86 than the CD14+ 
CD16+ population. However, this observation was made on the basis of one AS patient and 
therefore may not be indicative of AS patient SF tissue-resident DCs. Overall, the surface 
phenotype of SF monocytes, at least in terms of CD11b expression, is similar to that 
observed in blood.  
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Figure 5.3: pDCs present in AS patient SF 
pDCs are present in AS patient SF. Mononuclear cells were isolated from SF as described in 
chapter 2. (A) Gating strategy used to identify SF pDCs. Cell debris was gated out by FSC-A and 
SSC-A. Doublets were excluded using the FSC-A and SSC-A gate and DAPI+ dead cells were also 
eliminated. Live single cells were analysed for expression of lineage markers (CD3, CD15, CD19 
and CD56) and MHC II. LIN- cells were assessed for MHC II and CD123 expression. CD123+ MHC 
II+ cells were analysed for CD304 expression; CD123+ CD304+ MHC II+ cells are SF pDCs. (B) 
pDCs were evaluated in terms of % of live cells in AS SF from 4 patients. pDCs (LIN- MHC II+ 
CD123+ CD304+) were identified as described in A.  
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Figure 5.4: Expression of CD11b and CD86 by SF cDC and monocyte subsets 
CD86 is minimally expressed on all cDC and monocyte SF subsets. cDC and monocyte subsets 
were analysed for the expression of CD11b and the activation marker CD86. CD141+ (left) and 
CD1c+ (right) SF DC subsets were analysed for expression of CD11b (A) and the co-stimulatory 
molecule CD86 (B). CD14+ CD16- (left) and CD14+ CD16+ (right) monocytes were assessed for 
expression of CD11b (C) and CD86 (D). Isotype (Mouse IgG1#) is depicted in grey shaded 
histogram. Marker expression for each subset is shown in red.  
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5.5 Quantification of cDCs   
In order to understand the role of cDCs at sites of inflammation, it is important to quantify 
them within these tissues. The data in Fig. 5.5 are collated from all four AS patient SF 
samples used in this study. Using the gating strategy presented in Fig. 5.1A, the 
proportions of CD141+ and CD1c+ cDCs, among CD11c+ MHC II+ DCs and total live cells 
were evaluated (Fig. 5.5A). As in blood (Fig. 3.4), CD1c+ DCs in SF, were the major cDC 
population accounting for approximately 60% of CD14- CD11c+ MHC II+ cells (Fig. 
5.5A). CD141+ cDCs in blood represented 1% of CD14- CD11c+ MHC II+ cells, whereas 
within SF, this increased to around 30% (Fig. 5.5A). However, it should be noted that we 
are unable to directly compare blood and SF DC populations in terms percentage of 
CD11c+ MHC II+ cells due to the presence of the CD14- CD16+ mononuclear population in 
blood, and their absence from SF. However, it is possible to directly compare blood and SF 
DCs in terms of percentage of live cells. In SF, each DC population accounted for 
approximately 1% of total live cells (Fig. 5.5A). This is in contrast to the blood where 
CD141+ and CD1c+ DC subsets accounted for approximately 0.02% and 0.6% of live cells, 
respectively (Fig. 3.4A and Fig. 3.4B). By all measures, CD141+ DCs represent a much 
greater proportion of leukocytes in SF than in blood. Overall, cDCs represent 
approximately 2% of total live cells isolated from SF aspirated from inflamed joints of AS 
patients. 
5.6 CD4+ T cells and chemokine receptor expression  
T cells are known to be involved in driving the pathology of AS, partly through their 
secretion of cytokines and inflammatory molecules (468, 470, 471, 479, 536). Thus, SF 
CD4+ T cells were analysed in terms of maturation (naïve, memory, activated and 
regulatory T cells) and chemokine receptor expression. The blood CD4+ T cell gating 
strategy (Fig. 4.1A) was adopted to identify naïve (CD45RA+ CD25-), activated (CD45RA- 
CD25int), memory (CD45RA- CD25-) and Treg (CD45RA- CD25hi) subsets in SF (Fig. 
5.6A). Cell debris was excluded from T cell analysis using the FSC-A vs SSC-A profile. 
Doublets and dead cells (DAPI+) were also excluded. Single DAPI- cells were analysed for 
CD3 and CD4 expression. Cells co-expressing these markers were subdivided on the basis 
of CD25 and CD45RA expression (Fig. 5.6A). Naïve T cells (CD25- CD45RA+) were 
absent from AS patient SF, although this statement is based on data from one patient (Fig. 
5.6A). T cells isolated from AS patient SF could be divided into two populations based on   
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Figure 5.5: Quantification of SF cDC subsets 
cDC subsets in SF from AS patients. (A) Using the gating strategy in Fig. 5.1A, CD141+ and CD1c+ 
DCs were enumerated in the SF of 4 AS patients. Proportion of LIN- CD14- CD11c+ MHC II+ CD1c+ 
and CD141+ DCs were enumerated as % of CD11c+ MHC II+ (left) and live cells (right). Empty 
circles – CD141+ DCs and filled circles – CD1c+ DCs.  
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Figure 5.6: CD4+ T cells infiltrate AS synovium and express CCR4 and CCR6 
CD4+ T cells infiltrate AS synovium and express the chemokine receptors CCR4 and CCR6. (A) 
Gating strategy used to analyse T cells subsets in AS SF. Firstly, cell debris was gated out on 
FSC-A vs SSC-A and doublets were excluded by FSC-A vs FSC-H. Dead cells (DAPI+) were 
removed from analysis. Live single cells were analysed for CD3 and CD4 expression. DAPI- CD3+ 
CD4+ T cells were assessed for CD25 and CD45RA expression. (B) Chemokine receptor (CCR) 
expression on SF T cells from one AS patient. CD3+ CD4+ T cells were analysed for the expression 
of CCR9, CCR10, CCR4 and CCR6.  
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CD25 expression: CD25lo CD4+ and CD25hi CD4+ T cells (Fig. 5.6A). Due to the fact that 
only one AS patient was assessed for the presence of T cells, further analysis on the 
identity of CD4+ T cells regarding memory, activated or Treg status was not performed. 
Chemokine receptor expression can direct migration and tissue localisation of leukocytes 
(59, 157). Therefore, expression of CCR9, CCR10, CCR4 and CCR6 on CD3+ CD4+ SF T 
cells isolated from one AS patient was assessed. The majority of the CD25hi cells 
expressed both CCR4 and CCR6 (Fig. 5.6B). In addition, a large proportion of the CD25lo 
T cells also expressed CCR4 and/or CCR6 (Fig. 5.6B). Very few AS SF T cells expressed 
CCR9 or CCR10 (Fig. 5.6B). Overall, a CD25hi population was identified within SF CD3+ 
CD4+ T cells, expressing chemokine receptors CCR4 and CCR6 (Fig. 5.6). This population 
could be represent tissue equivalents of CD25hi T regs observed in blood (Fig. 4.1). 
5.7 Blood and SF cDC and pDC populations 
Enumerative and phenotypic comparison of blood DCs with those at sites of inflammation, 
including the SF, can further elucidate the function and involvement of DCs in AS 
pathogenesis (217, 640). We therefore analysed, using matched patient blood and SF 
samples, DC subsets present in blood and SF.   
Matched blood and SF samples from two AS patients were analysed on the same day for 
the presence of cDC and pDC populations (Fig. 5.7). Using the gating strategies described 
in Fig. 3.1A and Fig. 5.1A, cDC subsets were compared for each AS patient between the 
two tissues: blood and SF (Fig. 5.7A). Both blood cDC subsets (CD141+ and CD1c+) could 
be identified in the SF isolated from AS patients (Fig. 5.7A). When expressed as 
percentage of live cells, total cDCs represent a larger leukocyte population in SF (4.82% 
(1) and 0.58% (2)) than in blood (0.024% (1) and 0.06% (2), Fig. 5.7A). Unfortunately, 
access to matched samples was limited and only two sets of samples were analysed in this 
way, and thus it is not possible to draw definitive conclusions. Furthermore, the 
proportions of blood and SF cDC subsets also differed between the two AS patients 
analysed. CD141+ cDCs isolated from the blood of AS patient 1 accounted for 10.4% of 
total DC, whereas they accounted for only 4.2% in SF. In contrast, 4% of blood cDCs 
expressed CD141 in AS patient 2 whilst this subset contributed 59.8% to the total SF cDC 
population (Fig. 5.7A). However, these differences may be attributed to the SF localisation 
(shoulder vs knee) and gender of the patients used for matched analysis. Overall, cDCs 
may represent a higher proportion of cells in SF than in the blood.  
 188 
Blood and SF analysis for pDCs was also performed on these two matched AS samples 
(Fig. 5.7B). pDCs, identified by the gating strategy described in Fig. 5.3A (DAPI- LIN- 
CD123+ MHC II+ CD304+), can be found in AS patient SF (Fig. 5.7B). pDCs, as a 
proportion of total DAPI- LIN- CD123+ MHC II+ cells, represented a larger leukocyte 
population in blood compared to SF, for both AS patients (Fig. 5.7B). However, when 
presented as proportion of total live cells only a slight increase in pDCs in SF compared to 
blood was observed for AS patient 1 (0.0158% vs 0.0224%), whereas pDCs were much 
more abundant in the SF in AS patient 2 (0.0149% vs 0.122%, Fig. 5.7B).  
5.8 Differences in cytokine profile between blood and SF 
Cytokines play many important roles in the development, perpetuation and resolution of 
immune responses. Consequently, it is of great importance to identify cytokines at sites of 
inflammation that may be involved in driving disease pathology. Therefore, we set out to 
determine the presence of SF cytokines and growth factors associated either with T cell 
subsets (Th1, Th2 and Th17) or inflammation (Fig. 5.8). Specifically, the concentrations of 
IFN#, IL-1", IL-5, IL-6, IL-10, IL-17A, TNF!, Flt3L and IL-23p19 were measured in the 
plasma and SF of two patients (Fig. 5.8A and 5.8B). IL-4, IL-12 and GM-CSF levels were 
also assessed but fell below the limit of detection (data not shown). Low levels (less than 
50+g/ml) of IFN#, IL-1", IL-5, IL-10, IL-17A, TNF! and IL-23p19 were observed in both 
plasma and SF for AS patient 1 (Fig. 5.8A) and AS patient 2 (Fig. 5.8B). Surprisingly, the 
two most prevalent cytokines in AS patient plasma and SF were IL-6 and Flt3L. However, 
no overall difference in Flt3L levels in AS patient SF and plasma could be detected, 
however less Flt3L was detected in the SF of one AS patient compared to plasma (Fig. 
5.8B and 5.8C). The most extreme difference observed between AS patient plasma and SF 
was the presence of IL-6 (Fig. 5.8C). IL-6 concentrations were much higher in AS patient 
SF than in matched blood samples. Overall, several inflammatory cytokines and growth 
factors could be detected in AS patient SF (Fig. 5.8). However, Flt3L and IL-6 were 
detected at the highest concentrations in both blood and SF, with IL-6 levels being higher 
in AS patient SF.  
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Figure 5.7: Comparison of cDCs and pDCs between peripheral blood and SF 
Comparison of cDCs and pDCs in matched peripheral blood (PB) and SF in two AS patients. (A) 
Two AS patients were assessed for the presence of CD141+ and CD1c+ DCs in blood (left) and SF 
(centre). Single DAPI- LIN- (CD3/CD15/CD19/CD56) CD14- CD11c+ MHC II+ cells were subdivided 
on expression of CD141 and CD16 (blood) or CD141 and CD1c (SF). Percentages represent 
proportion of live cells. Comparison of blood and SF CD141+ and CD1c+ DCs - % of live cells 
(right). (B) Presence of pDCs in PB and SF was compared for two AS patients. pDCs were 
identified as single DAPI- LIN- CD123+ MHC II+ CD304+ cells in both blood (left) and SF (centre). 
Percentages in contour plots represent proportion of total DAPI- LIN- CD123+ MHC II+ cells. 
Comparison of blood and SF DCs as % of live cells (right). 
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Figure 5.8: Comparison of cytokine levels in AS plasma and SF 
IL-6 is highly upregulated in AS patient SF. Using Luminex and ELISA assays, plasma and SF 
cytokine levels were compared for two AS patients. Levels of specific cytokines were compared 
between plasma (black) and SF (red) levels for AS patient 1 (A) and AS patient 2 (B). Cytokines 
measured: IFN$, IL-1!, IL-5, IL-6, IL-10, IL-17, TNF", Flt3L and IL-23p19. (C) Combined data from 
both AS patients for SF concentrations of IL-10, IL-17, TNF", Flt3L and IL-6 in plasma (black) and 
SF (red). Error bars show mean + SD, n = 2 AS patients. 
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5.9 Discussion   
AS pathogenesis is poorly understood. Most groups, including ourselves, use blood 
populations to delineate AS development. Unfortunately, these studies do not address the 
inflammatory processes occurring within afflicted tissues. Excitingly, several studies have 
explored new avenues of research using samples from the intestine (468, 551, 553, 554). 
Furthermore, SF is occasionally collected from AS patients with lower limb arthritis (4). 
Although a useful resource, there are caveats that must be considered when analysing SF in 
order to assess AS pathology. Inflamed synovial joints are more commonly associated with 
diseases such as RA (641) and are not typical of AS pathology. Therefore, data from 
peripheral joint SF may not be disease specific or reflect the biological processes occurring 
within the inflamed SIJs characteristic of AS. Despite this, SF studies may provide 
immunological information relating to peripheral joint and extra-articular disease 
manifestations and AS development, improving understanding of this complex disease. 
Many AS SF studies focus on T cell antigen reactivity, identification of functional T cell 
subsets (Tregs and Th17) and presence/role of HLA-B272 molecules (502, 540, 549, 615). 
DCs migrate from sites of inflammation via lymphatics to draining lymph nodes and 
interact with naïve T cells to induce immune responses, whether they be tolerogenic or 
pro-inflammatory. They also affect T cell maturation and differentiation, and consequently 
instruct T cell migration to inflamed tissues. Despite their central role in immune response 
initiation, no published study has analysed myeloid cell subsets in SF from AS patients. 
Identifying the cell populations involved in AS disease pathogenesis may facilitate 
generation of new therapeutics, as has been achieved for RA and ulcerative colitis (UC) 
(217, 641-645). 
Within our small cohort, 75% of patients were male, with SF aspirated from the knee 
(Table 5.1). Patient 1, receiving anti-TNF! treatment (Adalimumab), had low CRP but 
high ESR levels. Anti-TNF! treatment may contribute to the low CRP value (646). In 
contrast, patient 2 received combination therapy and suffered from high levels of 
inflammation (Table 5.1). Patient 3, who at the time of analysis was not receiving any 
therapeutics, suffered from severe inflammation. These data support previous observations 
that treatment strategies may affect the inflammatory status of AS patients (647-649). 
Two cDC subsets were identified by surface marker expression in AS SF: CD1c+ and 
CD141+ DCs (Fig. 5.2A). Only CD1c+ SF DCs expressed CD11b, and this differential 
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expression of CD11b on cDC subsets is similar to that observed in blood (Fig. 3.16A). 
Surprisingly, AS SF cDCs appeared to be relatively immature given the negligible levels 
of surface CD86 detected (Fig. 5.4B). Our results suggest that these subsets are 
phenotypically similar to the more fully characterised mature blood cDC subsets. Although 
detailed functional analyses of these subsets was not possible during this study, the relative 
immaturity of SF cDCs compared to their blood counterparts suggests potential alterations 
to the functional attributes of DCs residing within inflamed tissues. DC immaturity is often 
associated with tolerance (329, 580, 596, 597). Therefore, AS DCs in SF might function to 
inhibit chronic inflammation, potentially through induction of Tregs. Low levels of co-
stimulatory molecule expression are additionally associated with DCs capable of antigen 
uptake, supporting functional antigen presentation properties of AS SF DCs. Interestingly, 
Jongbloed et al found that following TLR stimulation, RA SF DCs preferentially secreted 
more tolerogenic IL-10 than their blood counterparts, despite their high expression of 
CD40 and CD86 (217). These data support the idea that SF DC may have tolerogenic 
properties. However, this statement is based solely on CD86 expression levels on AS SF 
DCs, highlighting the need for further functional analyses of SF DCs: antigen presentation, 
T cell priming and cytokine secretion. Interestingly, the AS patient receiving anti-TNF! 
therapy had a greater proportion of SF cDCs compared to the patient treated with 
combination therapy. Thus, SF cDCs may be expanded indirectly through anti-TNF! 
therapy. Alternatively, SF cDCs may exacerbate peripheral symptoms leading to the 
requirement for biological therapy. These results highlight the importance to functionally 
characterise AS SF DCs, to elucidate the disease processes occurring within peripheral 
joints and extra-articular tissues.  
CD1c+ cDCs represented approximately 60% of total SF cDCs, with each cDC population 
representing 1% of total live cells (Fig. 5.5A). Of total live PBMCs, CD1c+ DCs greatly 
outnumbered the CD141+ subset. Our matched blood/SF analysis demonstrated that DCs 
were found at a higher frequency within SF (Fig. 5.7). Taken together, total DCs and the 
CD141+ subset represented a greater proportion of leukocytes within SF. Studies in RA 
patients revealed a similar increased frequency of SF DC populations (217), but did not 
investigate the presence and proportion of CD141+ DC in RA SF. CD141+ cDCs are 
thought to be equivalent to and share the tolerogenic and cross-presenting properties of 
murine CD8!+ DCs (200, 212, 332, 340, 650, 651). Therefore, a preferential increase in SF 
CD141+ DCs might indicate that regulatory processes are being implemented within sites 
of inflammation. These data suggest that within AS SF, abundant immature DCs may 
function to inhibit and control ongoing inflammation.  
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As described above, our studies and others’ report accumulation of DCs in SF of inflamed 
joints. Jongbloed at al suggested that this reflected increased migration of blood DCs into 
the tissues (217). However, these experiments are unable to elucidate the origin and 
relationship of blood and SF DCs. Equivalent circulating blood DCs in mouse peripheral 
blood are difficult to identify (390, 652), and animal studies have suggested that mature 
DCs do not enter non-lymphoid tissues and peripheral lymph nodes via blood (652, 653). 
In contrast, Robinson et al propose tissue DC replenishment from human blood 
populations (216). If mature blood DCs do not migrate into tissue, do precursors seed and 
differentiate within tissue as occurs in mice (288, 380)? CD34+ stem cells may represent 
circulating human DC progenitors (600, 654). To address this question, isolated blood 
cDCs could be transferred and tracked using the NOD/SCID mouse model, both under 
steady state and inflammatory conditions.  
Monocytes have been suggested to develop into tissue DCs under inflammatory conditions 
in vivo (227, 228, 655, 656). Furthermore, monocytes isolated from RA SF promote Th17 
responses within sites of inflammation (657). Consequently, we set out to identify and 
phenotypically characterise AS SF monocytes. Two monocyte subsets (CD14+ CD16- and 
CD14+ CD16+) could be identified in AS SF (Fig. 5.1B). Both subsets expressed high 
levels of CD11b, similarly to blood (Fig. 5.4C and Fig. 3.18A). As observed for SF cDCs, 
CD86 expression was very low on both monocyte populations compared to their blood 
counterparts (Fig. 5.4D and 3.14). This apparent downregulation of CD86 within SF could 
result from the surrounding cytokine milieu, or indicate a potential anti-inflammatory role 
for these populations within the inflamed tissue. Our SF cytokine analyses however do not 
support this hypothesis with regards to an anti-inflammatory cytokine milieu, as only low 
levels of IL-10 were detected (Fig. 5.8). Interestingly, Evans et al found SF monocytes in 
RA to express high levels of co-stimulatory molecules CD40 and CD86, and promote 
Th17 responses (657). It will be important to understand these phenotypic differences 
between AS and RA to better understand pathology. In addition to DCs, tissue infiltrating 
monocytes can give rise to tissue macrophages, at least in certain tissues (225). However, 
macrophage specific markers such as CD206 and CD33 were not included here and CD14+ 
CD11c+ MHC II+ cells were considered tissue monocytes due to their similarities with 
blood monocytes. Consequently, we cannot exclude the possibility that these monocyte 
populations contain macrophages, or are transiting through the macrophage differentiation 
process. 
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Blood CD14- CD16+ mononuclear cells patrol blood vessels, survey the epithelium and 
potentially enter inflamed tissues (229, 237, 356). Despite acceptance that CD14- CD16+ 
mononuclear cells contain SLAN- and SLAN+ subsets, the functional attributes of these 
populations in blood and peripheral tissue have not yet been investigated. The distinction 
between SLAN subsets is important, with evidence suggesting CD14- CD16+ SLAN+ cells 
to be DCs (239, 240, 359). We observed a complete absence of CD14- CD16+ 
mononuclear cells from AS SF (Fig. 5.1B and 5.2C). Absence of this population could 
reflect in situ differentiation resulting in loss of CD16 and SLAN expression. SLAN+ cells 
could be detected within AS SF, however this population was very minor. Dermal SLAN+ 
cells have previously been described under inflammatory conditions, suggesting that this 
potential in situ differentiation would be restricted to inflamed tissues (249, 250, 252). 
Blood SLAN+ cells could be cultured in vitro in the presence of cytokines that reflect AS 
SF milieu, with marker expression being assessed over time. Loss of markers including 
CD16 and SLAN during culture could indicate in situ tissue differentiation of SLAN+ 
cells. Furthermore, SLAN expression may not represent functional differentiation given 
that total CD14- CD16+ cells have been described to migrate through blood vasculature and 
perform surveillance functions (237). If SLAN expression does not infer population 
distinction then a lack of a distinct SLAN+ population is supported through the absence of 
CD14- CD16+ mononuclear cells. SLAN expression may therefore reflect phases of 
monocyte maturation or differentiation. To address this, CD14- CD16+ SLAN+/- subsets 
could be cultured in vitro. Cultures could be supplemented with growth factors and/or 
cytokines including Flt3L, M-CSF, TGF" (358) with SLAN expression being monitored 
over time. These experiments would determine if SLAN+/- subsets represent distinct 
populations. To complement these studies, functional analyses of blood SLAN- and 
SLAN+ subsets could be performed including T cell proliferation and chemokine receptor 
induction. 
In RA and psoriatic arthritis (PsA), pDCs have been shown to accumulate within joint SF 
and possess an immature phenotype (217, 640). CD123+ CD304+ pDCs were identified in 
all four AS patient samples (Fig. 5.3). In contrast to RA and PsA, pDCs as a proportion of 
total leukocytes were reduced in SF compared to blood (Fig. 5.5B and Fig. 3.4C), although 
no consistent difference was observed when represented as frequency of live cells. 
Consequently, pDCs may not contribute to disease pathogenesis within SF. To assess their 
role, phenotypic and functional assessments should be performed, including expression of 
TLR 7 and 9 (219) and type I IFN production. Jongbloed et al observed RA SF pDCs to be 
immature, but responsive to TLR stimulation (217). Interestingly, pDCs in a patient 
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receiving combination therapy represented a larger SF leukocyte population than in a 
patient on anti-TNF! therapy (Fig. 5.7). Anti-TNF! treatment might therefore inhibit 
expansion or recruitment of SF pDCs. Recent studies suggest that anti-TNF! treatment 
may inhibit further radiographic disease progression, and thereby potentially implicate 
pDCs in disease development (557, 558). Future studies using larger patient cohorts to 
assess the functional capabilities of AS SF pDCs are required to determine the role of these 
cells in AS pathology. 
T cell migration is dependent on upregulation of surface molecules following DC: T cell 
interactions (468, 479, 536, 658). Specific chemokine receptor profiles are associated with 
cells infiltrating the synovium in several arthritic diseases (116, 658-660). Consequently, 
identification and phenotypic analysis of AS SF T cell subsets can help delineate pathways 
involved in pathology and identify potential therapeutic targets. In addition, these studies 
may additionally elucidate further roles for DCs in disease pathogenesis through their 
influence on T cell priming. We identified CD25hi and CD25int CD4+ T cell subsets in AS 
SF (Fig. 5.6A). Insufficient sample numbers precluded analyses of FOXP3, ROR#t and 
CD45RO expression, and thus its was not possible to clearly define the T cell subsets in 
AS SF. Functional circulating FOXP3+ cells identified in AS blood suggest that the SF 
CD25hi population may contain Tregs (548, 661). In addition to identifying T cell 
populations, analysis of the T cell chemokine receptor profile was performed. 
Interestingly, CCR4 and CCR6 were co-expressed on all SF CD25hi cells (Fig. 5.6B). As 
discussed in chapter four, CCR4 and CCR6 are involved in the migration of cells 
predominantly to the skin and intestine/joint respectively. Of those analysed, CCR4 and 
CCR6 were the only chemokine receptors detected in SF. Therefore, CCR4 and CCR6 may 
be involved in migration to or retention within AS SF, and may therefore represent 
potential therapeutic targets. Maraviroc, a CCR5 antagonist, is approved for clinical use in 
treatment of individuals infected with human immunodeficiency virus (HIV), supporting 
the idea that it may be possible to develop therapeutics targeting this type of molecule 
(662, 663). Furthermore, as discussed previously, CCR6 is expressed on Th17 cells, 
lending support to the notion that AS is a Th17 mediated disease. 
Having identified immature myeloid cell subsets in AS SF, we analysed the cytokine 
profile of two matched blood and SF samples to assess the contribution of the surrounding 
cytokine milieu to this observed phenotype. The two dominant cytokines in AS patient 
plasma and SF were IL-6 and Flt3L (Fig. 5.8). Flt3L is a haematopoietic growth factor 
known to expand cDCs and pDCs in vivo (571, 572). Patient SF Flt3L levels could 
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promote development of immature myeloid cells to restore tissue homeostasis, given their 
potential tolerogenic capacity (Fig. 3.4). Alternatively, in situ expansion or development of 
cDC and pDCs may be detrimental to joint function. These hypotheses highlight the need 
for functional analyses of SF DC. IL-6 was increased in AS patient SF compared to 
plasma. Additionally, SF IL-6 levels were considerably higher in the patient receiving anti-
TNF! treatment compared to the patient receiving DMARD/NSAID combination therapy. 
High levels of SF IL-6 may contribute to disease pathology through generation of Th17 
cells, supported also by the presence of CCR6+ cell population in the SF, as discussed 
above. Consequently, increased IL-6 levels may be indicative of requirement for biological 
therapy, previously shown to indirectly reduce pro-inflammatory molecules including IL-6 
(621). Furthermore, plasma IL-6 has been noted to correlate with RA radiographic 
progression, supporting a pathogenic role for this molecule (664). Thus, cytokines may 
contribute to disease pathogenesis through their role in lineage development and cell 
activation, and they also represent attractive therapeutic candidates: anti-TNF! treatment is 
a well-established therapy for AS and RA (665-667). Trials in PsA patients suggest that 
molecules targeting IL-12/23 (668, 669) and IL-17A (670) may provide partial 
symptomatic relief. Despite these advances, many AS patients remain unresponsive to 
current therapeutics. Identifying specific molecules associated with AS disease 
pathogenesis could provide symptomatic relief for this cohort of patients. Our data and that 
of published studies highlight a role for IL-6 in disease pathogenesis, however anti-IL-6 
treatment (Tocilizumab) remains ineffective (23). Further studies are therefore required to 
assess cytokine function, specifically IL-6 and Flt3L, within AS allowing us to classify the 
role of Th17 cells, DCs and other immune populations in driving the inflammation 
observed within peripheral joints and extra-articular tissues of AS patients. 
We have identified two cDC subsets, two monocyte populations and pDCs in AS patient 
SF. CD14- CD16+ mononuclear cells were absent from SF, supporting the concept that 
they function as a blood surveillance population (237, 356). Although the functions of 
these subsets in AS SF were not assessed, a larger population of cDCs was found in SF 
than in blood, while pDCs were found in similar proportions in both tissues. Anti-TNF! 
treatment may influence SF DC populations, although further investigation is required. 
Given the altered T cell chemokine receptor profile of blood in patients, we examined 
resident SF CD4+ T cells in AS SF. CCR4 and CCR6 may be required to prevent 
extravasation from or allow entry of CD25hi CD4+ T cells to inflamed synovium. IL-17-
secreting CD4+ T cells express CCR6, indicating a potential role for Th17s in disease 
pathogenesis given the association between CCR6 expression and the Th17 phenotype. 
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High levels of IL-6 and Flt3L were also observed in AS SF and may contribute to disease 
pathology. Overall, observations relating to the cellular infiltrate and cytokine milieu in AS 
SF were made, but due to the small sample number and lack of functional assessment, 
follow up studies will be required to understand the immunopathology of AS SF. 
Following these investigations identifying and quantifying DC and T cell populations in 
AS patients, we next aimed to assess DC function in AS patients. In the next chapter, I will 
address the abilities of individual blood myeloid populations to stimulate T cell 
proliferation, cytokine production and chemokine receptor expression. 
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Chapter 6: Functional characterisation of 
circulating DCs  
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6.1 Introduction 
In previous chapters we have identified populations of DCs and T cells in the blood and SF 
of AS patients. Analyses of T cell subsets in AS patients revealed differences in the 
expression of T cell chemokine receptors that may be influenced by interactions with DCs. 
Previous work from our laboratory identified deficiencies within the DC populations of 
HLA-B27 TG rats (480). Specifically, loss of CD103+ CD11bint CD172alo DCs correlated 
with secretion of IL-17 by interacting T cells, potentially driving a pathogenic Th17 
response. These results suggest that loss of specific DC populations or alterations to DC 
function can lead to the induction of aberrant responses. Previous work assessing the 
function of AS patient DCs has wholly focused on monocyte-derived DCs (moDCs) 
cultured from monocytes in vitro in the presence of GM-CSF and IL-4. These cultures, 
despite generating considerable cell numbers, generate inflammatory DCs and 
consequently cannot be considered to truly represent in vivo DC populations (545). In 
addition, both circulating DC populations are not represented within these monocyte-
derived cultures. Nevertheless, their findings suggested that moDCs generated from AS 
patients did not differ in their expression of co-stimulatory molecules and cytokine 
secretion, including IL-23, although resting moDCs may express less MHC II compared to 
HC control populations (546, 547). Because the influence of circulating DCs in the 
induction and control of peripheral immune responses in AS remains unknown, we set out 
to assess the functions of blood DCs directly isolated from HCs and AS patients. 
6.2 Patient characteristics  
Patients were recruited from the Glasgow Royal Infirmary AS clinic run by Dr David 
McCarey and Dr Anne McEntegart. Patient Information regarding disease severity, 
treatment and duration was collated. Data for the AS patients and HCs used for in the 
analyses of DC function are summarised in Table 3.1.  
Table 6.1: Patient characteristics for DC function experiments 
For analysis, 18 AS patients and 11 HCs were used. Patient characteristics were collated and are 
summarised below. For some parameters, records were not available for all patients. Percentages 
represent proportion of all patients used in the study. Spinal disease was assessed based on the 
presence or absence of cervical, thoracic and lumbar involvement. Levels were categorised on the 
number of sites involved: 1 site = level 1, 2 sites = level 2 and 3 sites = level 3. Combination 
therapy consists of DMARD and NSAID treatment. N/A = Not applicable. Mean ± SD is shown. 
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 AS Patients Healthy Controls 
Age (yrs) 53.3  ± 12.1 46.4 ± 13 
Sex – Male/Female 15/3 8/3 
Disease Duration (yrs) 26.2 ± 12.8  N/A 
B27 – Pos/Neg (% B27+) 15/1 (83%) 1/11 (9%) 
BASDAI 3.5 ± 2.5 N/A 
BASMI 4.7 ± 2.4 N/A 
ESR (mm/hr) 11.7 ± 11.2  N/A 
CRP (mg/L) 9.7 ± 13.8 N/A 
Bilateral Sacroiliitis – No. (%) 17 (94.4%) N/A 
Spinal disease   
    Absent – No. (%) 8 (44%) N/A 
    Level 1 – No. (%) 4 (22%) N/A 
    Level 2 – No. (%) 4 (22%) N/A 
    Level 3 – No. (%) 1 (5.6%) N/A 
Extra-articular Disease   
    IBD – No. (%) 1 (5.6%) N/A 
    Uveitis – No. (%) 0 (0%) N/A 
    Psoriasis – No. (%) 1 (5.6%) N/A 
    Arthritis – No. (%) 4 (22%) N/A 
Medication   
    Nil – No. (%) 5 (27.8%) N/A 
    NSAIDs – No. (%) 10 (55.6%) N/A 
    Combination – No. (%) 1 (5.6%) N/A 
    Biologics – No. (%) 1 (5.6%) N/A 
 
6.3 Induction of T cell proliferation 
DCs prime the adaptive immune response. Several landmark papers in the 1970s identified 
DCs residing within lymphoid tissues of mice, where their primary function was to 
stimulate proliferation of naïve T cells (185, 186, 671, 672). As previous studies in AS 
patients using moDCs have focused on expression of co-stimulatory molecules and 
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cytokine secretion, we initially set out to examine the outcome of DC: T cell interactions, 
with an initial read out of T cell proliferation. To do this we used the gold standard assay to 
assess T cell proliferation following DC interaction: the mixed leukocyte reaction (MLR) 
(186). Monocytes were included in some MLR experiments as a comparative population. 
To perform these experiments, we flow sorted DC subsets or monocytes from AS patients 
and HCs. DCs and monocytes were resuspended at concentrations ranging from 1,500 to 
24,000 DCs/100µl in complete media and co-cultured with mismatched HC purified naïve 
CD4+ T cells (20,000 cells) for 5 days. T cell proliferation was then assessed by CFSE 
dilution. The gating strategy used to identify proliferating T cells following culture is 
depicted in Fig. 6.1. Cell debris, doublets and dead cells (DAPI+) were excluded as 
previously described. Single live cells were analysed for CD4 and CFSE expression. Total 
CD4+ T cells were then assessed for their CFSE level; with the CD4+ CFSElo cells 
classified as the proliferating CD4+ T cell population (Fig. 6.1A). Representative FACS 
plots obtained for each DC/monocyte population are depicted in Fig. 6.1B. Based on these 
plots, CD1c+ DCs were the most proficient subset at inducing T cell proliferation. CD141+ 
DCs were efficient at inducing T cell proliferation despite a maximum of only 1,500 DCs 
being available for co-culture with naïve T cells. For each MLR experiment, T cells alone 
were stimulated with 10µg/ml of ConA and proliferation and chemokine receptor induction 
were assessed as a control (Fig. 6.2A). ConA induced significant levels of T cell 
proliferation and CXCR3 expression (Fig. 6.2A and 6.2B). Induction of CXCR3 was 
assessed given the reported association with the Th1 phenotype and given the 
downregulation of CXCR3 expression on AS patient activated and memory T cells (Fig. 
4.8). Following optimisation of the MLR conditions, quantification of multiple MLRs was 
performed (Fig. 6.2C). No significant differences between AS patients and HCs were 
observed for MLRs containing the following myeloid populations: CD141+ and CD1c+ 
DCs, CD14- CD16+ mononuclear cells and CD14+ CD16- monocytes (Fig. 6.2C).  As DC 
numbers were diluted, reduced T cell proliferation was observed for each population (Fig. 
6.2C). The ability to induce T cell proliferation was compared between all four subsets in 
AS patients and HCs. When HC DC and monocyte subsets were compared for their ability 
to induce T cell proliferation, CD1c+ DCs were the most efficient population at inducing T 
cell proliferation with 12,000 DCs inducing approximately 40% proliferation (Fig. 6.3A). 
Following quantification of 9 independent experiments, 12,000 CD14- CD16+ 
mononuclear cells and 1,500 CD141+ DCs induced 25% and 20% T cell proliferation 
respectively. Of all the subsets, HC monocytes were the poorest inducers of T cell 
proliferation with approximately ~8% of CD4+ T cells showing CFSE dilution following 
co-culture with 12,000 monocytes (Fig. 6.3A). AS patient myeloid populations induce  
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Figure 6.1: Induction of T cell proliferation by blood DC/monocyte subsets 
Ability of human blood DC/monocyte subsets to induce naïve T cell proliferation. Naïve CFSE+ 
CD4+ T cells were co-cultured with DC/monocyte subsets for 5 days. Proliferation assessed by 
CFSE dilution. (A) Single DAPI- cells were assessed for CD4 expression (bottom – left). The 
proportion of proliferating CD4+ T cells was used for further analysis (bottom – right). (B) 
Characteristic FACS plots of T cell proliferation induced by DC/monocyte subsets: - CD141+ DCs 
(1,500 cells), CD1c+ DCs (12,000 cells), CD16+ mononuclear cells (12,000 cells) and CD14+ 
monocytes (12,000 cells). Numbers represent % of T cells undergoing proliferation.  
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Figure 6.2: T cell proliferation induction by HC and AS blood DC/monocyte subsets 
DC/monocytes were cultured with 20,000 naïve CFSE+ CD4+ T cells for 5 days to assess T cell 
DC/monocyte function. Proliferation was assessed by CFSE dilution. T cells alone (left) and 
10µg/ml concanavalin A (ConA - right) were assed for T cell proliferation (A) and chemokine 
receptor (B) induction. (C) Proportions of proliferating T cells for each subset were compared 
between AS patients (red) and HCs (black). Error bars represent mean +/- SD. Subsets used for 
analysis: - CD141+ DCs (8 HCs, 13 AS patients), CD1c+ DCs (10 HCs, 16 AS patients), CD14- 
CD16+ mononuclear cells (9 HC, 15 AS patients) and CD14+ monocytes (4 HC, 6 AS patients).  
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Figure 6.3: Comparison of T cell proliferation by blood DC/monocyte subsets 
DC/monocyte subsets have different abilities to induce T cell proliferation. Different numbers of 
DC/monocytes were cultured with 20,000 naïve CFSE+ CD4+ T cells for 5 days. T cell proliferation 
was assessed by CFSE dilution. Proportion of proliferating T cells for HC (A) and AS patient (B) 
induced by CD141+ (green) and CD1c+ DCs (red), CD14- CD16+ mononuclear cells (purple) and 
CD14+ monocytes was compared. Error bars represent mean +/- SD. Numbers used for analysis: - 
CD141+ DCs (8 HCs/13 AS patients), CD1c+ DCs (10 HCs/16 AS patients), CD14- CD16+ 
mononuclear cells (9 HC/15 AS patients) and CD14+ monocytes (4 HC/6 AS patients). 
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proliferation of naïve CD4+ T cells at levels indistinguishable from the equivalent HC 
myeloid populations (Fig. 6.3B). 
Overall, no difference was observed between AS patient and HC subsets in their ability to 
induce T cell stimulation. However, we did observe differences in the ability of the 
individual subsets to induce T cell proliferation. In our hands, CD1c+ DCs were the most 
proficient subset at inducing proliferation of naïve CD4+ T cells. In contrast, monocytes 
stimulated very little T cell proliferation.  
6.4 Upregulation of chemokine receptors  
In addition to simulating proliferation of naïve CD4+ T cells, DCs direct T cell migration, 
development and maturation. Following uptake of pathogenic or harmless antigen DCs 
migrate from peripheral tissue to the draining lymph node. Following interaction with 
migrating DCs, differentiated T cells acquire specific molecules assisting cell migration, 
including chemokine receptors and integrins. Intestinal DCs induce molecules, including 
CCR9 and !4"7, promoting migration of responding T cells to mucosal tissues (171, 172, 
413, 673). Consequently, analyses of circulating T cells in terms of chemokine receptor 
(CCR) expression can infer the dominant location of T cell priming in steady state and 
inflammatory conditions. Our results suggested that AS patient DCs preferentially induced 
CCR6 on interacting CD4+ T cells. This observation was accompanied by a reduction in 
CXCR3 priming. Accordingly we set out to assess the ability of blood DC subsets, isolated 
from both AS patients and HCs, to induce CCR6 and CXCR3 on the surface of interacting 
T cells in an MLR setting. To identify CCR+ T cells, cell debris, doublets and dead 
(DAPI+) cells were excluded from analysis (Fig. 6.4A). CD4+ CFSElo T cells were 
subsequently analysed for the expression of chemokine receptors. CCR+ cells were 
compared to the appropriate isotype-matched control. Representative plots of CCR6 
expression on CD4+ proliferating T cells, following co-culture with CD141+ and CD1c+ 
DCs and CD14- CD16+ mononuclear cells are depicted in Fig. 6.4B. These demonstrate 
that, CD141+ and CD1c+ DCs were the principal inducers of CCR6 on interacting T cells. 
Quantification of T cell CCR6 upregulation following MLR co-culture with CD141+ and 
CD1c+ DCs, CD14- CD16+ mononuclear cells and CD14+ CD16- monocytes is shown in 
Fig. 6.5A. Only one MLR co-culture was used to assess CCR6 expression using CD14+ 
CD16- monocytes. AS patient myeloid populations did not significantly differ in their 
ability to induce CCR6 on interacting CD4+ T cells compared to their HC counterparts  
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Figure 6.4: Ability of human blood DCs/monocytes to induce T cell homing markers 
Capability of DC/monocyte subsets to induce chemokine receptor (CCR) induction. (A) Gating 
strategy to identify proliferating CCR+ CD4+ T cells after MLR co-culture. Doublets and dead cells 
were excluded from analysis (top row). Single live cells were then analysed for expression of CD4 
(bottom, left). Proliferating CD4+ T cells (bottom, centre) were analysed for expression of CCR 
(bottom, right). (B) 1,500 CD141+ DCs (left), 12, 000 CD1c+ DCs (centre, left) and 12,000 CD14- 
CD16+ mononuclear cells (centre, right) are able to induce CCR6. Numbers represent % of CCR6+ 
proliferating T cells. Isotype used to set CCR+ gate in some cases (right). 
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Figure 6.5: CCR6 induction by HC and AS blood DC/monocyte subsets 
No difference in the ability of HC (black) and AS patients (red) DC/monocyte subsets to induce 
CCR6 on interacting T cells in an MLR co-culture system. (A) CD141+ DCs (4 HC, 6 AS), CD1c+ 
DCs (4 HC, 7 AS), CD14- CD16+ mononuclear cells (5 HC, 8 AS) and CD14+ monocytes (1 HC, 1 
AS) were tested for their ability to induce CCR6. Error bars show mean +/- SD. Ability of 24,000 
CD14+ monocytes (right) and 12,000 CD1c+ DCs (left) to induce T cell proliferation (B) and CCR6 
induction on interacting T cells (C). Gates were set on isotype.  
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(Fig. 6.5A). FACS plots depicting the proliferative capacity and CCR induction of CD1c+ 
DCs and CD14+ CD16- monocytes are shown in Fig. 6.5B and 6.5C.  
We next established the ability of AS patient and HC myeloid cells to induce CXCR3 
expression. Representative FACS plots showing proportion of CXCR3+ CD4+ T cells 
following MLR co-culture with CD141+ and CD1c+ DCs, CD14- CD16+ mononuclear cells 
and CD14+ CD16- monocytes are presented in Fig. 6.6A. All subsets were capable of 
inducing CXCR3 expression on proliferating T cells. Interestingly, co-cultures containing 
all myeloid populations induced 90% of proliferating T cells to express CXCR3. Following 
co-culture of 1,500 CD141+ DCs and 20,000 naïve CD4+ T cells, no difference between 
AS patients and HCs was observed (Fig. 6.6B). Similarly, no difference was observed 
between AS patient and HC CD1c+ DCs, CD14- CD16+ mononuclear cells and CD14+ 
CD16- monocytes in their ability to induce CXCR3 expression at any DC: T cell ratio (Fig. 
6.6B). 
Overall we observed no increase in CCR6 induction by AS patient DCs when compared to 
their HC counterparts. In addition, no difference in CXCR3 induction was observed 
between AS patient or HC myeloid subsets. 
6.5 Induction of T cell responses 
DCs direct T cell differentiation, polarising effector T cell towards Th1/Th2/Th17 or Treg 
phenotypes. Following MLR co-culture, T cell differentiation can be assessed by 
measuring the cytokines secreted. Luminex and ELISA technology was used to assess the 
levels of cytokines secreted from MLR cultures (Fig. 6.7 and 6.8). Cytokines IL-1", IL-4, 
IL-5, IL-6, IL-10, IL-17A, IFN#, TNF! and the growth factor Flt3L were chosen for 
analysis because of their association with inflammation, T cell and myeloid populations. 
Levels of IFN# (Th1) and IL-4 and IL-5 (Th2) did not differ between HC and AS patients 
(Fig. 6.7A). However, CD14- CD16+ mononuclear cell co-cultures secreted highest levels 
of both IFN# and IL-5 (Fig. 6.7A). MLR supernatants obtained from AS patient and HC 
CD1c+ and CD141+ DCs and CD14- CD16+ mononuclear cell co-cultures contained 
variable levels of IL-10 and IL-17 (Fig. 6.7A). HC CD1c+ and CD141+ DC co-cultures 
may induce elevated levels of IL-10 when compared to AS patients (Fig. 6.7A). HC CD1c+ 
DC co-cultures resulted in the preferential secretion of IL-17A compared to their AS 
counterparts (Fig. 6.7A). This result is based solely on one HC and two AS patient myeloid 
co-cultures. Secretion of the inflammatory cytokines IL-1", IL-6 and TNF! following AS  
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Figure 6.6: CXCR3 induction by HC and AS blood DC/monocyte subsets 
No difference in the ability of HC (black) and AS patients (red) DC/monocyte subsets to induce 
CXCR3 on interacting T cells in an MLR co-culture system. (A) Representative FACS plots of 
CXCR3 induction by HC and AS DC/monocyte subsets. Number represent % of CXCR3+ 
proliferating T cells. (B) CD141+ DCs (2 HC – empty circles, 4 AS – filled circles), CD1c+ DCs (3 
HC, 5 AS), CD14- CD16+ mononuclear cells (3 HC, 5 AS) and CD14+ monocytes (3 HC, 5 AS) 
were tested for their ability to induce CXCR3. Error bars show mean +/- SD.  
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Figure 6.7: Secretion of T cell-associated cytokines following MLR 
Secretion of T cell-associated cytokines following co-culture of CD141+ and CD1c+ DCs and CD14- 
CD16+ mononuclear cells with CD4+ CD45RA+ naïve T cells. (A) Secretion of IFN$, IL-4, IL-5, IL-10 
and IL-17A following myeloid cell co-culture with CD4+ naïve T cells for 5 days. Cytokine levels 
were analysed by Luminex. For co-culture 1,500 CD141+ DCs, 12,000 CD1c+ DCs and 12,000 
CD14- CD16+ mononuclear cells were incubated with 20,000 CD4+ T cells. For HCs (empty bars) 
one CD141+, one CD1c+ and two CD14- CD16+ mononuclear cell co-cultures were analysed. The 
MLR supernatants of two CD141+, two CD1c+ and 3 CD14- CD16+ mononuclear cell AS patient 
(filled bars) co-cultures were assessed. Error bars represent SD.  
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Figure 6.8: Secretion of inflammatory cytokines and growth factors following MLR 
Secretion of T cell-associated cytokines following co-culture of CD141+ and CD1c+ DCs and CD14- 
CD16+ mononuclear cells with CD4+ CD45RA+ naïve T cells. Secretion of IL-1!, IL-6 and TNF" (A) 
and Flt3L (B) following myeloid cell co-culture with CD4+ naïve T cells for 5 days. Cytokine levels 
were analysed by Luminex. For co-culture 1,500 CD141+ DCs, 12,000 CD1c+ DCs and 12,000 
CD14- CD16+ mononuclear cells were incubated with 20,000 CD4+ T cells. For HCs (empty bars) 
one CD141+, one CD1c+ and two CD14- CD16+ mononuclear cell co-cultures were analysed. The 
MLR supernatants of two CD141+, two CD1c+ and 3 CD14- CD16+ mononuclear cell AS patient 
(filled bars) co-cultures were assessed. Error bars represent SD.  
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patient and HC myeloid population co-cultures did not differ between AS patients and HCs 
(Fig. 6.8A). CD14- CD16+ mononuclear co-cultures secreted higher concentrations of IL-
1" and IL-6 than all other myeloid: T cell co-cultures, in both AS patients and HCs (Fig. 
6.8A). HC and AS patient CD141+ DC: naïve T cell co-cultures secreted the lowest levels 
of IL-10 (Fig. 6.8A). AS patient and HC CD1c+ DC and CD14- CD16+ mononuclear MLR 
supernatants were assessed for the presence of Flt3L (Fig. 6.8B). The single HC CD1c co-
culture failed to induce Flt3L production, and only very low levels of Flt3L could be 
detected in the co-cultures involving AS patient CD1c+ DCs and HC and AS patient CD14- 
CD16+ mononuclear cells (Fig. 6.8B). GM-CSF was undetectable in all of the MLR 
experiments (data not shown). In order to confirm many of these results, these experiments 
should be repeated. 
6.6 Assessment of cell survival  
Following analysis of blood DC subsets in AS patient and HC blood, we observed a 
significant reduction in the proportion of CD1c+ DCs as a percentage of CD11c+ MHC II+ 
DCs, and an increase in CD14- CD16+ mononuclear cells. One hypothesis that may 
account for this is that AS patient CD1c+ DCs may have a reduced lifespan in vivo. 
Consistent with this hypothesis, research using the HLA-B27 TG SpA rat model has 
suggested a role for ER stress in the development of Th17 responses and SpA (481, 520). 
Following activation of the ER stress pathway, cells may die by apoptosis. Furthermore, 
Flt3L induced HLA-B27 TG BM-derived DCs exhibit enhanced caspase-mediated cell 
death compared to their WT counterparts (480). Therefore because of the reduction of 
circulating CD1c+ DCs in AS patients, and the contribution of ER stress to SpA 
pathogenesis, we set out to assess survival of AS patient and HC myeloid cells using an in 
vitro assay. CD1c+ DCs, CD14- CD16+ mononuclear cells and CD14+ CD16- monocytes 
from AS patients and HCs were flow sorted, stained with fluorescent dyes and mixed 1:1. 
The proportions of live HC and AS cells in the cultures were analysed at 24 and 48 hours 
later by flow cytometry. Initially, HC cells were stained with CFSE and AS cells were 
identified using the V450 proliferation dye. No differences were observed in the ratio 
between AS patient and HC CD1c+ DCs and CD14- CD16+ mononuclear cells after 24 
(Fig. 6.9A) or 48 (Fig. 6.9B) hours. Survival of CD1c+ DCs was only assessed after 24 
hours. In contrast, cell survival of AS patient CD14+ CD16- monocytes appeared to be 
significantly greater than that of monocytes isolated from a HC at both time points (Fig. 
6.9A and 6.9B). Representative FACS plots of monocyte cell survival as assessed by HC: 
AS ratio are depicted in Fig. 6.9A and 6.9B.  These plots confirm that at both 24 and 48 
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hours, AS patient monocytes outnumbered their HC counterparts. However, to control for 
the use of different cell proliferation dyes to identify the AS patient and HC myeloid 
populations, the V450 and CFSE proliferation dyes were swapped between the HC and AS 
patient subsets, with HC cells now stained with V450 and the AS cells with CFSE. This 
alteration resulted in reduced survival of AS patient monocytes compared to their HC 
counterparts (Fig. 6.9C). Together, these results suggest that the survival of AS patient and 
HC cell subsets using this in vitro assay did not differ. Additionally, CFSE was observed to 
specifically affect survival of CD14+ CD16- monocytes.  
Quantification of cell death was also performed. For each assay, the proportion of dead 
cells as defined by FSC and SSC, were converted to a ratio: AS: HC. Once again, initial 
experiments used CFSE and V450 proliferating dyes to identify HC and AS patient 
populations respectively. At 24 hours CD1c+ DC and CD14+ CD16- monocytes isolated 
from AS patients showed enhanced cell survival compared to that of HC populations (Fig. 
6.10A). At 48 hours, survival of AS patient CD14- CD16+ mononuclear cells and CD14+ 
CD16- monocytes were again enhanced compared to their HC counterparts (Fig. 6.10A). 
To control for the effect of these differential dyes, the V450 and CFSE proliferation dyes 
were swapped between the HC and AS patient subsets. Similar to the results obtained 
above (Fig. 6.9), a greater proportion of dead cells were observed for all myeloid 
populations from AS patients (Fig. 6.10B). Specifically enhanced HC survival was 
observed for CD1c+ DC and CD14+ CD16- monocytes at 24 hours and CD14+ CD16- 
monocytes at 48 hours (Fig. 6.10B). Representative FACS plots depicting cell death are 
shown in Fig. 6.10C. At 24 and 48 hours, CD14+ CD16- monocytes isolated from AS 
patients and HCs were assessed for SSC profile. Proportions of live cells are presented. 
Our results using this in vitro assay suggest that, AS patient myeloid populations do not 
differ in their survival capacity when compared to HC counterparts. In addition, CFSE was 
found to induce cell death of flow sorted populations, predominantly CD14+ CD16- 
monocytes. 
6.7 ER stress in circulating myeloid populations 
Animal model experiments indicate that the unfolded protein response (UPR) induced by 
ER stress is upregulated in SpA, specifically within myeloid populations (481, 520). 
However, human studies using monocyte-derived macrophages and PBMCs have so far 
failed to identify preferential induction of the ER stress pathway in AS (505, 523). Given  
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Figure 6.9: Survival of cDC and monocyte subsets isolated from AS patients and HCs 
Survival of blood cDC and monocyte subsets. HC (CFSE) and AS (V450) cDC and monocyte 
subsets, after cell sorting, were mixed 1:1 (dotted line) and cultured for 24 (A) or 48 (B) hours. Cell 
proportions (AS: HC ratio) analysed at 0 (empty bars) or 24/48 hours (filled bars). Representative 
FACS plots of monocyte survival at 24 (A – right) and 48 (B – right) hours. Data from 4 
independent experiments. Percentages represent proportion of single live cells (FSC vs SSC 
profile). (C) Cell sorted HC (V450) and AS (CFSE) cDC and monocyte subsets were mixed 1:1 and 
cultured for 24 (left) or 48 (right) hours. Cell proportions (AS: HC ratio) were analysed at 0 (empty 
bars) or 24/48 hours (filled bars). CD16+ subset contains SLAN+ and SLAN- subsets and 
monocytes are CD14+ CD16-. One independent experiment. * p = < 0.05, unpaired T test.   
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Figure 6.10: Survival of AS patient and HC CD1c, CD16 and monocyte populations 
Survival of blood cDC and monocyte subsets. (A) HC (CFSE) and AS (V450) cDC and monocyte 
subsets, after cell sorting, were mixed 1:1 (dotted line) and cultured for 24 (left) or 48 (right) hours. 
Percent of dead cells was converted to a ratio (AS: HC) and analysed at 0, 24 and 48 hours. Data 
from 4 independent experiments. (B) Cell sorted HC (V450) and AS (CFSE) cDC and monocyte 
subsets were mixed 1:1 and cultured for 24 (left) or 48 (right) hours. Percentage of dead cells was 
converted to a ratio (AS: HC) and analysed at 0, 24 and 48 hours. CD16+ subset contains SLAN+ 
and SLAN- subsets and monocytes are CD14+ CD16-. One independent experiment. (C) 
Representative FACS plots of monocyte survival after 24 (left) and 48 (right) hours. Percentages 
represent proportion of dead cells (FSC vs SSC). One independent experiment.  
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our expertise in the isolation and characterisation of circulating DC populations, we set out 
to fully characterise the induction of the ER stress pathway in AS patient and HC CD1c+ 
DCs (Fig. 6.11) and CD14- CD16+ mononuclear cells (Fig. 6.12). ER stress can be 
transmitted through three pathways, each of which was investigated for both myeloid 
populations. ER stress sensed through PERK activation leads to the phosphorylation of 
EIF2! and ATF4. Blood CD1c+ DCs isolated from AS patients and HCs did not differ in 
their expression levels of ATF4, PERK and EIF2! (Fig. 6.11A). IRE1 activation leads to 
the splicing of XBP-1, so the levels of unspliced and spliced XBP-1 in AS patient and HC 
CD1c+ DCs were assessed. Unspliced XBP-1 (uXBP-1) and spliced XBP-1 (sXBP-1) 
levels in CD1c+ DCs isolated from both AS patients and HCs were not different (Fig. 
6.11B). The third pathway for nuclear transmission of ER stress involves the activation of 
ATF6. ATF6 was not differentially expressed between CD1c+ DCs isolated from AS 
patients and HCs (Fig. 6.11C). BiP, a chaperone molecule, regulates the activation IRE1, 
PERK and ATF6 and is released from these ER stress-sensing molecules following ER 
stress induction. Examination of BiP transcripts in AS patient and HC CD1c+ DCs failed to 
identify differential expression between these populations (Fig. 6.11D). 
CD14- CD16+ mononuclear cells isolated from AS patients and HCs were also analysed for 
the expression of genes involved in the ER stress induction pathway. As for CD1c+ DCs, 
genes involved in the PERK (PERK, ATF4 and EIF2! – Fig. 6.12A), IRE1 (uXBP-1 and 
sXBP-1 – Fig. 6.12B) and ATF6 (Fig. 6.12C) ER stress pathways were not differentially 
expressed between CD14- CD16+ mononuclear cells isolated from HCs and AS patients. In 
contrast, BiP expression was elevated in AS patient CD14- CD16+ mononuclear cells 
compared to their HC counterparts (Fig. 6.12D). 
In this study, we were unable to assess the induction of the UPR via ER stress in 
circulating CD141+ DCs due to insufficient cells numbers. However, our data suggest that 
the presence of HLA-B27 in AS patient myeloid DCs and mononuclear cells does not 
induce ER stress. 
6.8 Role of myeloid A20 expression in AS 
Deficient expression of A20 (TNFAIP3) specifically within the myeloid compartment of a 
murine model led to the development of lymphocyte-dependent colitis, arthritis and 
enthesitis (674). A20 is a protein that negatively regulates NF'B activation; A20-deficient 
mice develop severe inflammatory disease (675, 676). A20 is therefore involved in the  
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Figure 6.11: Expression of ER stress genes in circulating CD1c+ DCs 
No evidence of ER stress induction in AS patient circulating CD1c+ DCs. Expression of ER stress 
genes on CD1c+ DCs isolated from the blood of AS patients (filled bars) and HCs (empty bars). 
Gene expression is presented as relative expression compared to that of the endogenous control, 
TBP: measured in arbitrary units (AU). (A) Expression of ATF4, EIF2" and PERK compared 
between AS patients and HCs. (B) Levels of unspliced XBP-1 (uXBP-1) and spliced XBP-1 (sXBP-
1) were compared between AS patients and HCs. Expression of ATF6 (C) and BiP (D) on CD1c+ 
DCs isolated from AS patients and HCs. For A, B and C, 4 HC and 3 AS patient CD1c+ samples 
were used in analysis. For BiP analysis (D), 13 HCs and 15 AS patient CD1c+ DC samples were 
used. Data normalised to HC CD1c+ DCs. 
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Figure 6.12: Expression of ER stress genes in circulating CD16+ mononuclear cells 
No evidence of ER stress gene induction within CD16 mononuclear cells isolated from AS patients 
(filled bars) and HCs (empty bars). Gene expression is presented as relative expression compared 
to that of the endogenous control, TBP: measured in arbitrary units (AU) and HC CD16+ 
mononuclear cells. (A) Expression of ATF4, EIF2" and PERK compared between AS patients and 
HCs. (B) Levels of unspliced XBP-1 (uXBP-1) and spliced XBP-1 (sXBP-1) were compared 
between AS patients and HCs. Expression of ATF6 (C) and BiP (D) on CD16+ mononuclear DCs 
isolated from AS patients and HCs. * p = <0.05, Mann-Whitney T test. For A, B and C, 4 HC and 3 
AS patient mononuclear samples were analysed. For BiP analysis (D), 10 HCs and 11 AS patient 
mononuclear samples were used. 
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Figure 6.13: Myeloid expression of A20 in AS patients and HCs 
CD16+ mononuclear cells isolated from AS patients express elevated levels of A20. (A) Level of 
A20 expression in CD1c+ DCs (top left), CD14- CD16+ mononuclear cells (top right) and CD14+ 
CD16- monocytes isolated from AS patients (filled bars) and HCs (empty bars). For analysis of 
CD1c+ DCs, 7 HCs and 7 AS patients were used for analysis. 4 AS patient and 4 HCs individual 
CD14- CD16+ mononuclear cells and 6 AS patients and 6 HCs were used for gene expression 
analyses. Gene expression is presented as relative expression compared to that of the 
endogenous control, TBP: measured in arbitrary units (AU). * p < 0.05, Mann-Whitney T test. 
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maintenance of immune homeostasis. Coeliac (677) and psoriatic (678, 679) patients have 
been shown to posses SNPs within the A20 locus, contributing to the genetic make-up of 
these complex autoimmune diseases. Given the systemic inflammatory nature of AS and 
the accompanied association with IBD and psoriasis, both of which involve A20 
polymorphisms, we set out to establish the expression of A20 within the circulating 
myeloid populations of AS patients and HCs. Blood CD1c+ DCs, CD14- CD16+ 
mononuclear cells and CD14+ CD16- monocytes isolated from AS patients and HCs were 
analysed for the expression of A20 (Fig. 6.13). For both CD1c+ DCs and CD14+ CD16- 
mononuclear cells, no difference in the expression of A20 was expressed (Fig. 6.13A). In 
contrast, A20 expression was elevated in AS patient CD14- CD16+ mononuclear cells 
when compared to HCs (Fig. 6.13A). Our results indicate that A20 is differentially 
expressed in AS patient CD14- CD16+ mononuclear cells, with elevated levels of this 
regulatory protein being observed. 
6.9 Discussion 
At the outset of my PhD, we hypothesised that circulating CD141+ DCs would be absent or 
diminished in AS patients, given our observations using the HLA-B27 TG rat SpA model 
(480). However, we found that AS patients have normal numbers of CD141+ DCs.  
When examining the DC populations, we identified variations in the circulating myeloid 
populations of AS patients. A reduction in CD1c+ DCs was accompanied by an increase in 
CD14- CD16+ mononuclear cells. In order to understand the contributions of these immune 
populations to disease pathogenesis, the functions of four circulating myeloid populations 
were examined: - CD141+ and CD1c+ DCs, CD14- CD16+ mononuclear cells and CD14+ 
CD16- classical monocytes. These investigations have not previously been performed. 
However, numerous studies have investigated the functional characteristics of these four 
myeloid populations under steady state conditions. Blood and tissue CD141+ DCs are 
potent inducers of Th1 cells, excel at antigen cross-presentation following TLR3 
stimulation, and are the principal inducers of CD8+ T cell proliferation (200, 212, 339, 340, 
347). In contrast, CD1c+ DCs are reported to possess both tolerogenic and immunogenic 
properties. CD1c+ DCs have been shown to secrete IL-10 and express highest levels of the 
tolerogenic molecule IDO (211). In contrast they have also been reported to induce Th17 
differentiation (277). CD14- CD16+ mononuclear cells are reported to possess endothelial 
surveillance properties (237) and are capable of pro-inflammatory Th1 and Th17 induction 
(249, 252, 346, 359). Finally, classical CD14+ CD16- monocytes are highly phagocytic, 
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express high levels of reactive oxygen species (ROS), lysozyme and are proficient in the 
induction of T cell proliferation (237). Given the functional attributes of these myeloid 
populations and their involvement in immune response generation, we set out to establish 
the functional attributes of AS patient circulating myeloid populations and whether they 
might be involved in the pathogenesis of this systemic disease. 
Patients recruited to this study were mostly male and HLA-B27+ (Table 6.1). Again, 
average disease score levels of approximately 4 for both BASDAI and BASMI categories 
were observed (Table 6.1). Levels of inflammation were not excessively high, with scores 
below 10 considered to be applicable to the general population (Dr David McCarey, 
personal communication).  Almost all recruited patients presented with evidence of 
bilateral sacroiliitis, determined through MRI and X-ray examination. 30% of patients 
exhibited extra-articular symptoms, with peripheral arthritis the most common.  Data were 
unavailable for one patient (Table 6.1). The majority of the patients were undergoing 
treatment through NSAID administration. These parameters are characteristic of the 
general AS population and are similar to the other patient cohorts used in this study. Males 
were preferentially recruited to the HC cohort, to replicate the bias in the patient cohort. 
The HCs had a slightly lower average age (53.3 vs 46.4 years). The majority of recruited 
healthy individuals lacked expression of the disease-associated HLA-B27 molecule (Table 
6.1). Overall AS patients included within this study exhibited similar disease profiles to the 
general AS population. 
We assessed the capacity of blood myeloid populations to induce T cell proliferation ex 
vivo using MLRs. All blood myeloid populations examined were capable of stimulating T 
cell proliferation in a 5-day co-culture with naïve CD4+ T cells (Fig. 6.2). However, there 
were no differences between AS patient and HC populations’ ability to drive T cell 
proliferation, at any DC: T cell ratio (Fig. 6.2). As discussed in chapter 4, AS patients did 
not possess a higher proportion of circulating effector T cell populations compared to HCs 
(Fig. 4.2 and 4.3). These observations may be connected given that DCs, as the principal 
APCs of the immune system, prime and direct T cell responses. Therefore, the similar 
capabilities of AS patient and HC myeloid populations may be consistent with the lack of 
change to the circulating effector T cell profile of AS patients. However, it should be noted 
that this experimental approach does not assess the antigen processing capabilities of AS 
patient DCs, and those isolated from HCs, as exogenous antigen is not processed and 
presented via MHC II in this setting. To address this, DCs isolated from tetanus-toxoid 
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immunised patients and HCs could be incubated with tetanus toxoid and autologous T 
cells.  
Due to the low numbers of CD141+ DCs isolated from peripheral blood, it was difficult to 
fully assess the induction of T cell proliferation by this blood DC subset. However, at the 
highest possible DC: T cell ratio (1,500 DCs: 20:000 naïve CD4+ T cells), CD141+ DCs 
were just as proficient as the CD1c+ DC subset in the induction of T cell proliferation in 
both HCs (Fig. 6.3A) and AS patients (Fig. 6.3B). CD141+ DCs have previously been 
reported to support elevated levels of CD8+ T cell proliferation. As SpA diseases are CD8+ 
T cell independent, at least in the HLA-B27 TG rats, the interaction between circulating 
myeloid populations and CD8+ T cells was not assessed in this study. However, our data 
indicate that CD141+ and CD1c+ DCs do not differ in their ability to induce CD4+ T cell 
proliferation. Future experiments using greater DC numbers could be performed to 
substantiate these observations. Both CD14- CD16+ mononuclear cells and CD14+ CD16- 
monocytes were less efficient at inducing T cell proliferation than CD1c+ DCs in both HCs 
(Fig. 6.3A) and AS patients (Fig. 6.3B). This observation was maintained at all DC: T cell 
ratios (Fig. 6.3). Interestingly, CD14- CD16+ mononuclear cells were consistently better at 
driving T cell proliferation than CD14+ CD16- monocytes, in both HC (Fig. 6.3A) and AS 
patient (Fig. 6.3B) myeloid: T cell co-cultures, and at all DC: T cell ratios. Thus, CD14- 
CD16+ mononuclear cells appear functionally distinct from CD14+ CD16- monocytes. The 
CD14- CD16+ mononuclear population contains both SLAN- and SLAN+ cells (Fig. 3.6A). 
In this study, the functional properties of these populations were not examined separately. 
However, given that SLAN+ cells are thought to represent a third blood DC subset (240, 
249, 250, 359) and DCs possess an enhanced capacity to drive T cell proliferation (Fig. 
6.3), functional assessment of the individual populations may delineate their relationship to 
monocytes and DCs. CD14+ CD16- monocytes possess a superior capacity to phagocytose 
beads (1µm biotinylated YG-Fluospheres) (237). Taken together, these data are consistent 
with previously reported functional differences between monocyte and dendritic cell 
populations.  
DC: T cell interactions drive T cell proliferation, migration and differentiation. Therefore, 
we assessed whether AS patient myeloid cells might drive aberrant immune responses 
through effects on T cell migration and differentiation. To do this, we determined the 
ability of the four myeloid populations to induce CCR6 and CXCR3 expression on 
interacting CD4+ T cells. CCR6 has been associated with Th17 cells and skin/gut homing, 
and CXCR3 with Th1 cells. CCR6 and CXCR3 were also chosen for investigation due to 
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their differential expression on T cells in AS patient blood; an elevated frequency of 
circulating activated CD4+ T cells in AS patients expressed CCR6, with the converse being 
true for CXCR3. Therefore, we hypothesised that AS patient myeloid populations would 
induce CCR6 expression on a higher proportion of proliferating T cells, potentially driving 
Th17 differentiation and therefore contribute to the pathogenesis of AS. In fact, all myeloid 
populations were capable of CCR6 induction on proliferating CD4+ T cells (Fig. 6.5) and 
no difference in CCR6 induction was observed between AS patient and HC myeloid 
populations. Around 20% of proliferating CD4+ T cells expressed CCR6 following co-
culture (Fig. 6.5A). Therefore, AS patient myeloid cells were no more proficient in their 
ability to drive CCR6 expression than their HC counterparts.  
We hypothesised that, given the reduction in circulating CXCR3+ T cells, AS patient 
myeloid populations may be less efficient at driving this T cell phenotype. In fact, all HC 
and AS patient myeloid populations (CD141+ and CD1c+ DCs, CD14- CD16+ mononuclear 
cells and CD14+ CD16- monocytes) were capable of CXCR3 induction (Fig. 6.6B). 
However, CXCR3 induction did not differ between AS patient and HC co-cultures (Fig. 
6.6B), leading us to reject our hypothesis. Taken together, these data suggest that AS 
patient myeloid cells do not differ in their ability to drive CCR6 or CXCR3 expression on 
interacting T cells. Given that the in vitro conditions used do not replicate those occurring 
in vivo it would be of interest to perform similar experiments using tissue-resident myeloid 
cell populations, particularly from AS-affected tissues. Exogenous signals will affect 
DC/myeloid function; therefore identifying the alternative exogenous signals present in AS 
and assessing their subsequent impact on DC/myeloid function may help elucidate the 
immune pathways occurring in vivo. Our plasma cytokine data demonstrated that several 
pro-inflammatory cytokines and Flt3L were dysregulated in AS that could affect 
DC/myeloid function. It may therefore be interesting to perform T cell: DC cultures in the 
presence of these cytokines. These experiments would help elucidate whether DCs 
contribute to the generation of aberrant T cell responses. 
Given the association of specific chemokine receptors with specific T cell phenotypes, our 
data may also indicate that AS patient myeloid populations do not preferentially induce 
Th17 responses, unlike in HLA-B27 TG rats (480). To address this question, intracellular 
cytokine staining of the proliferating T cells would need to be performed. We performed 
preliminary experiments to address this question by examining the cytokines secreted 
following DC: T cell co-culture (Fig. 6.7 and 6.8). For these experiments, supernatants 
were collected from CD141+ and CD1c+ DC, and CD14- CD16+ mononuclear cell MLR 
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cultures with naïve CD4+ T cells, and analysed the resulting cytokine and growth factor 
milieu. Due to the limited sample numbers, it is difficult to draw conclusions, but our data 
indicate that co-cultures with CD14- CD16+ mononuclear cells preferentially secrete IFN#, 
IL-5, IL-1" and IL-6 (Fig. 6.7 and 6.8). Of these cytokines, IL-6 levels were highest, 
suggesting that these cultures may support Th17 generation, given the involvement of IL-6 
in Th17 differentiation in humans (107, 109). MLRs containing CD141+ DCs induced 
secretion of very few cytokines (Fig. 6.7 and 6.8). No difference in the cytokine profiles 
from these co-culture supernatants were observed between AS patient and HCs. Therefore 
all myeloid populations were capable of CCR6 induction in the MLR setting, with CD14- 
CD16+ mononuclear co-cultures favouring the production of IL-6 that may promote Th17 
generation. 
Given the altered circulating myeloid population profile of AS patients, we assessed 
whether differential cell survival could account for our observations. As proportion of 
CD11c+ MHC II+ cells, AS patients had fewer circulating CD1c+ DCs (Fig. 3.4B) and 
more CD14- CD16+ mononuclear cells (Fig. 3.7A). Initial experiments suggested that a 
greater proportion of AS patient DCs died following overnight culture (data not shown). 
Therefore, we set out to determine if AS patient myeloid populations differed in their 
survival capacity. We identified selective CFSE toxicity, resulting in increased cell death 
of blood monocytes (Fig. 6.7C, 6.8B and 6.8C), but no underlying difference in cell 
survival between the circulating myeloid cells of AS patients and HCs. 
Despite more than 40 years of research investigating the association between HLA-B27 
and AS development, the pathogenic role of this MHC class I molecule remains elusive. It 
was postulated that HLA-B27-induced ER stress may be a critical process, largely due to 
the observed induction of ER stress in myeloid populations of HLA-B27 TG rats, which 
leads to IL-23 production (481, 511, 520, 522). IL-23 promotes the Th17 phenotype and 
may therefore promote AS development and pathogenesis in the rats. To date evidence for 
ER stress induction in human myeloid populations is limited (505, 523, 524). Therefore I 
aimed to determine the activation of the UPR in circulating myeloid populations isolated 
from AS patients and HCs, and its potential involvement in AS pathogenesis. We 
examined the expression of 5 genes involved in the nuclear transduction of ER stress, in 
addition to the chaperone molecule BiP. CD1c+ DCs and CD14- CD16+ mononuclear cells 
isolated from AS patients failed to show evidence of ER stress induction either via the 
PERK, IRE1 or ATF6 pathways (Fig. 6.11A, 6.11B and 6.11C). These results indicate that 
HLA-B27 misfolding does not drive ER stress, in myeloid cells, and that this mechanism is 
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therefore unlikely to contribute to AS pathogenesis. Our data are consistent with previous 
human studies (505, 523, 524). However, we did observe upregulation of the ER 
chaperone molecule BiP specifically within AS patient CD14- CD16+ mononuclear cells 
(Fig. 6.11D and 6.12D). However, given that this upregulation of BiP was not associated 
with increased expression of additional ER stress genes, it is possible that enhanced HLA-
B27 misfolding within CD14- CD16+ cells results in the activation of alternative stress-
associated signalling pathways. A recent study by Ciccia et al found the autophagy process 
to be upregulated in lamina propria mononuclear cells (LPMCs) isolated from AS patients, 
instead of the UPR pathway (524). Future analyses could therefore investigate the 
activation of autophagy, perhaps through expression of genes including autophagy protein 
5 (ATG5) and ATG12 in circulating myeloid populations of AS patients. 
Our final functional analysis involved expression of A20, otherwise known as TNFAIP3. 
A20 SNPs are associated with susceptibility to coeliac disease (677) and psoriasis (678, 
679). Furthermore, A20 is a negative regulator of NF'B, with expression required for 
immune homeostasis (675, 676). CD1c+ DCs and CD14+ CD16- monocytes isolated from 
AS patients and HCs expressed similar levels of this regulatory gene (Fig. 6.13A). In 
contrast, CD14- CD16+ mononuclear cells isolated from AS patients expressed elevated 
levels of A20 compared to their HC counterparts (Fig. 6.13A). Given that A20 regulates 
NF'B expression, CD14- CD16+ mononuclear cells isolated from AS patients may exhibit 
altered cytokine production, which may subsequently affect T cell differentiation and 
immune response induction. To test this hypothesis, the activation of genes directly 
targeted by A20 could be investigated, including receptor-interacting protein 1 (RIP1) and 
TNF receptor-associated factor 6 (TRAF6). 
Overall, AS circulating myeloid populations did not differ in their ability to induce T cell 
proliferation or CCR6/CXCR3 expression compared to their HC counterparts. However, 
co-culture of AS patient and HC CD14- CD16+ mononuclear cells with CD4+ T cells 
induced large quantities of IL-6, required for Th17 differentiation. Furthermore, we failed 
to detect evidence of ER stress upregulation in the circulating myeloid populations of AS 
patients, as has been observed in SpA animal models (481, 520, 522). 
In order to further delineate the immune pathways involved in the development of AS, we 
next set out to correlate AS patient clinical parameters with their immunological profile. 
These correlative analyses are designed to test the effects of therapeutics, disease severity, 
inflammation and existence of extra-articular symptoms, on circulating immune 
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populations. These analyses may aid understanding of disease-associated pathways and 
mechanisms of current therapeutics. 
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Chapter 7: Comparisons between patient 
characteristics and immunological 
parameters 
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7.1 Introduction 
In previous chapters, using clinical samples, differences were identified in the circulating 
myeloid DC and lymphoid populations of AS patients. The clinical attributes of AS 
patients differed in terms of their inflammatory status, treatment strategies, disease 
duration, age, and HLA-B27 status. As each of these factors could influence the patients’ 
immunopathology, it was decided to perform correlative analyses between the patients’ 
clinical attributes and several immunological parameters, as detailed in table 7.2. Due to 
low numbers of HLA-B27+ HCs and HLA-B27- AS patients, the impact of HLA-B27 
expression on disease pathogenesis was not analysed, however, the effects of other clinical 
parameters are assessed in detail. The aim of these analyses was to identify molecules or 
cell populations associated with AS development. Specifically, we set out to determine if 
circulating myeloid populations and T lymphocytes in AS patients were affected by 
specific clinical parameters. Given the involvement of DCs in driving and directing 
immune responses, it was hypothesised that DC populations would be affected by the 
ongoing inflammatory response.  
7.2 Patient Characteristics 
As for previous analyses, clinical factors such as disease score and treatment regimens 
were recorded during clinical consultation. Collated patient and HC data used for the 
correlative analyses are summarised in Table 7.1. The majority of analyses used a 
subgroup of the AS patients described below.  
Table 7.1: Clinical characteristics of AS patients and healthy controls 
All or a subset of the 50 AS patients and 30 HCs were used for correlative analyses. Patient 
characteristics are depicted in Table 7.1. Details for each clinical factor were not available for all 
patients. Subsequently, percentages represent proportion of all patients used in this study. Spinal 
disease was assessed based on the presence or absence of cervical, thoracic and lumbar 
involvement. Levels were categorised based on the number of sites affected: 1 site = level 1, 2 
sites = level 2 and 3 sites = level 3. Mean ± SD is shown. N/A = not applicable. 
 AS Patients 
 
Healthy Controls 
Age (yrs) 54.4 ± 12.3 40.3 ± 12.4 
Sex – Male/Female 39/11 17/12 
Disease Duration (yrs) 28.1 ± 12.5 N/A 
B27 – Pos/Neg (% B27+) 46/4 (92%) 6/23 (26%) 
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BASDAI 4.04 ± 2.24 N/A 
BASMI 4 ± 2.58 N/A 
ESR (mm/hr) 13.27 ± 12.78 N/A 
CRP (mg/L) 6.6 ± 8.76 N/A 
Bilateral Sacroiliitis – No. (%) 68% N/A 
Spinal disease   
    Absent – No. (%) 5 (10%) N/A 
    Level 1 – No. (%) 9 (18%) N/A 
    Level 2 – No. (%) 7 (14%) N/A 
    Level 3 – No. (%) 7 (14%) N/A 
Extra-articular Disease   
    IBD – No. (%) 3 (6%) N/A 
    Uveitis – No. (%) 4 (8%) N/A 
    Psoriasis – No. (%) 3 (6%) N/A 
    Arthritis – No. (%) 8 (16%) N/A 
Medication   
    DMARDs – No. (%) 1 (2%) N/A 
    NSAIDs – No. (%) 24 (48%) N/A 
    Biologics – No. (%) 4 (8%) N/A 
    DMARD + NSAID – No. (%) 4 (8%) N/A 
    DMARD + Biologic – No. (%) 1 (2%) N/A 
    NSAID + Biologic – No. (%) 2 (4%) N/A 
 
Within the patient cohort, approximately 80% were male with an average age of 55 years. 
60% of recruited HCs were male with a slightly lower average age of 40 years. Over 90% 
of AS patients expressed the MHC class I molecule HLA-B27, whilst 26% of the HC 
cohort showed similar expression. Patients presented with average disease scores and low 
levels of inflammation (Table 7.1). Levels below 10 for both inflammatory markers – ESR 
and CRP – are considered normal for the Glasgow population (Dr David McCarey, 
personal communication). Approximately 70% of AS patients presented with bilateral 
sacroiliitis, a characteristic feature of AS (Table 7.1). However, data regarding this disease 
trait was unavailable for 14 patients, whilst 2 individuals did not exhibit evidence of 
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sacroiliitis. Data regarding levels of spinal disease was available for only 23 individuals. 
Of these patients, spinal abnormalities predominantly affected one spinal region, 
commonly the lumbar or cervical areas. Approximately 35% of AS patients presented with 
a minimum of one extra-articular manifestation, with peripheral arthritis being the 
dominant form of affliction (Table 7.1). Data regarding the development of extra-articular 
manifestations was not available for 10 patients. NSAIDs including ibuprofen and 
etoricoxib were the most common form of treatment. Overall, the majority of our patient 
cohort was male and HLA-B27+ with low levels of disease severity and inflammation. 
Correlations between the clinical factors presented in Table 7.1 and several immunological 
parameters (Table 7.2) are discussed below. 
7.3 Correlative analyses 
The immunological parameters listed in Table 7.2 were each compared with the several 
clinical parameters in AS patients: disease treatment and duration, presence of extra-
articular manifestations, age, ESR, CRP, BASFI, BASMI and BASDAI. 
Table 7.2: Immunological parameters assessed for correlative analyses 
Clinical parameters were assessed for their correlation with the immunological factors below: 
Cytokines detected in patient plasma (pg/ml); myeloid cell and T cell populations analysed in 
patient blood; chemokine receptors expressed on the surface of circulating CD4+ T cells; total 
PBMC numbers/ml of blood. 
Cytokines Myeloid cells T cells Chemokine 
receptors 
Others 
IL-1# CD141 CD4+ CCR4 PBMC number 
IL-4 CD1c Naïve CCR6  
IL-5 CD14- CD16+ Memory CCR9  
IL-6 pDC Activated CCR10  
IL-10  Regulatory CXCR3  
IL-17A     
IL-23p19     
Flt3L     
IFN!     
TNF"     
 
For these analyses, all myeloid and T cell populations, except pDCs, were analysed both as 
proportion of parent population and of live cells. pDCs were assessed only as proportion of 
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live cells. Expression of chemokine receptors on memory, activated and regulatory CD4+ T 
cell populations were similarly compared both as percentage of total live cells and of total 
CD4+ T cells. Naïve T cells were not included in chemokine receptor analysis. To 
statistically analyse the patient correlative analyses, linear regression and Kruskal Wallis 
Spearman correlative tests were performed, followed by the Dunn multiple comparisons 
post test. Those showing significance are described in more detail and discussed below.  
7.4 The influence of disease severity 
Many patients are unresponsive to currently available therapeutics, and thus elucidation of 
immunopathogenic pathways may direct future investigations into new therapeutics. 
Therefore, this study set out to identify immunological parameters associated with disease 
severity, treatment regimens and inflammatory status. 
The BASDAI and BASMI scales indicate disease severity, and are evaluated between 0-
10. The patient cohort here presented with low to average scores, averaging approximately 
4 for both measurements. It was hypothesised that changes in disease severity would be 
associated with changes in blood cell populations. Despite not reaching significance 
(p=0.069), a trend towards an increase in the proportion of circulating activated CD4+ T 
cells with increasing disease severity was observed (Fig. 7.1A). In contrast, the proportion 
of naïve T cells decreased significantly with an increase in disease score (Fig. 7.1A). 
Several interesting correlations relating disease severity to chemokine receptor expression 
were also observed. A significant (p=0.015) negative correlation between BASDAI and 
CCR4+ activated T cells (Fig. 7.2A) was seen; as disease severity increased, the 
proportions of circulating CCR4+ CD25int T cells decreased. In addition, the proportion of 
circulating CCR4 expressing memory T cells also fell with higher BASDAI scores (Fig. 
7.2A). In contrast, increased proportions of CCR6+ regulatory T cells (CD25hi) correlated 
with elevated BASMI (p=0.018) and BASFI (p=0.007) scores (Fig. 7.2B). Additional 
analyses revealed that the proportion of CXCR3+ activated T cells also correlated with 
increasing disease severity; elevated BASDAI scores were associated with a larger 
proportion of circulating CXCR3+ activated CD4+ T cells (Fig. 7.2C). These results 
suggest an association between increased disease severity and higher proportions of 
activated circulating T cells with specific chemokine receptor profiles. Analysis of CCR9 
or CCR10 expression did not correlate with disease severity.  
  
 232 
 
Figure 7.1: T cell proportional correlations with disease severity 
Disease severity is associated with a reduction in circulating naïve CD4+ T cells. (A) BASMI scores 
(0-10) were plotted against activated T cells (CD4+ CD25int - left), as proportion of live cells and 
CD4+ CD45RA+ naïve T cells (right) as proportion of T cells for AS patients (n = 14/15). Linear 
regression and spearman correlation statistical test were performed for every correlation. * = p < 
0.05, ns = not significant.   
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Figure 7.2: CD4+ T cell chemokine profile correlations with disease severity 
Disease severity is associated with CCR6+ activated and regulatory T cells. (A) Effect of BASDAI 
(0-10) on CCR4+ activated (left) and memory (right) as proportion of total CD4+ T cells. n = 14-16. 
(B) CCR6+ regulatory T cells, as proportion of live cells were correlated with BASMI (left) and 
BASFI (right) scores. BASFI scores are rated on a scale of 1-10. n = 10-12. (C) BASDAI score (0-
10) association with percentage of CXCR3+ CD25int (activated) T cells as percentage of total T 
cells, n = 10 AS patients. Linear regression and spearman correlation statistical test were 
performed for every correlation. * = p < 0.05, ** = p < 0.01.   
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Correlations between clinical parameters and plasma cytokines reveal that only IL-23p19 
correlated with disease activity, with low levels correlating with increased disease activity. 
Although AS patients had significantly elevated plasma IL-23p19 levels compared to HCs 
(Fig. 4.13D), a significant (p=0.017) negative correlation between elevated BASDAI 
scores and plasma IL-23p19 levels was observed (Fig. 7.3A). To complement this finding, 
BASMI and plasma IL-23p19 levels were similarly negatively correlated, despite not 
reaching significance (p=0.119 – Fig. 7.3A). It therefore appears that patients experiencing 
elevated levels of disease activity have lower levels of systemic IL-23p19. However, only 
10 patients were used for these analyses, indicating a requirement for further investigation. 
Interestingly, higher plasma IL-23p19 levels in AS patients were significantly associated 
with fewer circulating CCR6+ regulatory T cells (p=0.017, Fig. 7.3B).   
7.5 Effect of inflammation on immunological parameters  
The influence of inflammation on immunological parameters including circulating DC and 
T cell populations and plasma cytokines was also investigated. Of all the factors assessed 
(Table 7.2), significant correlations were only observed between levels of inflammation 
and the proportions of specific populations of CCR+ CD4+ T cells. 
Comparison of ESR with the proportion of circulating CCR9+ activated CD4+ T cells in 
AS patients revealed a significant (p=0.004) positive correlation between these parameters 
(Fig. 7.4A). Not only were elevated ESR levels associated with a higher proportion of 
circulating CCR9-expressing activated T cells, but elevated CRP levels also positively 
correlated with increased proportions of CCR9+ activated CD4+ T cells in the blood (Fig. 
7.4A). This CCR9 correlation with CRP was conserved when CCR9+ T cells were 
analysed either as proportion of total T cells (p=0.0001) or of total live cells (p=0.041 - 
Fig. 7.4A). CCR6 expressing cells also correlated with inflammation: in a cohort of 22 
patients, the proportions of CCR6+ activated CD4+ T cells significantly correlated with 
higher ESR levels (Fig. 7.4B). Furthermore, elevated CRP levels positively correlated with 
higher proportions of circulating CCR9+ memory (p=0.028) and regulatory (p=0.022) T 
cell populations (Fig. 7.5A). These data highlight changes to the chemokine receptor 
profile of circulating T cells in patients with more severe systemic inflammation, and 
support a role for CCR9+ T cells in responding to, or driving, inflammatory processes in 
patients with AS.  
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Figure 7.3: Immunological correlations related to disease severity and IL-23p19 
Disease severity is negatively associated with plasma IL-23p19. (A) Levels of plasma IL-23p19, 
measured by ELISA, were plotted against scores of disease severity: BASDAI (left) and BASMI 
(right), n = 10 AS patients. (B) Correlation between CCR6+ CD25hi CD4+ T cells (regulatory) and 
plasma IL-23p19 (pg/ml) levels, n = 12 AS patients. Linear regression and spearman correlation 
statistical test were performed for every correlation. * = p < 0.05, ns = not significant.   
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Figure 7.4: Influence of inflammation on activated CD4+ T cell chemokine profiles 
Elevated levels of inflammation increase proportion of circulating CCR6+ and CCR9+ activated 
CD4+ T cells. (A) Correlation between proportion of circulating CD4+ CCR9+ CD25int (activated) T 
cells and ESR (top left) and CRP (top right) as proportion of CD4+ T cells and as proportion of live 
cells (bottom). n = 16 AS patients. (B) Assessment of ESR and percentage of circulating activated 
CD4+ CCR6+ T cells (CD25int). 22 patients used in analysis. Linear regression and spearman 
correlation statistical test were performed for every correlation. * = p < 0.05, ** = p < 0.01.  
  
0 5 10 15 20
0
1
2
3
4
0 10 20 30 40 50
0
1
2
3
4
0 10 20 30 40 50
30
40
50
60
70
80
A 
%
 o
f C
C
R
6+
 C
D
25
in
t  T
 c
el
ls
 
ESR (mm/hr) 
 Spearman r = 0.50 
p = 0.012 (*) 
ESR (mm/hr) 
%
 o
f C
C
R
9+
 C
D
25
in
t  T
 c
el
ls
 
Spearman r = 0.70  
p = 0.004 (**) 
CRP (mg/L) 
%
 o
f C
C
R
9+
 C
D
25
in
t  T
 c
el
ls
 
Spearman r = 0.83  
p = 0.0001 (***) 
0 3 6 9 12 15 18
0.00
0.05
0.10
0.15
0.20
CRP (mg/L) 
%
 o
f C
C
R
9+
 C
D
25
in
t  (
%
 li
ve
) 
Spearman r = 0.52  
p = 0.041 (*) 
B 
 237 
 
Figure 7.5: CCR9 association with inflammation 
Elevated levels of inflammation increase proportion of circulating CCR9+ memory and regulatory 
CD4+ T cells. (A) Correlation between proportion of circulating CD4+ CCR9+ CD25- (memory) T 
cells and CD4+ CCR9+ CD25hi (regulatory) T cells CRP (mg/L). n = 16 AS patients. Linear 
regression and spearman correlation statistical tests were performed for both correlations. * = p < 
0.05.  
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7.6 Disease treatment protocols and plasma cytokines 
AS patients were administered a diverse range of therapeutics partially dependent upon 
their disease activity level, and thus it was investigated if patient therapeutic regimens 
correlated with the immunological parameters summarised in Table 7.2. Within the patient 
cohort, six treatment groups were identified: NSAIDs, DMARDs, biologics (anti-TNF!), 
or combinations of NSAIDs and DMARDs, DMARDs and biologics, and NSAIDs and 
biologics (Table 7.1). Due to insufficient numbers of samples, the following treatment 
groups were excluded from these analyses: DMARDs; DMARD and biologics; and 
NSAIDS and biologics. Consequently, the effect of DMARD treatment on immunological 
parameters could not be assessed.  
HCs, and patients prescribed NSAIDs had significantly fewer circulating CCR4+ activated 
and memory CD4+ T cells compared to those receiving biological therapy (Fig. 7.6A). No 
other alterations to the cellular immune profile of AS patients were associated with disease 
treatment. As shown in chapter 3, compared to HCs, AS patients had elevated plasma IL-
23p19 and TNF! levels (Fig. 3.13D and 3.14A). Accordingly, patients prescribed NSAID 
therapy had significantly elevated levels of plasma IL-23p19 compared to HCs (p=0.0183, 
Fig. 7.6B). Differences in plasma concentrations of IL-23p19 between HCs and the 
remaining treatment protocols did not reach significance (Fig. 7.6B). Analysis of plasma 
TNF! levels revealed that, compared to HCs, patients receiving biological therapy 
(predominantly adalimumab), had significantly elevated plasma TNF! levels (p=0.0069, 
Fig. 7.6B). No other significant differences were observed. Overall, these results 
complement our plasma cytokine observations and indicate that different therapeutics, 
particularly biological therapy, may be associated with specific plasma cytokine profiles 
and cell populations. 
7.7 Influence of extra-articular disease manifestation 
Approximately 35% of the patient cohort experienced symptoms of extra-articular disease. 
In this study, the development of four common comorbidities was recorded: uveitis, 
psoriasis, IBD, and peripheral arthritis. Due to the small numbers of patients included in 
each of the individual groups, it was decided to categorise the patients into two groups 
based on the presence or absence of extra-articular disease. Of the immunological 
parameters assessed (Table 7.2), only plasma cytokine levels of IL-6 and TNF!, and   
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Figure 7.6: Influence of disease treatment strategies on cytokines and chemokines 
Patients receiving NSAIDs have higher circulating levels of IL-23p19 compared to HCs. (A) 
Analysis of CCR4+ activated (left) and memory (right) T cells, as proportion of live cells, for HCs 
and AS patients. (B) Effect of disease treatment protocols on plasma IL-23p19 (left) and TNF" 
plasma levels (right). Groups analysed: HCs (HC - empty), NSAIDs (N - black), Biological therapy 
(B – blue) and combination therapy consisting of DMARDs and NSAIDs (C – red). One-way anova: 
Kruskal Wallis test with Dunn multiple comparisons performed for statistical analyses. * = p < 0.05, 
** = p < 0.01. 13 HCs, 9 NSAID, 4 biologic and 1 combination treated patients were used for 
analysis in A. Patient numbers used for IL-23p19 analysis: HC = 17, N = 10, B = 2 and C = 2. 
Patient numbers used for TNF" analysis: HC: 27, N = 13, B = 4 and C = 2. Mean + SD. 
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PBMC numbers were significantly associated with the presence or absence of extra-
articular disease. Compared to HCs, patients without extra-articular disease had 
significantly greater numbers of PBMCs/ml of blood (Fig. 7.7A). No difference was 
observed in PBMCs/ml of blood between HCs and patients with extra-articular disease, 
and no significant differences were observed between the patient groups. These results 
support the previous observation that AS patients have a greater number of circulating 
PBMCs compared to HCs. 
Interestingly, patients with extra-articular disease showed significantly elevated plasma IL-
6 and TNF! levels compared to HCs (Fig. 7.7B). Both cytokines were previously observed 
to be upregulated in AS patient plasma (Fig. 4.14A). Additionally, TNF! was significantly 
elevated in patients without extra-articular disease compared to HCs (Fig. 7.7B). Overall, 
patients with extra-articular disease showed elevated levels of the inflammatory cytokines 
IL-6 and TNF! compared to HCs. 
7.8 DC related correlations 
At the outset of this project, it was hypothesised that CD141+ DCs in patients would be 
altered based on our observations in the HLA-B27 TG SpA rat model (480). Comparisons 
between HC and AS patient samples disproved this hypothesis, as no differences were seen 
in the proportions of circulating CD141+ DCs. Despite no observed differences in this DC 
population, some changes were seen in AS patient blood myeloid populations and plasma 
Flt3L levels, and it was subsequently decided to examine whether these were affected by 
patient clinical or immunological parameters. 
Interestingly, a significantly greater proportion of circulating CD141+ DCs, as proportion 
of total live cells, was observed in older patients (n=31, p=0.022 – Fig. 7.8A). No 
correlation was detected between age and CD141+ DCs within the HC cohort (Fig. 7.8A). 
These observations indicate that with increasing age, CD141+ DCs in AS patients represent 
a greater proportion of circulating leukocytes. In accordance, despite not reaching 
significance (p=0.063), a positive correlation was observed in AS patients between disease 
duration and elevated frequencies of CD141+ DCs (Fig. 7.8B). Additionally, the proportion 
of CD141+ DCs among live cells increased with BASDAI scores (Fig. 7.8B). This 
correlation reached significance (p=0.014). Taken together these results suggest that with 
long-term disease and increased disease severity, the proportion of circulating CD141+ 
DCs in patients increases. 
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Given that DCs direct immune response perpetuation through priming of T cells, we set 
out to identify relationships between specific DC populations and the T cell phenotype 
profiles observed in AS patients. It was hypothesised that the observed differences in AS 
patient myeloid populations and T cells would correlate with altered plasma cytokine 
profiles. However, analyses performed disproved this hypothesis (data not shown) - no 
significant relationships between these factors were observed. Unexpectedly, a correlation 
between AS patient CD141+ DCs and circulating CCR6+ activated T cells was observed, 
with increased CD141+ DCs (% of CD11c+ MHC II+) associated with an increase in the 
proportion of activated CCR6 expressing T cells (Fig. 7.8C). This correlation reached 
significance (p=0.016). Additional analyses of correlations between circulating DCs and 
age were performed, and they revealed that the proportion of CD1c+ DCs in AS patients 
also increased with age, although no association with disease duration was observed (Fig. 
7.9A, data not shown). No significant correlation between age and CD14- CD16+ 
mononuclear cells was observed in AS patients (Fig. 7.9A). In contrast, age was observed 
to have no effect on HC circulating CD14- CD16+ and CD1c+ populations (Fig. 7.9B). 
Overall, changes in the proportion of CD141+ DCs appear to correlate with several factors 
in AS patients including age, disease duration and disease severity.  
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Figure 7.7: Influence of extra-articular manifestations on immunological parameters 
AS patients who have developed extra-articular manifestations exhibit elevated plasma levels of IL-
6 and TNF". (A) Comparison of HCs (empty bars), patients without extra-articular disease (-
/hashed bars) and patients with extra-articular manifestations (+/filled bars) were compared 
regarding total PBMC number/ml of blood. Extra-articular manifestations include: IBD, psoriasis, 
uveitis and peripheral arthritis. (B) Plasma IL-6 (left) and TNF" (right) levels were measured in HCs 
and AS patients with or without extra-articular disease. One-way anova: Kruskal Wallis test with 
Dunn multiple comparisons performed for statistical analyses. * = p < 0.05, *** = p < 0.001. For 
analysis, 24-33 HCs, 18-20 patients without extra-articular disease and 9-13 patients with extra-
articular disease were used. Mean + SD.  
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Figure 7.8: Influence of clinical and immunological factors on CD141+ DCs 
CD141+ DCs in AS patients are positively associated with disease severity and age. (A) 
Association between age and circulating CD141+ DCs in HCs (left) and AS patients (right). For 
analysis, 26 HCs and 44 AS patients were used. (B) Effect of disease duration (years - left) and 
BASDAI (right) on proportion of circulating CD141+ DCs in AS patients, as proportion of live cells (n 
= 27-31). (C) Association between % of CD141+ DCs of total CD11c+ MHC II+ cells and % of 
CCR6+ activated T cells. 25 patients used for analysis. Linear regression and spearman correlation 
statistical tests were used to assess significance of correlations. * = p < 0.05, ns = not significant.  
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Figure 7.9: Influence of age on DC populations in AS patient and HCs 
CD1c+ DCs increase with age in AS patients. Correlation between proportion of circulating CD16+ 
mononuclear cells (left) and CD1c+ DCs (right) with age (years) in AS patients (A) and HCs (B). 
For all analyses, 42 AS patients and 25 HCs were used. Linear regression and spearman 
correlation statistical test were performed for every correlation. * = p < 0.05, ** = p < 0.01.  
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7.9 Discussion  
The focus of this PhD project was to understand the role of DCs in AS pathogenesis. With 
only slight differences noted in the proportions of circulating DC populations between AS 
patients and HCs, other cell types were also investigated, including T cells and monocytes. 
Subsequently, differences in the T cell chemokine receptor and plasma cytokine profiles of 
AS patients were identified. To fully comprehend the relationships between the observed 
altered immunological profiles and disease development, there is a need to understand how 
immunological parameters and patient clinical characteristics are related (Table 7.2). 
Consequently, the impact of several clinical and immunological parameters was assessed 
on circulating cell populations and plasma cytokine levels in patients.  
Comparison of the HC and AS patient cohorts revealed several disparities. Approximately 
15 years separated the average ages of the AS patient and HC cohorts and analyses 
presented here suggest that age influences immunological parameters. Furthermore, there 
was an unintentional bias towards female and HLA-B27+ individuals within the HC cohort. 
As AS is predominantly associated with a young male population, this HC cohort does not 
sufficiently replicate this gender bias. Furthermore, the proportion of HLA-B27+ HC 
individuals is five times that of the general Caucasian population (508). The institutional 
ethics required HCs to be recruited from within the Institute of Infection, Immunity and 
Inflammation at the University of Glasgow. This resulted in a limited pool of eligible 
candidates. Consequently differences in age, gender and HLA-B27 expression should be 
considered when directly comparing HC and AS patient cohorts.  
Most patients were treated with NSAIDs. Only 8% of patients received biologics, 
predominantly anti-TNF!. Compared to HCs, patients receiving biological therapeutics 
had elevated levels of plasma TNF! (Fig. 7.6B). This observation could suggest that 
TNF!, a marker of inflammation, could be used to assess progression between treatment 
regimens. Following etanercept treatment in AS patients, ex vivo stimulated cells have 
been shown to be capable of enhanced TNF! secretion (562, 680). Longitudinal studies 
could be performed to assess patient immunological responses to different treatment 
strategies, including naïve patients who have not yet experienced therapeutic benefit. 
Unfortunately, no treatment-naïve patients were recruited during this study. Information 
regarding medication prescribed to HCs was not recorded, and thus due to the prevalence 
of NSAIDs it is possible that HCs at time of recruitment were actively self-administering 
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NSAIDs. It would therefore be useful to record such details for HCs recruited to future 
studies to further elucidate the effect of NSAIDs.  
Disease severity, determined by degree of joint pain, stiffness and fatigue might be 
influenced by numerous factors including current therapeutics and development of extra-
articular manifestations. Patients with higher levels of disease severity tended to have a 
greater proportion of circulating activated T cells, with fewer expressing CCR4 (Fig. 
7.2A). The chemokine receptor profile of these circulating T cells was additionally altered 
in AS patients in terms of CCR6 and CXCR3. Blood CCR6+ regulatory (Fig. 7.2B) and 
CXCR3+ activated CD4+ T cells (Fig. 7.2C) were observed to increase with disease score. 
CD4+ T cells are thought to contribute to human pathogenesis and are essential for disease 
development in HLA-B27 TG rats (181, 470, 471, 495, 530). A greater proportion of 
circulating activated T cells may indicate enhanced clonal expansion, and these activated T 
cells propagate immune responses and therefore potentially contribute to disease 
pathogenesis. These observations could indicate that T cell migration patterns change 
during disease. Alternatively, given that chemokine receptors are associated with specific 
T cell phenotypes, CCR6 with Th17, CCR4 with Th2, and CXCR3 with Th1, these results 
may imply skewing of the CD4+ T cell response during disease development. These 
associations imply that Th1 effector cells and CCR6+ Tregs may contribute to disease 
progression and pathogenesis. These results are consistent with previous publications 
regarding the involvement of Th1 cells in disease development (526, 527, 532). However, 
as only 14 patients were included in this analysis, it will be important to corroborate these 
results using a larger cohort. That being said, the correlation between increased disease 
severity and proportions of CCR6+ regulatory T cells was observed using both BASMI and 
BASFI assessments (Fig. 7.2B), adding credence to this particular observation. Overall, 
these results suggest that CCR6, CCR4 and CXCR3 expressing CD4+ T cells may be 
contributing to AS pathogenesis. 
The idea that T cell migration changes in AS is supported by the observation presented in 
chapter 5 that AS SF-resident T cells predominantly express CCR4 and CCR6 (Fig. 5.6B). 
Thus, enhanced migration of activated CCR4+ T cells to tissues including SF and skin, 
could account for the observed decrease in the proportion of circulating CCR4+ cells. The 
opposite appears to be true for CCR6 expressing cells; elevated BASMI and BASFI scores 
were associated with a greater proportion of circulating CCR6+ regulatory T cells. Changes 
to the systemic inflammatory environment and location of T cell priming associated with 
increased disease severity may affect the chemokine receptor profile of circulating T cell 
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populations. CCR4 mediates skin migration of infiltrating leukocytes, whilst CXCR3 aids 
leukocyte entry into inflamed tissues (173, 175, 182, 183, 614, 627).  
CCR6 is involved in directing migration of lymphocytes to the intestine. It is expressed on 
Th17 cells, with the largest population of tissue resident Th17 cells in mice located within 
the intestine (681, 682). Additionally, resident Th17 populations have been identified in 
human intestinal tissue (683). However, Th17 cells have not been demonstrated to play a 
role in AS intestinal pathogenesis, and indeed Ciccia et al found IL-17 not to be associated 
with subclinical intestinal inflammation in AS patients (551). Nevertheless, the increase in 
CCR6 expression among CD4+ T cells may implicate the intestine in AS pathogenesis. To 
assess this proposal, investigation of intestinal homing markers not analysed in this study, 
including !4"7, would be important. Furthermore, it would be interesting to categorise 
patients based on their specific extra-articular disease manifestations, enabling 
identification of the origins of T cell priming associated with specific disease phenotypes. 
As described previously, elevated IL-23p19 levels in AS patient plasma were observed 
compared to HCs (Fig. 4.13D). The recent literature suggests a high association between 
AS, Th17 cells and the IL-23R (39, 181, 495, 538, 684). It was therefore interesting that 
patients with higher BASDAI and BASMI scores generally had low levels of plasma IL-23 
(Fig. 7.3A), suggesting a degree of IL-23-mediated protection, despite the requirement for 
IL-23 in the maintenance of Th17 cells (112), believed to be pathogenic in AS. 
Surprisingly, AS patients with highest systemic levels of IL-23p19 had low levels of 
circulating CCR6+ regulatory T cells (Fig. 7.3B). These correlative data suggest that the 
protection afforded by IL-23 is not mediated through induction/function of CCR6+ Tregs. 
Although, inflamed patients exhibited a higher proportion of circulating CCR6+ activated 
T cells (Fig. 7.4B), insinuating their involvement in the perpetuation of systemic 
inflammation in AS patients. 
Several experimental considerations need to be taken into account when determining the 
role of IL-23 in disease development: levels of detectable IL-23p19 in AS patient and HC 
plasma were very low (<30pg/ml) and may be below level of accurate detection (Fig. 
4.13D), and only 10 patients were available for analysis (Fig. 7.3). Therefore it will be 
important to further assess the influence of disease severity and inflammation on plasma 
IL-23p19 and CCR6+ CD4+ T cells using a larger patient cohort. However these 
correlations allow us to draw several conclusions: IL-23 may in fact be protective through 
inhibition of disease progression; IL-23 in AS may not function to maintain Th17 cells in 
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vivo; and inflammation in AS patients may be perpetuated by CCR6+ activated T cells or 
may be driven from mucosa-associated tissues. 
While the aetiology of AS remains unclear, there are clear associations between the 
intestinal environment and the development of disease. HLA-B27 TG rats raised in germ-
free conditions do not develop SpA-like symptoms (444). There is also a strong association 
between IBD and AS (4, 13). Correlative analyses between clinical and immunological 
parameters have provided support for this hypothesis. For instance, it was observed that 
elevated frequencies of circulating CCR9+ cells were associated with increased ESR and 
CRP levels (Fig. 7.4A). This observation held true for circulating activated, memory and 
regulatory CCR9+ CD4+ T cell populations (Fig. 7.4 and 7.5). These correlations strongly 
suggest an association between inflammation and circulating CCR9+ CD4+ T cell 
populations. Activation of T cells by intestinal DCs preferentially induces CCR9, 
important for intestinal homing of activated T cells (171). The association between CCR9 
and markers of inflammation indicate that systemic inflammation may be initiated from the 
intestine. It would therefore be interesting to group patients depending on their extra-
articular disease symptoms and assess their chemokine receptor expression profiles. These 
analyses would determine whether CCR9 involvement was specific to AS IBD sufferers or 
involved in systemic AS disease pathogenesis. The cohort here did permit categorisation of 
patients based on the presence or absence of extra-articular involvement. No AS patients 
with IBD were included in the correlative analyses relating CCR9, ESR and CRP, 
suggesting that the association between CCR9 and inflammation may not be specific to AS 
IBD sufferers, and therefore may be characteristic of the general AS population. 
Furthermore, analyses of gut-resident immune populations, specifically DCs and T cells 
may elucidate the role and function of these intestinal populations in driving systemic 
disease. It may therefore be of interest to investigate circulating CCR9+ populations to 
elucidate any potential role for the intestine in disease initiation and development.  
These observations, and published studies, suggest that ESR and CRP do not correlate with 
disease activity in AS patients (685, 686). Therefore it is perhaps unjust to directly 
compare disease activity with levels of systemic inflammation with relation to 
immunological parameters. Biological molecules including cytokines and growth factors 
may be more representative of disease severity. IL-6 is an attractive candidate for such a 
biological disease marker, with lower plasma IL-6 levels correlating with reduced disease 
score in AS (525, 561, 687). However, no correlations were detected between ESR, disease 
severity and IL-6 in this study.  
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Immunological correlations associated with different treatment regimens may identify the 
modes of action of current therapeutics, or the immunological processes involved in 
disease activity. Dombrecht et al observed reduced circulating activated CD4+ T cells 
following anti-TNF! treatment (622). However, no correlations between treatment 
regimens and T cell proportional parameters were detected. Despite the fact that no 
difference was observed between AS patients and HCs in the circulating CCR4+ T cells 
subsets (Fig. 4.7), anti-TNF! treated patients had a significantly higher proportion of 
CCR4+ activated and memory CD4+ T cells compared to HCs and NSAID treated patients 
(Fig. 7.6A). The increase in CCR4+ activated and memory T cells in anti-TNF! treated 
patients could reflect a change in the cytokine milieu, thereby promoting a shift in the 
balance towards the CCR4 associated Th2 phenotype. However, no elevated levels of IL-4 
and IL-5 were detected to support this idea (Fig. 4.13C). In fact, no significant reductions 
in plasma cytokines were observed following anti-TNF! therapy. These results suggest 
that biological therapy (anti-TNF!) may increase circulating CCR4+ T cell populations, 
although further investigation is required given that a maximum of 4 patients were 
included in the biological group. To fully address the mode of action for these varied 
regimens, comparison with naïve patients would be beneficial. 
As previously discussed, categorisation of patients according to extra-articular disease 
status may illuminate pathogenic processes. The cohort contained only 50 AS patients, 
preventing comprehensive analyses of individual extra-articular disease manifestations. It 
was possible, however, to analyse patient groups defined by the presence or absence of 
extra-articular symptoms. Interestingly, plasma IL-6 and TNF! levels were elevated in 
patients with extra-articular disease (Fig. 7.7B). These results indicate that patients with 
extra-articular disease have a higher degree of systemic inflammation than HCs and AS 
patients with only spinal disease. Conversely, patients without extra-articular involvement 
had more PBMCs per ml of blood compared to HCs (Fig. 7.7A). These results suggest that 
the immunological profiles of patients with and without extra-articular disease may be 
different.  
As described above, the initial hypothesis was developed from the observation that the rat 
DC analogue of the human CD141+ DC population was absent from HLA-B27 TG animals 
(480). However, no difference in the proportion of circulating CD141+ DCs was observed 
in AS patients compared to HCs (Fig. 3.4A). However, direct comparisons between human 
blood and rat intestinal findings may be inappropriate given the differences in cell origin 
and function between human blood DCs and their counterparts in rat tissues. Therefore, in 
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future, the aim is to examine CD141+ DCs in patient intestinal tissue. In the correlative 
analysis, several CD141+ DC associated observations were identified. Interestingly, AS 
patients have a higher proportion of CD141+ and CD1c+ DCs as they age (Fig. 7.8A and 
7.9A). Similar correlations in HCs were not observed (Fig. 7.8A and 7.9B). Additionally, 
elevated disease scores (BASDAI) were associated with higher proportions of circulating 
CD141+ DCs (Fig. 7.8B). Taken together, these results suggest that the proportion of 
CD141+ DCs increases with disease progression. Recent evidence suggests that CD141+ 
DCs in the skin may be tolerogenic, secreting IL-10 and inducing Tregs (332). CD141+ 
DCs may therefore increase in AS patients as disease progresses to control pathogenic T 
cell responses. Alternatively, AS CD141+ DCs may promote disease activity. It should be 
noted however that correlations between inflammation, Flt3L concentrations and CD141+ 
DCs were not observed (data not shown). In future, functional investigations of this subset 
in HCs and AS patients may be fundamental to understanding disease pathogenesis.  
To address the biological consequence of CD141+ DCs in disease pathogenesis, 
correlations between immunological parameters and CD141+ DCs were examined. 
Interestingly, an increase in CD141+ DCs was associated with a higher proportion of 
circulating CCR6+ activated CD4+ T cells (Fig. 7.8C). This observation might indicate that 
CD141+ promote CCR6+ T cell responses. As IL-17-secreting Th17 cells predominantly 
express CCR6 (Fig. 4.10D), CD141+ DCs in AS patients could promote disease 
development through this pathogenic subset. However, AS patient blood CD141+ DCs did 
not differ in their ability to induce T cell proliferation or CCR6 compared to HCs (Fig. 
6.2C and 6.5A). To establish if a direct relationship exists between CCR6+ activated T 
cells and CD141+ DCs, DCs isolated from peripheral/extra-articular tissue should be 
assessed for their ability to induce T cell proliferation and chemokine receptor induction. 
In conclusion, several correlations between clinical parameters and the immunological 
profile of AS patients have been identified. Of note, elevated inflammatory markers were 
associated with greater proportions of circulating CCR9+ activated T cells suggesting 
intestinal involvement in inflammatory processes. Th17 cells may be involved in disease 
perpetuation; elevated proportions of CCR6+ regulatory cells correlate with disease 
severity. However the role of plasma IL-23p19 appears to be more complicated than was 
initially imagined. Interestingly, the proportion of AS patient CD141+ DCs increased with 
age, disease duration and disease severity suggesting CD141+ DC involvement in late stage 
disease. It is therefore important to establish the function of this population in AS. 
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Following observations that intestinal migrating DC populations were altered in SpA rats, 
and the strong association between CCR9 expression and intestinal inflammation in AS 
patients, I set out to establish techniques to isolate and functionally analyse DC and T cell 
subsets from human intestinal specimens. Following optimisation of these protocols, the 
aim is to apply these techniques to intestinal biopsy samples from AS patients, in order to 
better understand the connections between the intestine and disease development. 
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Chapter 8: Intestinal Phagocytes 
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8.1 Introduction 
Diseases belonging to the SpA family, including AS, PsA and ReA (688) share many 
genetic and pathophysiological factors. AS, like other SpA family members, is often 
associated with development of extra-articular clinical manifestations including uveitis, 
psoriasis, arthritis and IBD (4, 619, 620, 688). The link between AS and intestinal 
pathology is particularly strong. For instance, it has been shown that approximately 50% of 
Crohn’s patients expressing HLA-B27 eventually develop AS (4, 440). In addition, 
approximately 50% of AS patients not clinically diagnosed with CD have subclinical 
intestinal inflammation, detectable at colonoscopy (4, 13, 441). These studies suggest a 
connection between the intestine and AS pathogenesis, and are supported by experiments 
using HLA-B27 TG animals where germ-free animals fail to develop SpA symptoms 
(444). In addition, the Milling lab has previously shown that HLA-B27 TG rats lack a 
subset of ‘tolerogenic’ CD11bint CD103+ CD172alo intestinal DCs and that this absence 
correlated with exaggerated Th17 type responses (480). Therefore, understanding the link 
between intestinal inflammation and AS may provide information that will facilitate the 
generation of effective, targeted therapies.  
DCs are the bridge between innate and adaptive immunity, and are directly responsible for 
inducing tolerance towards self-antigens and commensal bacteria, whilst directing robust 
protective immunity against harmful pathogens. When these processes become 
dysregulated in genetically susceptible individuals, aberrant responses directed against 
commensal bacteria may develop, resulting in the development of IBD including CD and 
UC (689). Previous studies have implicated mononuclear phagocytes (MP) with altered 
behaviour in the development of IBD (225, 425, 690-693). Specifically, these studies have 
identified altered activation status, TLR expression, cytokine secretion, NOD2 
polymorphisms and NF'B dysregulation of MP of IBD patients (225, 234, 403, 404, 427, 
692, 694-697). However it should be noted that many of these studies simply used co-
expression of CD11c and MHC II to identify intestinal DCs, an approach now considered 
insufficient for distinguishing between different MP populations in most non-lymphoid 
tissues (225, 234). This is due to the realisation that many surface markers regarded as 
‘DC-specific’, such as CD11c and MHC II, are in fact expressed by multiple cell types 
including tissue macrophages. For example, although ‘pro-inflammatory’ MHC II+ 
CD172a+ “DCs” have been suggested to accumulate in the colonic mucosa of Crohn’s 
patients (698), macrophages were not excluded from these analyses and thus it remains 
unclear whether these truly represent bona fide DC. In contrast to IBD where intestinal 
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‘DCs’ have been studied, intestinal DCs in AS patients have not been investigated. This is 
somewhat surprising given the strong association between intestinal inflammation and AS. 
Recent data indicate that the addition of antibodies specific for CD64 enable rigorous 
discrimination of tissue macrophages from DCs in both mouse and man (225, 234). 
However, to the best of my knowledge, this method of discrimination and DC 
identification has not yet been applied to the setting of human IBD. Therefore we aimed to 
apply this identification strategy in an attempt to understand more fully the role of 
intestinal DCs in AS development. Specifically, our objective was to identify any 
phenotypic and/or functional differences in DC subsets isolated from AS patient intestinal 
tissue, or alterations in their abundance compared to those in HCs. Unfortunately, during 
the course of my PhD I did not receive any intestinal samples from HLA-B27+ or HLA-
B27- AS patients. However with the tissue samples we did receive, I developed methods to 
characterise intestinal cDC, macrophage and T cell populations from HCs and IBD 
patients. I developed efficient purification techniques and performed precise phenotypic 
analyses. These will be applied to AS patient intestinal samples in the future, with the aim 
of understanding the link between intestinal inflammation and AS pathogenesis. 
8.2 Patient characteristics 
Intestinal tissue samples were provided by and collected from the Biorepository NHSGGC 
at the Southern General Hospital. All tissue samples were processed within 3 hours 
following surgery. Several patient characteristics were provided for every fresh tissue 
sample and are detailed in Table 8.1. 
Table 8.1: Patient characteristics for intestinal tissue specimens 
In total, 15 intestinal tissue samples were processed for analysis. Surgical resections included 
specimens of colonic and small intestinal tissue. Health status refers to whether the processed 
tissue specimen was healthy (normal) or diseased. Diseased tissue was isolated from patients 
suffering from CD or UC. 
Tissue Type Health Status Sample No. Sex (M/F) Average age (yrs) 
Colon Normal 9 5/4 65.1 
 Diseased 4 2/2 35.5 
Small Intestine Normal 2 0/2 60.5 
 Diseased 0 N/A N/A 
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The majority of samples processed were colonic surgical resections from male HCs 
undergoing surgery to remove tumour tissue. The average age for HC tissue collection was 
>60yrs for both tissue types. Diseased patients tended to be younger with an average age of 
35.5yrs. Three of the four diseased colonic tissue samples were isolated from UC patients 
and the remaining patient suffered from CD. Approximately 80% of HC individuals were 
suffering from intestinal adenocarcinoma. Unfortunately, we did not receive any inflamed 
SI samples, meaning that I could not carry out a direct comparison of the inflammatory 
infiltrate present in the small intestinal lamina propria (SILP) versus the colon. In the end, 
the majority of tissue samples were utilised for the optimisation of tissue digestion 
protocols in order to achieve high cell yields and viability, and to avoid enzymatic 
cleavage of specific surface markers. 
8.3 Isolation of intestinal phagocytes    
Published protocols to isolate mononuclear populations from human intestinal tissue vary 
greatly. Several groups use “walk-out” assays, where migratory cells leave intact intestinal 
tissue following overnight culture at 37°C (405, 699, 700). However, the majority of 
investigators enzymatically digest tissue to isolate specific populations, although the 
enzyme cocktails used differ dramatically (225, 427, 690). Within our department, the 
laboratory group led by Professor Allan Mowat have developed and refined protocols for 
the enzymatic digestion of intestinal tissues in mice. Therefore, we initially assessed the 
suitability of these protocols for the isolation of DCs and macrophages from human 
intestinal samples. To begin with, we used a combination of collagenase V (0.85mg/ml), 
collagenase D (1.25mg/ml), dispase (1mg/ml) and DNase (0.03mg/ml), which is used 
routinely by the Mowat laboratory to isolate murine colonic leukocytes. Following 
epithelial layer removal, tissue was digested until completely disintegrated. Remaining 
cells were subsequently analysed using flow cytometry to identify cDC subsets. To 
identify intestinal (colonic) cDCs, a gating strategy similar to that for blood DC 
characterisation was adopted (Fig. 8.1A). Firstly, cell debris and aggregates were gated out 
using their FSC and SSC properties (Fig. 8.1A). Intestinal leukocytes were then identified 
amongst live colonic isolates by their expression of the common leukocyte antigen, CD45 
(Fig. 8.1A).  T- and B-lymphocytes, as well as neutrophils and NK cells were gated out by 
selecting leukocytes lacking the lineage (LIN) markers CD3, CD15, CD19 and CD56 (Fig. 
8.1A). LIN- cells were further assessed for the expression of CD14, and CD14+ cells were 
excluded from cDC analysis as CD14 has been shown to identify cells of the 
monocyte/macrophage lineage (225, 425, 427, 691). Following exclusion of CD14+ cells, 
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live CD45+ LIN- CD14- cells were analysed for co-expression of CD11c and MHC II (Fig. 
8.1B). This revealed a distinct population of CD11c+ MHC II+ cells in which DC subsets 
could be identified on the basis of CD141 and CD1c expression (Fig. 8.1B and 8.1C).  
Because tissue samples were routinely delivered late in the afternoon, we wanted to assess 
the feasibility of storing the tissue overnight and performing the isolation and analysis the 
following day. We therefore stored whole tissue overnight at 4°C, digested the following 
day and assessed the viability of the LP isolates retrieved (Fig. 8.1C). Although the 
viability of isolated cells after overnight storage was satisfactory, CD141+ DCs could not 
be detected (data not shown). Therefore, in all subsequent analyses we performed digestion 
of intestinal tissue immediately upon collection.   
However it became apparent that several markers used in blood cDC and monocyte 
analysis were not expressed on cells isolated from intestinal tissue using the protocol 
(digest A) described above. For example, expression of CX3CR1 by intestinal 
macrophages (7AAD- CD45+ LIN- MHC II+ CD14+) isolated from the duodenum of a HC 
was surprisingly low given that these cells have been reported to express high levels of this 
chemokine receptor (Fig. 8.2A) (427, 701). In addition, CD16+ cells could not be detected 
within the 7AAD- CD45+ LIN- CD14- CD11c+ MHC II+ population, but were abundant in 
the same population in blood (Fig. 8.2B). However, it should be noted that despite their 
absence amongst CD11c+ MHC II+ DCs, CD16+ cells could be detected amongst total 
leukocytes (Fig. 8.2C and 3.1A). Indeed, healthy duodenal tissue appeared to contain 
CD45+ LIN+ CD16+ and CD45+ LIN- CD16+ cell populations, when compared with a 
CD16 FMO (Fig. 8.2C). To determine whether the absence of specific markers was the 
result of enzymatic cleavage, expression of CX3CR1 and CD16 by freshly isolated 
PBMCs was compared with PBMCs that had been incubated for 45 minutes in the 
presence of the digestive enzymes (Fig. 8.2D and 8.2E). In contrast to freshly isolated 
PBMCs, CX3CR1 expression on DAPI- LIN- CD14+ cells was absent on PBMCs 
following enzymatic digestion (Fig. 8.2D). Within circulating DAPI- LIN- CD14- CD11c+ 
MHC II+ cells, CD14- CD16+ mononuclear cells could be detected. However following 
enzymatic digestion, expression of CD16 on this population was degraded (Fig. 8.2E). We 
concluded that the enzymatic cocktail (digest A) including collagenase V, collagenase D, 
dispase and DNase caused loss of CD16 and CX3CR1 from the surface of cell populations.  
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Figure 8.1: Initial gating strategy for identification of intestinal phagocyte subsets 
Isolation of intestinal phagocytic subsets from HCs using digest A. (A) Colonic tissue was digested 
using digest A: Collagenase V (0.85mg/ml), Collagenase D (1.25mg/ml), Dispase (1mg/ml) and 
DNase (0.03mg/ml). Gating strategy to identify intestinal phagocytes: - After gating out cell debris, 
single cells were selected by their FSC-A vs FSC-H profile and dead cells were excluded with live 
CD45+ cells used for further analysis. Lineage+ (CD3, CD15, CD19 and CD56) cells were excluded. 
LIN- cells were subdivided on CD14 expression. cDC and macrophage subsets were identified in 
colonic tissue processed immediately (B) or 24 hours later (C). DAPI- CD45+ LIN- CD14- CD11c+ 
MHC II+ cells contained CD141+ and CD1c+ subsets. DAPI- CD45+ LIN- CD14+ CD11c+ MHC II+ 
cells are intestinal macrophages, subdivided into CD14lo and CD14hi populations. 
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Figure 8.2: Cleavage of CX3CR1 and CD16 by enzymatic digestion  
CX3CR1 and CD16 markers were cleaved following enzymatic digestion with digest A: collagenase 
V (0.85mg/ml), collagenase D (1.25mg/ml), dispase (1mg/ml) and DNase (0.03mg/ml). (A) 
CX3CR1 expression on live CD45+ LIN- MHC II+ CD14+ cells isolated from duodenal tissue. Isotype 
(filled histograms), markers (red). (B) CD16 expression on total HC duodenal DCs (Live CD45+ 
LIN- CD14- CD11c+ MHC II+). (C) Total 7AAD- CD45+ cells were subdivided on LIN and CD16 
expression (right). CD16+ populations were identified based on the CD16 FMO.  (D) Expression of 
surface CX3CR1 on PBMCs freshly isolated (left) or following enzymatic digestion (right). Live 
(DAPI-) LIN- CD14+ cells were used for analysis (E) CD16 expression on DAPI- LIN- CD14- CD11c+ 
MHC II+ cells freshly isolated (left) or after enzymatic digestion (right).  
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These results prompted us to adapt the original enzymatic digestion protocol. We next set 
out to test the suitability of two other enzyme cocktails: collagenase D together with 
DNase (digest 1), and liberase plus DNase (digest 2 - Fig. 8.3). We incubated PBMCs with 
each enzyme mix and then assessed CX3CR1 expression. Unlike in previous experiments, 
CX3CR1 on total live cells was expressed at similar levels under all conditions (Fig. 8.3A). 
Furthermore, all subsets of DCs (CD141+ cDCs and CD1c+ cDCs), as well as CD14- 
CD16+ mononuclear cells could be identified amongst total live LIN- CD14- CD11c+ MHC 
II+ cells (Fig. 8.3B). It should be noted however that marginal CD16 cleavage was 
apparent following enzymatic digestion (digests 1 and 2 – Fig. 8.3B). To further assess 
cleavage of CD16, total 7AAD- cells were analysed for expression of the monocyte 
markers CD14 and CD16 (Fig. 8.3C). CD14+ CD16- and CD14+ CD16+ monocyte 
populations were present under all conditions. However, a small population expressing 
highest levels of CD16 could not be detected following digestion with liberase and DNase 
(digest 2 – Fig. 8.3C). This observation was further confirmed when analysing total live 
cells for expression of CD16 and CD11c (Fig. 8.3D). Based on these results, we decided to 
test whether the digest 1 enzyme cocktail (collagenase D (1mg/ml) and DNase 
(0.03mg/ml)) was sufficient for digesting colonic tissue. Unfortunately, this enzyme 
cocktail failed to efficiently digest tissue. Therefore, in a final attempt to find a suitable 
enzyme cocktail, collagenase D and DNase was supplemented with collagense VIII 
(1mg/ml) and dispase (1mg/ml - referred to as digest B). This new enzyme cocktail 
efficiently digested intestinal tissue and CD16 expression did not fall following digestion, 
compared to the initial enzyme digest formula (digest A - Fig. 8.4A). For example, 0.988% 
of live CD45+ cells expressed CD16 and LIN (digest B), compared to just 0.0763% using 
the initial protocol (digest A). Using this optimised enzyme combination, we set out to 
ascertain the presence of CD14- CD16+ mononuclear cells within extra-articular tissues, 
given the dubiety regarding their classification and function as previously described 
(Chapter 3). Very few LIN- CD16+ cells were observed within healthy colonic tissue 
(0.026%), leading us to conclude that CD11c+ MHC II+ CD14- CD16+ mononuclear cells 
were largely absent from intestinal tissue (Fig. 8.4A). Unfortunately, CX3CR1 expression 
on cDCs, as well as CD14+ MHC II+ cells, did not differ between the two digestion 
protocols (Fig. 8.4B). Therefore, we cannot exclude the possibility that our adapted 
enzyme protocol (digest B) cleaves CX3CR1 from the cell surface. In addition to CD16 
and CX3CR1 expression, we analysed expression of CD64 and CD11c on total cDCs and 
CD14+ MHC II+ macrophages (Fig. 8.4C and 8.4D). Expression of CD64 (Fig. 8.4C) and 
CD11c (Fig. 8.4D) did not differ between digestion protocols. All populations expressed 
relatively high levels of CD64 (Fig. 8.4C) and CD11c (Fig. 8.4D). Based on our findings,   
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Figure 8.3: Marker expression is dependent on enzymatic digestion conditions 
Freshly isolated PBMCs or PBMCs digested with digest 1 (collagenase D (1mg/ml) and DNase 
(0.03mg/ml, centre)) or digest 2 (liberase (0.4WU/ml) and DNase (0.03mg/ml, right)) were 
examined for CX3CR1 and CD16 expression. (A) Total live (7AAD-) cells were analysed for 
CX3CR1 and MHC II expression. (B) Blood DCs (7AAD- LIN- CD14- CD11c+ MHC II+) were divided 
based on CD141 and CD16 expression. (C) Live (7AAD-) cells were assessed for CD14 and CD16 
expression to identify monocyte subsets. (D) Total live cells were analysed for CD16 and CD11c 
expression to identify PBMC CD16+ subsets. 
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Figure 8.4: Surface marker expression following enzymatic digestion 
Colonic macrophage and cDC populations were analysed for the expression of CD16, CX3CR1, 
CD64 and CD11c under different enzymatic digestion conditions. Digest A (red) involves 
collagenase V (0.85mg/ml), collagenase D (1.25mg/ml), dispase (1mg/ml) and DNase (0.03mg/ml). 
Digest B (blue) includes the following enzymes: collagenase VIII, collagenase D, dispase and 
DNase. (A) Total 7AAD- CD45+ cells amongst colonic isolates were assessed for LIN (CD3, CD15, 
CD19 and CD56) and CD16 expression. Percentages reflect proportion of parent population. Total 
live CD45+ LIN- CD14+ MHC II+ macrophages (left) and CD14- cDCs (right) were analysed for the 
expression of CX3CR1 (B), CD64 (C) and CD11c (D) under the different enzymatic digestion 
conditions. CD11c- cells (grey histogram) were used as a control population.   
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we decided to use our digest B enzyme cocktail (collagenase D, collagenase VIII, dispase 
and DNase) in all subsequent experiments involving human intestinal tissue, despite the 
uncertainty relating to CX3CR1 expression.  
CD14- CD16+ mononuclear cells in blood express SLAN and so to verify our original 
observation that CD14- CD16+ mononuclear cells are essentially absent from healthy 
human intestinal mucosa, total single live CD45+ cells were analysed for the expression of 
SLAN (Fig. 8.5A) and CD16 (Fig. 8.5B). Very few SLAN+ cells could be identified, some 
of which expressed CD11c and MHC II. No clear populations could be identified from the 
FSC-A and SSC-A profile, suggesting that the few apparent SLAN+ cells may have been 
dead or the product of non-specific antibody binding (Fig. 8.5A). Furthermore, despite the 
identification of two populations expressing CD16 (Fig. 8.5B), neither population appeared 
to contain genuine CD16+ mononuclear cells. The LIN- CD16+ population did not express 
CD11c and MHC II while the LIN+ CD16+ population appeared to be granulocytic, based 
on its FSC-A and SSC-A characteristics (Fig. 8.5B). Our results suggest that CD14- CD16+ 
mononuclear cells are rare in steady state human intestine.  
During these experiments, it became evident that exclusion of cells expressing LIN 
markers was not required for identification of intestinal cDCs. Therefore a revised gating 
strategy was used in the following experiments. This involved the exclusion of cell debris, 
doublets and dead cells as previously described, before selecting CD45-expressing 
leukocytes, which were subsequently analysed for expression of CD14 to exclude 
macrophages (Fig. 8.6A). Live CD45+ CD14- cells that co-expressed CD11c and MHC II, 
at this point were considered cDCs. However, to assess contamination of this population 
with LIN+ (CD3, CD15, CD19 and CD56) cells, 7AAD- CD45+ CD14- CD11c+ MHC II+ 
cells were assessed for expression of LIN and MHC II, and back-gated on total 7AAD- 
CD45+ cells (Fig. 8.6B). The gate confirms that all cDCs are contained within the LIN- 
population. Consequently, LIN markers were no longer required and were not included in 
subsequent cDC analyses. 
8.4 Identification of intestinal cDCs 
Following development of the digestion and staining protocols, we set out to identify cDC 
populations in human intestinal samples. Comparisons between mouse and human DC 
subsets to date have suggested that mouse CD103+ CD8+ DCs may be equivalent to 
CD141+ human DCs, whereas CD1c+ cDCs correspond to mouse splenic CD4+ DCs   
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Figure 8.5: Identification of CD14- CD16+ intestinal mononuclear cells 
CD14- CD16+ mononuclear cells do not enter colonic mucosa under steady state conditions. (A) 
Single 7AAD- CD45+ cells were analysed for expression of LIN (CD3, CD15, CD19 and CD56) and 
SLAN. SLAN+ LIN- cells were assessed for expression of CD11c and MHC II (centre), and FSC-A 
and SSC-A profiles (right). Percentages represent proportion of parent population. (B) Total single 
live CD45+ leukocytes were analysed for the expression of LIN and CD16. LIN- CD16+ cells were 
analysed for expression of CD11c and MHC II (centre). LIN+ CD16+ cells were back-gated on FSC-
A and SSC-A (right). Data from a single experiment using colonic tissue isolated from one HC.  
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Figure 8.6: Lineage exclusion not required for the identification of intestinal cDCs 
Live CD45+ CD14- CD11c+ MHC II+ cells lack expression of LIN markers. (A) Cell debris and 
aggregates were gated out on FSC and SSC characteristics, and live cells selected as 7AAD-. 
Single live (7AAD-) cells were analysed for expression of CD45. CD45+ CD14- cells were further 
assessed for co-expression of CD11c and MHC II, and were classified as DCs. (B) DCs (red) were 
backgated for LIN and MHC II expression. Total 7AAD- CD45+ cells are used as staining 
comparison (grey). Gate depicts cells included within LIN- fraction. 
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(200, 203, 212, 277, 340, 393). These species comparative analyses shape the investigative 
field of human disease research and that of therapeutic development. However, additional 
functional and phenotypic analyses of human immune populations are required to 
substantiate these functional and phenotypic relationships. As described above, analysis of 
human intestinal DC subsets under resting and inflammatory conditions has not been 
performed in detail. In mice, recently published data where contaminating macrophages 
are excluded through the use of specific cell population markers (e.g. CD64), identifies 
four populations of intestinal cDC based on expression of CD103 and CD11b (234, 389). 
Jaensson et al identified LIN- CD11c+ MHC II+ CD103+ DCs in human MLNs capable of 
inducing the gut homing markers CCR9 and !4"7 on responding CD8+ T cells (274). 
Similarly, Persson et al identified CD103+ cDCs in small intestinal tissue isolated from 
HCs (275), however this study did not consider the possibility of CD103- cDCs existing in 
the mucosa. Therefore, in addition to the traditional blood/tissue cDC markers CD1c and 
CD141, we included CD103 in our staining protocol to try to identify all the intestinal DC 
subsets, including any potential CD103- DCs (203, 210, 265, 271, 340, 702). The gating 
strategy adopted to identify human intestinal cDC subsets is depicted in Fig. 8.7. CD64+ 
CD14+ cells amongst live leukocytes were excluded from analysis due to their 
classification as macrophages. Live CD45+ CD14- CD64- cells expressing CD11c and 
MHC II were considered to be human intestinal DCs (Fig. 8.7A). As stated above, murine 
intestinal DCs are identified through CD103 and CD11b expression (389). However, low 
expression of CD11b on blood DCs directed us to use SIRP! for identification of human 
intestinal DC populations, given their reported co-expression. This cell population can be 
subdivided into 4 distinct populations based on expression of CD103 and SIRP! (Fig. 
8.7A): CD103+ SIRP!+ (red), CD103+ SIRP!- (blue), CD103- SIRP!+ (green) and CD103- 
SIRP!- cDC subsets (orange). In blood, we and others can identify CD141+ (BDCA-3) and 
CD1c+ (BDCA-1) cDC populations (202, 203, 209, 210, 393, 576). Thus, we analysed 
CD141 and CD1c expression on all four populations of human intestinal DC to align these 
newly identified populations with those found in blood. The CD103- SIRP!- population 
was distinctly heterogeneous for CD141 expression, whereas CD103+ SIRP!+ and CD103- 
SIRP!+ DCs expressed intermediate levels of this surface marker (Fig. 8.7B). Importantly, 
CD103+ SIRP!- DC expressed uniformly high levels of CD141 (Fig. 8.7B). CD1c 
expression was observed to correlate with SIRP! expression on DC populations (Fig. 
8.7B). Therefore, only the CD103+ SIRP!+ and CD103- SIRP!+ subsets expressed 
significant levels of CD1c. The CD103- SIRP!- subset was heterogeneous for expression 
of CD1c (Fig. 8.7B). Overall we have identified four populations of intestinal DC that 
differ in their surface marker expression of CD103, SIRP!, CD1c and CD141.  
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Figure 8.7: Identification of intestinal cDC subsets 
Four intestinal cDC subsets can be identified based on the expression of CD103, CD141, SIRP" 
and CD1c. (A) Gating strategy used to identify intestinal cDC subsets digested using the enzymatic 
cocktail (digest 2): collagenase VIII, collagenase D, dispase and DNase. Doublets and live cells 
(7AAD-) were excluded from further analysis. Single live CD45+ cells were assessed for expression 
of CD14 and CD64. LIN- CD14- CD64- cells were analysed for CD11c and MHC II expression. 
CD11c+ MHC II+ cells were assessed for expression of CD103 and SIRP". cDC gates were set 
based on CD103 isotype. (B) Expression of CD141 (left) and CD1c (right) on CD013- and SIRP"-
defined cDC subsets. 7AAD- CD45+ CD11c- MHC II- cells were used as controls for marker 
expression. Data are representative of four individual experiments. 
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8.5 Steady state vs inflammation 
Having established reliable protocols for the identification of intestinal DC populations, we 
wished to ascertain whether there were any differences in these populations between HCs, 
HLA-B27+ and HLA-B27- AS patients. However, the only tissue available was colonic and 
duodenal tissue from HCs, UC and CD patients. Representative histological sections of 
colonic tissue isolated from a UC patient are presented in Fig. 8.8. These transverse and 
longitudinal sections demonstrate the presence of intestinal inflammation in our UC 
samples, as evidenced by elongated crypts (Fig. 8.8A), epithelial erosions, cellular 
infiltrate (Fig. 8.8B) and numerous goblet cells (Fig. 8.8C). Unfortunately uninflamed 
specimens were not available to act as control sections. 
Using the gating strategy described in Fig. 8.7A, cDC populations digested from colonic 
tissue isolated from a HC and a CD patient were identified and compared. As before, four 
populations could be identified amongst CD11c+ MHC II+ cells on the basis of CD103 and 
SIRP! expression in healthy colon (Fig. 8.9A). Importantly, all four populations of cDC 
were present in inflamed CD colon, albeit at different proportions (Fig. 8.9A). Within 
inflamed intestinal tissue, CD103+ SIRP!+ cDCs appear to be diminished compared with 
HCs (Fig. 8.9A). In addition, the proportion of the CD103- SIRP!- population was 
increased in CD tissue compared with the HC. The remaining cDC populations (CD103- 
SIRP!+ and CD103+ SIRP!-) remained comparatively stable. The results here suggested 
that colonic cDC populations may be altered in CD. However given that these observations 
compared only one HC with one CD sample, these experiments would need to be repeated 
to establish whether these alterations are reproducible.  
8.6 Expression of CCR2 by intestinal DC populations 
During these experiments, a PhD student in Prof Mowat’s laboratory (Charlotte Scott) was 
examining the phenotype, function and ontogeny of murine intestinal DCs. Interestingly, 
she observed differential CCR2 expression on mouse intestinal DC subsets. Specifically, 
she found that intestinal CD103- CD11b+ DCs were heterogeneous for CCR2 expression. 
Therefore, I set out to examine CCR2 expression on human intestinal DC subsets. In HC 
colonic tissue, CCR2 was expressed at varying levels on all DC subsets except the CD103+ 
SIRP!- population (Fig. 8.9B). For both the CD103- SIRP!+ and CD103+ SIRP!+ 
populations, CCR2 expression was heterogeneous (Fig. 8.9B). Interestingly, the CD103-  
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Figure 8.8: Histology of colonic tissue from an Ulcerative Colitis patient 
Histological sections of colonic tissue removed from an ulcerative colitis (UC) patient show signs of 
crypt hyperplasia, erosions and cellular infiltrate. (A) Sections of colonic UC tissue show elongation 
of crypts. Pictures taken at 10X magnification. (B) Evidence of erosions and cellular infiltrate in 
colonic tissue from a UC patient. Pictures taken at 10X magnification. (C) Sections at 40X 
magnification of colonic tissue from a UC patient. Goblet cells appear to be numerous within 
colonic crypts. Arrows indicate points of interest.  
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Figure 8.9: Expression of CCR2 by cDC subsets from steady state and inflamed colon 
CD103+ SIRP"- intestinal DCs lack expression of CCR2. (A) Identification of colonic cDC 
populations in a HC (centre) and a Crohn’s patient (right). 7AAD- CD45+ CD14- CD64- CD11c+ 
MHC II+ cells were subdivided into four cDC populations based on CD103 and SIRP" expression. 
Percentages represent proportion of CD11c+ MHC II+ cells. Histograms depict CCR2 expression on 
each intestinal cDC subset from a HC (B) and a Crohn’s disease patient (C): CD103+ SIRP"+, 
CD103+ SIRP"-, CD103- SIRP"+ and CD103- SIRP"-. CCR2 isotype = mouse IgG2b. Data are 
representative of 3 individual tissue samples. 
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SIRP!- DC subset appeared distinctly bimodal for CCR2 expression (Fig. 8.9B). This 
staining pattern was replicated in three independent experiments using HC intestinal tissue. 
We can therefore conclusively say that all human DC intestinal populations, except the 
CD103+ SIRP!- population, express CCR2. In addition, CCR2 expression on DC subsets 
isolated from one CD sample was assessed. In contrast to HCs, all DC subsets lacked 
expression of CCR2 (Fig. 8.9C). This comparison is based only on one HC sample and one 
CD patient. However, these results suggest that CCR2 is differentially expressed on 
intestinal DC subsets and may be altered in the presence of inflammation. 
8.7 Intestinal macrophages 
It has recently be shown in mice that Ly6Chi blood monocytes can give rise to both 
‘resident’ and pro-inflammatory macrophages in the intestine (225, 234). Under steady 
state conditions Ly6Chi monocytes give rise to resident, anti-inflammatory macrophages 
identified by their unusually high expression of CX3CR1. In contrast, during inflammation 
this process is disrupted leading to the accumulation of pro-inflammatory CX3CR1int 
macrophages (225). In addition, two macrophage populations were identified in the human 
small intestine that may correlate with macrophage populations in mice: CD14lo and 
CD14hi subsets (225). Based on these findings we set out to identify macrophage 
populations in colonic tissue of HCs and CD patients. The gating strategy used to identify 
macrophage subsets is depicted in Fig. 8.10. Macrophages were identified amongst CD45+ 
LIN- (CD3, CD15, CD19 and CD56) cells as CD206+ cells (Fig. 8.10A). Within this 
population, two colonic macrophage subsets could be identified: CD14hi and CD14lo. Both 
populations were next analysed for the expression of a variety of markers previously 
reported to be expressed by intestinal macrophages including CD11c, MHC II, CD33 and 
CD209. Whereas both subsets highly expressed CD206, MHC II and CD33 (Fig. 8.10B), 
the CD14hi population expressed CD64 at higher levels than CD14lo macrophages (Fig. 
8.10B). CD209 (also known as DC-SIGN) has previously been reported to be 
preferentially expressed on immature human DCs (703, 704), with current studies focusing 
on CD209 as a potential target for DC therapeutics (705). However, in our hands we found 
expression of CD209 to be higher on both intestinal macrophage populations than on total 
CD14- CD64- CD11c+ MHC II+ DCs (Fig. 8.10C). In addition, CD14hi macrophages 
appeared to have lower levels of CD11c compared to both CD14lo macrophages and total 
CD14- CD64- CD11c+ MHC II+ DC (Fig. 8.10C). To the best of my knowledge, this is the 
most comprehensive analysis of human intestinal macrophages to date. These data 
emphasise the need for inclusion of phenotypic markers to allow discrimination of CD11c+ 
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MHC II+ macrophages from CD11c+ MHC II+ DC. Furthermore, we have identified two 
populations of colonic macrophages that differ in their expression of CD11c and CD64.  
8.8 Macrophages in inflammation 
To prepare for future studies of intestinal tissue from AS patients, we aimed to analyse the 
proportions of colonic macrophage populations under steady state and inflammatory 
conditions. Our results suggest that proportions of both colonic macrophage populations 
change following inflammation in CD (Fig. 8.11A). In our hands, CD14hi macrophages 
dominated in healthy colonic tissue, representing ~10% of all 7AAD- CD45+ LIN- cells, 
compared with ~1.3% occupied by CD14lo. Again this distribution of intestinal 
macrophages is representative of three independent experiments using HC intestinal tissue. 
Under inflammatory conditions, the proportion of CD14hi colonic macrophages appeared 
to decrease (Fig. 8.11A). In the CD sample, CD14hi macrophages represented 3.9% of total 
live CD45+ LIN- cells compared to 10% for the HC CD14hi population. In addition, we 
noted the accumulation of CD45+ LIN- CD206- CD14+ cells in CD (2.64%), which were 
essentially absent in the healthy mucosa (0.386%). This population could represent 
infiltrating monocytes and will be discussed later (Fig. 8.11A). Due to the expansion of 
this CD206- CD14+ population in CD, we next determined expression of several 
macrophage/myeloid markers including CD11c, MHC II, CD33 and CD64 on all three 
populations (Fig. 8.11B). CD206- CD14+ cells uniformly expressed CD64 and expressed 
CD11c and CD33 at similar levels to CD14hi and CD14lo macrophages. However these 
CD206- CD14+ cells expressed MHC II at lower levels than the other macrophage 
populations (Fig. 8.11B).  
In addition to changes in the macrophage populations, there were other changes in the 
CD45+ LIN- compartment. Notably, a population of CD11c+ MHC II- cells expanded 
markedly in CD compared to HC tissue (Fig. 8.11C). 
In summary, following identification of CD14hi and CD14lo intestinal macrophages, we 
observed differences in the proportions of colonic macrophage subsets in CD, although this 
observation was only based on one HC and one CD sample. 
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Figure 8.10: Identification of intestinal macrophages in healthy colon 
Intestinal macrophage populations express varying levels of CD14. (A) Gating strategy to identify 
intestinal macrophages. Cells debris was excluded based on FSC vs SSC characteristics. CD45+ 
leukocytes were identified within the single 7AAD- population. CD45+ cells were analysed for 
expression of lineage (CD3, CD15, CD19 and CD56) and MHC II. LIN- cells were then subdivided 
based on CD206 and CD14 expression. (B) Histograms depict expression of CD206, CD64, MHC 
II and CD33 on CD14hi (purple) and CD14lo (pink) macrophages. Single 7AAD- CD45+ LIN- CD206- 
CD14- cells were used as a control population (grey). (C) CD209 and CD11c expression on CD14hi 
and CD14lo macrophages and CD45+ CD11c+ MHC II+ CD14- DCs (black). All expression data 
except CD33 (Crohn’s) was from a HC. Data representative of 7 independent tissue samples. 
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Figure 8.11: Macrophages in steady state and Crohn’s disease 
CD206- CD14+ cells infiltrate intestinal tissue isolated from a Crohn’s patient. (A) Comparison of 
intestinal macrophage populations in a HC (left) and a Crohn’s patient (right). Single 7AAD- CD45+ 
LIN- cells were assessed for the expression of CD206 and CD14. LIN = CD3, CD15, CD19 and 
CD56. Percentages represent proportion of LIN- cells. (B) Expression of CD11c, MHC II, CD33 and 
CD64 on CD14hi macrophages (purple), CD14lo macrophages(pink) and CD206- CD14+ cells (light 
blue) from a Crohn’s patient. LIN+ cells were used as a control population for marker expression. 
(C) Total live CD45+ LIN- cells were assessed for expression of CD11c and MHC II in a HC (left) 
and a Crohn’s patient (right).  
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8.9 In vivo turnover of intestinal macrophages 
Unpublished results from the Mowat laboratory (Calum Bain and Alberto Bravo) identified 
differences in the proliferation of intestinal macrophage populations during development in 
mice (unpublished observations). We therefore set up a collaboration to investigate the 
proliferative capabilities of intestinal macrophage populations in humans. Ki67 is a nuclear 
antigen expressed exclusively by cells in active cell cycle and can be detected by 
intracellular antibody staining. Therefore we examined the expression of Ki67 by intestinal 
macrophages from healthy and inflamed mucosa. To ensure we could detect Ki67 
expression by colonic isolates, we first examined the expression by total live leukocytes. 
Only 0.427% of CD206- cells expressed Ki67 in the steady state (Fig. 8.12A). In contrast, 
4.67% of live CD45+ CD206- colonic cells from inflamed tissue expressed Ki67 (Fig. 
8.12A). These results suggest that proliferation of immune populations is enhanced in the 
presence of inflammation and additionally indicate that our Ki67 staining protocol 
accurately identifies proliferating cells. We next examined the proliferation potential of the 
CD206+ macrophage subsets and CD206- CD14+ cells directly (Fig. 8.12B and 8.12C). 
Neither CD14hi macrophages nor the CD206- CD14+ population proliferate rapidly in vivo 
in the steady state (Fig. 8.12B) or during inflammatory conditions (Fig. 8.12C). In contrast, 
the CD14lo macrophage subset both in the HC (Fig. 8.12B) and CD tissue (Fig. 8.12C) 
showed some proliferation (~5%). These results are representative of three independent 
experiments using HC intestinal tissue. To the best of my knowledge, the proliferative 
capacity of human intestinal macrophage populations has not previously been described. 
These findings predominantly corroborate those observations in the murine studies and 
therefore we hope to include these data in a future manuscript (Calum Bain and Alberto 
Bravo, unpublished observations).  
Although we were unable to definitively assess in vivo proliferation of intestinal DC 
subsets due to the lack of appropriate markers, we examined CD45+ LIN- CD11c+ CD14- 
CD206- cells that may represent DCs. These cells showed levels of Ki67 expression 
similar to that of CD14lo macrophages (Fig. 8.12D). Thus putative DCs and CD14lo 
macrophages appear to turnover in situ. 
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Figure 8.12: Macrophage subset proliferation potential from HC and inflamed colon 
Colonic macrophages do not proliferate in vivo. (A) Ki67 staining was used to assess cell 
proliferation in vivo on total single 7AAD- CD45+ cells isolated from a HC (centre) and a Crohn’s 
patient (left). Ki67 isotype was used to set Ki67+ gate (red). Percentages represent proportion of 
parent population. Analysis of Ki67 on macrophage subsets from a HC (B) and a Crohn’s patient 
(C). Live CD45+ LIN- cells were subdivided into CD14lo (pink) and CD14hi (purple) macrophages 
and CD206- CD14+ (light blue) cells and assessed for Ki67. Percentages represent proportion of 
Ki67+ cells within each subset. (D) Live CD45+ LIN- cells were analysed for CD11c and CD14 
expression. CD11c+ CD14- CD206- cells were assessed for Ki67. Percentage represents proportion 
of dividing cells within subset. Data representative of 3 independent experiments.   
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8.10 Discussion 
The majority of AS studies focus on blood due to ease of tissue access and recruitment of 
HCs. Using blood, we have identified small differences in the proportions of circulating 
immune populations in AS patients compared to HCs: a reduction of CD1c+ cDCs 
accompanied by an increase in CD14- CD16+ mononuclear cells and differential 
expression of chemokine receptors on CD4+ T cells (Chapter 3 and 4). However, blood 
profiling is insufficient to fully characterise and understand the immune pathways involved 
in AS development. In contrast, use of disease-affected tissue can aid elucidation of the 
precise mechanisms involved and thereby improve our understanding of disease pathology 
and generation of disease specific therapies. The main sites of inflammation and aberrant 
bone processes in AS are within the spine and SIJs (4). However access to spinal tissue is 
limited. Consequently, most studies investigating AS pathogenesis through the use of 
extra-articular and peripheral tissues focus on SF and the intestine. We have identified 
DCs, CCR4+ and CCR6+ CD4+ T cells and described the cytokine milieu within the SF of 
AS patients (Chapter 5). However, excess joint SF is often associated with lower limb 
peripheral arthritis in AS patients, meaning that the ongoing inflammatory processes 
within AS SF may, in fact, be more characteristic of RA pathogenesis.  
Data from animal models and patients suggest a connection between the intestine and AS 
pathogenesis. Taurog et al observed alleviation of intestinal and joint pathology in HLA-
B27 TG rats when housed in germ-free conditions (444). In Crohn’s patients, 50% of those 
expressing the MHC class I molecule HLA-B27 developed AS (4, 440). In addition, the 
study by Van Praet et al reported that 50% of their SpA cohort presented with evidence of 
subclinical gut inflammation (441, 706). Furthermore, intestinal inflammation has been 
observed to correlate with disease severity (441, 706). These studies suggest that intestinal 
inflammation, joint pathology and AS pathogenesis are inextricably linked. 
Intestinal studies in AS patients have focused on cytokine expression, T cell subsets 
(Tregs), NK cells and a basic characterisation of cellular infiltrate (551-554, 707). No 
study to date has investigated and characterised the intestinal DC populations in AS 
patients. This is surprising given their primary role in inducing and directing immune 
responses. This statement is confounded through the use of overlapping myeloid markers, 
difficulties in isolating significant cell numbers and limited tissue availability. Using our 
knowledge of blood DCs and mouse intestinal DC subsets, we aimed to analyse intestinal 
DC populations in AS patients and HCs. Starting from our observation that CD172alo 
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migratory intestinal DCs were absent in the HLA-B27 TG rats, we hypothesised that 
intestinal CD141+ DCs would be absent from AS intestinal tissue, and that this defect 
would contribute to disease pathogenesis and development. In the time available to 
perform these studies I have developed techniques for the analysis of human intestinal DC 
populations, which have contributed to two important projects. These results are herein 
described. Unfortunately I did not receive any AS patient intestinal samples or those from 
HLA-B27+ IBD patients, and have therefore not been able to test my hypothesis. However, 
using HC and IBD intestinal tissue samples, we developed techniques to successfully 
isolate immune populations, including DCs and macrophages, from human intestinal 
surgical resections. Following successful isolation, we performed preliminary comparisons 
of the DC and macrophage populations residing within HC and IBD intestinal tissue. In 
contrast to AS, numerous studies have identified and quantified the DC populations present 
in UC and CD intestinal tissue. For instance, DCs present within the inflamed mucosa of 
CD patients have been found to accumulate and congregate with T cells and express higher 
levels of CD40, TLR2 and TLR4 (404, 694, 695, 698). Recently, cell specific markers 
have been identified that enable greater distinction between macrophage and DC 
populations. These markers include CD64 (225, 234). It is now clear that groups 
previously thought to be investigating IBD ‘DC’ biology have unintentionally been 
isolating and characterising mixed populations of DCs and macrophages. Therefore, in 
addition to refining intestinal cell isolation protocols, we performed experiments 
investigating DC and macrophage subsets in the human intestine under steady state and 
inflammatory conditions. 
The majority of HC intestinal tissue used in this study was excised from patients suffering 
with intestinal adenocarcinoma. Healthy tissue surrounding the tumour was used for 
analysis, however we are unable to exclude the possibility that this HC tissue was actively 
inflamed. Therefore when performing correlative analysis between HCs and IBD patients, 
the health status of HCs must be taken into consideration. To eliminate this uncertainty in 
future studies, histological analysis could be performed on all tissue samples.  
Intestinal cell populations were initially isolated using a protocol developed by the 
laboratory of Professor Allan Mowat. However this protocol was found to induce cleavage 
of at least two cell surface markers used to identify mononuclear populations in blood, 
CD16 and CX3CR1 (Fig. 8.2D and 8.2E). In blood, CD14- CD16+ mononuclear cells were 
slightly increased in AS patients compared to HCs (Fig. 3.7A). It was therefore vital to 
adapt the isolation protocol to identify and functionally assess the role, if any, played by 
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CD14- CD16+ mononuclear cells within inflamed tissues. Alterations to the enzyme 
cocktail, specifically the replacement of collagenase V with collagenase VIII, resulted in 
efficient tissue digestion without degradation of CD16 (Fig. 8.4A). Despite these protocol 
alterations, CX3CR1 expression remained difficult to detect following digestion (Fig. 
8.4B). This could either signify that CX3CR1 is expressed at low levels within the human 
intestine, or that CX3CR1 is still cleaved by the enzyme cocktail. As published studies 
have detected CX3CR1 expression on CD14+ intestinal mononuclear cells (427, 701), the 
latter option is the more plausible explanation. If CX3CR1 expression data are required for 
further characterisation of immune populations, this protocol will have to be adapted. 
Overall, we successfully developed a protocol for the isolation of intestinal immune 
populations, which did not induce cleavage of the majority of DC and macrophage 
markers, excluding CX3CR1. 
Using this adapted protocol, we repeated our experiments to detect CD14- CD16+ 
mononuclear cells in the human intestine under steady state conditions. The results indicate 
that in the absence of inflammation, CD14- CD16+ cells do not enter the intestinal mucosa 
(Fig. 8.5B). In blood, this CD14- CD16+ population is heterogeneous, as discussed above, 
containing both SLAN+ and SLAN- cells. CD16 has been shown to be rapidly shed, in a 
protease-dependent manner, from the surface of maturing SLAN+ DCs (588). To exclude 
the possibility that intestinal migration of this mononuclear population may be associated 
with CD16 downregulation, we analysed total live cells for expression of SLAN. 
Somewhat surprisingly, we were unable to clearly identify a distinct SLAN+ population in 
the human intestine under steady state conditions (Fig. 8.5A). However, this analysis was 
performed using only one HC colonic tissue sample; further experiments are clearly 
necessary. These data are further complicated because the CD14- CD16+ population is not 
definitively characterised. CD14- CD16+ SLAN- cells are described as putative monocytes, 
whilst SLAN+ cells may represent a population of DCs (229, 237, 239). Comparison of 
these findings with analogous murine studies supports the idea that CD14- CD16+ 
populations may be absent from peripheral and/or extra-articular tissue under steady state 
conditions; their proposed function is as a blood vessel surveillance population in the 
steady state (229, 237, 248, 356). Inflammation may alter migration of this blood CD14- 
CD16+ population, leading to accumulation within inflamed tissues and potential 
involvement in disease pathogenesis (223, 237). Therefore, characterisation of CD14- 
CD16+ mononuclear cells under inflammatory conditions should be performed to elucidate 
the function and identity of this subset in humans. However, our data suggest that both 
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subsets (SLAN- and SLAN+) of the CD14- CD16+ population do not enter intestinal 
mucosa under resting conditions, supporting their proposed role in blood surveillance. 
If CD14- CD16+ SLAN+ cells represent a third human DC subset, then our data indicate 
that this subset does not develop within or migrate to the intestinal mucosa under steady 
state conditions. Several groups have identified SLAN+ cells in healthy skin by 
immunohistochemistry, but these skin-residing SLAN+ cells lacked expression of CD11c 
(249, 250), and are therefore unlikely to represent tissue equivalents of the blood CD14- 
CD16+ SLAN+ cells. The apparent exclusion of SLAN+ cells from the intestinal mucosa 
may be the result of intestinal conditioning. Several intestinal myeloid populations have 
been shown to be refractory to stimulation (424, 436, 708-710), thereby preventing 
generation of aberrant responses to harmless antigens. This anti-inflammatory environment 
in the intestine may also inhibit in situ development of the potentially inflammatory 
SLAN+ DC population. Inflammation affects the development of the murine intestinal 
macrophages (225); inflammation may affect in situ development of SLAN+ DCs in 
tissues. To support this hypothesis, SLAN+ cells have been identified in inflamed human 
tonsil, psoriatic skin, PPs and CD ileal mucosa (249-252). The majority of these studies 
depend on single stain immunohistochemistry, hindering characterisation of these SLAN+ 
cells. However these data may indicate that during inflammation, DC precursors seeding 
peripheral tissue may acquire the ability to generate CD14- CD16+ SLAN+ DCs. Thus, the 
observed increase in circulating CD14- CD16+ cells in AS patients, may be the result of 
increased development of this cell population under inflammatory conditions in peripheral 
tissues of patients.  
We next set out to examine the cDC populations (CD141+ and CD1c+) in human intestinal 
mucosa. Recent advances in murine DC classification have led to the identification of four 
DC populations based on expression of CD103 and CD11b (234, 389). Jaensson et al also 
identified CD103+ DCs in the human MLN (274). The recent use of CD64 as a 
macrophage-specific marker in mice and men (225, 234) has highlighted the heterogeneity 
of the populations previously considered to be homogenous populations of DCs or 
macrophages. Using a combination of these markers, we set out characterise human 
intestinal DC populations. Through definitive exclusion of macrophages (CD64+ and 
CD14+), we have now identified four intestinal DC subsets, based on their expression of 
cell surface markers CD103 and SIRP!: CD103+ SIRP!-, CD103+ SIRP!+, CD103- SIPR!- 
and CD103- SIRP!+ populations (Fig. 8.7A). Due to the low expression of CD11b on 
CD1c+ blood DCs, we used SIRP! expression instead of CD11b to identify DC 
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populations (Fig. 3.16A). To the best of my knowledge, DC subsets characterised using 
these markers have not previously been described in human peripheral tissue. To align 
these subsets with the mature circulating DC populations in humans, CD141 and CD1c 
expression was assessed. CD1c was found to be predominantly co-expressed with SIRP! 
(Fig. 8.7B). As all murine lymph-migrating CD11b+ DCs also expressed SIRP! (389), it is 
not surprising that intestinal equivalents of the circulating human CD11b+ DC population 
(CD1c+ DCs) similarly express SIRP!. CD103+ SIRP!- DCs were the only DC subset to 
homogenously express CD141 (Fig. 8.7B). This supports the idea that human CD141+ DCs 
are analogous to the murine CD103+ SIRP!- non-lymphoid and lymphoid CD8!+ DC 
populations (222, 334, 380). Additionally, the CD103- SIRP!- population was observed to 
be heterogeneous for CD141 and CD1c expression (Fig. 8.7B). It is therefore interesting to 
speculate that this CD103- SIRP!- population could either contain multiple populations 
that may be subdivided on markers not yet analysed. Further analysis of human intestinal 
DC subsets is required to fully characterise these populations.  
In CD we observed a reduction in the CD103+ SIRP!+ DC population, accompanied by an 
increase in the CD103- SIRP!- DC subset (Fig. 8.9A). However, this comparison is based 
on one HC and one CD patient and further study is required using additional samples. 
Furthermore, as these were proportional differences they may be influenced by the 
presence of other leukocytes that accumulate during inflammation. However, if this 
observation were conserved, it would open interesting avenues for understanding the role 
of human intestinal DCs in IBD pathogenesis. 
Despite limited availability of samples, further surface phenotyping of these novel human 
intestinal DC subsets was performed, specifically in relation to their expression of CCR2. 
As discussed, work from the Mowat group uncovered heterogeneity in CCR2 expression in 
murine intestinal DCs (Charlotte Scott, unpublished data). Furthermore, the CCR2+ and 
CCR2- populations displayed different functions. Specifically, murine CD103- CD11b+ 
DCs could be subdivided on the basis of CCR2 expression, with the CCR2+ subset 
preferentially inducing IL-17A production from interacting antigen-specific T cells 
(Charlotte Scott, unpublished data). In addition, CCR2-/- mice are less able to induce Th17 
responses. Consequently, I aimed to establish whether this heterogeneity also existed in 
human intestinal DC subsets. Interestingly, all intestinal DC subsets except the CD103+ 
SIRP!- DC population exhibited signs of heterogeneity with respect to CCR2 expression 
(Fig. 8.9B). Strikingly within the CD103- SIRP!- subset, as for CD141, two distinct 
subsets could be differentiated by CCR2 expression levels. These data have been combined 
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with the data from the murine CCR2 DC data, and have been submitted for publication. 
Surprisingly in CD, we observed a complete lack of CCR2 expression on all DC subsets 
(Fig. 8.9C). 
The role of CCR2 on these DC subsets remains elusive. Jimenez et al have postulated that 
CCR2 expression on Langerhans cells is required for complete maturation, migration and 
cytokine secretion (711). In addition, thymic SIRP!+ DCs have been suggested to induce 
negative selection, migration and antigen uptake in a CCR2 dependent manner (712, 713). 
It will therefore be important to perform further experiments to establish the role of CCR2 
on steady state DCs, and on DCs in inflamed tissues. 
Overall, we have established a protocol for the successful isolation of immune populations 
from intestinal surgical resections from HCs and IBD patients. Using this protocol, we 
have for the first time identified at least 4 intestinal DC subsets based on the expression of 
CD103 and SIRP!. In addition, our preliminary results suggest that CCR2 is differentially 
expressed within human intestinal DC subsets. 
Inflammatory/classical monocytes (Ly6Chi) have recently been shown develop into 
intestinal macrophages in mice under both steady state and inflammatory conditions (225, 
234). Blood monocyte contribution to tissue macrophage development appears to be 
unique to the gut as recent reports have suggested that the majority of tissue macrophage 
populations are maintained independent of blood monocytes (714, 715). The fate of newly 
extravasated monocytes in the gut mucosa appears to be dependent on the context of the 
environment into which they arrive. For instance, during intestinal inflammation monocyte 
maturation is disrupted, leading to a shift in the balance between resident and pro-
inflammatory macrophage populations (225). Additionally, Bain et al observed equivalent 
processes occurring in human small intestinal tissue, with accumulation of CD14hi 
macrophages in inflammation (225). Based on this data, we examined macrophage 
populations residing in colonic tissue under steady state and pro-inflammatory conditions. 
Early work suggested that only inflammatory macrophages within human intestinal 
mucosa expressed CD14 (423, 424, 716). However, several recent studies have identified 
CD14lo macrophages in resting and inflammatory mucosal tissue (225, 234, 427, 691). In 
our hands, we could identify two intestinal macrophage populations based on expression of 
CD206 and CD14: CD14hi CD206+ and CD14lo CD206+ subsets (Fig. 8.10A). Both subsets 
expressed high levels of MHC II, CD33 and CD209 (Fig. 8.10B). Interestingly CD209 
(DC-SIGN) is regarded as a DC-associated marker and consequently thought to be a 
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potential candidate for DC targeting (704, 705, 717). However, we observed higher 
expression of CD209 on both intestinal macrophage populations compared with total DCs 
(Fig. 8.10C). This observation could have important consequences for the efficiency of DC 
targeting. However this macrophage surface phenotyping is based on limited samples and 
so it is important that further studies are carried out. Both populations expressed CD64, 
recently shown to discriminate between DCs and macrophages in mice and men (Fig. 
8.10B) (225, 234). In contrast to Bain et al where CD14lo macrophages were found to lack 
CD11c expression, in our hands CD14hi macrophages expressed lower levels of CD11c 
compared to CD14lo macrophages and DCs.  
Another interesting discrepancy between the two studies refers to the abundance of the 
individual macrophage subsets. Bain et al found the CD14lo population in HC small 
intestinal tissue to dominate over the CD14hi subset, with expansion of the CD14hi 
population being observed in CD patients (225). These observations suggest that the 
CD14hi population may represent the pro-inflammatory human macrophage population and 
would agree with previous studies showing that intestinal CD14+ macrophages only exist 
under inflammatory conditions (425, 427). Although referred to as ‘proinflammatory’, the 
precise functions of human intestinal macrophage populations have not yet been 
elucidated. In addition, our studies consistently (n=3) found the CD14hi subset to represent 
the largest intestinal macrophage population in HC colonic tissue (Fig. 8.11A).  
These disparities could reflect differences between macrophage tissue localisation. Tissue 
samples used by both studies differ not only in terms of anatomical location (colon vs 
small intestine) but also in terms of tissue processing. Both studies involved removal of 
muscle and fat layers, however differences in tissue processing could affect the proportion 
of isolated immune populations. The functions of these subsets as previously discussed 
remain unknown. Therefore understanding the roles of these populations in resting and 
inflammatory conditions may help elucidate these apparent differences. If CD14hi 
macrophages are equivalent to the CX3CR1int mouse pro-inflammatory subset (225), our 
results could suggest that HC tissue used in our studies may not be truly representative of 
steady state conditions. As previously stated, the study by Bain et al characterised 
populations isolated from the small intestine (225). In contrast, the majority of our studies 
were performed using colonic populations. Therefore anatomical location of immune 
populations could alter cell function. The colon harbours more commensal bacteria 
compared to the small intestine (718, 719). The presence of bacteria may affect cell 
function and phenotype. Given their expansion in disease, one could postulate that within 
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the small intestine, CD14hi macrophages are the proinflammatory population that are 
outnumbered in the steady state by the CD14lo resident population (225). In contrast, we 
observed domination of the CD14hi subset in HC colonic tissue. Given the increased 
bacterial load and the need to prevent generation of aberrant responses to commensal 
bacteria, colonic CD14hi macrophages may represent the resident, refractory population in 
contrast to the small intestine. These tissue differences highlight the requirement for 
functional characterisation of both CD14lo and CD14hi macrophages in the colon and small 
intestine. Furthermore, the role of intestinal flora on human intestinal macrophage 
populations remains an interesting avenue of research. Therefore several factors may 
contribute to the difference between these studies, emphasising the need for further 
investigation.  
When analysing macrophage populations under inflammatory conditions, we observed 
expansion or infiltration of a population of CD206- CD14+ cells within CD mucosa 
compared to HC tissue (Fig. 8.11A). This population expressed high levels of CD11c, 
CD64 and CD33, to the same level observed on ‘resident’ macrophage subsets (Fig. 
8.11B). However, these cells did express slightly lower levels of MHC II. This surface 
phenotype corresponds to that of blood monocytes. Grimm et al demonstrated that CD14+ 
blood monocytes in IBD patients migrated to the inflamed mucosa (690). Therefore, our 
observed CD206- CD14+ population could represent infiltrating monocytes in the process 
of differentiating into inflammatory macrophages, which may contribute to the 
perpetuation of IBD. In CD, although the CD14hi population appeared to dominate (Fig. 
8.11A), the comparative difference between CD14lo and CD14hi macrophages was not as 
great as that observed in the steady state. This observation, although only based on one CD 
patient again highlights the need for further investigation. Again, expansion of other 
leukocyte populations may affect the proportional analyses of these populations. 
As stated previously, intestinal macrophages are unique in their development from 
circulating blood monocytes. Langerhans cell (LC) precursors in mice have recently been 
shown to seed the epidermis and mature into LCs, undergo rapid initial proliferation with 
continual low level proliferation being observed throughout life (720, 721). With regards 
to the development of tissue-resident macrophage populations, lung alveolar macrophages, 
kupffer cells and CNS-resident microglia appear to adopt similar replenishment 
mechanisms in situ, as described for LCs (589, 722-724). Members of Prof Mowat’s 
laboratory investigating macrophage development in mice have generated data suggesting 
that intestinal macrophages lose the ability to proliferate in situ during development from 
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the neonatal period into adulthood (Calum Bain and Alberto Bravo, unpublished 
observations). Subsequently we set out to replicate their findings by assessing the 
proliferative capacity of intestinal macrophages in adults. CD14hi macrophages did not 
proliferate in vivo (Fig. 8.12B). In contrast, the CD14lo population exhibited very low 
levels of proliferation (Fig. 8.12B). These results suggest that macrophages in humans may 
turnover in situ, although further experiments will have to be performed to confirm this 
analysis. It would be interesting to study macrophage proliferation in colonic and small 
intestinal tissue due to the observed differences regarding macrophage populations 
previously described between tissue locations. 
Overall, to the best of my knowledge we have identified and defined four populations of 
intestinal DC subsets. Initial studies suggest that these populations may be altered in IBD 
patients based on proportional analysis and expression of CCR2. Interestingly, we 
identified two macrophage populations in human intestinal mucosa, which may differ in 
function and phenotype depending on anatomical location and ability to proliferate in vivo. 
Following successful identification of DCs, macrophages and T cells, we hope to apply 
these techniques to AS patients in order to elucidate mechanisms and tissues involved in 
disease pathogenesis. 
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Chapter 9: Final discussion 
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9.1 General discussion 
The aim of my PhD project was to investigate the immunopathogenesis of AS, focusing on 
the phenotype and function of circulating DCs to elucidate their role in this systemic, 
inflammatory disease. We hypothesised that human CD141+ DCs would be absent or 
diminished in AS patients, given that HLA-B27 TG SpA rats lack the equivalent DC 
subset (480). Our results led us to reject our initial hypothesis. However, our investigations 
of AS immunopathogenesis have elucidated several immunological pathways that may 
contribute to the development and perpetuation of AS. 
Firstly, alterations to the proportions of circulating myeloid populations in AS patients may 
perpetuate aberrant immune responses. Our cohort of AS patients had significantly 
elevated levels of circulating CCR6+ activated T cells, and plasma IL-6 and IL-23, both 
involved in generation and maintenance of Th17 cells in vivo (107, 109, 112). These data, 
and the observation that most IL-17-secreting cells express CCR6, implicate Th17 
involvement in disease pathogenesis. In AS patients, a significantly reduced proportion of 
their CD11c+ MHC II+ cells were of the CD1c+ DC subset. This was accompanied by an 
increase in total CD14- CD16+ mononuclear cells. Functional analyses of these populations 
revealed an inherent ability of both subsets to induce CCR6 on interacting CD4+ T cells. 
Complementing this observation, preliminary data suggests that co-cultures containing 
CD14- CD16+ mononuclear cells and allogeneic CD4+ T cells preferentially induce high 
levels of IL-6 production. Our data therefore indicate that in AS patients, a shift in their 
myeloid immune populations towards the CCR6-inducing CD14- CD16+ mononuclear 
population may contribute to the induction of T cell-mediated pathogenesis through an IL-
6-dependent induction of a Th17 phenotype (Fig. 9.1).  
AS is a systemic inflammatory disease for which the aetiology remains elusive. Patient 
data and experimental results from HLA-B27 TG rats reveal an intriguing relationship 
between AS, the intestine and disease pathogenesis. Of the 90% of AS patients that fail to 
develop overt IBD, at least 50% display evidence of subclinical intestinal inflammation (4, 
13, 441). Furthermore, HLA-B27 TG rats maintained under germ-free conditions do not 
develop SpA-like symptoms. These observations suggest a link between intestinal 
inflammation and disease pathogenesis. We provide an immunological basis for this 
relationship. We observed elevated levels of systemic inflammation, as determined by ESR 
and CRP, to be associated with a higher proportion of circulating CCR9+ and CCR6+ 
activated T cells. Both CCR9 and CCR6 mediate homing of immune populations to 
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mucosal tissues, particularly the intestine (171, 172, 176, 413). Our results indicate that 
systemic inflammation in AS patients is either driven from the intestine, or drives activated 
T cells to the intestine. Given that no correlations between disease severity and these CCR+ 
T populations were observed, this intestinal-linked systemic inflammation in AS patients 
may be transitory.  
 
Figure 9.1: Role of DCs in disease pathogenesis 
Circulating myeloid populations in AS patients are altered. Circulating CD14- CD16+ mononuclear 
cells are increased in patient blood compared to CD1c+ DCs. CD14- CD16+ mononuclear cell 
interactions with CD4+ T cells result in IL-6 secretion and CCR6 induction. These conditions 
support the generation of Th17 cells, presumed to be pathogenic in AS. 
Many AS patient studies focus on the involvement of Th17 cells in disease pathogenesis. 
This emphasis has been fostered by numerous studies indicating promotion of aberrant 
Th17 responses in both humans (527, 528, 530) and HLA-B27 TG rats (479, 480). 
However, direct functional evidence regarding their contribution to human disease 
pathogenesis is negligible. Furthermore, analysis of extra-articular tissue involvement in 
AS patients reveals little involvement of IL-17-secreting lymphocytes in disease (540, 
551). Our correlative analyses and immunological profiling of AS patients suggest a role 
for IL-23 in AS pathogenesis unconnected with maintenance of Th17 cells (112). Based on 
our data, we hypothesise that IL-23 may even be protective in AS (Fig. 9.2).  
AS patients with elevated levels of circulating IL-23 have low levels of disease severity, 
suggesting that IL-23 may inhibit disease progression. Given this observation, we propose 
the following model: HLA-B27-induced loss of intestinal barrier integrity in AS patients 
promotes development of gut inflammation. The subsequent immune response is driven 
CCR6 
IL-6?? 
Th17 
CD14- CD16+ 
CD1c+ DCs 
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innately by IL-23, and protective immunity depends upon engagement of the IL-23R on 
macrophages, neutrophils, T cells, DCs and numerous other immune populations. These 
IL-23-driven populations function to restore the integrity of the mucosal barrier, eradicate 
any potentially harmful pathogen and contain the potentially pathogenic inflammatory 
response in a Treg independent manner. However, if an adaptive immune response is 
developed, then disease progresses in an IL-23-independent manner. A side effect of this 
detrimental T cell response relates to the generation of intestinal-homing CCR6+ Tregs; 
Patients with elevated proportions of circulating CCR6-expressing Tregs were observed to 
be those patients with highest disease scores (BASMI and BASFI).  
Overall, our data indicate that induction of intestinal responses, involving Treg priming 
within the MLN, promote disease progression in AS. Alternatively, when the intestinal 
immune response is dominated by IL-23, and in the absence of Tregs, patients are 
protected from disease progression. These differential outcomes may be determined by an 
individuals’ genetic profile; compared to protected IL-23hi patients, AS patients with low 
plasma IL-23 levels may have a distinct genetic background with specific SNPs that 
contribute to the loss of immune control and disease progression. Several other distinct 
factors may also contribute to this switch from regulation to disease progression. In 
addition, our data clearly highlight a pathway that connects intestinally activated T cells 
with systemic inflammation, which is uncoupled from overall disease progression. 
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Figure 9.2: Immunopathogenesis of AS 
Diagram depicting a potential mechanism for disease progression. Patients with low disease 
severity have high circulating levels of IL-23 that may provide protection by an undefined 
mechanism. In the absence of IL-23, a pathogenic adaptive immune response develops. This 
response generates CCR6+ Tregs that fail to control disease progression. m& = macrophage, DC 
= dendritic cell, MLN = mesenteric lymph node, Ag = antigen. 
9.2 Conclusion 
To date, no study has investigated the involvement of circulating DCs in the 
immunopathogenesis of AS. Therefore, the data presented here contribute significantly to 
our understanding of AS. Specifically, we observed alterations to the circulating myeloid 
profile of AS patients, which may promote the induction of aberrant immune responses 
through induction of CCR6 and secretion of IL-6. Furthermore, this study highlights the 
importance of the intestinal environment in driving systemic inflammation and indicates 
the potential for intestine-driven disease progression. In the future, we would aim to fully 
characterise the involvement of the intestinal immune system in the development and 
perpetuation of AS, through assessment of the functional attributes of tissue-resident DCs. 
Furthermore, investigation of the functions of IL-23 in the intestinal immune response may 
elucidate mechanisms of disease pathogenesis and aid development of future AS-targeted 
therapies.   
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